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Pain is a global public health problem resulting from complex 
interactions of multiple biopsychosocial factors. Most published pain research 
comes from developed countries using samples from western countries; 
developing countries continue to face challenges in conducting high-quality 
pain research. This thesis illustrates a systematic approach to planning a pain 
research programme in a (resource-limited) country, using my country of 
Nepal as an example. It also demonstrates ways to overcome preliminary 
barriers to conducting high-quality pain research in developing countries.  
This thesis has 10 chapters and includes ten manuscripts published in 
international peer-reviewed journals. Chapter 1 is a general introduction 
providing an overview of pain and includes the aims of the thesis. Chapter 2 
is a scoping review of published pain research conducted in Nepal (last search 
updated in November 2018) with an aim to describe the findings from this 
research, identify research gaps, and inform pain research priorities. This 
chapter also informed the need for Chapters 5 through 9. Chapter 3 is a 
systematic review aiming to explore between-country and -language 
differences in chronic pain beliefs, coping, and catastrophizing. Chapter 4 
prepares the readers for the four chapters that follow (Chapter 5 – 8) that 
describe the translation, cross-cultural adaptation, and validation of five 
patient-reported outcome measures (PROMs) that assesses four domains into 
Nepalese that can be used in future pain research in Nepal. These domains 
were identified as important domains to measure in individuals with pain in 
Nepal based on the recommendations of the core outcome sets of several pain 
conditions. Instruments translated to assess these domains were the 
Numerical Pain Rating Scale (NPRS), the Patient-Specific Functional Scale 
(PSFS), the Pain Catastrophizing Scale (PCS), the Connor Davidson Resilience 
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Scale (CDRISC), and the Global Rating of Change (GRoC). Chapter 9 
describes the development of pain education materials in Nepali and the 
results of a feasibility clinical trial that aimed to explore if conducting a high-
quality clinical trial is feasible in the Nepalese healthcare system. The final 
chapter, Chapter 10 is a general discussion of the thesis with implications of 
the studies on pain policy, future research, and clinical practice in Nepal, as 
well as the overall significance, recommendations, strengths, and limitations 
of the work presented.  
In summary, the current thesis identified two important knowledge 
gaps in the current pain literature in Nepal: (1) the general unavailability of 
PROMs that are in the Nepali language and that could be used to assess pain 
and other important pain-related domains significant to advancing scientific 
knowledge and (2) the biopsychosocial management of pain in Nepal. The 
research reported here addressed these knowledge gaps by translating and 
cross-culturally adapting and validating 5 PROMs that can be used in the 
assessment of pain conditions, and developing a credible and acceptable pain 
education programme in Nepali. Moreover, the systematic review found 
important country and language effects on the beliefs people have and the 
response they engage in to cope with pain, suggesting that these factors may 
be considered when developing treatments for and adapting treatments to 
individuals living in a specific country or speaking a specific language. 
Finally, the results indicate that a definitive high-quality clinical trial to 
investigate the effectiveness of the pain education programme is feasible and 
warranted in Nepal.   
Keywords: Chronic Pain, Cross-cultural comparison, Developing countries, 
Low back pain, Low-income countries, Musculoskeletal pain, Nepal, Outcome 
measurement, Patient-reported Outcome Measures, Pain, Resilience, Pain 





I am grateful to all who helped me directly or indirectly to complete 
my Ph.D. First, I would like to thank my supervisors Professor J. Haxby 
Abbott and Professor Mark P. Jensen for trusting in me and collaborating 
with me since 2014. This Ph.D. would not have been initiated and completed 
without their continuing support. They went above and beyond this Ph.D. to 
support me in my overall professional and career development. I am grateful 
to Prof. Abbott especially for accepting my “wish” to undertake this line of 
research in Nepal, developing me as an independent researcher, and teaching 
me ways to write succinctly (I am still trying which is evident from this long 
Acknowledgement section). Thank you also for encouraging me to collaborate 
outside of my Ph.D. research and supporting me to present my work at 
conferences globally.      
Mark, you deserve my sincere gratitude for keeping my research on 
the top of your priority. This always made me feel that my research is 
important. This is a blessing for any Ph.D. student which motivates the 
students to continue the studies. Moreover, your insightful and timely 
responses to all my queries (despite the geographical barriers) have made me 
a critical thinker and allowed to keep the ball rolling. The informal lunchtime 
discussions with you about time and project management facilitated me to 
plan my Ph.D. well, and therefore to complete my Ph.D. timely. Mark, there is 
always so much to learn from you, may it be about research or general aspects 
of life. You motivate me to become a better person and a scientist. Your 
contribution to my life and career can be a book in itself. Thank you for 
everything.  
I also feel privileged to work with other leading experts in pain 
research during my Ph.D., whom I should thank for providing richness in my 
research experience. I would like to extend my special thanks to Dr. Amanda 
ACKNOWLEDGEMENTS 
iv 
c de Williams for tireless support during the conduct and writing of the 
systematic review and Prof. Andrew Briggs for helping me learn about health 
system strengthening approaches.  
I would also like to thank other important persons who I worked with 
during the Ph.D. who contributed to my Ph.D. studies Dr. M. Alexandra F. 
Valente, Dr. Darren Reed, Prof. Lorimer Moseley, Dr. Adrian Traeger, Dr. 
David Butler, Tim Cocks, Anupa Pathak, Joshna Palanchoke, Riju Maharjan, 
Soniya Maharjan, and Bandana Gautam. I would also like to thank the 
developers of the instruments (Prof. Paul Stratford, Prof. Michael Sullivan, 
and Dr. Jonathan Davidson) who granted permission to translate the 
instruments they developed into Nepali as part of this Ph.D. 
I would also like to thank my team members: Aroha Meikle, Ruth 
Mullenger, Jason Chua, Dr. Ross Wilson, Dr. Yana Pryymachenko, Dr. David 
Gwynne-Jones, and Anupa Pathak for being extremely supportive and 
making the work environment both fun and peaceful. Aroha’s big warm 
greetings and Jason’s charming personality always made my day. Thank you, 
Ross, for teaching us how to use ‘R’ and for helping me out even during very 
short notice. I am also thankful to Dr. Mark Thompson-Fawcett for extending 
positive support and approving all my travel requests (and timely). I should 
also thank Prof. Leigh Hale and Dr. Dan Ribeiro for not just providing me 
part-time employments but also for improving my psychological well-being. 
Leigh, thank you for your incredible kindness and trust.   
Various departments and persons at the University of Otago have been 
helpful to me and have supported me during my Ph.D. who taught me better 
ways to do things: librarians (Richard German, Thelma Fisher), IT support, 
and HEDC staff (especially Clinton Golding for tips on good writing habits).   
I should also thank all my study participants who extended a generous 
amount of time in this study, and without whom research would not have 
been possible. The sacrifice of their time has probably not gone wasted and 
that many people with pain such as them will benefit from the assessment 
and treatment programme developed during this Ph.D. I should also thank 
ACKNOWLEDGEMENTS 
v 
Sahara Care Hospital for allowing me to use their office space and recruit 
patients for the feasibility trial.   
I am indebted to the organisations that provided me financial support 
during this PhD which enabled me to conduct the studies and disseminate the 
results. First, thank you University of Otago Doctoral Scholarship for 
providing me with a scholarship and stipend to pursue this Ph.D. Thank you, 
Department of Surgical Sciences for supporting my travels to Nepal and other 
costs related to data collection. I should also thank other organisations for 
supporting my travel (and sometimes accommodation) to present my 
research in one national and 12 international conferences during my Ph.D. 
The funding bodies that provided me with travel grants are University of 
Otago, Pain Otago Research Theme, Global Challenge Research Funds 
(GCRF) of the University of Dundee (and collaborators: Prof. Lesley Colvin, 
Prof. Blair Smith, Prof. Timothy Hales, and Prof. Paul Cameron), the 
International Association for the Study of Pain (IASP), Pain, Mind, and 
Movement Special Interest Group of the IASP, World Confederation for 
Physical Therapy (WCPT), International Network of Physiotherapy 
Regulatory Authorities (INPTRA), North American Pain School (NAPS), and 
Maurice and Phyllis Paykel Travel (MPPT) Grant. Thank you very much! 
I am grateful to have a very supportive family who makes my life 
worth living: Mom, Sweekriti, Dipendra, Binita aunty, Subas dai, and Anupa. 
Thank you for your unconditional love and support during good and bad 
times. Anupa, thank you for being a support pillar. Without you, completing 
this Ph.D. would have been impossible. Finally, thank you all my friends, 
extended family members, and all my well-wishers living across the globe for 
your kind encouragement throughout the Ph.D. journey and making this 





TABLE OF CONTENTS 
 
ABSTRACT ......................................................................................................... i 
ACKNOWLEDGEMENTS .............................................................................. iii 
TABLE OF CONTENTS ................................................................................. vii 
GRANTS AND RESEARCH OUTPUTS ..................................................... xvi 
Awards and grants ..................................................................................... xvi 
Manuscripts included in this PhD .......................................................... xvii 
Other research output during PhD ....................................................... xviii 
Manuscripts under review ........................................................................ xix 
Conference presentations ........................................................................... xx 
Invited presentations and podcasts ........................................................ xxii 
LIST OF ABBREVIATIONS ........................................................................ xxiii 
LIST OF FIGURES ......................................................................................... xxv 
LIST OF TABLES .......................................................................................... xxvi 
PREFACE ...................................................................................................... xxix 
HOW TO NAVIGATE THIS THESIS? ...................................................... xxxi 
Chapter 1 : INTRODUCTION ......................................................................... 1 
Musculoskeletal pain .................................................................................... 2 
Chronic pain ................................................................................................... 3 
The global burden of pain ............................................................................ 4 
Prevalence of pain................................................................................................ 5 
The cost of pain .................................................................................................... 8 
Overview of Nepal ........................................................................................ 9 
Ethnic groups and languages ............................................................................. 9 
Occupation and economy ................................................................................... 9 
Nepalese healthcare system ............................................................................... 9 
TABLE OF CONTENTS 
viii 
Pain in Nepal ...................................................................................................... 10 
Summary of the burden of pain ................................................................ 12 
The biopsychosocial model of pain .......................................................... 12 
Assessment of pain...................................................................................... 13 
Treatment of pain ........................................................................................ 16 
Statement of the problem ........................................................................... 18 
Aims of the thesis ........................................................................................ 19 
Summary ...................................................................................................... 20 
Chapter 2 : PAIN RESEARCH IN NEPAL .................................................. 22 
INTRODUCTION ........................................................................................ 22 
METHODS ................................................................................................... 23 
Study eligibility criteria .................................................................................... 24 
Search strategy ................................................................................................... 24 
Data screening .................................................................................................... 24 
Data charting process ........................................................................................ 25 
Data items ........................................................................................................... 25 
Synthesis of results ............................................................................................ 25 
RESULTS....................................................................................................... 26 
Search results ...................................................................................................... 26 
Characteristics of sources of evidence ............................................................ 27 
Study participant characteristics ..................................................................... 28 
DISCUSSION ............................................................................................... 37 
Areas of research redundancy in current pain research in Nepal .............. 37 
Knowledge gaps ................................................................................................ 38 
Recommendations for research ....................................................................... 39 
Recommendations for practice ........................................................................ 40 
Study strengths and limitations ....................................................................... 40 
CONCLUSIONS .......................................................................................... 41 
TABLE OF CONTENTS 
ix 
Chapter 3 : BETWEEN-COUNTRY AND -LANGUAGE DIFFERENCES IN 
CHRONIC PAIN ............................................................................................. 42 
INTRODUCTION ........................................................................................ 42 
METHODS ................................................................................................... 44 
Review protocol and registration .................................................................... 44 
Eligibility criteria ............................................................................................... 45 
Information sources and search strategies ..................................................... 45 
Domains of interest ........................................................................................... 46 
Study selection and data management ........................................................... 49 
Data extraction ................................................................................................... 49 
Quality assessment ............................................................................................ 50 
Data analysis plan .............................................................................................. 51 
Addressing missing data .................................................................................. 53 
RESULTS....................................................................................................... 53 
Description of the included studies ................................................................ 54 
Participants ......................................................................................................... 59 
The methodological quality of studies ........................................................... 59 
Deviation from the original study protocol ................................................... 60 
Differences in pain-related beliefs ................................................................... 62 
Differences in pain-related coping .................................................................. 65 
Differences in pain catastrophizing ................................................................ 66 
DISCUSSION ............................................................................................... 71 
Differences in pain-related beliefs ................................................................... 71 
Differences in pain-related coping .................................................................. 72 
Differences in pain catastrophizing ................................................................ 73 
Research recommendations ............................................................................. 73 
Limitations .......................................................................................................... 75 
CONCLUSIONS .......................................................................................... 76 
Chapter 4 : TRANSLATION AND MEASUREMENT PROPERTIES ..... 79 
TABLE OF CONTENTS 
x 
Patient-reported outcome measures (PROMs) ....................................... 79 
How are PROMs developed? .................................................................... 79 
Translation of a PROMs into a target language ...................................... 81 
Measurement properties ............................................................................ 82 
Reliability ............................................................................................................ 84 
Measurement error ............................................................................................ 85 
Validity ................................................................................................................ 86 
Responsiveness .................................................................................................. 87 
The need for the translation and adaptation studies ............................. 88 
Summary ...................................................................................................... 88 
Chapter 5 : The NUMERICAL PAIN RATING SCALE AND The GLOBAL 
RATING OF CHANGE .................................................................................. 91 
INTRODUCTION ........................................................................................ 91 
METHODS ................................................................................................... 93 
Participants ......................................................................................................... 93 
Phase 1: The translation process ...................................................................... 94 
Phase 2: NPRS-NP measurement testing procedure .................................... 96 
Data analysis....................................................................................................... 96 
RESULTS....................................................................................................... 99 
Phase 1: Translation and cross-cultural adaptation ...................................... 99 
Phase 2: Measurement properties of the NPRS-NP .................................... 100 
DISCUSSION ............................................................................................. 106 
Translation and cross-cultural adaptation ................................................... 106 
Reliability .......................................................................................................... 107 
Validity .............................................................................................................. 108 
Responsiveness ................................................................................................ 109 
Strengths and Limitations .............................................................................. 110 
CONCLUSIONS ........................................................................................ 112 
Chapter 6 : THE PATIENT-SPECIFIC FUNCTIONAL SCALE ............. 113 
TABLE OF CONTENTS 
xi 
INTRODUCTION ...................................................................................... 113 
METHODS ................................................................................................. 114 
Phase 1: Translation of PSFS .................................................................... 114 
Phase 2: Assessment of measurement properties ................................. 116 
Participants and settings ................................................................................. 116 
Measures ........................................................................................................... 116 
Procedures ........................................................................................................ 118 
Reliability .......................................................................................................... 119 
Validity .............................................................................................................. 120 
Responsiveness ................................................................................................ 120 
RESULTS..................................................................................................... 121 
Reliability .......................................................................................................... 123 
Construct validity ............................................................................................ 123 
Responsiveness ................................................................................................ 124 
DISCUSSION ............................................................................................. 125 
Reliability .......................................................................................................... 125 
Construct validity ............................................................................................ 126 
Responsiveness ................................................................................................ 127 
Minimum important change .......................................................................... 127 
Strengths and limitatations ............................................................................ 127 
CONCLUSIONS ........................................................................................ 128 
Chapter 7 : THE PAIN CATASTROPHIZING SCALE ........................... 130 
INTRODUCTION ...................................................................................... 130 
METHODS ................................................................................................. 131 
Translation procedure ..................................................................................... 132 
Participants ....................................................................................................... 135 
Measures ........................................................................................................... 135 
Statistical analyses ........................................................................................... 137 
RESULTS..................................................................................................... 139 
TABLE OF CONTENTS 
xii 
Demographic characteristics .......................................................................... 140 
Factor analyses ................................................................................................. 141 
Reliability .......................................................................................................... 144 
Validity .............................................................................................................. 146 
DISCUSSION ............................................................................................. 147 
Factor analysis .................................................................................................. 147 
Reliability .......................................................................................................... 148 
Measurement error .......................................................................................... 149 
Validity .............................................................................................................. 151 
Strengths and limitations ................................................................................ 151 
CONCLUSIONS ........................................................................................ 152 
Chapter 8 : THE CONNOR DAVIDSON RESILIENCE SCALE ............ 153 
INTRODUCTION ...................................................................................... 153 
METHODS ................................................................................................. 155 
Translation procedures ................................................................................... 155 
Evaluation of measurement properties ........................................................ 156 
Participants ....................................................................................................... 157 
Measures ........................................................................................................... 158 
Data analysis..................................................................................................... 160 
RESULTS..................................................................................................... 162 
Translation of CD-RISC-10 into Nepali ........................................................ 162 
CD-RISC Scores ................................................................................................ 163 
Handling missing items .................................................................................. 163 
Demographic characteristics .......................................................................... 163 
Factor analyses results .................................................................................... 165 
Reliability .......................................................................................................... 166 
Validity .............................................................................................................. 169 
DISCUSSION ............................................................................................. 169 
Factor analyses ................................................................................................. 170 
TABLE OF CONTENTS 
xiii 
Reliability .......................................................................................................... 170 
Validity .............................................................................................................. 171 
Strengths and limitations ................................................................................ 172 
CONCLUSIONS ........................................................................................ 174 
Chapter 9 : THE PEN-LBP FEASIBILITY TRIAL ..................................... 175 
INTRODUCTION ...................................................................................... 175 
Interventions for the management of low back pain.................................. 176 
Pain education for low back pain .................................................................. 176 
METHODS ................................................................................................. 178 
Study Design and setting ................................................................................ 178 
Overview of the study .................................................................................... 179 
Development of pain education in Nepali ................................................... 181 
Participants ....................................................................................................... 182 
Participant screening and recruitment ......................................................... 184 
Group Allocation, Randomisation, and Blinding ....................................... 184 
Interventions ..................................................................................................... 185 
Outcome Measures .......................................................................................... 188 
Criteria for feasibility ...................................................................................... 197 
Statistical methods ........................................................................................... 199 
RESULTS..................................................................................................... 200 
Sample characteristics ..................................................................................... 200 
Missing data ..................................................................................................... 202 
Primary (feasibility) outcomes ....................................................................... 202 
Other findings .................................................................................................. 210 
DISCUSSION ............................................................................................. 210 
Primary feasibility outcomes ................................................................... 210 
Secondary outcomes ................................................................................. 213 
Recommendations ..................................................................................... 213 
Strengths and limitations ......................................................................... 214 
TABLE OF CONTENTS 
xiv 
Summary and conclusions ....................................................................... 216 
Chapter 10 : GENERAL DISCUSSION AND CONCLUSIONS ............. 217 
State of pain research in Nepal ................................................................ 218 
Potential facilitators to pain research in Nepal ........................................... 219 
Barriers to pain research in developing countries ...................................... 219 
Strategies to facilitate pain research .............................................................. 219 
Strategies to uptake pain knowledge ............................................................ 221 
Culture and pain ........................................................................................ 221 
Outcome measures .................................................................................... 223 
Pain education ........................................................................................... 224 
PEN-LBP feasibility trial .......................................................................... 224 
Strategies used in the feasibility trial that worked ..................................... 225 
Implications of the thesis .......................................................................... 226 
Policy implications .......................................................................................... 226 
Research implications ..................................................................................... 228 
Clinical implications ........................................................................................ 229 
Overall significance ................................................................................... 229 
Recommendations ..................................................................................... 230 
Overall strengths and limitations ........................................................... 231 
Strengths ........................................................................................................... 231 
Limitations ........................................................................................................ 231 
Conclusions ................................................................................................ 233 
APPENDICES ................................................................................................ 235 
Appendix 1 Search strategies used for the scoping review ................ 235 
Appendix 2. Results of scoping review .................................................. 238 
Appendix 2.1. Evidence on medical management...................................... 238 
Appendix 2.2. Evidence on surgical management...................................... 255 
Appendix 2. 3. Rehabilitation. ....................................................................... 258 
TABLE OF CONTENTS 
xv 
Appendix 2.4. Prevalence and incidence of pain conditions..................... 259 
Appendix 2.5. Studies on outcome measurement. ..................................... 265 
Appendix 2.6. Studies on diagnosis and imaging. ..................................... 268 
Appendix 3. Search strategy used for the systematic review. ............ 272 
Appendix 4. Nepali Numerical Pain Rating Scale ................................ 273 
Appendix 5. Nepali Global Rating of Change ...................................... 274 
Appendix 6. Nepali Patient-Specific Functional Scale ......................... 275 
Appendix 7. Pain education curriculum for Nepalese with non-specific low 
back pain. .................................................................................................... 276 
Appendix 8. Ethics Approval letters ...................................................... 282 
Appendix 9.   Participant information sheets ........................................ 288 
Appendix 10. Consent forms ................................................................... 292 
REFERENCES ................................................................................................ 295 





GRANTS AND RESEARCH OUTPUTS  
 
Awards and grants  
1. Maurice and Phyllis Paykel Travel Grant to attend Back and Neck Pain Forum 
to present a paper, 3 – 6 July, 2019 [NZ$ 1000 towards travel support and 
registration] 
2. Global Challenges Research Fund (x2) from the University of Dundee to 
collaborate on chronic (neuropathic and non-neuropathic) pain research in 
Nepal; 2018 – 2019 [total award: GBP 21,500] 
3. The North American Pain School (NAPS) Scholarship to attend the NAPS Pain 
Research Training in Montebello, Quebec, Canada; 23 – 28 June 2019 [Can$ 1500 
towards travel support and registration with free accommodation].  
4. The Pain, Mind, and Movement Special Interest Group of International 
Association for the Study of Pain travel grant to attend and present at Pain 
Science in Motion Conference on 1 – 2 June, 2019, in Savona, Italy [US$1000]  
5. The Pain@Otago Research Theme Conference Travel Grant to attend Pain 
Science and Motion Conference from 31 May – 2 June, 2019 in Savona, Italy 
[NZ$1000 towards travel and accommodation support] 
6. The University of Otago Conference Travel Support Grant to attend the World 
Confederation for Physical Therapy in Geneva, Switzerland from 10 – 13 May, 
2019 [NZ$2000 towards travel, registration and accommodation support] 
7. The International Association for the Study of Pain (IASP) to attend IASP Pain 
Conference in Boston, USA from 12 – 16 September, 2018 [US$ 1,600 and 
registration waiver]  
8. The World Confederation for Physical Therapy (WCPT) to attend and present 
papers at WCPT Congress 2017 in Cape Town from 2 – 4 July, 2017 [US$ 950 and 
registration waiver]. 
9. The International Federation of Physiotherapy Regulator Authorities 
(INPTRA) to deliver a talk at INPTRA conference on 30th June and 1st July 2017 in 
Cape Town, South Africa [US$ 2,500 and registration waiver].  
GRANTS AND RESEARCH OUTPUTS 
xvii 
Manuscripts included in this PhD 
1. Sharma, S., Palanchoke, J., Reed, D., & Abbott, J.H. (2017). Translation, cross-
cultural adaptation and psychometric properties of the Nepali versions of 
numerical pain rating scale and global rating of change. Health and Quality of Life 
Outcomes, 15(1). http://dx.doi.org/10.1186/s12955-017-0812-8  
2. Sharma, S., Palanchoke, J., & Abbott, J. H. (2018). Cross-cultural Adaptation and 
Validation of the Nepali Translation of the Patient-Specific Functional Scale. J 
Orthop Sports Phys Ther, 48(8), 659-664. doi:10.2519/jospt.2018.7925 
3. Sharma, S., Thibault, P., Abbott, J. H., & Jensen, M. P. (2018). Clinimetric 
properties of the Nepali version of the Pain Catastrophizing Scale in individuals 
with chronic pain. Journal of Pain Research, 2018, 265-276. 
https://doi.org/10.2147/JPR.S153061 
4. Sharma, S., Abbott, J. H., Pathak, A., Jensen, M.P. (2018). Psychometric 
properties of the Nepali version of the Connor Davidson Resilience Scales in 
individuals with chronic pain. Health and Quality of Life Outcomes, 16(56). 
https://doi.org/10.1186/s12955-018-0884-0 
5. Sharma, S., Jensen, M.P., Moseley, G.L., Abbott, J. H. (2018). Pain Education for 
patients with non-specific low back pain in Nepal: Protocol of a feasibility 
randomized clinical trial (PEN-LBP Trial). BMJ Open, 8(8), e022423.  
6. Sharma, S., Jensen, M. P., Moseley, G. L., & Abbott, J. H. (2019). Results of a 
feasibility randomised clinical trial on pain education for low back pain in 
Nepal: the Pain Education in Nepal-Low Back Pain (PEN-LBP) feasibility trial. 
BMJ Open, 9(3), e026874. doi:10.1136/bmjopen-2018-026874 
http://dx.doi.org/10.1136/bmjopen-2018-022423 
7. Sharma, S., Jensen, M. P., Pathak, A., Sharma, S., Pokharel, M., & Abbott, J. H. 
(2019). State of clinical pain research in Nepal: a systematic scoping review. Pain 
Reports, 4(6), e788. doi:10.1097/pr9.0000000000000788 
8. Sharma, S. †, Ferreira-Valente, A. †, Williams, A.C., Abbott, J.H., Pais-Ribeiro, J., 
Jensen, M.P. (2019). Between-country and between-language differences in pain-
related beliefs, coping, and catastrophizing: A systematic review. Pain Medicine. 
Doi:10.1093/pm/pnz373. († Both the authors contributed equally) 
 
GRANTS AND RESEARCH OUTPUTS 
xviii 
9. Sharma, S., Abbott, J. H., & Jensen, M. P. (2018). Why clinicians should consider 
the role of culture in chronic pain. Braz J Phys Ther, 22(5), 345-346. 
doi:10.1016/j.bjpt.2018.07.002 
10. Sharma, S., Blyth, F. M., Mishra, S. R., & Briggs, A. M. (2019). Health system 
strengthening is needed to respond to the burden of pain in low-and middle-
income countries and to support healthy ageing. Journal of Global Health, 9(2). 
doi: 10.7189/jogh.09.020317 
Other research output during PhD 
11. Croft P, Sharma S, Foster NE: Primary care for low back pain: we don't know 
the half of it. Pain 2020, 161(4):663-665. 
12. Lim WS, Sharma S, Devan H: Physiotherapists’ attitudes towards and 
challenges of working in a referral-based practice setting – a systematic scoping 
review. European Journal of Physiotherapy 2020:1-12. 
13. Pathak, A., Sharma, S., & Jensen, M. P. (2020). Hypnosis for clinical pain 
management: A scoping review of systematic reviews. OBM Integrative and 
Complementary Medicine 2020;5(1):27. 
14. Sharma, S., & Jensen, M. P. (2019). Cross-cultural adaptations of patient-
reported outcome measures can be very useful. Ann Phys Rehabil Med. 
doi:10.1016/j.rehab.2019.09.012 
15. Nepal, G. M., Basaula, M., & Sharma, S. (2019). Inter-rater reliability of Timed 
Up and Go test in older adults measured by physiotherapists and caregivers. Eur 
J Physiother, 1-7. doi:10.1080/21679169.2019.1623313  
16. Kc, S., Sharma, S. ‡, Ginn, K., Almadi, T., & Reed, D. (2019). Nepali translation, 
cross-cultural adaptation and measurement properties of the Shoulder Pain and 
Disability Index (SPADI). J Orthop Surg Res, 14(1), 284. doi:10.1186/s13018-019-
1285-8 (‡ Corresponding author) 
17. Kc, S., Sharma, S. ‡, Ginn, K., Almadi, T., & Reed, D. (2019). Nepali translation, 
cross-cultural adaptation and measurement properties of the Shoulder Pain and 
Disability Index (SPADI). J Orthop Surg Res, 14(1), 284. doi:10.1186/s13018-019-
1285-8 (‡Corresponding author) 
18. Ferreira-Valente, A. †, Sharma, S. †, Torres, S., Smothers, Z., Pais-Ribeiro, J., 
Abbott, J. H., & Jensen, M. P. (2019). Does Religiosity/Spirituality Play a Role in 
GRANTS AND RESEARCH OUTPUTS 
xix 
Function, Pain-Related Beliefs, and Coping in Patients with Chronic Pain? A 
Systematic Review. J Relig Health. doi:10.1007/s10943-019-00914-7 († Both the 
authors contributed equally) 
19. Ribeiro, D. C., Abbott, J. H., Sharma, S., & Lamb, S. E. (2019). Process evaluation 
of complex interventions tested in randomised controlled trials in 
musculoskeletal disorders: a systematic review protocol. BMJ Open, 9(5), 
e028160. doi:10.1136/bmjopen-2018-028160  
20. Sharma, S., Traeger, A.C., Mishra, S.R., Sharma, S., Maher, C.G. (2019). 
Delivering the right care to people with low back pain in low- and middle-
income countries: the case of Nepal. Journal of Global Health. 9(1): 010304. doi: 
10.7189/jogh.09.010304. 
21. Brown, P., Consortium, R. (…Sharma, S…..), & Zhou, Y. (2019). Large expert-
curated database for benchmarking document similarity detection in biomedical 
literature search. Database, 2019, baz085, doi:10.1093/database/baz085 
22. Sharma, S., Pathak, A., Jha, J., & Jensen, M. P. (2018). Socioeconomic factors, 
psychological factors, and function in adults with chronic musculoskeletal pain 
from rural Nepal. Journal of Pain Research, 11, 2385. doi:10.2147/JPR.S173851 
23. Pathak, A., Sharma, S., Jensen, M.P. (2018). The Utility and Validity of Pain 
Intensity Rating Scales for use in Developing Countries. Pain Reports. PR9 00 
(2018) e672 http://dx.doi.org/10.1097/PR9.0000000000000672  
Manuscripts under review 
24. Sharma, S., Jha, J., Pathak, A., & Neblett, R. Translation, cross-cultural 
adaptation, and measurement properties of the Nepali version of the Central 
Sensitization Inventory (CSI).   
25. KC, S., Sharma, S., Almadi, T., Ginn, K., Reed, D. Measurement properties of the 
translated versions of the Shoulder Pain and Disability Index (SPADI): a 
systematic review. Clinical Rehabilitation. 
26. Pathak, A., Sharma, S., & Jensen, M. P. Hypnosis for clinical pain management: 
A scoping review of systematic reviews.  
27. Lewis, J. S., Stokes, E. K., Gojanovic, B., Gellatly, P., Mbada, C., Sharma, S., 
Diener, I., Sullivan, P. O. Reframing how we care for people with persistent non-
GRANTS AND RESEARCH OUTPUTS 
xx 
traumatic musculoskeletal pain. From editorial to (the start of) action. J Orthop 
Sports Phys Ther.  
Conference presentations 
1. Oral presentation on “Cultural differences in pain-related beliefs, coping, and 
catastrophizing in chronic pain:  A systematic review”, at Transform 2019: 
Conference of Australian Physiotherapy Association at Adelaide Convention Centre, 
Adelaide, Australia held on 17 – 19 October 2019.  
2. Oral presentation on “State of clinical pain research in Nepal:   
A systematic scoping review”, at Transform 2019: Conference of Australian 
Physiotherapy Association at Adelaide Convention Centre, Adelaide, Australia held 
on 17 – 19 October 2019.  
3. Oral presentation on “Development and testing of patient education package for 
patients with low back pain in Nepal: PEN-LBP feasibility trial” at International 
Forum on Back and Neck Pain Research in Primary Care at Quebec City Convention 
Center, Quebec City, Canada held on 2 – 6 July 2019. 
4. Oral presentation on “Pain in the top of the world” presented at North American 
Pain School training at Montebello, Quebec, Canada, held on 24 – 28 June 2019.  
5. Oral presentation on “Pain education for patients with low back pain in Nepal: 
Results from PEN-LBP feasibility clinical trial” at Pain Science in Motion Conference 
at the University of Genoa in Savona, Italy held on 31 May – 2 June 2019. Abstract 
published in Pain Reports: May/June 2019 - Volume 4 - Issue 3 - p e753; doi: 
10.1097/PR9.0000000000000753 
6. Indaba session presentation on “Starting a physiotherapy/pain research centre 
in Nepal” at World Confederation for Physical Therapy Conference in Geneva, 
Switzerland, held on 11 – 13 May 2019. 
7. Oral presentation on “Development and testing of pain education resources in 
Nepali” at World Confederation for Physical Therapy Conference in Geneva, 
Switzerland, held on 11 – 13 May 2019. 
8. Seminar presentation on “Reframing the care for musculoskeletal pain” at World 
Confederation for Physical Therapy Conference in Geneva, Switzerland, held on 11 – 
13 May 2019. 
GRANTS AND RESEARCH OUTPUTS 
xxi 
9. Oral Presentation on “Randomized clinical trial evaluating the effectiveness of 
patient education for low back pain in Nepal is feasible: The PEN-LBP trial”; 
presented at the New Zealand Pain Society Conference at Rydges Latimer Hotel, 
Christchurch, New Zealand, on 9th March 2019. 
10. Oral presentation on “The role of culture in pain-related beliefs, coping, and 
catastrophizing: a systematic review”; presented at Pain@Otago Early Career 
Researcher networking event on 19th November 2019, Pain Research Theme of 
University of Otago, School of Physiotherapy, Dunedin, New Zealand.   
11. Poster presentation on “Responsiveness and minimum important change of the 
Pain Catastrophizing Scale and Connor Davidson Resilience Scales in individuals 
with chronic pain”; presented at International Association for the Study of Pain 
Congress on 15th September 2018, Boston Convention and Exhibition Centre, 
Boston, MA, USA. 
12. Ph.D student speaker award presentation - “A randomized clinical trial 
evaluating the effectiveness of pain education for low back pain in Nepal is 
feasible: The PEN-LBP trial”. Otago Medical School Research Society Conference, 
University of Otago, Dunedin, New Zealand, 22nd August 2018.  
13. Twitter Presentation on “Understanding pain… can cure pain…”, Dunedin School 
of Medicine TWittEr CONference (#DSMTweCon) –Dunedin School of Medicine, 
University of Otago, Dunedin, New Zealand, 26th July 2018.  
14. Oral presentation on “Understanding pain… can cure pain…” Three Minute 
Thesis competition, University of Otago, Dunedin, New Zealand, 20th July 2018  
15. Poster presentation on “Psychometric properties of Nepali versions of the 
Connor Davidson Resilience Scales and the Pain Catastrophising Scale in 
individuals with chronic pain,” Anaheim, California, USA, 4th – 6th March 2018. 
Abstract published in the Journal of Pain. Vol. 19, Issue 3, S59.  
DOI: https://doi.org/10.1016/j.jpain.2017.12.150. 
16. Poster presentation on “Psychometric properties of Nepali versions of PROMIS 
short-form measures of pain intensity, pain interference, pain behavior, 
depression and sleep disturbance,” Anaheim, California, USA, 4th – 6th March 
2018. Abstract published in the Journal of Pain. Vol. 19, Issue 3, S59. 
DOI: https://doi.org/10.1016/j.jpain.2017.12.152.  
17. Rapid five oral presentation on “Pain catastrophizing and resilience as 
predictors of psychological and physical function in individuals with chronic 
GRANTS AND RESEARCH OUTPUTS 
xxii 
musculoskeletal pain” at World Confederation for Physical Therapy Congress in Cape 
Town International Convention Centre, Cape Town, South Africa on 4th July 
2017.  
18. Seminar presentation on “Outcome measures” at World Confederation for Physical 
Therapy Congress in Cape Town International Convention Centre, Cape Town, 
South Africa on 2nd July 2017.   
Invited presentations and podcasts 
1. Invited presentation – talk on “Translating evidence into practice” for health 
professionals in Bangladesh, organised by Humanity and Inclusion, Bangladesh.  
14th May, 2020.  
2. Podcast on “Facilitating high-value care in low- and middle-income countries” 
for Healing Pain Podcast with Dr. Joe Tatta, on 19th November 2019.  
3. “Pain in Nepal”, presented at Grand Round of University of Dundee, Dundee, 
Scotland, on 24th May 2019.  
4.  “Current Update on Low back pain” at 9th International Conference of Nepal 
Physiotherapy Association, on 30 November 2018.  
5. “Pain in Nepal” presented at Pain, Mind, and Movement SIG business meeting at 
The International Association for the Study of Pain Congress on 15th September 2018, 
Boston Convention and Exhibition Centre, Boston, MA, USA.   
6. Podcast on “Evidence-based physiotherapy in Nepal” for Global Health Division of 
Physiotherapy Association of Canada on Evidence-based practice in Nepal on 12th 
December 2017. http://globalphysio.ca/gp013-evidence-based-practice-with-
saurab-sharma/ 
7. “Regulation of Physiotherapy in Nepal” presented at International Network of 
Physiotherapy Regulatory Authorities Conference on 30th June 2017 in African Pride 
15 on Orange Hotel, Cape Town, South Africa. 
 
 
LIST OF ABBREVIATIONS 
AUC  Area Under the Curve 
BAI Beck Anxiety Inventory 
BDI Beck Depression Inventory  
CD-RISC-2 2-item Connor-Davidson Resilience Scale  
CD-RISC-10  2-item Connor-Davidson Resilience Scale  
CD-RISC-2-NP  Nepali version of 2-item Connor-Davidson Resilience Scale  
CD-RISC-10-NP  Nepali version of the 10-item Connor-Davidson Resilience 
Scale  
CFA Confirmatory Factor Analysis 
CFI Comparative Fit Index 
CI  Confidence Interval 
COS Core Outcome Set 
COSMIN  COnsensus Based Standards for the selection of health 
Measurement INstruments 
CPCI  Chronic Pain Coping Inventory 
CSQ  Coping Strategies Questionnaire 
FABQ  Fear-Avoidance Beliefs Questionnaire 
EFA Exploratory Factor Analysis 
GRoC Global Rating of Change 
GRoC-NP  Nepali version of Global Rating of Change 
HICs High-income countries; 
IASP  International Association for the Study of Pain 
ICC  Intraclass Correlation Coefficient 
IMMPACT  Initiative on Methods, Measurement, and Pain Assessment 
in Clinical Trials  
IPQ-R Illness Perception Questionnaire - Revised 
LBP  Low back pain 
LBPBQ  Low Back Pain Beliefs Questionnaire 
LIST OF ABBREVIATIONS 
xxiv 
LMIC  Low middle-income country 
MSK Musculoskeletal 
MIC  Minimum Important Change 
NPRS  Numerical Pain Rating Scale  
NPRS-NP  Nepali version of the Numerical Pain Rating Scale 
PCS Pain Catastrophizing Scale 
PCS-NP  Nepali version of the Pain Catastrophizing Scale 
PEN-LBP Trial Pain Education for Low Back Pain in Nepal Trial  
PGFI Parsimony Goodness-of-Fit Index  
PROMs Patient-Reported Outcome Measures 
PROMIS Patient-Reported Outcome Measurement Information 
System 
PRSS  Pain-Related Self-Statements Scale 
PSEQ Pain Self-Efficacy Questionnaire 
RMSEA Root Mean Squared Error of Approximation  
ROC  Receiver Operating Characteristic  
SD  Standard Deviation 
SDC  Smallest Detectable Change 
SDC90  Smallest Detectable Change at 90% confidence margin 
SDC95  Smallest Detectable Change at 95% confidence margin 
SEM Standard Error of Measurement 
SOPA Survey of Pain Attitudes 
SPSS Statistical Software for Social Sciences 
TSK Tampa Scale for Kinesiophobia 
UMIC  Upper middle-income country 
 
 
LIST OF FIGURES 
Figure 1.1 Years lived with disability (Global, both sexes, all ages, YLDs per 
100,000) ......................................................................................................................... 5 
Figure 1.2 Years lived with disability in Nepal (Both sexes, all ages, YLDs per 
100,000) ....................................................................................................................... 11 
Figure 1.3 The proportion of biopsychosocial contribution to pain is different 
for two individuals with pain ................................................................................. 13 
Figure 2.1  PRISMA flow diagram .......................................................................... 26 
Figure 2.2 The number of publications in the past 8 years. ................................ 27 
Figure 2.3 Scope of pain research in Nepal. .......................................................... 30 
Figure 3.1 PRISMA flow diagram ........................................................................... 54 
Figure 4.1 COSMIN taxonomy ................................................................................ 83 
Figure 5.1 Bland-Altman Plot for the Nepali Numerical Pain Rating Scale. .. 103 
Figure 5.2 Receiver operating characteristic (ROC) curves. ............................. 105 
Figure 6.1 Translation history ............................................................................... 115 
Figure 6.2 Bland Altman Plot for Nepali Patient-Specific Functional Scale. .. 123 
Figure 6.3 Receiver Operating Characteristic (ROC) curves. ........................... 124 
Figure 7.1 Translation history. .............................................................................. 134 
Figure 7.2 Path diagram after CFAs, two-factor model and one-factor model 
with adjustment for the covariance of error terms in CFA sample (N=272). . 143 
Figure 7.3 Bland-Altman Plots. ............................................................................. 145 
Figure 8.1 Translation history. .............................................................................. 156 
Figure 8.2 Key cross-cultural adaptation of the Nepali CD-RISC-10 items .... 162 
Figure 8.3 Path diagram after confirmatory factor analysis of CD-RISC-10 and 
covariance of error terms. ...................................................................................... 166 
Figure 8.4 Bland-Altman Plots. ............................................................................. 168 
Figure 9.1 Steps in the development of pain education handbook ................. 182 
Figure 9.2 Participant flow. .................................................................................... 205 
 
xxvi 
LIST OF TABLES 
Table 1.1 The global prevalence of chronic pain .................................................... 7 
Table 1.2 Recommended domains for the assessment of pain ........................... 15 
Table 2.1 Characteristics of sources of evidence ................................................... 29 
Table 2.2 Prevalence of pain conditions in Nepal ................................................ 32 
Table 3.1 Characteristics of included studies ........................................................ 56 
Table 3.2 Methodological quality of included studies. ........................................ 61 
Table 3.3 Standardized mean differences in pain beliefs across countries and 
languages. ................................................................................................................... 63 
Table 3.4 Standardized mean differences in pain coping across countries. ..... 67 
Table 3.5 Standardized mean differences in pain catastrophizing across 
countries and languages. ......................................................................................... 70 
Table 5.1 Description of the participants with scores of the Numerical Pain 
Rating Scale and the Global Rating of Change. .................................................. 101 
Table 5.2 Reliability of Nepali- Numerical Pain Rating Scale. ......................... 103 
Table 5.3 Responsiveness of Nepali- Numerical Pain Rating Scale. ................ 106 
Table 6.1 Nepali versions of Patient-Reported Outcome Measures (PROMs) 
used in the Study..................................................................................................... 119 
Table 6.2 Description of the participants. ............................................................ 121 
Table 6.3 Responsiveness of Nepali- Patient Specific Functional Scale. ......... 125 
Table 7.1 Patient-Reported Outcome Measures (PROMs) used....................... 135 
Table 7.2 Description of the study participants. ................................................. 140 
Table 7.3 Pattern matrix after maximum likelihood factor extraction and 
oblimin rotation. ...................................................................................................... 141 
Table 7.4 Results of the confirmatory factor analyses for the Nepalese Pain 
Catastrophizing Scale (PCS-NP) in the CFA sample (N=272). ......................... 143 
Table 7.5 Reliability of the Nepali- Pain Catastrophizing Scale. ...................... 146 
Table 8.1 Description of the study participants and the CD-RISC scores. ..... 164 
Table 8.2 Confirmatory factor analysis of the CD-RISC-10-NP. ...................... 166 
LIST OF TABLES 
xxvii 
Table 8.3 Reliability of the CD-RISC-10-NP and CDRISC-2-NP. ..................... 167 
Table 8.4 Construct validity. .................................................................................. 169 
Table 9.1 Schedule of enrolment, assessment, and interventions. ................... 180 
Table 9.2 Feasibility outcomes. .............................................................................. 190 
Table 9.3 Secondary outcome measures. ............................................................. 195 
Table 9.4 Criteria for feasibility. ............................................................................ 198 
Table 9.5 Baseline characteristics of the two study groups. .............................. 200 
Table 9.6 Feasibility results for the two study groups ....................................... 202 
Table 9.7 Were the feasibility criteria met? ......................................................... 204 





I acquired the inspiration to conduct this thesis work from my clinical 
experience practicing as a musculoskeletal physiotherapist in a tertiary care 
hospital serving rural communities of Nepal. I aimed to improve the care of 
patients with musculoskeletal pain and integrate evidence-informed care in 
the management but was challenging. The main reasons were: (1)  outcome 
measures to assess pain and psychosocial domains in Nepali were unavailable 
and (2) delivering evidence-informed interventions such as patient education 
in Nepali was difficult because of cultural and language barriers as all 
educational resources are developed in English for western cultures — very 
different language and culture to Nepali. These two questions also emerged 
as important research areas based on my scoping review of pain research in 
Nepal (see Chapter 2). 
The meaning (and perhaps the effects of the intervention) was lost in 
the translation of materials from English to Nepali. Similarly, some contents 
were not relevant to Nepalese patients because of cultural differences. 
Although I did attempt to deliver education on pain, I was not sure if patients 
benefited from it; because there were also no reliable, valid, and responsive 
measurement instruments in Nepali to track patients’ progress.  
The main reason why I conducted a series of studies as a part of my 
Ph.D. thesis was to address these important clinical challenges with 
overarching primary aims to improve pain assessment, management, and 
research in my country of Nepal.   
 By conducting this thesis, I wished to (1) identify knowledge we have 
on “pain” in Nepal and identify priority research area by comprehensive 
literature search, (2) understand if important cognitive and psychological 
construct important in pain management (pain beliefs, coping, and 
catastrophizing) differ between people living in different countries or 
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speaking different languages, (3) translate, cross-culturally adapt, and 
validate patient-reported outcome measures to assess pain and function (both 
physical and psychological) in Nepali, and (4) develop pain education 
programme for the treatment of low back pain in Nepal.  
This Ph.D. research will help me (and others) to lay the foundation for 
evidence-informed assessment and treatment of pain in Nepal. The 
immediate next step after my Ph.D. is to continue disseminating the thesis 
findings to patients with pain and health professionals treating pain, promote 
evidence-based management of pain conditions to facilitate the 
implementation of outcome measurement in clinical practice. The ultimate 
goal is to influence policy level to utilize contemporary guideline-based care 
for the treatment of pain in Nepal. This thesis will help me get a step closer to 
my aims. The work can be expanded beyond this thesis to develop other 
scales in Nepali that are important to use in patients with pain conditions, 
and adapting the pain education programme to treat other pain populations 
such as paediatric pain, cancer pain, post-operative pain, and chronic pain in 
general. 
I expect to facilitate evidence-based pain assessment and management 
in Nepal. I also hope that my Ph.D. research can serve as a model for 
developing pain assessment and management programme in other 
developing countries like ours in addition to the implications within Nepal.  
The studies conducted as part of this Ph.D. are published in peer-
reviewed journals. Therefore, the contents from the published manuscripts 
are included in the thesis with required modifications to fit the thesis format. 





HOW TO NAVIGATE THIS THESIS? 
The thesis presents ten papers published in international peer-
reviewed journals divided into 10 chapters.  
Chapter 1 provides (1) the overall introduction to the topic area, (2) an 
overview of musculoskeletal pain which was identified as important pain 
problem in Nepal in Chapter 2, which is the focus of this thesis, and (3) why 
musculoskeletal pain is a huge public health problem globally and in Nepal, 
and (4) aims of the thesis.  An overview text is presented at the end of this 
chapter to link with the rest of the thesis. The texts presented in this chapter 
are not published.  
Chapter 2 is a scoping review of literature that captures the current 
state of pain research in Nepal, research gaps, therefore, informing pain 
research needs in Nepal. An original review was conducted in 2014/15 when 
planning the pain research priority agenda in Nepal which informs Chapters 
5 through 9. The search terms and the number of databases were updated in 
November 2018 before submitting the paper for publication, which caused 
papers that are part of Chapters 5 through 9 to be included in this Chapter. 
This is a published paper [1].  
Chapter 3 explores between-country and between-language differences 
in the psychological domains (pain beliefs, coping, and catastrophising) in 
chronic pain using a systematic review method with an aim to inform pain 
education intervention developed in Chapter 9, which largely targets one’s 
pain beliefs, coping strategies, and aims to reduce pain-related concerns (i.e. 
catastrophising). This chapter is also a published manuscript [2].  
Chapter 4 provides an introduction to different terminologies used in 
describing the measurement properties of PROMs with an aim to provide 
clarification of the terms used in the thesis which is a new chapter not yet 
published.  
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Chapters 5 through 8 are four manuscripts that describe the 
translation, cross-cultural adaptation, and assessment of measurement 
properties of five PROMs in Nepali all previously published [3-6]. This was 
informed largely by the scoping review of pain research in Nepal (Chapter 2) 
and my prior experience working as a musculoskeletal physiotherapist in 
Nepal. As the scoping review was updated after these papers were published, 
these papers are included in Chapter 2.  
Chapter 9 consolidates two manuscripts (protocol [7] and final report 
[8]) describing the development of pain education programme for people 
with low back pain in Nepal; and a study assessing the feasibility of 
conducting a definitive clinical trial evaluating the effectiveness of the newly 
developed pain education programme in the Nepalese healthcare system. 
This feasibility study uses some of the outcome measures; development of 
which are described in Chapters 5 to 8.  
Chapters 10 describes the overall discussion, the implications and 
significance of the thesis, overall strengths and limitations, recommendations 
for future studies, and overall conclusions. This section includes some of the 
contents of two papers (an Editorial [9] and a Viewpoint [10]) I wrote which 
are both published. These describe why clinicians should consider the role of 
culture in chronic pain and why system strengthening approaches are needed 
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CHAPTER 1 : INTRODUCTION 
Pain is inevitable, suffering is optional.  
(A Buddhist saying) 
*** 
 
Pain is defined by the International Association for the Study of Pain 
(IASP) as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” [11]. Although this 
definition is 40 years old and in the process of revision, pain has been 
acknowledged to also be “an emotional experience” and not only a result of 
purely biological processes [11]. This key component of pain is often not 
recognised by patients and healthcare professionals, especially in developing 
countries.  
For the ease of studying and understanding pain, it can be classified 
into different types based on, for example, pain mechanism (nociceptive, 
neuropathic, nociplastic, or pain of unknown origin) [12], or the duration of 
pain (acute and chronic pain).  
Nociceptive pain is the pain that is due to the activation of nociceptors 
and arises from actual or threatened damage to nonneural tissue [12]. 
Neuropathic pain, on the other hand, is caused by a lesion or disease of the 
somatosensory nervous system [12]. A newly proposed pain mechanism, 
previously referred to as central sensitization — nociplastic pain — is the pain 
that arises from altered nociception without (1) clear evidence of actual or 
threatened tissue damage, and (2) evidence for disease or lesion of the 
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somatosensory system causing the pain [12]. Pain of unknown origin does not 
meet the criteria for any of the above types.  
Pain can also be classified based on the structures or sites involved, 
such as musculoskeletal pain (low back pain, neck pain), neuropathic pain, 
headache, abdominal pain. Musculoskeletal pain including back pain is a 
common clinical presentation in primary care [13].  
Musculoskeletal pain 
Musculoskeletal pain is one of the most common health conditions. Its 
prevalence ranges from 26% to 91% in different populations [14-18].  The 
highest prevalence is seen among farmers (91%), musicians (up to 90%) [14, 
15, 18], and  elite athletes (up to 70%) [19]. Musculoskeletal pain is reported to 
be the number one cause of disability in all age groups including children and 
older age [20]. It leads to interference with activities of daily living and social 
life and is associated with poorer mental health and quality of life [21-23].  
Musculoskeletal pain is also common in children and adolescents. The 
presence of pain in children is predictive of poor health and pain in adult life 
[24-27]. Musculoskeletal pain is commonly classified based on the site of pain, 
for example, pain in the low back or the neck. Low back pain is the most 
common and burdensome pain conditions, commonly classified under 
musculoskeletal pain.  
Low back pain is a highly prevalent health condition worldwide with 
the single cause of the highest-burden globally [20, 28].  It is the leading cause 
of disability [20] and imposes a huge economic burden, at individual and 
societal levels, both in developed and developing countries [29-31]. For a 
majority (about 90%) of low back pain, pathoanatomical cause of the pain 
(e.g., infection, inflammatory arthritis, or malignancy) cannot be determined. 
It is commonly referred to as non-specific low back pain [28].  
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Chronic pain 
Based on the duration of the onset, pain can also be classified as acute 
or chronic pain. Any pain that lasts for three months or longer is termed as 
“chronic pain” or “persistent pain” [32]. Although immediate onset pain (i.e., 
acute pain) is usually protective because as it may indicate tissue damage (but 
not always), chronic pain is pain that persists beyond the expected time for 
the tissue healing to occur if the inciting event is an injury [32, 33]. As a result, 
it rarely serves the purpose of protection. Chronic pain is considered a disease 
in its own right and not merely a symptom of other conditions [34]. Although 
the majority of people with pain recover rapidly in the first two to six weeks 
[35], a significant proportion of patients do not recover completely. For 
example, 28% of patients with acute low back pain were found not to recover 
completely 1 year after the initial onset of pain in a large multi-centred 
inception cohort study in Australia [36].  
The IASP task force for ICD-11 has classified chronic pain into seven 
different types: (1) chronic primary pain, (2) chronic cancer pain, (3) chronic 
post-surgical and post-traumatic pain, (4) chronic neuropathic pain, (5) 
chronic headache and orofacial pain, (6) chronic visceral pain, and (7) chronic 
musculoskeletal pain [37]. Based on this classification, chronic 
musculoskeletal pain is only reserved for the pain due to nociceptive causes 
of structures of musculoskeletal system i.e. bones, joints, tendons, ligaments. 
Examples of musculoskeletal pain based on this classification are 
osteoarthritis, rheumatoid arthritis, fractures. Nonspecific forms of chronic 
pain such as non-specific low back pain or fibromyalgia are categorised under 
“chronic primary pain” if (1) pain persisted for or recurred for longer than 
three months, (2) it is not accounted for by any other diagnosis, and (3) is 
associated with significant emotional distress and/or significant functional 
disability [37, 38]. 
Chapter 1: INTRODUCTION 
4 
The global burden of pain 
Pain, especially chronic (musculoskeletal) pain is one of the most 
significant public health concerns. It is one of the most common clinical 
conditions, with an annual prevalence from 11% to 79% (see Section 1.2.1 
below). It is one of the most common reasons for a general practitioner visit. 
For example, osteoarthritis with back problems together formed a cumulative 
57% of 142,377 individual visits to a GP in the USA from 2005 to 2009 [39]. 
Ongoing pain is also a common reason for the loss of employment [40, 41]. 
The social impact of pain affects outside just individuals experiencing pain 
but also their and family (partners, children, parents) [42]. The influence of 
pain at individual (i.e., physical and psychological factors) and social levels 
imposes an enormous economic impact at both individual and societal levels 
[40, 41, 43].  
Musculoskeletal disorders, including low back pain, is among the 
largest contributors to the years lived with disability globally according to the 
Global Burden of Disease studies (see Figure 1.1) [20, 44]. The pattern for 
years lived with disability in Nepal is similar to global rates with the top four 
disorders identical (see Figure 1.2). Low back pain with neck pain is the 
number one cause of years lived with disability globally in the majority of 
low- and middle-income countries (LMICs) and high-income countries (HICs) 
[20, 44]. Other conditions such as diabetes can lead to painful diabetic 
neuropathy. Mental health problems such as anxiety and depression are other 
two top-ranking burgeoning problems that are often associated with pain 
conditions; the relationship could be bidirectional [45-47], and some evidence 
exist that intervention targeted at one could influence the other [46-48].  
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Figure 1.1 Years lived with disability (Global, both sexes, all ages, YLDs per 
100,000) 
(Created using https://vizhub.healthdata.org/gbd-compare/ on 18th November 2019) 
Prevalence of pain  
As alluded earlier, pain is one of the most common clinical problems. It 
is not only a problem among older individuals or in individuals from 
developed nations, but it is also prevalent in younger individuals and 
individuals from developing nations. The lifetime prevalence of low back 
pain among adolescents has been reported to range from 7% to 72%, with a 
higher prevalence for older adolescents based on a systematic review of 56 
epidemiological studies [49]. The prevalence of pain in older adolescents (age 
of 16 to 18 years) is similar to that of the adult population (age >18 years) [49]. 
Another systematic review of population-based studies by Hoy and 
colleagues that included 165 cross-sectional studies from 54 countries found 
that the average prevalence of low back pain is 31% regardless of prevalence 
period [50]. Point prevalence was reported to be 18%, and the one-year 
prevalence was 38% [50].   
In another systematic review of national surveys with representative 
samples in the UK reported the prevalence of chronic pain ranged from 35% 
to 51% [51]. The prevalence of moderate to severely disabling chronic pain 
ranged from 10% to 14%. A trend towards increasing prevalence by age group 
was observed: a prevalence of 14% in age 18 to 25 years compared to 62% in 
the age over 75 years. However, this finding that the prevalence of chronic 
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pain increases with age is not universally supported. For example, in a 
systematic review in 2006, Dionne and colleagues [52] found that the 
prevalence of low back pain was positively associated with age only in case of 
severe pain. The relationship was curvilinear with prevalence higher in age 
for benign and mixed back pain with a peak prevalence at about 55 years for 
non-severe pain [52]. The review is inconclusive, more than 13 years old, and 
therefore, an update of the review that incorporates newer studies may 
provide a more definitive answer. 
As indicated earlier, chronic pain has also been shown to be common 
in developing countries, although pain research in individuals from 
developing countries remains limited. One systematic review of studies 
related to chronic pain (n = 119 studies from 28 low- and middle-income 
countries) found that the prevalence of chronic pain (including 
musculoskeletal and low back pain) ranged from 21% to 62%, with greater 
odds of experiencing pain in working populations and older adults in the 
general population [53]. These investigators also found that the prevalence of 
chronic musculoskeletal pain was about 3.1 times more common in the 
working population compared to the general population and the prevalence 
of chronic low back pain was 2.5 times more. The odds of prevalence of 
unspecified general chronic pain in older adults were from 1.7 to 2.4 times 
more in the older population compared to the general population.  Despite a 
comprehensive search of the literature in six databases, Jackson and 
colleagues [53] found no studies about the prevalence of pain in individuals 
from Nepal. I performed a review of the literature on prevalence studies of 
chronic pain on PubMed and Scopus in November 2019, the results are 
summarised in Table 1.1 below.  
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Table 1.1 The global prevalence of chronic pain 
Study Country  Study type Pain condition Prevalence [95% CI] 
Alonso 
Monteiro 
Bezerra 2018 [54] 
Brazil National health 
survey 






Niger  A hospital-based 
survey 







Chronic pain  Point prevalence of 








based survey (age 
and sex-adjusted) 
Chronic regional pain  12-month prevalence 







France A prospective 
national 
multicentre study 
Chronic cancer pain *Non-neuropathic: 
28.2% (26.3% - 30.5%) 
*Neuropathic: 5.9% 
[4.8% - 7.0%] 
Breivik 2006 [59] 15 European 
countries 
and Israel 




Chronic pain  *19.0% moderate to 
severe pain lasting 
for at least 6 months.  
Range: 12% to 30% 
Chen 2016 [60] China A national survey Chronic pain  *39.9% (women) 
32.2% (men) 
 






Chronic pain  Pooled estimate 
43.5% [38.4% - 48.6%) 








Any pain  *40.3% had pain in 
the last week 


















Chronic pain in the 
general population 
*Range: 34.0% [26.0% 
- 42.0%] to  62.0% 
[41.0% - 81.0%] 
Chronic low back pain 
in the general 
population  
*Range: 21.0% [15.0% 
- 17.0%] to 28.0% 
[16.0% - 42.0%]  
Chronic low back pain 
in the working 
population 
*52.0% [26.0% - 
77.0%] 
Chronic 
musculoskeletal pain in 
the general population 
*Range: 25.0% [19.0 – 
33.0%] to 44.0% 
[28.0% – 62.0%] 
Chronic 
musculoskeletal pain in 
the working population 
79.0% [60.0% - 94.0%] 
Abbreviations: CI, Confidence Interval; LMICs, Low- and Middle-Income Countries; UK, United 
Kingdom.  
*Prevalence period: Not reported.  
 
A trend of the increasing prevalence of pain over time is seen. For 
example, the prevalence of chronic disabling low back pain increased by 162% 
(from 3.9% to 10.2%) in a representative sample from North Carolina, the 
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USA from 1990 to 2006 [62].  This increasing prevalence of chronic pain is 
expected to continue to rise in the future [63].  
Several factors may account for the increased rates of chronic pain over 
time. The Institute of Medicine’s report on chronic pain [43] has highlighted 
five possible causes of increasing its prevalence in the USA, which could 
potentially be true for other countries. These causes are (1) increasing 
population age, (2) rising prevalence of obesity, (3) improved medical 
advances that save lives after injuries and other illnesses such as cancer, (4) 
increasing number of surgeries (leading to chronic post-surgical pain), and (5) 
increased access to healthcare. All of these causes are also expected to be 
increasing in the LMICs, including Nepal.   
The cost of pain 
Pain is one of the most expensive problems to treat both in the HICs 
and the LMICs. The total cost of pain is composed of direct and indirect costs 
[64]. Direct cost involves the direct cost for the treatment of pain, whereas, 
indirect cost involves cost other than the cost of treatment including costs 
related to the loss of employment, reduced income, or cost associated with 
disability.  
The total cost of pain ranges from hundreds of millions to hundreds of 
billions of dollars in HICs. For example, the total cost of chronic pain in the 
United States is US$ 650 billion per year [43]. The total cost of musculoskeletal 
pain alone is US$ 215.5 billion [43]. The annual cost of treatment of chronic 
pain in New Zealand ranges from NZ$ 13.0 to 14.8 billion [65]; AS$ 73.2 
billion in Australia [66]; and €441 billion in Europe [67] with a range from 
€740 million to €50 billion in individual European countries [41]. The direct 
cost for pain treatment in the US ranged from $261 to $300 billion, whereas, 
the indirect cost in terms of lost productivity ranged from $297 to $336 billion 
[68]. These statistics are about a decade old and may have increased in recent 
years. 
Chapter 1: INTRODUCTION 
9 
Overview of Nepal 
Nepal is a landlocked, low-income country located in South Asia. It has 
an area of 147,516 square kilometres, and a population of slightly less than 29 
million in 2016 (https://www.who.int/countries/npl/en/; accessed on June 
26, 2020). To put this in context, Nepal is about half the size of New Zealand, 
but over five times more people live in Nepal compared to New Zealand.  
Ethnic groups and languages  
There are 125 different ethnic groups and 123 languages in Nepal [69]. 
Although all Nepalese share some common traits, different ethnic groups 
share different values and beliefs about various aspects of life. The national 
and official language of Nepal is Nepali. It is spoken by 46% of Nepalese as 
the first language [69]. It is also taught in primary school and onwards until 
high school. With the overall increase in literacy rates, many more people in 
Nepal are expected to speak Nepali in the future.   
Occupation and economy 
About 39% of the population in Nepal is estimated to be poor in 2019 
based on the international poverty line (at the $3.20 per person per day) [70]. 
The main source of economy is agriculture with 65% of the population 
employed as farmers [70]. Because of low socioeconomic conditions, many 
farmers work manually in the fields imposing huge physical demands, which 
may be associated with pain conditions such as osteoarthritis [71].  
Nepalese healthcare system 
The Nepalese health system is poorly funded, and suffers suboptimal 
staffing and resources. The care is disproportionately centred in urban areas. 
About 40% of Nepalese living in rural locations do not have access to a 
healthcare facility within 30 minutes [72]. Although the Nepalese constitution 
states that every Nepalese has the right to access free basic healthcare, most 
healthcare costs (81%) are spent out-of-pocket [72]. Nepal has less than 1 
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doctors per 1000 people in 2018 (www.worldbank.org), which is significantly 
less compared to the World Health Organisation’s estimate of requirement of 
2.3 health care workers (doctors, nurses, and midwives) per 1000 people to 
meet the health care needs in the primary care.  
Alarmingly, based on the World Confederation for Physical Therapy 
data, Nepal only has less than 7 physiotherapists for every 100,000 people to 
provide rehabilitative services including pain care in 2020 (www.wcpt.org). 
Factors such as inadequate financing, low pay scale, and lack of opportunity 
for in-service training lead to low retention of health professionals in both the 
public and private sectors [73]. 
The Nepalese health system is ill-prepared to handle the growing 
burden of non-communicable diseases (including pain care) along with the 
existing burden of communicable diseases and problems related to maternal 
and child health. The Nepalese health care system should introduce 
innovative strategies to provide high-value care (care with large clinical 
benefits and no harm at low costs).  One such way is by introducing 
population-level public health interventions.   
Pain in Nepal 
In the context of Nepal, although the first pain-related study was 
conducted in 1980 [74], it took many years before pain research began to gain 
momentum in Nepal. This very first study compared pain tolerance in 
healthy Nepalese porters with non-Nepali English speaking trekkers (without 
pain) and found that the Nepalese porters evidenced higher pain tolerance to 
electrical current compared to the non-Nepali comparator group [74]. The 
next published study was an ethnographic study on musculoskeletal pain in 
rural Nepal (with quantitative reports) in 1984 [75]. Both of these studies were 
conducted by non-Nepalese researchers. It then took almost two decades 
before the next clinical pain studies were published in Nepal [76-78]. In the 
same year, 2003, Nepalese scientists published the first paper on pain [77]. 
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Musculoskeletal pain including low back pain is common in Nepal. 
Musculoskeletal complaints are the number one reason for hospitalization 
[79]. Low back pain is the number one health condition contributing to years 
lived with disability [20]. Although not much is known about chronic pain in 
Nepal, its prevalence has been reported to be as high as 50% [80].   
The burden of musculoskeletal pain in Nepal is comparable to the 
global estimates (see Figures 1.1 and 1.2). Musculoskeletal disorders, 
including low back pain, rank number 1 in years lived with disability in 
Nepal (Figures 1.2). The top four reasons for years lived with disability in 
Nepal is identical to the global estimates (see Figure 1.2).  
 
Figure 1.2 Years lived with disability in Nepal (Both sexes, all ages, YLDs 
per 100,000) 
(Created using https://vizhub.healthdata.org/gbd-compare/ on 18th November 2019) 
 
It is noteworthy that both globally (Figure 1.1) and in Nepal (Figure 1.2), 
years lived with disability because of musculoskeletal conditions increased 
from 2nd to top rank since 1990’s indicating that this condition needs urgent 
attention both at global and local levels. Scientists predict that the burden will 
increase in the next decades if “right” and “urgent” measures are not taken 
[81]. One step forward in a positive direction could be utilising guideline-
based care for the management of musculoskeletal pain conditions including 
low back pain, and relying on education and advice promoting guideline-
recommended interventions [82, 83].  
Very little is known about direct or indirect costs associated with pain 
Nepal and other LMICs. The burden of pain is thought to be substantial given 
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the lack of universal health coverage resulting in out-of-pocket expenses and 
low socioeconomic conditions of individuals in Nepal [10, 84]. In two recent 
viewpoints, we described the urgent need for managing pain to improve 
productivity at work and using health system strengthening approaches to 
combat the burden of pain in LMICs including Nepal [10, 84]. More details on 
the status of pain in Nepal are described in Chapter 2. 
Summary of the burden of pain 
To summarise, musculoskeletal pain including low back pain is a 
common problem globally and in Nepal. Its prevalence can range up to 91% 
in different populations. Chronic pain prevalence, in general, appears to be 
higher in developing countries compared to developed countries. The 
prevalence of chronic pain is 50% in Nepal. Several hundreds of billions of 
dollars are lost because of chronic musculoskeletal pain in high-income 
countries, the least is known about the costs related to pain in LMICs.  
Pain is complex and multifaceted, therefore it requires interventions 
that can target each of its biopsychosocial contributors.  
The biopsychosocial model of pain 
Pain is thought to be a biopsychosocial problem because of a complex 
interaction among biological (e.g., physical or physiological factors, genetics), 
psychological (e.g., cognition, depression, stress, anxiety, resilience, 
optimism) and social factors (e.g., family, work, socioeconomic status, social 
relationships, culture) that are associated with pain [85]. As reflected in the 
definition of pain, it is an emotional experience that is created by the brain 
which may or may not be a result of tissue damage.  
Pain can also be influenced by cognitive (beliefs about causes of pain) 
and social factors (family, friends, or work-related factors). The factors that 
contribute to pain for any one individual can also change over time. For 
example, pain that is caused primarily because of biological reasons (e.g., 
fracture due to injury) can become chronic attributing to emotional distress 
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and social factors. For every patient, the contributors to pain differ making it a 
difficult problem to treat. That is, every individual with pain has a unique 
pain experience with unique contributors that require individualised care.  
Figure 1.3 depicts that extent of contributions of biological, 
psychological, and social factors in two different individuals with pain may 
vary. Although the figure does not show the complex interactions of these 
factors with each other, it indicates varying levels of contributions of each of 
these factors. These two figures reflect “usual” predominant mechanisms in 
acute and chronic pain respectively. Therefore, the assessment of all the 
components: biological, psychological, and social factors is important and 






Figure 1.3 The proportion of biopsychosocial contribution to pain is 
different for two individuals with pain 
Assessment of pain 
 Patient-centred assessment is integral to the patient-centred care for 
people with pain conditions. Patient-reported outcome measures (PROMs) 
are one of the foundations of patient-centred assessment and care in pain 
management or any health conditions in general. PROMs aim to assess 
outcomes that are most important to the patients, for example, symptoms 
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quality of life. There are no other (valid) ways to assess these domains than 
self-report. Incorporating PROMs in routine clinical care improves the active 
patient involvement in the management of their own condition, minimises 
observer bias as the information is first hand from the patients themselves, 
saves clinicians’ time in completing proxy measures for patients, therefore 
improves response rates [86].  With greater involvement of patients in their 
treatment, it may also improve their overall health outcomes.  
 Numerous domains can be assessed in any pain condition. Although 
assessing more domains is desirable, it demands excessive participant-burden 
and therefore may reduce response rates. Each domain has multiple PROMs 
that can be used. The key questions for clinicians or researchers are: what 
domains to assess, and which PROMs to use? This decision-making is 
simplified by the development of core outcome sets (COSs).   
A COS is a set of recommended outcome measures for a specific health 
condition. COSs have been proposed to make consensus-based 
recommendations for the assessment of pain in clinical practice and research 
[87] for chronic pain [88], chronic musculoskeletal pain [89], low back pain 
[90, 91], osteoarthritis of hip and knee [92], and complex regional pain 
syndrome [93]. Recently, a COS was also developed for the assessment of key 
domains after interdisciplinary multimodal treatment of pain [94]. Some of 
these COSs are being updated — for example — COS for low back pain [90, 
95]. Table 1.2 lists the main outcomes recommended by different COSs that 
are important in different pain conditions or therapies.  
 Using these recommended outcome domains and measures in the 
assessment of pain conditions will gather data that are important to both 
patients and clinicians and therefore advance research and clinical 
management. However, most or all of these measures recommended by the 
COSs are developed in HICs, for western cultures, mostly in English, their 
unavailability in other languages and cultures limit their use in these 
languages or cultures. Before they can be used in clinical practice or research 
in a different country/language or culture, recommended guidelines for 
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translation and cross-cultural adaptation of PROMs need to be used to 
translate the measures into the target language (e.g., [96-98]).  
Table 1.2 Recommended domains for the assessment of pain 
COS for  Recommended domains  
Low back pain [90, 95] Pain intensity, physical function, emotional distress, and 
quality of life.  
Chronic pain (IMMPACT 
recommendations) [88] 
Pain intensity 
Physical function/pain interference 




Quality of life 
Hip and/or knee steoarthritis [92] Pain, physical function, quality of life, patients’ global 
assessment of the taget joint, adverse events, and deaths.   
Chronic musculoskeletal pain [89] Pain intensity, pain interference, physical function, 
Depression, Sleep, Anxiety, Patient-Reported Global 
Impression of Change.   
Interdisciplinary multimodal pain 
therapy [94] 
Pain intensity, Pain frequency, Physical activity, Emotional 
wellbeing, Satisfaction with social roles and activities 
Productivity (paid and unpaid, at home and at work, inclusive 
presentism and absenteeism) 
Health-related quality of life 
Patient’s perception of treatment goal achievement 
Complex regional pain syndrome 
(COMPACT recommendation) [93] 
Pain: Numerical Rating Scale, PROMIS 29 version 2, McGill 
Pain Questionnaire 
Disease severity: CRPS Severity Score, CRPS symptom 
questions 
Participation and physical function: PROMIS 29 profile, EQ-
5D-5L 
Emotional and psychological function: PROMIS 29 profile 
version 2, PROMIS suicidal ideation question 
Catastrophizing: Pain Catastrophizing Scale  
Self-efficacy: Pain Self-efficacy Questionnaire 
Patient Global Impression of Change 
Abbreviations: COMPACT, Core Outcome Measurement set for complex regional PAin syndrome 
Clinical sTudies; COS, Core Outcome Set; CRPS, Complex Regional Pain Syndrome; IMMPACT, the 
Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; PROMIS, Patient-
Reported Outcome Measurement Information System. 
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Treatment of pain 
Patient education is critical in all stages of prevention (i.e. primary, 
secondary, or tertiary prevention) [99] and treatment of health conditions 
[100-107]. Patient education is commonly defined as “any set of planned 
educational activities designed to improve patients’ health behaviours and/or 
health status” [99, 108]. The journal Nature describes patient education as the 
procedure in which individuals with health occupations impart information 
to patients about their own health status and needs 
(https://www.nature.com/subjects/patient-education). In simpler terms, 
patient education is the information that healthcare professionals deliver to 
patients about their health status and needs. It aims to enable patients to 
improve their own health by changing their health-related beliefs and 
behaviours.  
Patient education is a first-line recommended treatment for the clinical 
practice guidelines of multiple clinical conditions [82, 109-112]. Patient 
education also improves patients’ adherence to medical interventions [113]. 
Empowering patients should be part of any therapy, education is an 
important way to achieve this.  
Patient education in pain conditions is primarily composed of advice to 
remain active, exercise, avoid bed rest, and continue working or return to 
work early. Experts debate that without education on pain (for example, why 
it hurts), this advice alone does not help [114]. Adding education about pain 
to this general advice to remain active can provide a rationale for other 
interventions such as behavioural modification and exercises [114]. This 
education about pain generally consists of education about why it hurts, how 
one can cope with pain, and addressing any “maladaptive” pain beliefs or 
coping. The overall goals of such education programmes are to empower 
patients with knowledge about their pain conditions so that they learn many 
ways to self-manage their pain conditions.  
This education about pain has been delivered in different ways and are 
referred to using many phrases, such as Explaining Pain or Pain Biology 
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Education [115, 116], Pain Neuroscience Education [117-119], Therapeutic 
Neuroscience Education [120, 121], Cognitive Patient Education [122], or 
Psychosocial education [123, 124]. These types of pain education have several 
overlaps and are largely focused on reassuring patients by explaining pain 
neuroscience. The overall goal is to promote physical activity, active pain 
coping strategies and self-management. However, the delivery duration and 
methods can widely differ. The duration of these pain educational 
interventions can last from several minutes to several hours spread over 
several weeks [125].  
For simplicity, I chose to use “Pain Education” to describe the 
educational interventions related to pain described in Chapter 9 of the thesis. I 
deliberately avoided using more complicated terms such as “Biology”, 
“Neuroscience” that can be intimidating to people especially with low-
educational backgrounds (i.e. at least a quarter of Nepalese). Consistent with 
the definition of and aims of “Patient Education” [99] as described earlier, I 
operationally defined “Pain Education” as planned educational strategies 
designed to improve patients’ self-management of their pain condition, pain-
related beliefs and coping or pain-related distresses with an aim to improve 
pain and/or overall health. 
Pain education can be delivered as a group lecture for large groups of 
people [123, 124], or as one-to-one education in person [126], or using 
telehealth [120]. One key advantage of pain education is that it can be used as 
a public health intervention. It can be delivered to larger populations using 
mass media campaigns such as television, radio, newspaper, or more recent 
technological developments using mobile applications and social media. 
Buchbinder and colleagues used mass media campaigns in Australia with 
simple messages to improve back pain beliefs among members of the general 
population and general practitioners [127]. The authors found that these mass 
media campaigns significantly improved beliefs about back pain in both the 
samples (general population and general practitioners) and improved other 
outcomes including a decline in the number of claims for back pain, rates of 
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days of compensation and claims for medical compensation for back pain 
throughout campaign [127].  
Pain education could be a useful treatment of pain in resource-limited 
countries such as Nepal, because, it can be delivered at population-level, 
therefore cost-effective [81]. It can also overcome the challenges of 
accessibility of healthcare due to geographical barriers. However, we cannot 
be sure that the educational intervention that is thought to be effective in 
western countries or cultures will be effective in eastern culture such as 
Nepal. Educational interventions developed for western cultures often use the 
local cultural contexts, patient stories, and metaphors that are locally 
applicable or understood. It cannot be assumed that these are understood, or 
acceptable by people of Nepal who are different in terms of culture, 
socioeconomic status, native language, levels of literacy. Therefore, 
developing a locally acceptable educational intervention tailored for lower 
socioeconomic conditions, in the Nepali language, for the local population is 
desirable.  
Statement of the problem 
Although pain appears to be a significant problem in Nepal as evident 
from the global burden of disease studies, a PubMed search to retrieve studies 
on “pain” and “Nepal” retrieve very few studies. Research on pain in Nepal is 
scarce and current pain care in Nepal is not viewed as optimal or evidence-
based.   
PROMs and treatments developed for (chronic) pain in developed 
countries may not be valid or applicable in Nepal — a different culture — 
which needs careful exploration. In addition, treatments such as cognitive and 
behavioural or educational interventions developed in and for one culture 
may not be acceptable and/or effective in another language or culture. 
Therefore, an intervention that is developed in the western world that is 
proven to be effective should be tested in a new culture before recommending 
its use in clinical practice.  
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The gold standard method of testing interventions — the randomised 
controlled trial — require high-levels of expertise to conduct and are resource-
intensive. The lack of evidence from high-quality randomised controlled trials 
on pain in Nepal and a failure of our previously planned trial [128] suggest 
that conducting such studies in Nepal may be very challenging. Therefore to 
save time and resources, it is important to identify barriers to the feasibility of 
a clinical trial in the Nepalese healthcare system and strategies to overcome 
these before conducting a large-scale trial.  
Aims of the thesis 
The overarching aim of this thesis is to (1) identify areas of pain 
research gaps in Nepal and then (2) take initial steps to fill them. The specific 
aims of this thesis are as follows: 
(1)  Review the published literature on pain in Nepal, identify existing 
knowledge and knowledge gaps to inform the subsequent components 
of the thesis.  
(2) Explore whether between-country and between-language differences 
in psychosocial factors in chronic pain exist, if so, utilize the knowledge 
gained in conducting future pain research in Nepal and in developing 
assessment measures and chronic pain treatment in Nepal.  
(3) Translate, cross-culturally adapt and validate PROMs (based on the 
core-outcome sets for chronic pain and low back pain) in Nepali. 
(4) Conduct a feasibility study to evaluate whether conducting a clinical 
trial to evaluate the effectiveness of newly developed pain education 
resources in Nepali and guideline-based care for the management of 
low back pain in Nepal is feasible.  
Chapter 1: INTRODUCTION 
20 
Summary 
To summarise, in Chapter 1, I explained why musculoskeletal pain is 
an important public health problem in Nepal and globally, and how I planned 
to improve musculoskeletal pain care in this thesis.  
The next chapter (i.e., Chapter 2) explores the knowledge gap in the 
current pain literature in Nepal (to inform future pain research agenda) and 
informed Chapters 5 through 9, which aimed to improve pain assessment and 
management in Nepal. In Chapter 3, I explored between-country and 
between-language differences in pain beliefs, coping, and catastrophizing, 
which are considered important treatment targets in pain educational 
programmes. Information from this Chapter was used to inform the 
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CHAPTER 2 : PAIN RESEARCH IN 
NEPAL 
[Sharma S, Jensen MP, Pathak A, Sharma S, Pokharel M, Abbott JH: State of clinical pain 
research in Nepal: a systematic scoping review. Pain Reports 2019, 4(6):e788.] 
*** 
INTRODUCTION 
Given its high prevalence, costs, and impact on physical, mental and 
social function, and all aspects of quality of life [129], pain remains a 
significant health problem worldwide [68]. One-year prevalence of chronic 
pain is more in developing countries (41%) compared to developed countries 
(37%) [130]. The economic burden of chronic pain is extremely high, with 
annual estimates of the cost of treatment in the US to be from US$ 560 billion 
and US$ 635 billion [68], and about £1 billion in the UK [130].  
Knowledge from pain research comes predominantly from developed 
countries; pain research in developing countries —including Nepal — is 
relatively sparse. Currently, musculoskeletal pain conditions are the number 
one cause of disability in Nepal; a 32% increase in the three decades [20, 44] 
since 1990, when musculoskeletal pain conditions were reported to be the 
second leading cause of years lived with disability in Nepal [44]. Despite this, 
pain is not currently viewed as a priority research area in Nepal. For example, 
the Nepal Health Research Council’s (NHRC) research priority agenda does 
not include pain research as one of its priorities [131]. However, recently there 
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have been promising signs that research related to pain in Nepal is growing 
[3, 8, 132-136]. 
Given the scarce resources for conducting research in Nepal in general, 
it is important that researchers should (1) avoid duplicating research efforts 
and (2) address the research questions that are most likely to be impactful. 
Thus, the purpose of this review is to clarify the current state of pain research 
in Nepal, identify the extent and nature of research published, identify 
significant knowledge gaps, and provide recommendations for future studies. 
To achieve these aims, here I sought to include research articles that used all 
types of study designs, as well as articles that focused on a range of topics, 
including research that evaluated interventional procedures (e.g., medical, 
surgical, and rehabilitation), epidemiological research, and outcome 
measurement studies, among others. As a part of this review, I also hoped to 
be able to estimate the prevalence of pain conditions, identify the outcome 
measures used to assess pain and related domains, and the treatment 
approaches used to treat pain conditions in Nepal.  
The original literature search, with an aim to inform this thesis, was 
conducted in 2014 and repeated in 2016. The search of the literature in 2014 
informed the planning and conduct of Chapters 5 to 8. The search update in 
2016 informed the need for Chapter 9. The Methods and Results described in 
this chapter are used from the published paper [1], which includes the 
updated literature search in November 2018, which was updated before 
submitting the paper for publication. 
 METHODS 
A scoping review was conducted using recent guidelines by the Joanna 
Briggs Institute [137]. The study aims and methods were defined a priori. An 
extension of PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analysis) guidelines for scoping reviews was followed for reporting the 
review [138].  
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Study eligibility criteria 
I included studies that: (1) were conducted in Nepal; (2) included 
participants who had a diagnosis of a clinical pain condition (e.g., complex 
regional pain syndrome, headache, chronic pain, musculoskeletal pain, 
neuropathic pain, post-surgical pain,  paediatric pain, cancer pain, etc.) or 
included pain as the primary outcome (e.g., fracture management); and (3) 
used either qualitative or quantitative research designs. I did not exclude 
studies based on the language of publication, year of publication, study 
design, or the age of study participants. However, I did exclude studies that: 
(1) included animals instead of human participants; (2) were editorials or 
review papers; (3) included participants who did not have a clear pain 
condition or diagnosis, or had pain as only one symptom of another primary 
condition being studied (e.g., infectious diseases such as typhoid); or (4) were 
conducted outside of Nepal.  
Search strategy 
I searched Medline, Embase, Scopus, Cochrane library, Google Scholar, 
and Nepal Journals Online (NepJOL, https://www.nepjol.info/) from 
inception to November 2018. I also searched the reference lists of included 
studies. I collated articles in the Endnote software and removed duplicates. I 
developed the search strategy and amended it after receiving feedback from 
all authors. I used a combination of terms “pain” or “analgesia” and “Nepal” 
or their alternative terms and adapted search strategies for each database. 
Details of search terms and strategies used can be found in Appendix 1.  
Data screening 
A pair of authors (SS, and SwS, and AP and MP) independently 
screened the title and abstract of all the articles. Disagreements about 
inclusion were resolved through discussions. A third independent reviewer 
(SS or AP) who was not a member of the original pair made a final decision in 
case consensus was not reached. I then performed the screening of the 206 
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full-text articles that required further reading. If I were an author of the paper, 
another reviewer who is not an author, screened the full-texts.  
Data charting process  
I then performed data charting using an Excel spreadsheet that I 
created for this review. I pretested the form using two studies. This was also 
confirmed by four other study authors (AP, SwS, MP, MPJ) for an additional 8 
studies. The form was modified with minor changes and then finalised. One 
of four authors (AP, MP, SS, and SwS) then extracted data from the included 
studies. I confirmed that the data were extracted correctly for the extraction I 
did not perform. AP confirmed the data that I extracted. If included studies 
were authored or co-authored by one of the authors of this review, a review 
author who was not an author of the study extracted the data. Any 
discrepancies were discussed with me and the final decision was made via 
consensus. Based on the results from all the studies included, I performed all 
analyses and classified the studies into key themes to organize the 
presentation and discussion.  
Data items  
We extracted data related to (1) the year of publication, (2) place of 
data collection/ research, (3) source of publication (local or international 
journal, PubMed indexed or not indexed journal), (4) study design 
(qualitative study, clinical trial, study protocol, observational design, case-
series or case studies), (5) study setting (clinical, community, mixed), (6) 
population studied (headache pain, musculoskeletal pain, post-operative 
pain, low back pain), (7) participant characteristics (age and sex), (8) measures 
used, (9) treatment delivered, and (10) key findings. 
Synthesis of results  
 I computed the frequency for publication types, setting (community or 
hospital), study design, type of pain condition, age categories, and scope of 
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the study. I then classified the results based on the broader themes of pain 
research, for example, interventional studies (medical or surgical 
management and rehabilitation), epidemiological studies, outcome 
measurement studies, and diagnostic studies.  
 RESULTS 
Search results 
A total of 1406 articles were identified. After removing duplicates, 1396 
articles were screened for titles and abstracts. We then read the full-texts of 
206 articles and included 116 studies in the review [3-7, 75-78, 80, 133, 134, 
136, 139-241].  See Figure 2.1 below for the total numbers of records screened, 
full texts read, and reasons for exclusion.  
 
Figure 2.1  PRISMA flow diagram 
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Characteristics of sources of evidence 
Publication characteristics 
Eighty-seven of 116 studies (75%) were published in local Nepalese 
journals and 27 (23%) were published in international journals. Two studies 
(2%) were published as conference abstracts [232, 233]. Within local journals, 
53 of 87 articles (61%) were in journals published by universities or medical 
schools in Nepal, followed by 27 (31%) which were in journals published by 
medical associations or societies. Only six (7%) were published in the journal 
of Nepal Health Research Council (NHRC – government body of Nepal 
regulating health research in Nepal) [146, 196, 197, 200, 235, 238], and one 
published in a local journal in India [176]. Of the included studies, 67 (58%) 
were not indexed in PubMed and were identified and included largely via 
NepJOL or from the reference lists of other included studies. A total of 74 
studies (64%) were published in the last 5 years, while only 20 papers (17%) 
were published in 2011 or earlier (see Figure 2.2). The majority of studies 
(n=113) included were full reports (97%), and one was a protocol of a clinical 
trial [7].  
 
Figure 2.2 The number of publications in the past 8 years. 
Study sites and designs 
Eighty-five studies (73%) were conducted in clinical settings (e.g., in a 
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university). Eleven (9%) studies collected data from both hospital and 
community settings and 6 studies (5%) collected data from work-sites (See 
Table 2.1).  
The most common study design was cross-sectional design (40%), 
followed by randomised controlled trial (35%), case studies or case series 
(12%), and longitudinal study (10%). One study each was a trial protocol [7] 
and a qualitative study [211]. We did not retrieve any studies which were a 
pilot or a feasibility study (except a protocol for a feasibility study [7]). 
Study participant characteristics 
 The most commonly studied pain condition was post-surgical pain 
(33%), followed by musculoskeletal pain (16%), headache (14%), low back 
pain (13%), and neuropathic pain and general chronic pain (5% each; see 
Table 2.1). 
 The majority of studies were conducted in adults (76%), followed by 
studies that included adolescents and adults together (9%). Only 3% of the 
studies were conducted in the pediatrics population. Another 4% studied all 
age groups. A total of 6% of studies did not report the age of study 
participants (Table 2.1).   
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Table 2.1 Characteristics of sources of evidence  
Study characteristic domain Frequency (n = 116) Percentage 
Pain types and or sites   
Post-surgical pain 38 33 
MSK pain (excluding low back pain) 18 16 
Headache pain of different origins 16 14 
Low back pain 15 13 
Chronic pain (general) 6 5 
Neuropathic pain  6 5 
Pelvic pain 3 3 
Labour pain  3 3 
Scrotal or penile pain 2 2 
Orofacial pain 2 2 
Abdominal pain  2 2 
Mixed pain (MSK and abdominal pain) 1 1 
Widespread pain  1 1 
Cancer-related pain 1 1 
Chest pain  1 1 
Others 2 2 
Age categories   
Adults (18 years and over) 88 76 
Adolescent and Adults (10 years and over) 11 9 
All ages  5 4 
Pediatrics  3 3 
Pediatrics and Adolescent (under 18 years) 2 2 
Missing 7 6 
Study designs   
Cross-sectional study 46  40 
Randomised trial* 41 35 
Case study or case-series 14 12 
Longitudinal study 12 10 
Trial protocol 1 1 
Qualitative study 1 1 
Non-randomised comparative study 1 1 
Setting   
Hospital/ clinical setting 85 73 
Mixed sample  11 9 
Community  8 7 
Workplace, or university sample 6 5 
Base camp (mountains) or trekking route 3 3 
Health camps** 2 2 
Online survey 1 1 
Abbreviation: MSK, Musculoskeletal.  
*As reported by the trial authors 
**Health professionals’ visits in rural communities for the diagnosis and treatment of health 
conditions.   
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 Themes of identified studies 
Almost half of the studies focused on biomedical management of pain: 
medical management (40%), and surgical management (8%). Twenty-one 
percentage were epidemiological studies that estimated prevalence/incidence 
of pain conditions. Fifteen percent were diagnostic studies, 8% outcome 
measurement studies, 7% were descriptive studies, and 3% related to 
rehabilitation. Although some of the more recent studies included 
psychosocial assessment [5, 6, 136], we did not find any studies related to 
psychological management of pain (except one protocol for a study that 
planned to deliver pain education by a physiotherapist [7]). See Figure 2.3 for 
a bar diagram of the scope of the included papers, based on the purpose of 
the study.  
 
Figure 2.3 Scope of pain research in Nepal. 
 
Interventional studies  
Medical management. A total of 46 studies (40%) studied medications 
for management of pain, of which 29 studies (63%) studied post-operative 
analgesia [76, 139, 142, 144, 145, 148, 151, 159, 163, 168-170, 172-175, 177, 179, 
181, 183-187, 189, 191, 192, 194, 198, 201-203, 207, 208, 212, 213, 215, 219, 222-
224, 230, 236, 238]. Four studies (9%) explored effectiveness of steroid 
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steroids for back pain [141, 145, 242] and two studies each explored 
effectiveness of intra-articular morphine [139, 163] and effectiveness of non-
steroidal anti-inflammatory drugs for high altitude headache [76, 150]. One 
study each explored effects of an anti-depressant for tension-type headache 
[174] and vitamin D for chronic widespread pain [189].  
The most commonly studied post-operative pain management drug 
was Bupivacaine, a local anaesthetic (n = 17) [142, 144, 148, 159, 170, 173, 175, 
177, 202, 203, 212, 223, 224, 230, 243-245]. Morphine was evaluated in nine 
studies [139, 142, 163, 170, 173, 179, 198, 215, 230], and Tramadol in six studies 
[163, 194, 207, 212, 224]. Butorphanol [144, 173, 184, 207] and Ketamine [172, 
184, 185, 213] were evaluated in four studies each. Sedatives were evaluated 
in three studies [170, 174, 185], Lignocaine [208, 222] and Gabapentin [168, 
215] in two studies each, and Pethidine [170], Fentanyl [172], and Ropivacaine 
[172] were evaluated in one study each. See Appendix 2.1 for the list of all 
studies on medical management.  
Surgical management. Nine studies (8%) evaluated the role of surgical 
techniques in pain (see Table 2.3). Four of these were clinical trials (Ns = 40 to 
100).  The other five studies were either a case study, case series, or 
observational studies (see Appendix 2.2).  
Rehabilitation. We identified only three studies evaluating 
rehabilitation as interventions for chronic pain. Two of these were 
randomised clinical trials conducted in the past two years to compare the 
effects of early mobilization versus 24-hour bed rest following spinal 
anaesthesia in post-operative spinal headache (Ns= 112 and 200) [231, 246]. 
Neither of the trials was prospectively registered in a clinical trial registry. 
The third study was the protocol of the PEN-LBP feasibility trial, which forms 
Chapter 9 of this thesis [7] (see Appendix 2.3).  
Prevalence and incidence of pain conditions 
Pain appears to be highly prevalent in Nepal. One large-sized study 
reported a 50% prevalence of (any) pain problems in community members of 
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Eastern Nepal [80]. Estimates of prevalence or incidence of musculoskeletal 
conditions (including low back pain and work-related problems) were most 
commonly studied (N = 9 studies) [75, 77, 134, 149, 154, 165, 188, 206, 216], 
followed by different headache disorders (N = 8 studies) [78, 152, 180, 190, 
199, 217, 220, 247], chronic pain (N = 2 studies) [80, 228], neuropathic pain (N 
= 2 studies) [135, 214]. One study each explored the prevalence of abdominal 
pain [80], temporomandibular disorders [229], and dysmenorrhea [227]. A list 
of prevalence/ incidence studies with details is presented in Table 2.2 below, 
and the details of studies on prevalence and incidence are presented in 
Appendix 2.4.  
Table 2.2 Prevalence of pain conditions in Nepal 





Community sample 44% 
Children working in a brick kiln 37% - 56%  
   
 
 Low back pain 
Dentists 52% – 91% 
Nurses 65%  
General working adults 63% 
Surgeons 60% 
Community sample 71% (w 74%; m 68%) 
   Neck pain Software professionals 57% 
Dentists 52% 
   Shoulder pain Dentists 50%  
Software professionals 38% 
  Upper back pain Dentists 42% 
  Wrist and hand pain Software professionals  40% 
Dentists  37% 
  General body pain Software professionals  36% 
Headaches 
  Headache Population survey  85% 
  Chronic headache Outpatients visit   1% 
 High-altitude 
headache 
Mountain climbers  83% 
  Spinal headache Patients undergoing spinal anesthesia  25% 
Chronic pain community sample   48% -50% 
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Pain condition Population Prevalence 
Any pain Leprosy  52% 
Neuropathic pain Leprosy  35% 
Dysmenorrhoea Women in reproductive age   85% 
Abbreviations: w, women; m, men. 
 
Low back pain. The annual prevalence of low back pain was estimated 
to be 52% to 91% in different occupational groups. Dentists had the highest 
one-year prevalence ranging from 52% to 91% [149, 188]. The one-year 
prevalence of low back pain was found to be 65% in nurses [134], 63% in 
working adults in general [216], 60% in surgeons [206], and 57% in software 
professionals [77]. The annual prevalence of low back pain in community 
dwellers was estimated to be 71% with the prevalence rate in women (74%) 
found to be higher than that in men (68%) [154].  
Other musculoskeletal pain. The prevalence of musculoskeletal 
complaints was as high as 70% in both adults and pediatric age groups. Forty-
four percent of a community sample in Eastern Nepal reported a current 
musculoskeletal pain [80]. Seventy percent of surgeons reported at least one 
musculoskeletal disorder [206]. One-year prevalence of neck pain was 52%, 
shoulder pain 50%, upper back pain 42%, and wrist and hand pain 37% in 
dentists [149]. Out of 1574 patients attending a community health camp, 19% 
complained of musculoskeletal pain [160]. Fifty-seven percent of software 
professionals experienced neck pain, 40% experienced hand pain, 38% 
shoulder pain, and 36% general body pain [216]. Similarly, 56% to 73% of 
children under the age of 17 years working in brick kiln experienced 
musculoskeletal pain in two districts of Nepal [165]. Working children were 8 
times more likely to experience musculoskeletal pain compared to non-
working children [165].  
Headache disorders. Headache disorder was also reported to be highly 
prevalent in Nepal. In a large population-level survey of 2100 individuals, 
85% of total participants reported headaches in the last year [199]. Chronic 
headache accounted for a total of 1% of general outpatient visits [190]. Of 168 
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adults with chronic headache, 20% had chronic migraine, 17% had chronic 
tension-type headache, with 51% not fitting any criteria [190]. In another 
sample of 150 individuals with primary headache, 69% had migraine 
headache, and 29% had tension-type headache [217]. Cervicogenic headache 
was not explored in both the samples [190, 217]. Anxiety and depression were 
associated with individuals with chronic migraine in 35% to 53% and 22% to 
29%, respectively [180, 217]. High-altitude headache was reported by 83% of 
individuals climbing a mountain in Nepal [78], and spinal headache by 25% 
of those undergoing spinal anesthesia [152].  
Chronic pain and neuropathic pain. The point prevalence of chronic 
pain in the Sunsari district of Eastern Nepal was 48% [80], with a similar 
prevalence rate in Kathmandu (48% to 50%) [228]. Of 85 patients with leprosy, 
52% experienced pain and a total of 35% were neuropathic pain [135]. 
Dysmenorrhea. The lifetime prevalence of dysmenorrhea was as high 
as 86%, with a point prevalence of 76% in a sample of 427 women in their 
reproductive age group (age 15 to 49 years). Thirty percent of the sample 
reported severe dysmenorrhea pain [227].  
Outcome measurement studies 
We identified a total of nine studies that focused on outcome 
measurement [3-6, 133, 176, 211, 232, 233], of which two were conference 
abstracts [232, 233]. Eight of these were the ones I (co)authored, seven of 
which were published during the PhD, therefore, are included in this thesis. 
Seven studies described the translation and cross-cultural adaptations of 
patient-reported outcome measures in Nepali including results on their 
measurement properties. The measures translated into Nepali were: five 
different versions of pain rating scales (Patient-Reported Outcomes 
Measurement Information System [PROMIS] pain intensity scale, Numerical 
Rating Scale, Verbal Rating Scale, Visual Analogue Scale, and Faces Rating 
Scale-Revised) [133, 233]; measures to assess physical function/disability 
(Oswestry Disability Index [176] Patient-Specific Functional Scale [4], and 
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PROMIS Pain Interference scale [233]); psychosocial measures (Pain 
Catastrophizing Scale [6], Connor-Davidson Resilience Scale [5], PROMIS 
Sleep Disturbance [233], PROMIS Pain Behaviour [233], and PROMIS 
Depression scales [233]); and the Global Rating of Change Scale [3-6, 133, 233]. 
All these measures were found to be valid and reliable in samples of patients 
with chronic pain or musculoskeletal pain. Among all types of scales, we, 
based on a study, recommended Faces Rating Scale-Revised or Verbal Rating 
Scale for assessing pain intensity over the Numerical Rating Scale or Visual 
Analogue Scale, because they are preferred by more Nepalese with 
musculoskeletal pain and were used by the participants with fewer errors 
[133]. 
One major problem identified was the use of translated measures 
without first validating them for the local use. Many studies did not report on 
the details of the instruments used, including their measurement properties 
(e.g., [135, 163, 191, 194, 215]). Also, many studies reported the use of the 
Visual Analogue Scale when in fact a Numerical Rating Scale was used [163, 
191, 194, 215]. See Appendix 2.5 for studies on outcome measurement.  
Diagnostic imaging and investigation studies  
Out of 17 diagnostic studies identified, three each explored headache 
disorders [161, 167, 193] and low back pain [200, 205, 248]; two each studied 
abdominal pain [153, 164], chronic pelvic pain [146, 155] and scrotal pain [157, 
178]; and one each studied rheumatological conditions [143], neck pain [197], 
chest pain [182], mastalgia (breast pain) [140], and juvenile arthritis [209]. 
Summaries of the findings from the diagnostic studies are presented in 
Appendix 2.6.  
 Headache. Three studies used CT scans in all the participants for the 
diagnosis of headache disorders (total N = 448) and found only 4% of the 
participants to have significant scan findings while a majority of the 
participants had either normal or insignificant findings [161, 167, 193].  
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 Chronic low back pain. Three studies using large samples of 
individuals with chronic low back pain performed magnetic resonance 
imaging (MRIs) to identify spine pathology in the study samples [196, 200, 
205]. Karki and colleagues presented data of MRI scans for chronic 
symptomatic individuals with low back pain over a three year period and 
found normal scans or degenerative changes in 94% of the patients [196]. Disc 
bulge along with disc desiccation was the most common degenerative 
findings noted in 82%. Disc herniation was seen in 51%, neural foraminal 
stenosis in 60%, central spinal canal in 56% and nerve root compression in 
32%. 
Chronic neck pain. Karki and colleagues reviewed 750 MRIs and 
found that degenerative disc disease (disc desiccation, disc bulge, or disc 
herniation) was the most common finding in 76% patients [197]. Fourteen 
percent of the MRIs had “normal” findings. 
Chronic pelvic pain. Two small studies (Ns= 48 and 55) explored 
different diagnostic categories in chronic pelvic pain using diagnostic 
laparoscopy and diagnostic ultrasound. Findings were normal in 29% [155] 
and 62% [146] in the two samples. Pelvic adhesions were common is 20% and 
29% of the samples which was the most common presentation in the latter 
sample. On the other hand, simple endometriosis was the most common 
presentation in the first sample. Pelvic congestions were presented in 15% and 
7% of the samples.  
Abdominal pain. In a sample of 300 adolescents and adults with 
abdominal pain presenting in a general outpatient clinic in Eastern Nepal, 
43% were classified as having a gastrointestinal cause, 29% a urogenital cause 
and 10% a psychiatric cause [153]. On the other hand, in 47 children aged 
under 15 years, 87% were classified as having an organic cause for their 
abdominal pain, with worm infestation (giardiasis) being the most common 
(46%) [164]. Similarly, abdominal pain was the most common symptom 
presented in 20% of the total sample in a health camp in rural Nepal [160].   
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Rheumatological disorders. Out of 365 patients presenting at 
Rheumatology Department in the Pokhara district of Nepal with any form of 
rheumatological disorders, soft tissue rheumatism was the most common 
disorder (40%), followed by inflammatory arthritis (21%) and bone and 
cartilage diseases (21%). Rheumatoid arthritis and fibromyalgia were present 
in 20% each, and osteoarthritis of either knee, hip or hand was present in 10% 
[143]. All the patients underwent imaging and laboratory investigations (both 
general and specific tests for each rheumatological conditions).  
Cost of treatment of pain conditions 
 Research related to the cost of treatment of a pain condition is very rare 
in Nepal. We identified only one community survey on a sample of 882 
participants in Eastern Nepal reporting the cost of chronic pain treatment [80]. 
The participants in this sample reported that they spent an average of 8.4% of 
their total income for the treatment of chronic pain.  
DISCUSSION 
This systematic scoping review of research related to pain in Nepal 
identified 116 papers. The great majority of the included studies evaluated the 
efficacy of biomedical interventions or studied pain prevalence. These 
findings indicate a predominance of the biomedical model of pain in Nepal. 
The review also identified some areas of research redundancy and critical 
knowledge gaps, which have both research and clinical implications for 
Nepal, and also perhaps for other similar developing countries.  
Areas of research redundancy in current pain research in Nepal 
The majority of the published studies asked similar (and sometimes 
even the same) research question(s) in identifying optimal medical 
management of post-operative pain, or the use of imaging for the diagnosis of 
non-specific pain conditions. This suggests a potential problem of a waste of 
limited research resources. Also, the focus on imaging research represents a 
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potential ethical problem, given that diagnostic imaging is rarely 
recommended for chronic pain management.  
Knowledge gaps 
 The key knowledge gaps identified after the scoping review of 
literature in 2016, before the start of the Ph.D. were (1) the unavailability of 
PROMs to assess pain and other related domains in individuals with pain 
conditions, and (2) the lack of rehabilitation interventions, including pain 
educational interventions that can be used in pain management. The 
knowledge gaps relating to the need for validating PROMs for use in adults 
with musculoskeletal pain conditions and developing pain education 
interventions in Nepal for managing adults with low back pain were 
addressed in this thesis in Chapters 5 through 9. 
The findings of this scoping review, with the results of updated 
literature search in November 2018 (after the Ph.D. projects were completed) 
highlight several additional gaps in the topic areas of pain research in Nepal. 
First, no studies were identified that sought to estimate the incidence or 
prevalence of a number of important pain conditions, or pain in specific 
populations, including pediatric pain, cancer pain, and pain in ageing 
populations. Also, the studies that estimated the prevalence of pain 
conditions were usually limited to very specific regions of the country, 
working populations (e.g., dentists, nurses, surgeons, software engineers) and 
had small samples. Large population-level studies to estimate the prevalence 
and incidence of various pain conditions would provide better estimates of 
disease burden. Third, research studies to cross-culturally adapt PROMs were 
limited to adult populations and patients with chronic pain or 
musculoskeletal pain. Cross-cultural adaptations of PROMs in other pain 
populations are needed to advance research in these areas. Finally, there were 
very few studies that focused on biopsychosocial assessment and pain 
management.  
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Recommendations for research  
Limiting redundant research 
 Several approaches could be adapted to limit redundant research. First, 
researchers should perform comprehensive reviews of the literature before 
conducting any clinical trial. If meta-analyses of intervention studies have not 
been reported in the literature, this would be a more valuable contribution 
than a redundant additional trial [249, 250]. Second, associations and the 
national research authority (NHRC, Nepal Medical Council, and Nepalese 
Association for the Study of Pain in the context of Nepal) should consider 
encouraging researchers to prospectively register clinical trials. Along these 
lines, national journals should mandate clinical trial registration prior to data 
collection in order for a paper to be considered for publication, consistent 
with the recommendations from the International Committee of Medical 
Journal Editors [251].  
Mobilizing research funding for pain research 
 Addressing the burgeoning pain problem in Nepal requires more 
thoughtful use of limited research funds. Identifying pain as a research 
priority is the first step. Funding should be directed towards: (1) developing 
additional culturally-appropriate outcome measures, (2) implementing 
clinical practice guidelines, (3) evaluating the challenges for the 
implementation of guidelines, and (4) conducting effectiveness trials of 
population-level interventions, including the analysis of cost-effectiveness.  
Administering scales and outcome measures 
 Researchers should consider using valid, reliable, and responsive 
instruments with reference to core-outcome sets for clinical trials (e.g., [88, 
90]). When a desirable instrument is unavailable in a local language, a first 
step would be to cross-culturally adapt and validate the needed instrument(s) 
using recommended guidelines (e.g., [96, 252]).  
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Recommendations for practice 
Overall, clinical assessment and treatment of pain should align more 
with contemporary evidence or clinical practice guidelines. This lack of 
adherence to evidence (or guidelines) is reflected by repeatedly asking the 
same research questions and exposing patients to potentially harmful 
investigations (e.g., medical imaging for non-specific pain conditions) or 
treatments (e.g., bed rest).  The respective regulatory authorities and pain 
society should reinforce the use of treatment guidelines among their 
members.  
Preventing overdiagnosis and overtreatment of pain conditions  
Clinicians should stop routinely using expensive and sometimes 
invasive diagnostic procedures, including imaging, for non-specific pain 
conditions [82, 253, 254]. These diagnostic procedures can have significant 
costs and have limited benefits [84]. ‘Choosing Wisely’ Campaign 
(www.choosingwisely.org) could help clinicians and consumers towards the 
appropriate use of diagnostic tests and interventions in Nepal.   
Invasive interventions, including surgeries and injections which 
continue to be provided for the management of pain conditions in Nepal, 
have significant risks and have been shown to have limited benefits [139, 145, 
151, 181, 204, 222]. Thus, some of these treatments should be avoided until 
further better quality evidence supports their safety and efficacy.  
Study strengths and limitations 
We adapted recommended guidelines for conducting and reporting a 
scoping review [137, 138], and performed comprehensive literature searches. 
However, we did not search the grey literature including theses (other than 
Google Scholar). A systematic review of the research literature that included a 
critical appraisal of the methodological quality of pain research conducted in 
Nepal would provide an overview of the quality of research conducted in the 
country.  
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CONCLUSIONS 
 The majority of articles identified focused on the biomedical diagnosis 
and treatment of pain, suggesting a biomedical focus of pain research and 
clinical practice in Nepal. Pain diagnosis and management should be in line 
with clinical practice guidelines, include more comprehensive contemporary 
biopsychosocial approaches, and a pain research priority agenda should be 
supported at the national level.  
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CHAPTER 3  
Between-country and –language 
differences in chronic pain 
CHAPTER 3 : BETWEEN-COUNTRY 
AND -LANGUAGE DIFFERENCES IN 
CHRONIC PAIN 
[Sharma S, Ferreira-Valente A, Williams A, Abbott JH, Pais-Ribeiro J, Jensen MP: Group 
differences between-countries and between-languages in pain-related beliefs, coping, and 
catastrophizing in chronic pain: A systematic review. Pain Medicine 2020, 0(0):1-16.] 
***
INTRODUCTION 
Chronic pain is a significant problem worldwide, influenced by a 
complex interaction between biological, psychological, and social factors [9]. 
One-year prevalence of chronic pain ranges from 37% to 41% in developed 
and developing countries [130], with substantial percentages having constant 
pain and moderate to severe pain [59]. Chronic pain imposes an enormous 
emotional and financial burden both at an individual and societal level [68], 
and psychological factors contribute to this. 
One such factor is pain beliefs. Pain beliefs can be defined as cognitions 
or thoughts related to the pain problem [255] (such as beliefs about the cause 
of pain, its meaning, or appropriate treatments for pain [256-259]). Such 
beliefs can be personally held, culturally shared, or both [260]. Another factor, 
coping, is defined as cognitive and behavioural responses intended to manage 
stressful events such as chronic pain [255, 261]. Pain-related beliefs and 
coping are often classified as adaptive (i.e., beliefs thought to lead to positive 
outcomes and adjustment) or maladaptive (i.e., beliefs thought to contribute 
to negative outcomes and poor adjustment) [260, 262]. However, it is likely 
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that adaptiveness varies with context – what is maladaptive in one context 
might be adaptive in another. Moreover, this classification disregards the 
cultural appropriateness of behaviour such as seeking others’ emotional 
support versus keeping problems to oneself [263, 264]. 
A third psychological factor – catastrophizing – can be defined as an 
exaggerated negative orientation towards pain [265]. Because catastrophizing 
is often significantly associated with greater pain intensity, pain interference, 
depressed mood, and anxiety [265-267], it is generally viewed as a 
maladaptive (coping) response to pain [268]. However, while catastrophizing 
is viewed in the west as maladaptive because it contributes to a depressive 
thinking bias, in other cultures it could be viewed as maladaptive for different 
reasons; for example, it may reflect a lack of acceptance of (divinely 
determined) fate. 
Cultural factors may, therefore, influence pain beliefs/appraisal, 
coping responses, and catastrophizing [269-272] – all of which are targeted by 
psychologically-based treatments [273-280]. However, “culture” is 
notoriously difficult to define and operationalize. Variables such as ethnicity, 
gender, nationality, language group are commonly used as proxy measures of 
culture in research studies because these variables are thought to reflect 
cultural differences [263, 281-283]. Consistent with this, previous systematic 
reviews related to culture have studied racial and ethnic differences [269, 
284], and religiosity and spirituality [285].  
Regardless of how culture is defined, however, it remains important to 
understand the associations between variables thought to reflect culture – 
variables such as country of origin and language – because these variables 
have the potential to influence the acceptability and efficacy of treatments that 
target pain beliefs, coping, and catastrophizing for change. The findings from 
research in this area could help us to understand the extent to which pain 
treatments may need to be adapted to make them most appropriate to new 
populations who may live in different countries or speak different languages 
than those for whom the interventions were first developed [263]. 
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One recently published review – registered in the PROSPERO registry 
two months after the current review was registered – sought to provide a 
summary of the state of knowledge in this area [284]. These investigators 
reviewed research studies examining differences in pain-related beliefs, 
cognitions, and behaviours as a function of race, ethnicity, and culture in 
samples of individuals with chronic musculoskeletal pain. However, this 
review was limited in that it (1) only included studies whose participants had 
chronic musculoskeletal pain and not other chronic pain problems, and (2) 
limited their search to only two databases. The current study sought to 
address these limitations by including studies whose participants had any 
chronic pain problem and by searching 15 databases. As a result, were we 
able to identify five additional studies not included in the previously 
published review. 
 The primary aim of this systematic review was to increase our 
understanding of the role of country of origin and language spoken on pain 
beliefs/appraisals, pain coping, and pain catastrophizing in individuals with 
chronic pain. We hypothesized that people living in two different countries or 
people living within a country but speaking different languages would 
endorse different levels of pain-related beliefs/appraisals, ways of coping 
with their chronic pain, and the extent of pain catastrophizing [9]. We also 
aimed to explore differences in pain beliefs/appraisals, coping, and 
catastrophizing between country’s income levels.  
METHODS  
Review protocol and registration  
We followed the PRISMA (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses) checklist and Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) guidelines for both the conduct and 
reporting of this systematic review [286, 287]. The review was prospectively 
registered in the PROSPERO registry (CRD42017082449).  
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Eligibility criteria 
We included studies if they: (1) compared pain-related 
beliefs/appraisals, coping, and catastrophizing in different countries or as 
groups within one country that speak different languages, or both in a single 
study; (2) included quantitative scale(s) of pain beliefs/appraisals, pain 
coping, and/or pain catastrophizing; (3) were an observational study (cohort, 
case-control, and cross-sectional studies) or a multi-country clinical trial with 
information on pain beliefs/appraisal, coping, or catastrophizing separately 
for the two countries; and (4) included adults (age 18 years or older) with 
chronic pain (defined as pain lasting for longer than three months), 
irrespective of aetiology (e.g., cancer, trauma, infection, nerve damage, 
musculoskeletal problems, surgery-related, other systemic illness), or body 
part (e.g., headache, neck pain, low back pain, upper or lower extremity pain). 
There were no restrictions in the language and date of publication. We 
excluded studies if: (1) the sample included individuals younger than 18 years 
old; (2) the study did not report a quantitative scale of pain beliefs/appraisal, 
coping, or catastrophizing; and (3) the study was a review, editorial or 
qualitative research.  
Information sources and search strategies 
I adapted several search strategies to identify relevant publications. 
First, we searched 15 databases or search engines for articles to include in the 
review; namely MEDLINE, Embase, Cochrane Central Register of Controlled 
Clinical Trial, PsycINFO, CINAHL, Web of Science, Scopus, PubMed, PEDro 
(Physiotherapy Evidence Database), Google Scholar, ASSIA (Applied Social 
Sciences Index and Abstracts, via PROQUEST), IBSS (International 
Bibliography for Social Sciences, via PROQUEST), LILACS (Literatura Latino 
Americana em Ciências da Saúde), opengrey.eu, and OpenSIGLE. Second, we 
searched unpublished literature in the largest and most widely used clinical 
trial registry platform, ClinicalTrials.gov. Finally, I screened the titles in the 
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reference list of included studies in order to identify articles that were not 
identified by the database search. 
 We searched databases for articles published before 15 January 2019. 
We used the search terms (1) chronic pain, AND (2) country, language, and 
socioeconomic status AND (3) belief OR coping OR catastrophizing, and their 
synonyms in various combinations. We repeated the search again on 
November 21, 2019, with additional search terms to incorporate “language” 
and “socioeconomic status,” but did not retrieve any additional eligible 
papers. A detailed search strategy for MEDLINE can be found in Appendix 3; 
we customised search strategies for each database.  
Domains of interest 
We were interested in studies reporting pain-related beliefs (or 
appraisal), coping, or catastrophizing in two or more countries or language 
groups within the same country. The following are commonly used self-
report questionnaires for the assessment of pain-related beliefs or appraisal, 
coping, and catastrophizing and were used in the included studies.  
Pain beliefs and appraisals 
The Survey of Pain Attitudes (SOPA) is commonly used to assess pain 
beliefs in pain research [256, 257]. It assesses seven belief domains, namely: (1) 
belief in one’s control over pain (Pain Control), (2) belief that one is disabled 
by pain (Disability), (3) belief in a medical cure for pain (Medical Cure), (4) 
belief that others should be solicitous in response to pain (Solicitude), (5) 
belief that medications are appropriate for pain management (Medications), 
(6) belief that emotions influence pain (Emotions), and (7) belief that pain is a 
signal of harm, and that therefore activity should be avoided (Harm) [257]. 
Internal consistencies of its subscales have been shown to be acceptable to 
good with Cronbach’s alphas ranging from 0.70 to 0.84 for its 57-item and 35-
item versions with an exception for Harm subscale (Alpha= 0.66) [288]. One-
item version of the SOPA was created to increase clinical and research utility 
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based on its strength of association with the parent subscale [257]. The single-
items have demonstrated their construct validity similar to that of their full 
version by moderate correlations with scales assessing depression, pain 
intensity, and physical disability [257].  
Goubert and colleagues developed the Low Back Pain Beliefs 
Questionnaire (LBPBQ) by using items from different scales assessing pain 
beliefs [271]. It assesses six domains of back pain beliefs related to harm, 
limited physical activity, beliefs in the medical cure, caution, lack of self-
control, and beliefs in pain medication. The internal consistencies of the 
LBPBQ subscales have not been reported. 
The Tampa Scale for Kinesiophobia (TSK) and the Fear-Avoidance 
Beliefs Questionnaire (FABQ) are the most common questionnaires to assess 
fear of movement, which is considered an important pain-related belief. The 
factor structure of the TSK is inconsistent, with reports of support for both a 
four and a two-factor structure, therefore, we plan to use total score only 
[289]. There are two versions of the TSK, a 17-item and an 11- item version. 
The FABQ assesses fear-based avoidance of physical activities and fear-based 
avoidance of work [290]. The internal consistencies of the TSK scales (both 
versions) have been reported to range from 0.79 and 0.89 for the total scores 
[291-293]. The internal consistencies of the FABQ subscales have been shown 
to range from 0.77 to 0.88 [290].  
The Revised Illness Perception Questionnaire (IPQ-R) assesses 
individuals’ perception of their illness using a self-report in a variety of 
clinical conditions including chronic pain [294]. The first section asks 
questions related to 14 symptoms (if present) that are related to the illness 
(chronic pain in this study). The IPQ-R assesses seven illness perception 
domains labeled identity, consequences, timeline acute/chronic, timeline 
cyclical, coherence and emotional dimension. Internal consistencies of the 
subscales range from 0.77 to 0.88 [294]. 
Finally, the Pain Self-Efficacy Questionnaire (PSEQ) is a questionnaire 
related to pain appraisal that assesses pain-related self-efficacy beliefs by 
Chapter 3: BETWEEN-COUNTRY AND -LANGUAGE DIFFERENCES IN CHRONIC PAIN 
48 
asking how confident the person is about engaging in a variety of activities, 
despite pain [295, 296]. The internal consistency of the original English 
version of the scale was reported to be 0.92 [296]. We considered pain 
appraisal assessed using PSEQ under a broad category of pain beliefs for the 
purpose of the review.  
Pain coping 
Pain-related coping is most commonly assessed using the Coping 
Strategies Questionnaire (CSQ) [297] or one of the versions of the Chronic 
Pain Coping Inventory (CPCI) [257, 298, 299]. The CSQ and CPCI items assess 
a variety of pain coping responses such as guarding, resting, asking for 
assistance, relaxing, task persistence, exercising/stretching, seeking support, 
coping self-statements, diverting attention, reinterpreting pain sensations, 
ignoring pain, praying and hoping, increasing behavioural activities, and 
catastrophizing [257, 297-299]. Although these questionnaires assess multiple 
domains, the scales from these questionnaires most consistently associated 
with patient function and or treatment outcome are those that assess 
catastrophizing [300, 301], guarding and resting [298, 300, 301], task 
persistence [298], and asking for assistance [300, 301]. Other domains 
sometimes associated (but less consistently or strongly) with function include 
exercising/stretching, seeking support, and praying and hoping [298, 300, 
301]. Internal consistencies of the sub-scales of CSQ are generally acceptable 
(range: alpha= 0.71-0.85), except for increasing pain behaviours (alpha= 0.28) 
[297]. Similarly, the internal consistencies of the CPCI sub-scales range from 
0.70 to 0.93 [298].  
Pain catastrophizing 
Pain catastrophizing is another domain sometimes considered as a 
pain belief, and sometimes as a pain coping. For the purpose of this review, 
we are classifying pain catastrophizing as an independent domain from pain 
beliefs and coping. As described previously, it is commonly assessed by the 
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Catastrophizing scale of the Coping Strategies Questionnaire (CSQ; internal 
consistency= 0.78) [297]. It is also assessed using that Pain Catastrophizing 
Scale (PCS; internal consistency= 0.87) [265] and the catastrophizing sub-scale 
of the Pain-Related Self-Statements Scale (PRSS; internal consistency= 0.88) 
[302].  
Study selection and data management 
I transferred references from the search into EndNote X8 (Clarivate 
Analytics) and deduplicated. I screened all the titles and abstracts for 
eligibility on an Excel spreadsheet. Two more senior co-authors than myself 
(JHA and AFV) shared and screened all titles and abstracts independent of 
my screening. I discussed disagreements on eligibility with the co-authors. 
We obtained copies of those that appeared possible to satisfy inclusion criteria 
as full papers. I and a co-author (AFV) then independently read the full-texts 
of these articles and decided on the final list of eligible studies. Any 
discrepancies were resolved by discussion and consensus with a third senior 
reviewer (MPJ) when necessary. The exclusion of the studies was recorded 
with reasons. I and a co-author (AFV) then independently extracted data from 
included studies. Any differences were resolved by discussion and consensus, 
and in the event a consensus was not achieved, a third senior author (MPJ) 
was consulted, who made the final decision. The reviewers were not blind to 
the authorship of the study. In case the screeners or data extractors were the 
authors of the included study, screening and data extraction were completed 
by an author who is not an author of the included studies. 
Data extraction  
We extracted the following data from each article into an Excel 
spreadsheet: authors, year of publication, countries of study, chronic pain 
diagnosis, the language of data collection, and sample sizes from the countries 
or language groups. The demographic characteristics of the samples (mean 
and SD of participants’ age and percentage of female participants) were also 
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extracted when reported. Data (mean and SD) on pain-related 
beliefs/appraisals, coping, and catastrophizing were extracted for the total 
scores or subscales (see below for details), as appropriate and available, if not 
authors were contacted to obtain the data.  
For pain beliefs, we extracted data related to beliefs about (1) control 
over pain, (2) being disabled by pain, (3) medical cure for pain, (4) solicitude 
from others, (5) medications being appropriate for pain management, (6) 
emotional influence on pain, and (7) pain as a sign of harm, from the SOPA 
scales. We extracted fear and avoidance beliefs about physical activity and 
work from the FABQ. We extracted beliefs about fear of movement/re-injury, 
and low back pain beliefs from the total scores on the TSK, and the LBPBQ 
respectively. Data related to pain-related self-efficacy or appraisals were 
extracted from the total scores of PSEQ. For pain coping, we extracted the 
means and SDs for scales assessing guarding, resting, asking for assistance, 
relaxing, task persistence, exercising /stretching, seeking support, coping self-
statements, diverting attention, reinterpreting pain sensations, ignoring pain, 
praying and hoping, and increasing behavioural activities from the CPCI and 
CSQ. Finally, we extracted the means and SDs of pain catastrophizing (i.e., 
CSQ Catastrophizing scale, PRSS-Catastrophizing scale, and PCS).  
Quality assessment 
We adapted the risk of bias tool based on the STROBE checklist [303] 
and Cochrane Collaboration risk of bias tool [304], used by Catley and 
colleagues [305] to assess the quality of studies. The a priori items we planned 
to use as reported in the PROSPERO registry consisted of a 9-item scale. Each 
item was scored as “Yes” (=1), “No” (=0) and “Unclear” (=?). However, we 
subsequently revised this to add one question (item #8 assessing validity and 
reliability of original scale), because after pre-testing data extraction from the 
first few papers, we found studies using modified scales without reports of 
reliability or validity. This potential source of bias needed to be assessed and 
incorporated in the quality ratings. Thus, the final risk of bias tool we used 
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constituted a 10-item checklist with one question on detection bias (diagnosis 
of chronic pain); two questions each on selection bias (if the cases consecutive 
or randomly selected, and if demographic characteristics of the participants 
similar between groups), statistical methods (sample size calculation and 
assessment of confounders), and reporting bias (flow of participants reported 
and dealing with missing items); and three items on validity and reliability of 
the scales used (validity and reliability of the original scales or in language in 
which they were developed, appropriate cross-cultural validity methods used 
if translated in a new language, and reliability of the scales in the population 
and language of interest). Total scores on quality assessment were computed 
for each study, where higher scores indicated better study quality. We then 
classified the quality scores into low (<50%), medium (50-80%), and high 
(>80%) [306, 307]. Two study authors (SS, and AFV) independently assessed 
the methodological quality for each study, resolving any discrepancies by 
consensus, and consulting a third author (MPJ) if consensus could not be 
reached. We did not exclude any articles based on methodological quality. 
Data analysis plan 
To test for possible between-countries and –language group differences 
in pain-related beliefs, appraisal, coping, and catastrophizing, we compared 
the mean scores of the scales assessing these domains across languages and 
countries. Additionally, we also compared the mean scores based on the 
income levels of the countries based on the World Bank indicating socio-
economic aspect of the country. We planned to conduct meta-analyses if two 
or more studies reported the same variable (pain beliefs, appraisals, coping, 
or catastrophizing) in two same languages, countries, or economic regions 
based on the World-Bank country classifications, and if the studies were 
deemed sufficiently homogenous (I2 less than 50%) [304]. When meta-analysis 
was not deemed necessary, the narrative synthesis was guided by a guideline 
on the conduct of narrative synthesis in systematic reviews proposed by 
Popay and colleagues [308]. 
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For the language-group within-country differences (Comparison 1) 
and between-country differences (Comparison 2) in pain beliefs, coping 
responses, and catastrophizing, we computed effect sizes using standardized 
mean differences (SMDs) for any differences between participants between 
pairs of countries (or who spoke two different languages within the same 
country) for each study for each domain separately using means and SDs. We 
pooled the results of two or more samples (languages or chronic pain 
conditions) from the same country to perform a pairwise comparison between 
countries for Comparison 2. If the individual studies included more than one 
language or country, then SMDs for all possible pairwise comparisons were 
computed. We used Hedge’s g to compute SMDs, a recommended method 
when group sizes are dissimilar [309]. It uses the pooling of “weighted” 
standard deviations. Effect sizes (Hedge’s g) of 0.20 were considered small, 
0.50 as medium, and 0.80 as large [310]. All data are presented as effect 
estimates with 95% confidence intervals (CIs). A statistically significant result 
is when the upper and lower bound of the CIs crosses 0 [309]. The results of 
the Comparison 1 and Comparison 2 analyses were collated, interpreted, and 
presented as per recommendations of Cochrane Collaboration [304]. For the 
reporting of the results for between-country and -language differences in pain 
beliefs, coping, and catastrophizing, we summarized the direction of effect, 
size of the effect, consistency of the effect across the studies, and quality of 
evidence. 
 We further compared pain beliefs/appraisals, pain coping, and pain 
catastrophizing scores from the economic region (World Bank classification; 
Comparison 3) if individual studies included data from two or more 
economic region. We pooled the results from two or more countries that 
represented the same economic region in a single study. We reported results 
as SMDs (using Hedge’s g) as in the primary analysis.  
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Addressing missing data  
If a particular study did not report complete data (e.g., SD), we emailed 
the authors with a request to provide data. A second email was sent to the 
study authors after about 3 weeks if they did not respond to the first. A third 
and final reminder email was sent to the authors after two weeks of the 
second email. 
RESULTS 
 We identified and screened 1365 potential articles through the database 
search. We read the full texts of 42 of these, and nine met criteria for inclusion. 
One additional article was identified as a citation in a key study. Figure 3.1 
presents the PRISMA flow diagram and describes the number of studies 
excluded (with reasons), the number of duplicates, and the total number of 
studies included. We contacted the authors of four studies and received data 
for our analysis from the authors of three studies [271, 272, 311].  
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Figure 3.1 PRISMA flow diagram 
Description of the included studies 
 All 10 studies included in the review were observational. Six scales 
were used to assess pain beliefs or appraisals (the LBPBQ, FABQ, TSK, SOPA-
brief, IPQ-R, and PSEQ), two were used to assess pain-related coping (the 
CSQ and CPCI), and three were used to assess pain-related catastrophizing 
(the CSQ- Catastrophizing subscale, PCS, and PRSS-Catastrophizing scale).  
The 10 studies used data from participants in 16 different countries. 
One used data from individuals with chronic pain from Asia (Singapore), two 
each from Australia (Australia), Africa (Ivory Coast, Morocco, South Africa, 
or Tunisia), and South America (Brazil). Similarly, four studies included data 
from individuals living in North America (either USA or Canada) and seven 
of the studies used data collected from participants from Europe (Belgium, 
Denmark, France, Netherlands, Portugal, Spain, or Sweden).  
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The majority of countries represented were high-income countries 
(n=11; Australia, Belgium, Canada, Denmark, France, Netherlands, Portugal, 
Singapore, Spain, Sweden, and the USA), followed by lower middle-income 
countries (n=3; Tunisia, Ivory Coast, and Morocco), and upper middle-income 
countries (n=2; Brazil and South Africa). No countries were represented by 
the low-income country category. The characteristics of the individual 
included studies with a year of publication, countries, and languages studied, 
scales used, diagnosis of chronic pain, study participants’ mean age, SD, and 
percentage of female participants are presented in Table 3.1. We identified 
two studies by Roelofs and colleagues [312, 313] presenting data from 
samples that were largely (but not completely) overlapping, and which had 
the aims of evaluating the psychometric properties of two versions of the TSK 
scale (TSK-11 and TSK-17). We decided to include both of these studies in the 
review for the qualitative synthesis of the results, which allowed us to 
determine if different versions of the same scale resulted in similar or 
different conclusions regarding fear of movement/re-injury beliefs between 
countries. All the studies and samples used the questionnaires in their first 
language or official language of the country (e.g., English is the official 
language of Singapore). 
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Table 3.1 Characteristics of included studies 
Study Chronic pain 
diagnosis 
(Setting) 
Measures of pain beliefs, coping and 
catastrophizing used (Score range) 
Number of 
countries and  
languages  









CPCI-16 (0-14 for each  subscale);  
CSQ-14 (0-12 for each subscale) 
Catastrophizing: 
CSQ Catastrophizing-2 (0-12) 
2 countries; 
2 languages 
Portugal (Portuguese) [117; 55.8 (15.0); 
71%] 
USA (English) [563; 50.8 (11.4); 10%] 
 
2 (Country: Portugal 
vs. USA).  
 





CSQ-6 subscales: Distraction (0-20), 
Dramatization (0-20),  
Reinterpretation of Pain (0-16),  
Efforts to Ignore Pain (0-16), 
Tendency to Pray (0-12) and  
Seeking Social Support (0-32) 
4 countries;  
1 language 
France (French) [83; 43 (11.6); 42%] 
Ivory Coast (French)  [75; 39.0 (9.8); 51%] 
Tunisia (French)  [84; 40.8 (11.2); 61%] 
Morocco (French) [36; 45.2 (11.2); 44%] 
2 (Countries: Ivory 
Coast vs. Tunisia vs 
Morocco vs France) 
3 (Country economic 








 LBPBQ (16-64) 
Two languages Belgium (Dutch) [338; 44.7 (15.8); 52%] 
Belgium (French) [341; 46.4 (17.0); 59%] 
1 (Two language 
speaking samples in 
Belgium) 
Kent, 2014 [311] Chronic LBP 
(Clinical samples) 
Beliefs: 
 FABQ Physical Activities subscale 
(0-40)* 
Catastrophizing: 
CSQ- Catastrophizing subscale (0-
36) 
2 countries;  
2 languages 
Australia (English) [91; 64.0 (?); 63%] 
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Study Chronic pain 
diagnosis 
(Setting) 
Measures of pain beliefs, coping and 
catastrophizing used (Score range) 
Number of 
countries and  
languages  
Country (Language) [n; mean age (SD); % 
Female] 
Comparisons  
Morris, 2012 [316] Fibromyalgia 
(Clinical samples) 
Beliefs: 
 TSK-17 (17-68) 
Catastrophizing: 
 PCS-13 (0-52) 
3 languages South Africa (African) [41; ? (?); ?%] 
South Africa (English) [33; ? (?); ?%] 
South Africa (Xhosa) [19; ? (?); ?%] 
1 (Three languages 
within same country 
– South Africa). 
Roelofs, 2007 
[312] 
Chronic MSK pain 






 TSK -11 (11-44) 
3 countries;  
4 languages;  
7 samples 
Sweden (Swedish) [336; 44.5 (?); 51%] 
Canada (English) [335; ? (?); 44%] 
Canada (French) [175; ? (?); ?%] 
Netherlands (Dutch) [1979; ? (?); ?%] 
1 (2 language 





Chronic MSK pain 







3 countries;  
4 languages;  
7 samples 
Sweden (Swedish) [336; 46.20 (9.40); 53%] 
 Canada (English) [335; 41.80 (8.60); 44%] 
Canada (French) [175; 41.40 (11.30); 53%] 
Netherlands (Dutch) [2236; 47.92 (11.23); 
69%] 
1 (2 language 









2 countries;  
2 languages 
Spain (Spanish) [107; 54.30 (7.10); 100%] 
Netherlands (Dutch) [218; 51.80 (7.20); 
100%] 
2 (Countries: Spain 
vs. Netherlands). 





PRSS-Catastrophizing- 9 (0-45) 
2 countries;  
2 languages 
Australia (English) [311; 49.20 (14.80); 73%] 
Brazil (Brazilian Portuguese) [311; 48.90 
(14.00); 74%] 
2 (Countries: 
Australia vs. Brazil) 
3 (Country economic 
level: HIC vs. 
UMIC). 




Brief SOPA (0-4 for each subscale)  
Coping:  
 CPCI-8 (0-7 for each subscale) 
2 countries;  
1 language 
Singapore (English) [101; 48.27 (?); 47%]  
USA (English) [100; 43.83 (?); 45%] 
 
2 (Country: Singapore 
vs. USA) 
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Study Chronic pain 
diagnosis 
(Setting) 
Measures of pain beliefs, coping and 
catastrophizing used (Score range) 
Number of 
countries and  
languages  
Country (Language) [n; mean age (SD); % 
Female] 
Comparisons  
Abbreviations: CPCI, Chronic Pain Coping Inventory; CSQ, Coping Strategies Questionnaire; FABQ, Fear-Avoidance Beliefs Questionnaire; HICs, High-income countries; 
IPQ-R, Revised Illness Perception Questionnaire; LBPBQ, Low Back Pain Beliefs Questionnaire; LBP, Low back pain; LMIC, Low middle-income country; MSK, 
Musculoskeletal; PCS, Pain Catastrophizing Scale; PRSS, Pain-Related Self-Statements Scale; PSEQ, Pain Self-Efficacy Questionnaire; SOPA, Survey of Pain Attitudes; TSK, 
Tampa Scale for Kinesiophobia; UMIC, Upper middle-income country. 
*Response option changed from 0 – 6 to 0 – 10 format by the study authors.    
? represents unavailable values.  
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Participants 
 The reviewed studies included 6797 individuals with chronic pain 
(excluding the study by Roelofs 2007 [312] which included the same 
participants plus a few additional participants in a subsequent 2011 study 
[313]). The most commonly studied diagnoses were chronic low back pain (n 
= 4 studies [271, 311, 313, 315]; 2224 participants), followed by chronic 
musculoskeletal pain (n = 2 studies [270, 313]; 1526 participants), chronic pain 
in general (n = 2 studies [272, 318]; 823 participants), and fibromyalgia (n =3 
studies [313, 316, 317]; 809 participants). Nine of 10 studies included clinical 
samples. The exception was a study by Goubert and colleagues which used a 
postal survey design to assess a sample representative of the population in 
Belgium [271].  
 The reports that were identified and included in this review were not 
sufficiently homogeneous to allow data pooling for a meta-analysis, because 
no two studies that met the criteria used comparable scales in the same two 
countries or languages. Therefore, we performed a narrative synthesis of the 
results without a meta-analysis.  
The methodological quality of studies  
 We rated four studies as being of moderate quality and remaining six 
as being low quality (see Table 3.2). No studies were classified as being of 
high quality. Only three of 10 studies (30%) included a representative sample 
of consecutive participants, and in only one study (10%) were the 
demographic characteristics of the study participants similar between the 
comparison groups. Seven studies (70%) defined chronic pain as pain lasting 
for at least 3 months consistent with the IASP definition of chronic pain, nine 
studies (90%) either used estimated a priori sample size or included at least 30 
participants in each group. Only one study (10%) controlled for the 
confounders (age, sex, socioeconomic status of the study participants). Two 
studies (20%) reported the flow of participants and how the missing data 
were handled. Seven studies (70%) used reliable and valid scales (i.e., in the 
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original language they were developed in), and eight studies (80%) met the 
criteria for cross-cultural adaptation of scales used. Half of the studies (50%) 
reported the internal consistency of the (multi-item) scales as being at least 
marginally adequate (i.e., internal consistency of at least 0.60 in the current 
sample or clear evidence of its reliability in the population of interest in a 
previous study).  
Deviation from the original study protocol 
Our original goal for this review was to evaluate the role of culture in 
pain beliefs, coping, and catastrophizing, operationalizing culture (as 
previous researchers have) as differences in country, differences in the 
language spoken, or differences in the socioeconomic status of the included 
countries. However, after we registered the study, we changed our views 
regarding the appropriateness of these variables as proxy measures of culture 
[319]. Thus, and although this did not affect the analyses performed, it did 
change how we discussed the findings; that is, we now discuss them as 
directly relating to differences as a function of the demographic variables, as 
opposed to as relating to differences due to “culture.” The second deviation 
from our original protocol was that we omitted the planned analysis to 
examine between-continent differences in pain beliefs, coping, and 
catastrophizing [320], because of changes in the conceptualisation of the 
review during its execution that made these contrasts uninterpretable. The 
third deviation was related to the quality assessment tool as described earlier. 
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Table 3.2 Methodological quality of included studies. 




































0 0 1 1 0 0 1 1 1 0 5/10 Moderat
e 
Genet, 2009 [315] 0 0 1 1 0 0 0 0 1 N/A* 3/9 Low 
Goubert, 2004 
[271] 
1 0 1 1 0 1 0 0 0 0 4/10 Low 
Kent, 2014 [311] 1 0 ? 1 0 0 0 1 1 0 3/10 Low 
Morris, 2012 
[316] 




0 0 ? 1 0 0 0 1 1 1 4/10 Low 
Roelofs, 2007 
[312] 
0 0 ? 1 0 0 0 1 1 1 4/10 Low 
Ruiz-Montero, 
2015 [317] 
? 0 1 1 0 0 ? 1 1 1 5/10 Moderat
e 




0 0 1 1 0 0 1 0 0 N/A* 4/9 Low 
Description of the items: 
1. Representativeness: Are the cases consecutive, or was the sample truly randomly selected from the population of interest? 
2. Similar demographic characteristics: Are the demographic characteristics of the groups (diagnosis, age, and sex) similar? 
3. Diagnosis of chronic pain: Were participants with pain for 3 months or longer included? 
4. Power: Was there a priori method for sample size estimation, or was sample size for each group 30 or more? 
5. Confounding variables: Were the confounding variables controlled for? (matched controls e.g., age, and sex; or use of statistical analysis to control for the confounders) 
6. Reporting flow of participants: Was the flow of participants reported? 
7. Dealing with missing data: Were methods for dealing with missing data described and appropriate? 
8. Validity and reliability: Is the scales in original language reliable and valid measures to assess pain beliefs, coping or catastrophizing? 
9. Cross-cultural adaptation: Did the scales undergo  accepted cross-cultural adaptation processes? 
10. Evidence of reliability: Was evidence presented supporting the reliability of the scales? 
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Differences in pain-related beliefs  
 Nine of 10 included studies (90%) used at least one questionnaire that 
is used to assess pain beliefs or pain appraisal. The results were collated from 
three studies [271, 312, 313] for Comparison 1, eight studies [271, 272, 311-313, 
315, 317, 318] for Comparison 2, and two studies [315, 318] for Comparison 3. 
Overall, we found that 24 of 40 (60%) between-group comparisons were 
statistically significant (8 large, medium, and small SMDs each). The results 
indicate that between-country, -economic region differences in pain beliefs 
exist (see Table 3.3). However, we found no statistically significant 
differences in pain beliefs in people living in the same country but speaking 
different languages based on three low-quality reports [271, 312, 313].  
 Overall, fear-avoidance beliefs (or fear of movement beliefs) were the 
most commonly studied pain beliefs, with 52% statistically significant 
between-group effects (12 of 23 ESs; 5 large, 1 medium, and 6 small) 
indicating the presence of between-country and –economic region differences 
in fear-avoidance beliefs. Similarly, 6 of 8 illness perception beliefs related to 
fibromyalgia (75%) were statistically different between patients with 
fibromyalgia in Spain and the Netherlands, based on one moderate quality 
study [317]. Patients from Spain endorsed more illness belief domains related 
to negative outcomes (e.g., identity, consequences, and cyclic timeline), 
whereas patients from the Netherlands endorsed statistically significantly 
more domains associated with positive outcomes (e.g., personal and 
treatment control, and illness coherence). See Table 3.3 for detailed results.  
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Table 3.3 Standardized mean differences in pain beliefs across countries and languages. 
Study Comparisons (groups) Domain/sub-domain Hedge’s g (size) 95% CI Effects direction 
 
 
Genet, 2009 [315] 
2 (FRA vs CIV) Fear-avoidance (PA) -1.14 (L) -1.48, -0.80 CIV > FRA 
Fear-avoidance (Work) -1.25 (L) -1.59, -0.91 CIV > FRA 
2 (FRA vs TUN)  Fear-avoidance (PA) -0.30 -0.60, 0.01 FRA = TUN 
Fear-avoidance (Work) -0.02 -0.32, 0.29 FRA = TUN  
2 (FRA vs MAR)  Fear-avoidance (PA) -0.27 -0.66, 0.12 FRA = MAR  
Fear-avoidance (Work)  0.28 -0.11, 0.67 FRA = MAR 
2 (CIV vs TUN)  Fear-avoidance (PA) -0.02 -0.33, 0.29 CIV = TUN 
Fear-avoidance (Work)  1.17 (L)  0.84, 1.51 CIV > TUN 
2 (CIV vs MAR) Fear-avoidance (PA)  0.83 (L)  0.42, 1.24 CIV > MAR 
Fear-avoidance (Work)  1.40 (L)  0.96, 1.83 CIV > MAR 
2 (TUN vs MAR)  Fear-avoidance (PA)  0.21 -0.18, 0.60 TUN = MAR 
Fear-avoidance (Work)  0.28 -0.11, 0.67 TUN = MAR 
3 (HIC vs LMIC) Fear-avoidance (PA) -0.26 (S) -0.52, -0.00 LMIC > HIC 
Fear-avoidance (Work) -0.34 (S) -0.60, -0.08 LMIC > HIC 
Goubert, 2004 [271] 1 (Dutch vs French - BEL) LBP beliefs -0.10 -0.25, 0.05 French = Dutch (BEL) 
Kent, 2014 [311] 2 (AUS vs DNK)  Fear-avoidance (PA) -0.19 -0.42, 0.04 AUS = DNK  
 
 
**Roelofs, 2007 [312] 
1 (English vs French - CAN) Fear of movement (TSK-11) -0.19 -0.37, 0.01 French = English (CAN) 
2 (CAN vs SWE)  Fear of movement (TSK-11)  0.62 (M)  0.48, 0.76 CAN > SWE 
2 (CAN vs NLD)  Fear of movement (TSK-11)  0.30 (S)  0.20, 0.39 CAN > NLD 
2 (SWE vs NLD) Fear of movement (TSK-11) -0.13 -0.25, -0.02 NLD > SWE 
 
 
**Roelofs, 2011 [313] 
1 (English vs French - CAN) Fear of movement (TSK-17)  0.04 -0.14, 0.22 French = English (CAN) 
2 (CAN vs SWE) Fear of movement (TSK-17)  0.38 (S)  0.23, 0.53 CAN > SWE 
2 (CAN vs NLD) Fear of movement (TSK-17)  0.44 (S)  0.33, 0.56 CAN > NLD 
2 (SWE vs NLD) Fear of movement (TSK-17)  0.23 (S)  0.12, 0.35 SWE > NLD 
Ruiz-Montero, 2015 
[317] 
2 (ESP vs NLD) IP – Identity  1.10 (L)  0.85, 1.35 ESP > NLD 
IP – Timeline  -0.04 -0.27, 0.19 ESP = NLD 
IP – Consequences  0.66 (M)  0.43, 0.90 ESP > NLD 
IP – Cyclic Timeline -0.21 -0.44, 0.02 ESP = NLD  
IP – Personal Control  -0.46 (S) -0.70, -0.23 NLD > ESP 
IP – Treatment Control  -0.80 (L) -1.04, -0.56 NLD > ESP 
IP – Illness Coherence  -0.58 (M) -0.81, -0.34 NLD > ESP 
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Study Comparisons (groups) Domain/sub-domain Hedge’s g (size) 95% CI Effects direction 
IP – Emotional Representation   0.92 (L)  0.68, 1.16 ESP > NLD 




Thong, 2017 [272] 
2 (USA vs SGP)  SOPA - Control  0.10 -0.18, 0.38 USA = SGP 
 SOPA - Medical cure -0.57 (M) -0.85, -0.29 SGP > USA 
 SOPA – Disability  0.66 (M)  0.37, 0.94 USA > SGP  
 SOPA – Solicitude -0.36 (S) -0.64, -0.08 SGP > USA 
 SOPA – Medication -0.62 (M) -0.90, -0.37 SGP > USA 
 SOPA – Emotions  0.17 -0.10, 0.45 USA = SGP 
 SOPA – Harm -0.57 (M) -0.85, -0.29 SGP > USA 
Abbreviations: d, Effect Size; CI, Confidence Interval; PA, Physical Activity; LBP, Low Back Pain; HIC, High-Income Country; IP, Illness perception; SOPA; Survey of Pain 
Attitudes; AUS, Australia; BEL, Belgium; BRA, Brazil; CAN, Canada; CIV; Ivory Coast; DNK, Denmark; ESP, Spain; FRA, France; MAR, Morocco; NLD, the Netherlands; 
SGP, Singapore; SWE, Sweden; TUN, Tunisia; USA, United States of America; ZAF, South Africa; UMIC, Upper Middle-Income Country. 
Size of effect: L, Large; M, Medium; S; Small. Large effect sizes are boldfaced.  
*Use of “>” indicates significant differences when the effect does not cross 0.  
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Differences in pain-related coping 
 Only three (30%) of studies included at least one questionnaire 
assessing pain coping [270, 272, 315]. Samples were recruited from seven 
countries that met the criteria for analysis for Comparisons 2 and 3. Only one 
study was included for Comparison 3 [315], and no studies met the criteria for 
Comparison 1. Thirty-four of 57 SMDs (60%) computed for differences in pain 
coping indicated that pain coping endorsement is significantly different 
between countries (see Table 3.4). We found that 7, 11 and 16 of these 
statistically significant ESs were large, medium, small respectively.  
 The most commonly observed between-country statistically significant 
difference in coping was for seeking social support (87%; 7 of 8 ESs; 1 large, 2 
medium, and 4 small), followed by 86% each (6 of 7 ESs) for praying and 
hoping (3 large, 2 medium and 1 small ESs), and diverting attention (1 large, 1 
medium, and 4 small ESs). These coping strategies were endorsed more often 
by patients with chronic pain from lower middle-income African countries 
(Tunisia, Ivory Coast, and Morocco) than a high-income European country - 
France. Similarly, guarding and resting was statistically significant in 2 of 2 
comparisons, with samples from the USA endorsing more guarding and 
resting than samples from Portugal or Singapore.  
 On the other hand, there was no statistically significant difference in 
ignoring pain between the same three African countries and France (6 of 6 
SMDs), whereas we found a small ES in ignoring pain between samples from 
the USA and Portugal. Results of pooled estimates of coping strategies listed 
in the CSQ from the three lower-middle income African countries compared 
with a high-income European country (France) showed that the former group 
endorsed statistically significantly more praying and hoping (large ES), seeking 
social support (medium ES), diverting attention (medium ES), and reinterpreting 
pain sensations (small ES) compared to the latter.  
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Differences in pain catastrophizing  
 Four of 10 included studies (40%) assessed pain catastrophizing in six 
countries [270, 311, 316, 318]. Findings from three studies were used for 
Comparison 2, whereas findings from one study were used to perform 
Comparisons 1 and 3. Three of six SMDs (2 medium and 1 small ES) indicated 
that pain catastrophizing reporting is different across countries/ economic 
regions. Of the medium ESs, patients with chronic musculoskeletal pain from 
the USA endorsed more pain catastrophizing (SMD = 0.79) than patients with 
chronic musculoskeletal pain from Portugal [270]. Similarly, patients with 
chronic low back pain from Australia endorsed more pain catastrophizing 
(SMD = 0.70) than those from Denmark [311]. Three non-significant 
differences concerned pain catastrophizing between samples of individuals 
who spoke different languages within South Africa [316] (see Table 3.5).  
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Table 3.4 Standardized mean differences in pain coping across countries. 
Study   Comparisons 
(Groups) 













2 (USA vs PRT) 
CPCI - Guarding   0.74 (M)  0.54, 0.94 USA > PRT 
CPCI – Resting   0.96 (L)  0.76, 1.17 USA > PRT 
CPCI – Asking for assistance  -0.07 -0.27, 0.13 USA = PRT 
CPCI – Relaxation  -0.15 -0.35, 0.05 USA = PRT 
CPCI – Task persistence  -0.50 (M) -0.70, -0.30 PRT > USA 
CPCI – Self-statements -0.05 -0.25, 0.14 USA = PRT 
CPCI – Exercise/ stretch  -0.34 (S) -0.54, -0.14 PRT > USA 
CPCI – Seeking social support  -0.20 (S) -0.40, -0.00 PRT > USA 
CSQ – Diverting attention  0.35 (S)  0.15, 0.55  USA > PRT 
CSQ – Ignoring pain  0.35 (S)  0.15, 0.55 USA > PRT 
CSQ – Reinterpreting pain sensations  -0.12 -0.32, 0.08 USA = PRT 
CSQ – Praying and hoping   0.44 (S)  0.24, 0.64 USA > PRT 








2 (FRA vs CIV) CSQ – Seeking social support -0.94 (L) -1.27, -0.61 CIV > FRA 
CSQ – Diverting attention  -0.95 (L) -1.28, -0.62 CIV > FRA 
CSQ – Ignoring pain -0.10 -0.41, 0.21 FRA = CIV 
CSQ – Reinterpreting pain sensations -0.32 (S) -0.63, -0.00 CIV > FRA 
CSQ – Praying and hoping -2.20 (L) -2.59, -1.80 CIV > FRA 
CSQ – Increase behavioural activities -0.56 (M) -0.88, -0.24 CIV > FRA 
2 (FRA vs TUN)  CSQ – Seeking social support -0.32 (S) -0.63, -0.02 TUN > FRA 
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Study   Comparisons 
(Groups) 
Scales - Sub-domain Hedge’s g (size) 95% CI Effects direction 
 
 
Genet, 2009 [315] 
CSQ – Diverting attention -0.50 (M) -0.81, -0.19 TUN > FRA  
CSQ – Ignoring pain -0.27 -0.57, 0.03 FRA = TUN 
CSQ – Reinterpreting pain sensations -0.49 (S) -0.80, -0.18 TUN > FRA 
CSQ – Praying and hoping -1.45 (L) -1.79, -1.11 TUN > FRA 
CSQ – Increase behavioural activities   0.05 -0.25, 0.35 FRA = TUN 
2 (FRA vs MAR)  CSQ – Seeking social support -0.39 (S) -0.78, -0.00 MAR > FRA 
CSQ – Diverting attention  -0.46 (S) -0.85, -0.06 MAR > FRA  
CSQ – Ignoring pain -0.14 -0.53, 0.25  FRA = MAR 
CSQ – Reinterpreting pain sensations -0.53 (M) -0.93, -0.13 MAR > FRA 
CSQ – Praying and hoping -1.27 (L) -1.70, -0.85 MAR > FRA 
CSQ – Increase behavioural activities   0.38 -0.01, 0.77 FRA = MAR 
2 (CIV vs TUN)  CSQ – Seeking social support  0.59 (M)  0.27, 0.91 CIV > TUN 
CSQ – Diverting attention   0.38 (S)   0.07, 0.70 CIV > TUN 
CSQ – Ignoring pain -0.17 -0.49, 0.14 CIV = TUN 
CSQ – Reinterpreting pain sensations -0.20 -0.51, 0.11 CIV = TUN 
CSQ – Praying and hoping  0.55 (M)  0.23, 0.86 CIV > TUN 
CSQ – Increase behavioural activities   0.60 (M)  0.28, 0.92 CIV > TUN 
2 (CIV vs MAR) CSQ – Seeking social support  0.49 (S)  0.09, 0.89 CIV > MAR 
CSQ – Diverting attention   0.49 (S)  0.09, 0.90  CIV > MAR 
CSQ – Ignoring pain  -0.04 -0.43, 0.36 
CSQ – Reinterpreting pain sensations -0.23 -0.63, 0.17 CIV = MAR 
CSQ – Praying and hoping  0.68 (M)  0.28, 1.09 CIV > MAR 
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Study   Comparisons 
(Groups) 
Scales - Sub-domain Hedge’s g (size) 95% CI Effects direction 
CSQ – Increase behavioural activities   1.02 (L)  0.60, 1.44 CIV > MAR 
2 (TUN vs MAR)  CSQ – Seeking social support -0.08 -0.47, 0.31 TUN = MAR 
CSQ – Diverting attention   0.05 -0.34, 0.44 TUN = MAR  
CSQ – Ignoring pain  0.14 -0.25, 0.53 TUN = MAR 
CSQ – Reinterpreting pain sensations -0.03 -0.42, 0.36 TUN = MAR 
CSQ – Praying and hoping  0.10 -0.29, 0.49 TUN = MAR 
CSQ – Increase behavioural activities   0.32 -0.07, 0.71 TUN = MAR 
3 (HIC vs LMIC) CSQ – Seeking social support -0.55 (M) -0.81, -0.29 LMIC > HIC 
CSQ – Diverting attention  -0.65 (M) -0.92, -0.39 LMIC > HIC 
CSQ – Ignoring pain -0.17 -0.43, 0.08  LMIC = HIC 
CSQ – Reinterpreting pain sensations -0.43 (S) -0.69, -0.17 LMIC > HIC 
CSQ – Praying and hoping -1.75 (L) -2.04, -1.45  LMIC > HIC 
CSQ – Increase behavioural activities  -0.03 -0.29, 0.22 LMIC = HIC 
Thong, 2017 [272] 2 (USA vs SGP) 
         
CPCI - Guarding   0.73 (M)  0.45, 1.02 USA > SGP  
CPCI - Resting   0.42 (S)  0.14, 0.70 USA > SGP 
CPCI - Asking for assistance   0.49 (S)  0.21, 0.77 USA > SGP 
CPCI – Relaxation  0.16 -0.12, 0.44 USA = SGP 
CPCI - Task persistence -0.17 -0.45, 0.10 USA = SGP 
CPCI - Self-statements   0.10 -0.18, 0.37 USA = SGP 
CPCI - Exercise/ stretching -0.04 -0.31, 0.24 USA = SGP 
CPCI - Seeking social support  0.50 (M)  0.22, 0.78 USA > SGP 
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Study   Comparisons 
(Groups) 
Scales - Sub-domain Hedge’s g (size) 95% CI Effects direction 
Abbreviations: d, Effect Size; CI, Confidence Interval; CPCI, Chronic Pain Coping Inventory; CSQ, Coping Strategies Questionnaire; CIV; Ivory Coast; FRA, France; MAR, 
Morocco; PRT, Portugal; SGP, Singapore; TUN, Tunisia; USA, United States of America; HIC, High-Income Country; LMIC, Lower Middle-Income Country. 
Size of effect: L, Large; M, Medium; S; Small. Large effect sizes are bold faced.  
Table 3.5 Standardized mean differences in pain catastrophizing across countries and languages. 
Study Comparisons (n) Scale used Hedge’s g 
(size) 
95% CI Effects direction 
Ferreira-Valente, 2011 [270] 2 (USA vs PRT) CSQ- Catastrophizing subscale  0.79 (M)  0.59, 0.99 USA > PRT 
Kent, 2014 [311] 2 (AUS vs DNK)  Brief Catastrophizing scale  0.70 (M)  0.47, 0.94 (AUS > DNK) 
Morris, 2012 [316] 1 (English vs Xhosa - ZAF) PCS  0.38 -0.19, 0.95 English = Xhosa 
1 (English vs African - ZAF) PCS  0.11 -0.35, 0.56 English = African 
1 (Xhosa vs African - ZAF) PCS -0.27 -0.82, 0.27 Xhosa = African 
Sarda, 2009 [318] 2, 3 (AUS/HIC vs BRA/UMIC) PRSS- Catastrophizing sub-scale  0.20 (S)  0.05, 0.36 AUS/HIC > 
BRA/UMIC 
Abbreviations: d, Effect Size; CI, Confidence Interval; CSQ, Coping Strategies Questionnaire; PCS, Pain Catastrophizing Scale; PRSS, Pain-Related Self-Statement Scale; HIC, 
High-Income Country; UMIC, Upper Middle-Income Country; AUS, Australia; BRA, Brazil; DNK, Denmark; PRT, Portugal; USA, United States of America; ZAF, South 
Africa.  
Size of effect: M, Medium; S; Small. Medium effect sizes are boldfaced.        
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DISCUSSION 
The primary aim of this systematic review was to determine if pain 
beliefs/appraisals, coping, and catastrophizing varied between-countries or 
between language groups within a country. The findings suggest that 
between-country differences in pain beliefs/appraisals, coping, and 
catastrophizing may exist for some pain-related domains, but not for all. If 
between-country differences do exist, the findings suggest that these are more 
likely to occur for fear of movement and re-injury, some subscales of pain 
coping (resting and guarding, seeking social support, diverting attention, and 
praying and hoping), and pain catastrophizing. However, as discussed later, 
these conclusions should be viewed as tentative at this point; additional 
studies using higher quality methods are needed to determine the reliability 
of the findings from the studies reviewed here. 
Differences in pain-related beliefs  
The findings from low- to moderate-quality evidence suggest that 
differences in fear-avoidance beliefs between countries appear to exist. 
Specifically, the mean values for fear-avoidance beliefs in the Ivory Coast 
were greater than in Tunisia, Morocco, and France; and Canadian samples 
endorsed higher levels of fear-avoidance beliefs than samples from Sweden 
and the Netherlands. Several factors could potentially explain the between-
country differences in patients’ observed fear-avoidance beliefs, including the 
pain treatments available in a country (a function of historical, political and 
economic influences) and health professionals’ pain beliefs [321]. For example, 
health professionals in some countries tend to advise about resting rather 
than an activity which is counter to evidence but may foster fearful beliefs in 
patients [1]. The factors that contribute to the between-country differences in 
fear-avoidance beliefs should further be explored using higher quality 
research designs (discussed later). 
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Between-country differences in other types of pain beliefs were fewer 
and less consistent than in fear-avoidance beliefs, in part because of the 
limited number of studies on pain beliefs using the same questionnaire(s). For 
example, three studies [272, 317, 318] compared differences in pain 
beliefs/appraisals using scales that assess somewhat different constructs 
(IPQ, PSEQ, SOPA), which were therefore not pooled. Whether or not 
systematic differences exist between pain beliefs other than fear-avoidance 
beliefs as a function of cultural difference will require additional research.  
Differences in pain-related coping  
We observed that individuals with chronic low back pain from the 
three lower middle-income African countries (Tunisia, Morocco and Ivory 
Coast) endorsed more praying and hoping (large effect size), seeking social 
support (medium effect size), and diverting attention (medium effect size) as 
pain coping responses, but no significant differences were found in ignoring 
pain and increasing behavioural activities, relative to individuals from France, 
based on a single low-quality study [315]. The differences identified in the 
studies reviewed here could be related to either differences in ethnicity, 
religiosity, socio-economic status, or some combination of these or other 
factors.  
Differences appeared in comparisons of guarding, resting, and task 
persistence between samples of people with chronic pain in the USA versus 
the samples from Portugal and Singapore, but not in relaxation. However, 
data used to compare coping responses in these two studies were not 
collected concurrently but 5 to 10 years apart. Additionally, it is possible that 
the between-country differences found could be in part due to differences in 
the overall health care systems of the countries, including the availability of 
more paid sick leave in the USA (especially compared to Singapore), which in 
turn may promote more passive forms of coping strategies such as resting 
and guarding. This possibility could be tested by specific comparisons 
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between countries that control for or evaluate the effects of measures of health 
care sick leave policy variables. 
Differences in pain catastrophizing  
We observed that pain catastrophizing was significantly different 
across countries based on findings from three studies. Specifically, a sample 
of people with chronic pain from the USA endorsed higher levels of pain 
catastrophizing than the sample from Portugal [270], and those from 
Australia endorsed more pain catastrophizing than samples from Denmark 
[311] and Brazil [318]. However, there were no significant differences in pain 
catastrophizing within different language speaking groups within South 
Africa [316] although the study was small. The small number of studies limits 
any conclusions regarding pain catastrophizing; additional studies from 
different countries (and different language groups within a single study), 
ideally using larger sample sizes, are needed.  
Research recommendations 
 The findings from the current review could help to guide future 
research on group differences between countries or between groups that 
speak different languages, or cultural differences in general, in pain beliefs, 
coping responses, and catastrophizing. Culture is a very complex concept, not 
yet satisfactorily defined or operationalized in the context of pain research. At 
present, for psychological domains such as pain beliefs/appraisals, coping, or 
catastrophizing, studies that describe themselves as “cross-cultural” 
predominantly use scales originally developed in western countries. It is 
challenging to determine if between-country differences in scores from 
(translated) questionnaires that are rooted in western philosophy and 
psychology reflect differences between respondents or non-equivalence of 
culture and/or translation, especially when research participants are recruited 
from a non-western country. Bicultural researchers with expertise in both 
qualitative and quantitative methods could help develop appropriate and 
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culturally sound ways of assessment of pain-related domains [322]. A meta-
synthesis of existing qualitative studies in this area may also further our 
understanding of the role of culture (however defined) in chronic pain.  
Ideally, cross-cultural comparison research would collect data from 
individuals from different cultures (however defined) concurrently rather 
than comparing with pre-existing data; using transparent sampling methods; 
and paying attention to local norms of social desirability [323]. Similarly, 
researchers should consider conducting longitudinal studies to explore how a 
coping strategy assessed at one point in time predicts subsequent pain and 
function. A study comparing the endorsement of certain pain coping 
strategies between individuals from different countries or who speak 
different languages using a cross-sectional design provides at best very 
limited information regarding the relative efficacy of the coping response in 
the population studied, because a coping strategy that is adaptive for one 
individual in one situation (or from one country) is not necessarily adaptive in 
another situation for the same person, or a person from another country.  
Given the current findings suggesting some between-country 
differences in pain beliefs, coping, and catastrophizing, another 
recommendation is that a treatment developed in and recommended for 
individuals from one country or who speak one language should not 
necessarily be assumed to be effective in individuals from another country or 
who speak another language without evidence of efficacy in the target 
population. There is a growing trend to apply psychological interventions for 
chronic pain that were developed in one country to individuals from a 
different country [7, 8, 324, 325]. However, before trying to change beliefs or 
coping strategies in individuals from a different country, it would be useful to 
first conduct research to identify the effects of particular pain beliefs and 
coping responses on pain and function in the target population in that 
country.  
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Limitations  
 Although we adapted high-quality systematic review methods 
recommended by Cochrane Collaboration and PRISMA guidelines (searching 
15 databases and grey literature without limiting our search to language or 
date of publication), it is important to recognize the review’s limitations.  
First, the cross-country comparison of pain beliefs, coping, and 
catastrophizing does not adequately consider individual factors such as 
race/ethnicity, socioeconomic status (occupation, education, and income), 
religion, lifestyle factors (e.g., generally active versus sedentary), individual 
access to healthcare, or country-related factors such as the health care system 
(e.g., self-funded versus publicly funded), worker compensation policies, and 
geography. We cannot confirm whether the between-country differences 
identified are due to racial differences [269], ethnic differences [284], or 
individual’s access to healthcare, or one or more of many other factors which 
might influence beliefs and that these could explain at least in part, the 
differences found. Further, ethnic groups within a country can be so diverse 
that grouping people together “simply on the basis of the country” obscures 
important differences. Similarly, immigrant individuals to a host country may 
not necessarily hold views of other individuals who live in that country; may 
or may not be partly or fully acculturated in different areas of life, and the 
level of acculturation could potentially influence their pain beliefs or coping 
responses, as well as the impact of those beliefs and coping responses on pain 
and function [326]. Differences under investigation need to be clearly 
specified. Although some may consider between-country differences as 
cultural differences [283, 327], while others argue that “country” is not a valid 
proxy for culture [319].  
The second limitation is related to the stringent inclusion criteria used 
for this review. For example, we chose to include studies based on their use of 
quantitative scales to assess pain beliefs, coping or catastrophizing. However, 
the use of quantitative scales to assess psychological functions has limitations 
that have been noted for decades [328, 329]. The widely accepted view is that 
Chapter 3: BETWEEN-COUNTRY AND -LANGUAGE DIFFERENCES IN CHRONIC PAIN 
76 
it is possible to quantify psychological domains using multiple-item 
questions, such as those used in the studies reviewed here. Either way, an 
additional way to address the role of culture in cognitive and behavioural 
responses to pain would be by qualitative studies across two or more 
countries, and comparison of emergent themes.  
  The third limitation of this and other systematic reviews on this topic 
is the limited number and heterogeneity of eligible studies (i.e., they studied 
different patient populations and used different scales to assess the same 
domain), many of low- to moderate-quality for comparison purposes, since 
most were designed to (1) evaluate measurement properties of patient-
reported questionnaires or (2) compare between-countries differences using 
pre-existing datasets [270, 272]. Findings from adequately powered 
quantitative and qualitative studies specifically designed to evaluate the 
effects of countries, and using the same set of measures and procedures 
concurrently, would be important to be able to draw firmer conclusions.  
 Finally, the between-country similarities and differences in the scale 
scores (of pain beliefs/appraisal, coping, and catastrophizing) identified in 
this review could have been influenced by the different language versions of 
the questionnaires used in eight of 10 studies included. To address this issue, 
future researchers should use cross-culturally adapted scales that are valid 
and reliable in both the countries/language being compared whenever 
possible. 
CONCLUSIONS 
Despite the review’s limitations, the findings indicate that between-
country differences appear to exist in a number of pain beliefs/appraisals 
(specifically, fear-avoidance beliefs), pain coping responses specifically, use of 
resting, guarding, praying, and hoping), and pain catastrophizing, while 
between-country differences do not appear to exist for other pain beliefs or 
coping responses.  
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The findings indicate that additional research on the role of the country 
(both country of origin as well as the country where an individual lives) on 
pain responses is warranted. Such research should: (1) use procedures 
specifically designed to address this question including the collection of data 
at the same time using measures that are known to be culturally relevant (e.g., 
have the same underlying meaning in the samples studied); and (2) use 
qualitative approaches to evaluate pain-related beliefs/appraisals, coping, 
and catastrophizing to determine identify similar and different themes in the 
different samples. 
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CHAPTER 4 : TRANSLATION AND 
MEASUREMENT PROPERTIES 
Chapter 4 presents a background to issues regarding the translation 
and cross-cultural adaptation of patient-reported outcome measures (PROMs) 
into new target languages, as well as a background on the measurement 
properties of PROMs. Specifically, this chapter describes important details 
about PROMs as well as a description of the measurement properties that will 
be considered when evaluating the measures discussed in Chapters 5 through 
8. These chapters describe the translations, cross-cultural adaptations and 
validation of five PROMs into Nepali.     
Patient-reported outcome measures (PROMs) 
PROMs are essential for monitoring and improving the quality and 
effectiveness of health care [330]. Assessment of pain intensity [331], physical 
function [332], patients’ impression of global change [333], pain 
catastrophizing [265], and resilience [334] are important “patient-centred” 
outcomes in both clinical practice and research in the area of pain [88, 335]. 
Further, an assessment of patients’ impression of global improvement is 
recommended as an anchor for the assessment of the measurement properties 
of patient-reported outcome measures (PROMs) [336].  
How are PROMs developed? 
Developing a PROM requires high levels of expertise, time and 
resources [337]. As a first step, a careful and systematic review of literature 
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needs to be performed before developing an instrument in order to avoid 
duplicating research and save time and resources [337, 338]. Following this, 
several steps are involved in developing a measurement instrument, 
including: defining the construct to be measured, developing items and 
response options, pilot-testing, and field-testing — all of which are performed 
in an iterative process [338]. When a PROM is already available to measure a 
construct in another language, it can save time and resources to translate this 
measure into the new (target) language [339]. However, pilot-testing (or 
cognitive debriefing) to assess the content validity (comprehensibility, 
comprehensiveness, and relevance), field-testing that involves factor analyses, 
and assessment of measurement properties (reliability, validity, and 
responsiveness) are still required when adapting a PROM from one language 
into another [96, 338, 340, 341].  
PROMs are generally developed using one of the two models: 
reflective or formative [342]. Most PROMs used in healthcare are developed 
using the reflective model. In this model, all items on a scale are developed to 
assess a single underlying construct and are therefore the indicators of the 
same construct. In this approach, all of the items within the scale are 
correlated with each other. As a result, missing responses to one or more 
items may not be of concern when computing a total score [338, 342]. For 
example, the Pain Catastrophizing Scale (PCS) [265] is developed based on 
the reflective model. Each item in the scale assesses and reflects the construct 
of pain catastrophizing (via its sub-scales rumination, helplessness, and 
magnification), and each item correlates with the others.   
On the other hand, in the formative model, each item within a scale are 
thought to be key to the whole construct being measures. Therefore, for 
measures developed using the formative model, the total score cannot be 
computed if any of the item responses are missing [338, 342]. Moreover, the 
items on a scale developed using a formative model do not necessarily, nor 
are they required to, correlate with each other. One example of a formative 
model that de Vet and colleagues describe in their book on Measurement in 
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Medicine [338] is the formation of the construct of socioeconomic status (SES). 
SES is a construct that is assessed by taking into account individuals’ levels of 
education, income, and occupations. Measures of all three of these domains 
are needed to create a measure of the SES construct. Moreover, these domains 
are not interchangeable, do not necessarily correlate highly, and missing 
information regarding one or more of these domains would compromise a 
comprehensive assessment of SES.  
Translation of a PROMs into a target language 
Development of a PROM is a time-consuming process that requires 
high-levels of expertise in both qualitative and quantitative research methods 
[338, 339]. Therefore, translation of an existing measure to assess a construct 
or a domain of health is recommended over developing a new instrument in a 
language when a valid and reliable instrument to assess that domain is 
available in another language [337, 338]. However, the translation process 
should involve cross-cultural adaptation processes.  
Several guidelines have been proposed to translate and cross-culturally 
adapt a PROM available in one language into a different language [96-98]. 
Although there are some nuances to the translation processes in different 
guidelines, the process primarily consists of forward translations of a PROM 
from the source language (the language in which a PROM was developed, and 
is being translated from) to the target language (the language that a PROM is 
being translated into), synthesis or reconciliation into a single version, back 
translation(s) into the source language, feedback on the translations usually in 
an expert committee meeting, and pre-testing of the final agreed version 
using cognitive debriefing methods.  
The expert committee is responsible to ensure the high-quality of 
translation, retain the original meaning, improve comprehensibility, and 
discuss any required cross-cultural adaptations [96]. It usually consists of the 
translators involved in the translations (forward and backward translators), 
researchers involved in the study, language professionals (or experts), health 
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professionals (i.e. subject expert) and methodologists (process experts). 
Although the developers of the PROMs form an integral part of the 
translation process, they may not be available throughout the translation 
phases. Their contribution is critical to review the back-translation of the final 
cross-culturally adapted PROMs. The expert committee ensures semantic (if 
meanings are the same in original and translated version), idiomatic (if the 
translations of idioms convey accurate meaning), experiential (if experiences 
of daily lives are captured accurately), and conceptual (if the conceptual 
meanings are accurately reflected between the cultures) equivalence [96].   
Alternatively, the FACIT guidelines for translation and cross-cultural 
adaptation of PROMs emphasise less on in-person committee meeting [252]. 
The meetings are viewed as being dominated by the person who is senior or 
is most vocal. Other alternative views or options can be suppressed in this 
process. For these reasons, FACIT recommends independent review reports 
from all members involved, with an aim to provide equal chances to all 
reviewers of the translations and therefore enable universality of translations 
[252].   
The cognitive debriefing process helps in cross-cultural adaptation and 
helps to retain the original meaning of the PROM in the source language. 
Cognitive debriefing is then followed by field testing and a standard 
assessment of the measurement properties of the translated measure.  
Measurement properties  
The literature on PROMs is inconsistent with respect to the definition 
of different measurement properties, reflecting ambiguity in the research in 
this space. It also confuses the consumers of cross-cultural adaptation 
research. To solve these discrepancies, the COSMIN (Consensus-based 
Standards for the selection of health Measurement INstruments) created a 
consensus statement to facilitate consistent use of terms related to 
measurement properties [340-348]. The COSMIN authors conducted a Delphi 
study including 43 experts in the area of PROMs with the background of 
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epidemiology, statistics, psychology, and clinical medicine from different 
countries, in order to agree in the terminologies, used [346]. Figure 4.1 
describes the different terms agreed by the COSMIN taxonomy of 
measurement properties. I have followed COSMIN recommendations for all 
definitions used in this thesis.  
 
Figure 4.1 COSMIN taxonomy 
Measurement properties refer to the reliability, validity, and 
responsiveness of a PROM. It is also commonly referred to as “psychometric 
properties” or “clinimetric properties”. I have chosen to use “measurement 
properties” to keep it consistent with COSMIN recommendations, throughout 
the thesis, which refers to ‘‘a feature of a measurement instrument that 
reflects the quality of the measurement instrument’’ [346].  
In order to use a multi-item scale for a cross-sectional study, at a 
minimum the PROM should have acceptable internal consistency and 
construct validity. In addition, when using a PROM in a longitudinal study, 
the PROM should also demonstrate at least adequate test-retest reliability 
with the reports of the standardized error of measurement (SEM). The 
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smallest detectable change (SDC) or the limits of agreement need to be 
assessed. In order to support the use of a PROM in a clinical trial, it is 
important to demonstrate that the PROM can change with treatment (i.e., 
there is evidence of responsiveness) and information regarding the measure’s 
minimum important change (MIC) is necessary. Below I have provided 
descriptions of each of the measurement properties. 
Reliability 
 Internal consistency. Internal consistency refers to “the 
interrelatedness of the items within an instrument”. This definition was 
proposed by Cortina [349] and endorsed by COSMIN recommendation [346]. 
For internal consistency to be interpretable, two key requirements are that: (1) 
all items within the scale are interrelated for the scales developed using a 
reflective model, and (2) all items reflect a common construct [342]. In other 
words, the scale (or its subscales when present) should reflect 
unidimensionality, which is a requirement of internal consistency. Cronbach’s 
alpha is commonly used to assess internal consistency. Internal consistency is 
not necessary for an instrument developed using a formative model because 
the items are not correlated with each other, instead they together form a 
construct.  
Test-retest reliability. Test-retest reliability refers to “the proportion of 
the total variance in the measurements, which is because of true differences 
between patients” [346, 350]. It is commonly assessed using the intraclass 
correlation coefficient (ICC). ICCagreement is more commonly used in the 
assessment of reliability in PROMs because we are interested in an agreement 
between two administrations of the measure at different time points. 
ICCagreement accounts for any systematic errors between the two (or more) 
measurements. On the other hand, neither the ICCconsistency nor the Pearson 
correlation coefficient accounts for the systematic error. Thus, both tend to 
overestimate reliability when systematic errors are present. That is, values of 
ICCconsistency are always greater than the values of ICCagreement when systematic 
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errors exist. But, both ICCconsistency and Pearson correlation coefficients will 
retrieve reliability values equal to ICCagreement when there is no systematic 
error, although this is rarely the case. In the context of PROMs, reliability is 
assessed using test-retest reliability by administering the PROMs to 
respondents on two or more occasions. Reliability coefficients can range from 
0 (no reliability) to 1 (perfect reliability).  
Measurement error  
Measurement error refers to “the systematic and random error of a 
patient’s score that is not attributed to true changes in the construct to be 
measured” [346]. Two important parameters of measurement errors used in 
the thesis are described below.  
The standard error of measurement (SEM). SEM is the commonly 
used parameter to report measurement errors of PROMs. It is the “standard 
deviation of errors of measurement that are associated with test scores from a 
particular group of examinees” [351]. In the context of PROMs, it is the 
standard deviation of errors of measurement that are associated with two 
scores in PROMs. It can be calculated in various ways. One popular way of 
computing SEM and that is used in this thesis in Chapters 5 through 8, is by 
using the formula, SEM = SDpooled √(1-ICC); where ICC is computed in the 
same population on which SEM is being computed [338].   
Limits of agreement. Limits of agreement assess agreement between 
repeated measurements (test-retest, inter-rater, or intra-rater), that is, how 
close the scores are between repeated measurements [352]. It is related to the 
measurement error. It falls under the same umbrella term of “reproducibility” 
along with reliability, which concerns the degree to which repeated 
measurements provide similar or reproducible results [352]. However, limits 
of agreement and reliability assess different things. Reliability is more 
concerned if patients can be distinguished from each other despite the 
measurement error [352]. 
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Validity 
It refers to “the degree to which a PROM measures the construct(s) it 
purports to measure” [346]. Validity can broadly be divided into three types: 
content, construct, and criterion-related.  
Content validity. It refers to “the degree to which the content of a 
PROM is an adequate reflection of the construct to be measured” [346]. The 
Delphi study published by the COSMIN group included two key components 
to assess content validity: relevance and comprehensiveness. To assess the 
relevance, each individual item is questioned if they assess the underlying 
construct, population, and purpose [342]. Comprehensiveness, on the other 
hand, assesses if all aspects of the construct are being assessed by items in the 
measurement instrument.  
More recent COSMIN guidelines to assess content validity [340, 341] 
also includes comprehensibility in addition to relevance and 
comprehensiveness. It means that the target population is able to understand 
the instructions, items, and response options and that they serve the purpose 
of why they were created.  
Construct validity. The degree to which the scores of a PROM are 
consistent with hypotheses (for instance with regard to internal relationships, 
relationships to scores of other instruments, or differences between relevant 
groups) based on the assumption that the PROM validly measures the 
construct to be measured [346]. Construct validity further consists of 
structural validity, cross-cultural validity, and hypothesis testing.  
Structural validity refers to the factor structure of the instrument. It is 
assessed using exploratory and confirmatory factor analyses.  
Cross-cultural validity refers to the degree to which the performance of 
the items on a translated/culturally adapted patient-reported instrument is an 
adequate reflection of the performance of the items of the original version of 
the same instrument. To assure cross-cultural validity, the steps in translation 
of a PROMs from one language to another should be completed carefully. 
Cross-cultural validity in classical test theory can be assessed using 
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confirmatory factor analysis whereas a differential item functioning is 
required if a PROM is originally developed using item response theory 
principles [344].  
Hypothesis testing refers to the scores of patient-reported instrument 
scores which are consistent with a priori hypotheses [346]. It is assessed by 
testing pre-specified hypotheses on direction and magnitude of correlation or 
difference and checking whether these a priori hypotheses are met. Evidence 
that 75% or more hypotheses tested are met, provides more evidence on the 
construct validity of an instrument.    
Criterion-related validity. It refers to “the degree to which the scores 
of an instrument are an adequate reflection of a gold standard” [346]. A gold 
standard instrument should assess the same construct as that of instrument in 
question with an implicit hypothesis that the new instrument is as good as the 
gold standard instrument. In the context of PROMs, the longer version 
instruments are the only criterion or the gold standard instruments for their 
short forms. Other than the longer version scales, there is no other acceptable 
“gold standard” measure in PROMs.  
Criterion-related validity is of two types. Concurrent validity is assessed 
in a similar way to hypothesis testing by administering the instrument in 
question and criterion instrument concurrently, with a priori hypotheses 
regarding the direction and magnitude of correlation. Predictive validity, on 
the other hand, seeks to find out whether the instrument under study predicts 
the gold standard instrument scores in the future. For the concurrent validity, 
the shorter version of the instrument being tested is expected to correlate 
strongly with the criterion instrument (i.e., longer versions of the same scale).  
The correlation coefficient of 0.70 is generally considered adequate [338].   
Responsiveness  
 Responsiveness refers to “the ability of an instrument to detect change 
over time in the construct to be measured” [346]. It is considered similar to 
construct and criterion validity with the only difference that responsiveness is 
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related to the validity of a change score whereas construct/criterion validity 
refers to the validity of a single score. It is assessed in a similar way to 
construct/criterion validity by testing of a priori hypothesis.  
The need for the translation and adaptation studies  
The use of outcome measures is limited in Nepal because of the low 
literacy levels of much of the population of Nepal, the general unavailability 
of measures in Nepali, and a lack of awareness of need and usefulness of 
outcome measures in clinicians and researchers in Nepal.  Despite the 
acceptable validity and reliability and wide applicability of various PROMs in 
different languages, many cross-culturally adapted, reliable, valid, and 
responsive measures are not available in Nepali [1].   
Before PROMs can be used in clinical practice and research, they 
should be translated, cross-culturally adapted and validated in the language 
of the target population [96, 337].  For a measure to be acceptable to use, it is 
important to know its measurement properties such as reliability, validity, 
and responsiveness to change as a result of treatment or time [96, 252]. 
Translation of these measures into Nepali using standard recommended 
guidelines can improve their wide use in both research and patient care in 
Nepal.   The translation of GRoC is particularly important, as this can provide 
an external anchor that researchers in the future can use to investigate the 
measurement properties of other PROMs in Nepal and to track change of 
health conditions in Nepal. The measurement properties of the GRoC should 
further be tested in future studies.  
Summary 
This chapter summarised the key measurement properties assessed in 
the following four Chapters (5 – 8) in this thesis.  Among the measurement 
properties, the key domains identified that are essential to test before using 
PROMs in clinical practice and research are: reliability (internal consistency, 
test-retest reliability, measurement errors) and validity (cross-cultural 
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validity, content, and construct validity). To use a scale as an outcome 
measure in clinics or research to track improvement in the domains, the 
additional requirement of responsiveness is necessary.  
The next four Chapters (5 – 8) were informed by a literature search on 
pain research in Nepal in 2014 (preliminary search of the scoping review 
presented in Chapter 2), as a result, these studies were conceived in 
2015/2016, and three sets of data were collected for these studies from 2015 to 
2017 (two datasets before thesis enrolment and one dataset after thesis 
enrolment). Analyses for Chapters 5 and 6 used the same dataset, and 
analyses for Chapters 7 and 8 used the same two datasets. I performed data 
cleaning, analysis, and wrote the manuscripts after my enrolment in the Ph.D. 





























CHAPTER 5  
The Numerical Pain Rating Scale 
and The Global Rating of Change 
CHAPTER 5 : THE NUMERICAL 
PAIN RATING SCALE AND THE 
GLOBAL RATING OF CHANGE 
[Sharma S, Palanchoke J, Reed D, Abbott JH: Translation, cross-cultural adaptation and psychometric 
properties of the Nepali versions of numerical pain rating scale and global rating of change. Health 
Qual Life Outcomes 2017, 15(1):236.] 
***
INTRODUCTION 
Outcome measurement is essential to monitoring and improving the 
quality and effectiveness of health care [330]. Assessment of pain intensity 
[331] and patients’ impression of global improvement [333] are important
“patient-centred” outcomes in both clinical practice and research, as patients 
are asked to rate their own pain intensity and global change in their health 
status [88, 335]. Further, assessment of patients’ impression of global 
improvement is recommended as an anchor for assessment of the 
measurement properties of patient-reported outcome measures (PROMs) 
[336]. 
Pain intensity is often the primary focus of treatment [353] and is a 
preferred outcome of the assessment in both clinical practice and research for 
conditions such as cancer, rheumatic diseases, low back/ neck conditions, and 
post-operatively [354-357]. Pain intensity is routinely assessed in clinical 
practice using the Numerical Pain Rating Scale (NPRS) [358]. It has acceptable 
measurement properties. Out of many versions of numerical rating scales, the 
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11-point NPRS is commonly used [88, 355]. The anchor at the left is 0, 
corresponding to “no pain”, and the anchor at the right side means “worst 
possible pain” or “maximum pain”. The NPRS is a very simple to use, can be 
administered by patient self-report, or verbally by face-to-face interview, or 
over a telephone, and has wide applicability to a variety of pain-related 
conditions [355, 359-361]. One of the advantages of this measure is that it can 
also be used in individuals with low literacy. It is used routinely in many 
countries and languages [355]. 
The global rating of change (GRoC) scale was developed to use as an 
external anchor to determine the minimal important differences of health-
related quality of life measures [362]. The GRoC scale is easy to administer, 
requires minimal skills or training, has good reproducibility, and is sensitive 
to change [330, 363].  While scores correlate with pain, disability and quality-
of-life measures, the open nature of the question allows the patient to take 
into account other factors that he or she may consider important in his or her 
clinical situation [333]. It is a Likert scale with a mid-point representing “no 
change”, a left anchor representing “very much worse” and a right anchor 
representing “very much better” or “recovered completely”. A variety of 
GRoC scales have been used in research including 15 points, 11 points and 7 
points [333].  The originally proposed scale was the 15-point scale [362], while 
in contemporary use 11-point and 7-point measures are recommended [333].  
The use of outcome measures is limited in Nepal because of low 
literacy levels, unavailability of measures in Nepali and unawareness of need 
and usefulness of outcome measures.  Despite the acceptable validity and 
reliability and wide applicability of NPRS and GRoC measures, neither the 
NPRS or GRoC are available in Nepali.  Before PROMs can be used in clinical 
practice and research, they should be translated, cross-culturally adapted and 
validated in the language of the target population [96].  For a measure to be 
acceptable to use, it is important to know its measurement properties such as 
reproducibility, validity, and responsiveness to change due to treatment or 
time [96, 252]. Translation of these measures to Nepali using standard 
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recommended guidelines can improve their wide use in both research and 
patient care in Nepal. Translation of GRoC is particularly important to 
provide an external anchor that researchers in the future can use to 
investigate the measurement properties of other PROMs in Nepal.  
Therefore, the primary aim of this study was to translate and cross-
culturally adapt the NPRS and GRoC in accordance with internationally 
accepted guidelines [96]. Secondary objectives of the study were to evaluate, 
using a GRoC anchor-based approach, the measurement properties of the 
Nepali version of the NPRS (NPRS-NP) including the: test-retest reliability, 
the smallest detectable change (SDC), construct and concurrent validity, and 
the minimum important change (MIC).  We hypothesized that the translation 
of the NPRS and the GRoC to Nepali would provide outcome measure 
instruments with acceptable measurement properties.  
METHODS 
The study protocol was approved by the Institutional Review 
Committee of Kathmandu University School of Medical Sciences, Dhulikhel, 
Nepal (Ethics approval number 74/15), and complies with the principles 
outlined in the Declaration of Helsinki. Every participant provided written 
informed consent prior to the start of the study. In the event participants were 
unable to sign the consent form themselves, a witness signed for them. The 
conduct and reporting of this research were guided by the guidelines 
proposed by Beaton and colleagues in 2000 for the process of cross-cultural 
adaptation of self-report measures [96] and by the COSMIN guidelines [345]. 
Participants 
To be eligible to participate in the study, participants were required to 
be: (1) over 18 years, (2) a citizen of Nepal, (3) able to understand and speak 
Nepali fluently, (4) count numbers from 0 to 10 in order, and (5) currently 
experiencing musculoskeletal pain irrespective of duration of pain.  Exclusion 
criteria included: any past surgeries related to the current pain; recent history 
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of trauma; the presence of red flags suggesting the presence of tumor and 
infection; and diagnosed psychiatric illnesses.  A sample more than 100 is 
considered adequate in order to assess the measurement properties of a self-
reported outcome measure [345], therefore, we recruited 104 individuals with 
musculoskeletal pain who consented to participate in the study and 
completed all the measures. Of these, 75 (72%) were recruited from the 
Physiotherapy Out-patient Department of Dhulikhel Hospital and 29 (28%) 
from the surrounding community. This gave a representative mix of rural and 
semi-urban participants. We recruited participants from November 2015 to 
April 2016.     
The study was conducted in two phases: Phase 1 - the translation and 
cross-cultural adaptation of NPRS and GRoC to Nepali, including the pre-
testing of the translated Nepali version; and Phase 2 – investigation of the 
measurement properties of NPRS-NP. 
Phase 1: The translation process 
The translation of NPRS and GRoC into Nepali followed the standard 
guidelines for translation and cross-cultural adaptation of outcome measures 
[96]. We chose to translate these measures into Nepali because Nepali is the 
national language of Nepal; it is the most common language spoken in Nepal, 
with 45% Nepalese speak Nepali as the first language, followed by “Maithili” 
(12%) [69]; and it is taught in schools as a compulsory subject. The translation 
process included: 
Forward translations.  Three native Nepali speakers (one 
physiotherapist, one professional translator and one naïve non-medical 
professional) independently translated the original English versions of the 
NPRS and GRoC to Nepali, resulting in 3 versions: T1, T2, and T3.   
Synthesis. A single Nepali version (T4) was created following 
discussion and consensus among the three translators and the principal 
investigator (SS).   
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Back-translations. T4 was then back-translated independently by three 
native English speakers unaware of the purpose of the translation and blind 
to the original English version resulting in 3 versions: T5, T6, and T7.  
Inconsistencies were discussed among the back translators and a single 
synthesized version was produced.   
Expert committee meeting.  An expert committee was formed which 
consisted of the researchers, translators, a methodologist, and a language 
expert. Discussions were undertaken to resolve any discrepancies in the 
translations that did not reflect the original English version. A final Nepali 
version (T8) was approved after significant (cross-cultural) modifications on 
both the measures (see the Results section below). Questionable words or 
phrases in the Nepali version were replaced with alternative Nepali wordings 
which the committee considered to be reasonable cultural adaptations that 
maintained the meaning of the English version but were not a direct literal 
translation. In some instances, two options were put forward to be evaluated 
during the pre-testing of the translation process to obtain the most 
appropriate option. One forward translator and all back translators who were 
not available to attend the meeting in person were contacted to confirm that 
all parties were in agreement. From these discussions, pre-final versions of the 
NPRS and GRoC were created (TNP). All translated versions along with the 
final back translation were then sent to a senior researcher (JHA) for final 
comments and approval.  
Pre-testing. The approved TNP versions of NPRS and GRoC were then 
pre-tested on 30 individuals with self-reported musculoskeletal pain. This 
sample selected was representative of population age, sex, and education 
level. During the pre-testing, participants were interviewed to complete the 
TNP versions of NPRS and GRoC.  The participants were asked if they 
understood the actual meaning of the TNP upon completion. The participants 
were also asked for their preference in any unresolved alternative Nepali 
translations of word choices put forward by the expert committee, and 
majority preferences were adopted. In response to participants’ feedback, 
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minor corrections were made to improve the sentence structure of the 
instructions to make it easier for the participants to understand, and the final 
Nepali versions of NPRS and GRoC were finalised (NPRS-NP and GRoC-NP 
respectively).  
Phase 2: NPRS-NP measurement testing procedure 
A longitudinal single-arm cohort design was adopted to assess the test-
retest reliability, the smallest detectable change (SDC) and minimal important 
change (MIC) of the NPRS-NP. Data were collected at two-time points, at an 
initial assessment and between 1-2 weeks at a follow-up assessment. No 
information about the previous NPRS-NP scores was provided to the study 
participants at the follow-up assessment. The 7 – item Nepali version of GRoC 
(GRoC-NP) was also administered independently at the follow-up to assess 
the participants’ perception of their global rating of change. I trained the 
research assistant (JP) administering the measures. All the research 
participants were interviewed in order to maintain the uniformity of the data 
collection and not to exclude illiterate participants. To minimize loss to 
follow-up, phone call interviews were conducted for any participants 
recruited from the hospital who could not attend subsequent follow-up 
appointments. To facilitate follow up among the community participants, a 
research assistant visited individuals at a time convenient to them.  
Data analysis 
Data were manually entered into Microsoft Excel and later were 
transferred to Statistical Package for Social Sciences (SPSS) version 24 for 
further analysis. Sociodemographic variables including age, sex, ethnicity, 
education, and occupation were reported using descriptive statistics. 
Distribution of pain was reported as frequency count and the percentage by 
body part affected, and duration of pain (in months) was reported as mean 
and standard deviation.  To differentiate the “Improved group” and  “Stable 
group” and to report small, medium, and large improvements (changes) in 
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their NPRS-NP scores, GRoC-NP was used as an external anchor [333].  
Participants who chose “same as before”, a score of ‘4’ on GRoC-NP were 
classified as the “stable” or “unchanged group”.  The participants who chose 
“slight improvement” ‘5’, “moderate improvement” ‘6’ or “a lot of 
improvement” ‘7’ were classified as “Improved group” [364].  Three 
sensitivity analyses were performed separately on the groups that achieved 
small, medium and large improvements [358].  
For both the initial measurement and final measurement, average 
scores of NPRS-NP current, minimum, and maximum pain intensities were 
reported. Change in NPRS-NP scores was computed for individual 
participants by subtracting the NPRS-NP final measurement from the baseline 
score.  
Reliability  
Test-retest reliability was evaluated for the stable group by using the 
Intraclass Correlation Coefficient (ICC2,1). ICC values closer to 1.0 indicate 
higher test-retest reliability [336]. We hypothesized that the test-retest 
reliability would be excellent for the stable group which will lie between 0.7 – 
0.9 [365-367]. 
It has been suggested that ICC scores do not take into account the scale 
of measurement and the size of the error that is clinically relevant [368]. 
Therefore, a complementary way of measuring reliability or limit of 
agreement was also performed using  ‘Bland-Altman Plots’, where the 
difference between baseline and final NPRS-NP values (in Y-axis) were 
plotted against the mean of NPRS-NP scores at baseline and final 
measurement (in X-axis) [368, 369]. 
Smallest detectable change (SDC) is the lowest estimate of change of an 
outcome measure beyond random measurement error [330]. SDC90 (SDC at 
the 90% confidence margin) was calculated for the NPRS-NP using the 
formula, SDC90 = z x √2 x SEM, where SEM is the standard error of 
measurement and z = 1.64 (z score for estimating a 90% confidence interval). 
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We used a square root of 2 because a total of two measurements were done 
for test-retest reliability. Finally, we calculated SEM manually by using the 
formula, SEM = SD (1 - ICC)1/2 [330] where SD is the standard deviation for 
the mean change of NPRS-NP score from baseline to final measurement, and 
ICC = Intra-class Correlation Coefficient (ICC) of the stable group. We 
hypothesized that the SDC90 value would lie between 0.5 and 2.5 [367, 370]. 
Validity 
The construct validity of the NPRS-NP was examined in two ways.  First, 
the mean change of the NPRS-NP score was tested within the improved 
group by using a one-sample t-test [330].  Second, the mean change scores 
were tested between stable and improved groups using independent samples 
t-test [330].  It was hypothesized the NPRS-NP would demonstrate construct 
validity with a significant difference P<0.05 in the NPRS-NP score within the 
group that “improved” and in the NPRS-NP scores between the stable group 
and the improved group. 
Responsiveness 
Responsiveness was evaluated by comparing the difference of NPRS-NP 
scores at baseline and final measurement with the score of the GRoC-NP. We 
hypothesized that NPRS-NP would moderately (but significantly P<0.05) 
correlate with GRoC-NP score considering Spearman correlation coefficients 
of 0.36 to 0.67 to be moderate correlation [371]. 
The area under the ROC curve (AUC) indicates the accuracy of NPRS-NP 
to discriminate between the group that improved or remained stable. The 
value of AUC for the difference of NPRS-NP closer to “1” indicates better 
agreement with the GRoC-NP as an external anchor. AUC = 0.5 means that 
NPRS-NP cannot accurately differentiate between the group that improves 
and that does not beyond chance [372, 373]. Sensitivity analyses were 
conducted, with ROC curves and values of AUC determined for the sub-
groups which demonstrated small improvement (GRoC = 5), medium 
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improvement (GRoC = 6) and large improvement (GRoC = 7).  It was 
hypothesized that the AUC values would be equal to or more than 0.7 in each 
instance.  
Minimal important change (MIC) for NPRS-NP was identified with 
reference to the GRoC-NP score to differentiate the group that improved and 
those who did not, at three levels of meaningful change as described above.  
Sensitivity and specificity values were also recorded.  We hypothesized that 
NPRS-NP would be sensitive to change with MIC values ranging from 1.1 to 
3.5 [358, 367, 370, 374, 375]. 
RESULTS  
Phase 1: Translation and cross-cultural adaptation  
NPRS: An important change was made to the right anchor of the T4 
version of NPRS-NP during the expert committee meeting.  The literal 
translation of “worst pain possible” or “worst imaginable pain” did not 
convey the original meaning in the Nepali language, it sounded ‘funny’. The 
expert committee’s proposal of two alternative anchors were more natural in 
Nepali and translated back to English as “extreme pain” and “unbearable 
pain”. Participants in the pre-testing phase, when given the choice of the three 
Nepali end anchor options, gave a unanimous preference for the two 
culturally adapted phrases. Therefore, the Nepali translation of “worst 
possible pain” was discarded and translations of both “extreme pain” and 
“intolerable pain” were retained. The final Nepali version of the NPRS is 
located in Appendix 4. 
GRoC: Initially, translation of the original 15-point GRoC [362] was 
attempted. The expert committee’s discussion however, highlighted that the 
Nepali translations for each item of GRoC were not reflective of the English 
items as the meaning of the items could not be replaced by Nepali words in 
the increasing order from 7 to 15 and decreasing order from 7 to 1, there were 
too many subtle gradations. The committee decided to adopt the 7-point 
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version of the GRoC which is a recommended version [333].  The 7-point 
measure is a numerical rating scale with a verbal descriptor for each item with 
the mid-point “4” which means “no change”, left anchor is “1” meaning “very 
much worse” and right anchor “7” means “recovered completely” or “very 
much better”. A score more than or equal to 6 on the scale is considered 
meaningful improvement [333, 376]. The most applicable seven items from 
the 15-item GRoC translations were retained to comprise the 7-item Nepali 
version of the GRoC (GRoC-NP) for pre-testing. During the pre-testing, all the 
participants (N=30) could identify numbers from 0 to 10, and could 
understand and complete the scale with some difficulty, especially on the 
NPRS, as repeated explanations were needed for the participants before they 
could complete it. Semantic equivalence of the GRoC-NP was assured. Only 
minor changes were made in the sentence structure of the instruction during 
the pre-testing after the feedback from the participants. The final version was 
later approved by the expert committee members. The final Nepali version of 
the GROC is located in Appendix 5 and freely available in Health and Quality 
of Life Oucomes Journal website [3]. 
Phase 2: Measurement properties of the NPRS-NP  
All of the 104 participants (100%) completed the follow-up assessment. 
The baseline and the final assessments for all the participants were performed 
with an average interval of 11.5 (SD 3.5) days while the duration ranged from 
6 – 18 days. 
Improved versus Stable Group  
Out of the 104 participants, 62% (n=64) reported >4 on the GRoC-NP 
scale and therefore were classified as the “improved group”. Whereas 35% 
(n=36) reported “no change” (4) on the GRoC scale and were considered the 
stable group. Four (4%) reported worsening (GRoC<4). 
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Demographic characteristics 
Demographic information collected from the participants is presented 
in Table 5.1. The majority of the participants were female, 69% (n = 72); and 
half the participants had only attended a primary school or less. More than 
half of the participants, 56% (n = 58) reported an active lifestyle as they either 
worked at home or on the fields as farmers.   
Assessment of pain site and outcomes 
Almost half the participants, 46% (n = 48) had low back pain and 20% (n 
= 22) had knee pain. Table 5.1 includes other sites of pain. 
Table 5.1 Description of the participants with scores of the Numerical Pain 
Rating Scale and the Global Rating of Change. 
Variables Frequency (%) Mean (SD) 
Age in years   41.2 (13.5)  
Sex   
    Male  32 (31%)  
    Female 72 (69%)  
    Total 104 (100%)  
Ethnicity   
    Newar 34 (33%)  
    Brahmin  23 (22%)  
    Chettri 16 (15%)  
    Others  31 (30%)  
Education    
    No school 41 (39%)  
    Primary  11 (11%)  
    Secondary 17 (16%)  
    Higher secondary 16 (15%)  
    Bachelor and above 19 (18%)  
Occupation    
    Agriculture and housework 28 (27%)  
    Housework only 22 (21%)  
    Agriculture only 8 (8%)  
    Sitting job (Office/ business) 8 (8%)  
    No work 6 (6%)  
    Others  32 (31%)  
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Variables Frequency (%) Mean (SD) 
Site of pain   
    Low back pain  48 (46%)  
    Knee pain  21 (20%)  
    Shoulder pain  13 (13%)  
    Neck  9 (9%)  
    Elbow pain  5 (5%)  
    Others  8 (8%)  
The total duration of pain (in months)  21.7 (34) 
The time between evaluations (in days)  11.5 (3.5) 
GRoC-NP at follow-up     
    Worsened (GRoC < 4)                                   4 (4%)  
    Stable group (GRoC = 4) 36 (35%)  
    Improved group (GRoC = 5 – 7) 64 (61%)  
    Small improvement (GRoC = 5) 30 (29%)  
    Medium improvement (GRoC = 6) 23 (22%)  
    Large improvement (GRoC = 7) 11 (11%)  
NPRS scores   
   NPRS-NP baseline 104 4.27 (1.63) 
   NPRS-NP follow-up 104 3.36 (1.56) 
   NPRS-NP change 104 0.90 (1.49) 
Abbreviations: GRoC-NP = Nepali version of Global Rating of Change, NPRS-NP = Nepali version 
of Numerical Pain Rating Scale, SD= Standard Deviation. 
Reliability 
The ICC statistic for the test-retest reliability of NPRS-NP for the stable 
group (n = 36) at a two-week follow-up, the SEM, and the SDC90 are 
presented in Table 5.2.  Bland-Altman Plot graphically represents random 
and systematic errors as  shown in Figure 5.1.  
 
Chapter 5: The NUMERICAL PAIN RATING SCALE and GLOBAL RATING OF CHANGE  
103 
 
Figure 5.1 Bland-Altman Plot for the Nepali Numerical Pain Rating Scale. 
Note: Y-axis is the change of NPRS-NP scores between baseline and follow-up measurements and X-
axis is the mean of NPRS-NP scores at the baseline and final measurements. The solid line is the mean 
change of score (d), and green lines are d ± Z x SDchange (where Z = 1.64 for 90% confidence interval.)   
 
Table 5.2 Reliability of Nepali- Numerical Pain Rating Scale. 
Validity 
The one sample t-test demonstrated a significant difference in mean 
NPRS-NP scores at baseline and follow-up- t(63) = 7.57, P < 0.001 in the 
improved group. The independent sample t-test also revealed a significant 





Sample (N) Test-retest reliability 
as ICC 
 (95% CI) 
SEM SDC90  
Stable group  4 36 0.81 (0.63, 0.90) 0.49 1.13 
Abbreviations: NPRS, Numerical Pain Rating Scale; GRoC, Global Rating of Change; ICC, Intraclass 
Correlation Coefficient; CI, Confidence Interval; SEM, Standard Error of Measurement; SDC90, Smallest 
Detectable Change at 90% CI. 
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Responsiveness  
The mean change of the NPRS-NP scores demonstrated a significant 
moderate correlation (r = 0.43, P < 0.001) with GRoC-NP scores for the total 
sample as hypothesised. 
The ROC curves for the differences of NPRS-NP scores at baseline and 
final measurements between the improved and stable groups are shown in 
Figure 5.2a. Secondary analyses are shown in Figures 5.2b, 5.2c and 5.2d for 
the; (1) small improvement group and stable group, (2) medium improvement 
group and stable group and, (3) large improvement group and stable group.  
The values of MIC for small and medium improvement was 1.17 and 1.33 for 
large improvement.  The values of AUC, sensitivity, and specificity are 
presented in Table 5.3.  
  





Figure 5.2a. ROC Curve for the stable group 








Figure 5.2c. ROC Curve for the medium 
improvement group (GRoC=6).  
 
 
Figure 5.2d. Receiver Operating Characteristic (ROC) 
Curve for the large improvement group (GRoC=7). 
 
Figure 5.2 Receiver operating characteristic (ROC) curves. 
The area under this curve (AUC) indicates the accuracy of NPRS-NP for differentiating 
between the stable group and the group that had a large improvement with the value of AUC 
closer to “1” indicating better agreement with the GRoC-NP as an external anchor. 
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Table 5.3 Responsiveness of Nepali- Numerical Pain Rating Scale. 
DISCUSSION 
We translated NPRS and GRoC into Nepali with significant cultural 
adaptations and that the NPRS-NP demonstrated good to excellent 
measurement properties as hypothesized.  
Translation and cross-cultural adaptation 
A direct translation of a PROM developed for one language or culture 
to another language may not result in a valid instrument [96, 211]. This study 
provides clear evidence for the need for cross-cultural adaptation after the 
translation of a measure to the target language. For example, “worst 
imaginable pain” or “pain as bad as you can imagine” are widely used as the 
right anchor on an NPRS [355] in many languages, and is recommended by 
IMMPACT [88].  In the current Nepalese sample, translation of this anchor to 
Nepali was attempted by three independent translators, however, none of the 
versions sounded “natural”. We proposed alternative Nepali translations that 
mean “maximum pain” and “intolerable pain” as a right anchor which are 
simpler and easily understood.  During the pre-testing phase, individuals 
with musculoskeletal pain were further interviewed and asked for their 
preference among the three options of the right anchor proposed.  None of the 





Specificity AUC  95% CI 
Primary analysis 
(GRoC 4 vs GRoC 5-7) 
0.74 0.64 0.84 1.17 0.53 0.89 
Small improvement 
(GRoC 4 vs GRoC=5) 
0.75 0.64 0.87 1.17 0.57 0.89 
Medium improvement 
(GRoC 4 vs GRoC=6)  
0.68 0.54 0.83 1.17 0.43 0.89 
Large improvement (GRoC 4 vs 
GRoC=7) 
0.82 0.67 0.98 1.33 0.64 0.89 
Abbreviations: AUC, Area Under the Curve; CI, Confidence Interval; MIC, Minimum Important Change; 
GRoC, Global Rating of Change. 
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participants chose the Nepali translation of “worst imaginable pain”, so it was 
omitted from final Nepali translation.  A previous systematic review reported 
that both “maximum pain” and “intolerable pain” are used as the right 
anchor for the NPRS in other languages [355].  
 Further, we encountered difficulties attempting to translate the 
original 15-item GRoC scale developed by Jaeschke and colleagues [362]. The 
ordinal gradations of the 15-item scale could not be adequately translated, so 
we produced a 7-item scale in the end.  This 7-item scale retained the ordinal 
property of the scale such that an increase of score from 4 to 7 reflect the 
gradual improvement in health status and decrease in score from 4 to 1 reflect 
worsening of the condition. The 7-item scale is extensively used in research 
[333, 377]. According to previous research in low back pain by Lauridsen and 
colleagues [377], reduction in the number of items from 15 to 7 does not 
appear to impact on the performance of the measure. In that study, both the 7-
item GRoC and 15-item GRoC were administered, finding that the 
classification of improvement did not significantly change by the choice of the 
GRoC scale. They further reported that there were no differences in the 
performance of the two versions of GRoC irrespective of how stringent the 
criteria was for the improved group. The briefer scale should be easier for the 
participants to complete because of the lesser number of items. Moreover, the 
7-item GRoC is also the recommended scale to use for chronic pain trials by 
the IMMPACT recommendations [88].  
Reliability 
The finding of the current study supported our hypothesis that NPRS 
would demonstrate excellent test-retest reliability (ICC = 0.81) for the stable 
group. The test-retest reliability of NPRS-NP is comparable to other studies 
investigating the measurement properties of the NPRS [367, 370], but lower 
than the 48-hour test-retest reliability of the Arabic version (ICC = 0.89) [378]. 
We followed up participants in the current study in about one to two weeks 
(mean 11.5 days with 3.5 days of SD), as recommended in the literature for the 
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test-retest reliability, which is long enough to avoid recall bias [336].  The 
duration of the follow-up in our study lies between the duration reported in 
the previous studies i.e., an interval of 2 to 4 days, and between 2 and 4 weeks 
in different studies [367, 370, 378]. This shows that the reliability of NPRS is 
similar or comparable irrespective of the duration of the follow-up.  Similarly, 
the value of SDC90 of NPRS-NP in the current study was 1.13, which was 
found to be lower than that of the English version (SDC = 2.1 and 2.5) [367, 
370], and the Arabic version (SDC = 1.96) [378]. This is because of the greater 
ICC values in the current sample compared to the previous samples.  
Validity  
As hypothesized, the NPRS-NP demonstrated good construct validity. 
We found the NPRS-NP demonstrated a significantly different score within 
the group that improved on the GRoC anchor. Further support of the 
construct validity of the NPRS-NP was provided by the between-group 
difference in the NPRS score change, between the stable and improved 
groups. As the NPRS and GRoC were translated and tested at the same time, 
validity and reliability of the GRoC could not be assessed. This can be done in 
the future in a new sample.   
The GRoC is commonly used as an external change criterion in 
research and to track patients’ progress in the clinic. However, we should be 
careful that when patients’ rate change using transition scales such as GRoC, 
it usually represents the current (health) status than “actual” change. 
According to Ross’s theory of implicit change, people are less likely to 
accurately recall a previous state or attitude; rather they create an impression 
of how much they have changed by considering their present condition and 
then retrospectively applying some idea of their change over time [379]. This 
can lead to over or understatement of their actual change [333].  GRoC ratings 
are also influenced by recall bias. Despite this limitation, the use of GRoC for 
this purpose is a widespread practice, because a better alternative is 
unavailable at this point.  
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Responsiveness 
The results also confirmed our hypothesis regarding the 
responsiveness of the NPRS-NP, with NPRS change scores moderately 
correlated with GRoC-NP (r = 0.43), which is within the range reported in the 
literature (rs = 0.26 - 0.57) [367, 370].   
The NPRS-NP was found to be sensitive to change with a MIC ranging 
from 1.17 to 1.33 for small to large improvements. The MIC in the current 
study meets the requirement of being greater than the SDC value for the 
NPRS-NP which means that the value for important change exceeds 
measurement error, in contrast to the previous studies [367, 370]. The 
previous studies have found the MIC for NPRS between 0.9 and 4.5 [358, 359, 
367, 370, 374-376, 380], with values closer to 2 as the most commonly accepted 
important change for the patients with both acute and chronic pain conditions 
[374, 375]. The MIC of NPRS-NP in the current study is comparable to the 
previous research by Cleland and colleagues (MIC 1.3) [367] and Mintken and 
colleagues (MIC 1.1) [370] who reported MIC values for neck pain and 
shoulder pain respectively. Higher MIC values (between 2.2 to 4.5) have also 
been reported in the studies on low back pain [376, 380].  
The range of MIC estimates across small, medium and large 
improvements is narrower than a previous report, which showed estimates 
for the NPRS of 1.5, 3.0 and 3.5, respectively [358]. Variations in the values of 
MIC can be a result of variations in the method of assessment of MIC [376, 
381], the population sampled, and chronicity of the condition [376]. For 
example, van der Roer and colleagues studied MIC in sub-acute and chronic 
low back pain and found that values of MIC were greater for chronic 
conditions compared to sub-acute for a number of outcome measures (which 
also included NPRS) [376]. Finally, the findings on the MIC of our study is 
slightly higher than MIC on children and adolescent (MIC = 0.9 – 1.0), as 
reported in a recent systematic review [359].  
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Strengths and Limitations 
The results of the current study are supported by a strong 
methodology, demonstrated by; no loss to follow-up, two independent 
measurement points at a mean interval of 11.5 days, and the external GRoC 
measurement confirming the stable and improved groups. However, the 
study also encounters a number of limitations. First, the COSMIN checklist 
rates the methodological quality of a study on test-retest reliability as 
excellent if the sample is more than 100 [382] a larger subset for each of the 
stable and improved groups may have strengthened the results on reliability. 
We recommend the use of more than a single measurement of pain intensity, 
including the assessment of worst pain, best pain, average pain and current 
pain in the clinical setting which is suggested to increase the reliability of the 
pain intensity assessment [336].  
Second, assessment of overall change using a GRoC scale is a standard 
practice in psychometrics study, the GRoC score depends on overall change 
and not just pain intensity. For the same reason, the COSMIN recommends 
asking patients' perception of improvement on the same construct (i.e. pain 
intensity in this case) than their global improvement [336]. Considering this 
recommendation, the construct validity of NPRS-NP was not entirely met. 
Future research might test the measurement properties of NPRS by utilizing 
two versions of GRoC i.e. one that asks participants to rate their (1) global 
improvement and (2) specific improvement in pain intensity to see if they 
yield different measurement properties of NPRS-NP.  
Third, the sensitivity values of NPRS-NP ranged between 0.43 to 0.64, 
which indicates that the diagnostic ability of NPRS-NP to distinguish between 
the stable and improved group should be reconsidered. De Vet and 
colleagues questioned the application of MIC at an individual level if the 
sensitivity and specificity of a measure are less than 75% [336]. The reasons 
for the lower values of the sensitivity of the NPRS-NP may be due to the 
difficulty in understanding the concept of the NPRS because the sample 
included a large proportion of the participants with low education level and 
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varied ethnicity. Although the number of participants who struggled to 
complete NPRS was not documented, it was noted that repeated explanations 
had to be given on the numerical nature of the NPRS-NP before some 
participants were able to complete the NPRS-NP scale. Other participants did 
not rate the pain intensity in a single number and reported their intensity of 
pain in a range; for example 3-5 out of 10. In these cases, we consistently 
recorded a higher number as the participant’s response. In contrast to the 
difficulties in completing the NPRS-NP, participants easily completed the 
GRoC scale, probably due to the descriptive nature of GRoC which has verbal 
response options in addition to numbers. We recommend that Nepalese 
should be asked for their preferences for the choice of measure for the 
assessment of pain intensity in future research to assess if they prefer other 
measures of pain assessment such as a verbal rating scale or a faces pain 
rating scales over numerical rating scale, due to this apparent difficulty with a 
numerical rating. 
Fourth, it is also worth noting that the sample used in this study 
comprised a variety of ethnic groups, which could also raise a question of 
whether differences in ethnicity may have affected the study findings. As we 
included only participants who could fluently speak and understand Nepali, 
variation in ethnicity may be unlikely to have influenced our results.  The 
inclusion of individuals with lower education and different ethnic groups 
could be considered a strength of the study, as it improves the external 
validity, or the generalisability of the study findings to the Nepalese 
population. 
Finally, as the NPRS is considered an ordinal scale, caution should be 
used with regard to treating it like a ratio scale (e.g., visual analogue scale); 
this is considered an important disadvantage of it as a measure for the 
assessment of pain intensity in research [383].  Nevertheless, researchers have 
argued that an outcome measure with multiple items using a Likert scale can 
generally be confidently treated as an interval scale [384]. Likewise, research 
investigating the correlations of NPRS with VAS have consistently found 
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strong correlations both in the adult (rs= 0.94 – 0.96) [385, 386] and pediatric 
populations (rs= 0.74 – 0.96) [359]. 
CONCLUSIONS 
The Nepali version of NPRS and GRoC were successfully translated 
after cultural adaptations.  NPRS-NP demonstrated good reliability, validity, 
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CHAPTER 6  
The Patient-Specific Functional 
Scale 
CHAPTER 6 : THE PATIENT-
SPECIFIC FUNCTIONAL SCALE 
[Sharma S, Palanchoke J, Abbott JH: Cross-cultural Adaptation and Validation of the Nepali 
Translation of the Patient-Specific Functional Scale. J Orthop Sports Phys Ther 2018, 48(8):659-664.] 
***
INTRODUCTION 
The Patient-Specific Functional Scale (PSFS) is a patient-reported 
outcome measure (PROM), in which patients themselves identify the 
activities that are most important to them, and rate them on a numerical scale 
from “0” to “10”.  Higher scores indicate better physical function [332]. The 
advantages of PSFS over other measures of physical functions or physical 
disability are that it is (1) brief, easy to understand and complete, thus can be 
completed in lesser time; (2) patient-generated, thus considers activities 
important at individual level; (3) possible to verbally administer, thus not 
requiring literacy of the patients; and (4) applicable across a variety of 
conditions and body regions, eliminating the need of multiple measures, and 
allows comparison of functional outcomes across conditions and between 
studies [332, 358, 387-389]. The validity of patient-specific scales for 
comparing across and between groups has been questioned, however, recent 
research has shown that the PSFS is valid for use in group-level research 
[387].  Additionally, a systematic review reported adequate measurement 
properties of the PSFS in various musculoskeletal conditions [390], and it is 
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also more responsive than other longer measures of physical disability [332, 
391]. 
Improving physical function is the primary focus of physiotherapy 
interventions, however, its assessment is limited in Nepal because of the 
limited availability of PROMs to assess physical function. Although, the 
Oswestry Disability Index (ODI) is validated in Nepali [392], administering it 
verbally can be challenging considering its length, and inclusion of sensitive 
questions (e.g., sex life).  The availability of PSFS in Nepali would facilitate 
the assessment of physical function across a variety of musculoskeletal 
conditions in both clinical practice and research in Nepal, considering its 
advantages.   
Thus, we aimed to translate the PSFS into Nepali, cross-culturally 
adapt it, and assess its measurement properties on Nepalese with 
musculoskeletal pain.  
METHODS 
A longitudinal single-arm cohort design was used. The methodology is 
described in greater detail in Chapter 5 [3].  The study was conducted in two 
phases.   
Phase 1: Translation of PSFS 
Phase 1 involved the translation and cross-cultural adaptation of PSFS into 
Nepali (PSFS-NP) using recommended guidelines and similar steps to the 
translation of NPRS and GRoC in Chapter 5 [96]. Please refer to Figure 6.1 
below for the steps in translation.  
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Figure 6.1 Translation history 
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Phase 2: Assessment of measurement properties 
Phase 2 involved the assessment of the measurement properties of the 
PSFS-NP. The conduct and reporting of the measurement properties were 
guided by COSMIN (COnsensus-based Standards for the selection of health 
Measurement INstruments) recommendations [346]. 
Participants and settings  
For this phase, adults experiencing musculoskeletal pain, who could 
count numbers from 0 to 10, and who could understand and fluently speak 
Nepali were recruited from Dhulikhel Hospital and rural and semi-urban 
community of Nepal. Participants were excluded if they had- undergone any 
surgeries, a recent history of trauma, a diagnosed psychiatric illness, and red-
flags suggestive of tumor or infection.  
Ethical approval was obtained from the Institutional Review 
Committee, Kathmandu University School of Medical Sciences (ethics 
approval number 74/15). Data were collected from November 2015 to April 
2016.  
Measures 
Patient-Specific Functional Scale (PSFS) 
The Patient-Specific Functional Scale (PSFS) [4] asks participants to list 
three activities that they are unable to do or are having difficulty doing 
because of musculoskeletal pain. Each respondent-generated item is then 
rated on a 11-point numerical scale from 0 (“Unable to perform the activity”) to 
10 (“100% able to perform the activity at the same level before your pain state”) 
[332]. Total score ranges from 0 and 30 for three items. The scores of all three 
items were averaged so that the final scoring was performed on a 0 to 10 scale 
with higher scores indicating higher levels of physical function. A systematic 
review of summarising the measurement properties of the PSFS concluded 
that the PSFS is a valid and reliable measure for assessing physical function in 
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individuals with musculoskeletal pain conditions [390]. The test-retest 
reliability of PSFS in the review ranged from 0.76 to 0.97 over a period of 1 
day to 5 weeks, indicating excellent reliability in individuals with chronic low 
back pain. The construct validity of the PSFS has been supported with 
moderate to strong associations with measures that have “fixed-items” such 
as the Roland Morris Disability Questionnaire, the Oswestry Disability Index, 
Lower Extremity Functional Scale, and Upper Extremity Functional Index in 
individuals with musculoskeletal pain (rs = 0.36 to 0.83) [387, 390].  
Numerical Pain Rating Scale 
Pain intensity in last 24 days was assessed using a Nepali version of 
the 11- point numerical rating scale (NPRS) with the anchors 0 (“No pain”) 
and 10 (“Maximum pain”) [3]. Eleven-point NRS scales have demonstrated 
validity and reliability as measures of pain intensity measure for a larger 
variety of painful conditions and different age groups and are recommended 
by consensus groups for use in pain research [88, 355, 393]. I showed that 
NPRS has acceptable measurement properties in a this sample of individuals 
with musculoskeletal pain in Chapter 5.  
Global Rating of Change (GRoC)  
The Nepali version of GRoC was used to assess the global impression 
of perceived change in their chronic pain-related problems in the second 
sample on a 7-point Likert scale ranging from 1 to 7 [3, 4, 333]. The middle 
score, “4” represents “No change”; scores greater than “4” indicate 
improvement and scores less than “4” indicate worsening. The GRoC was 
used to categorize the sample to “improved” and “stable” group, considering 
one-point change as a significant improvement [333]. We classified 
participants with a GRoC score of 4 as “stable”, and participants with GRoC 
scores of 5-7 as “improved”.  Using this classification, participants in the 
stable group were used for computing the test-retest reliability, SEM, SDC, 
and limits of agreement statistics [394]. 
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Oswestry disability Index (ODI) 
A Nepali version of the ODI was used to assess back pain related 
disability in a subset of sample reporting low back pain. The Nepali version of 
ODI has been shown to be comprehensible and reliable instrument to assess 
back pain related disability in adult Nepalese with low back pain [392].  
Procedures 
Sociodemographic characteristics, pain history, PSFS-NP, and Nepali 
versions of the Numerical Pain Rating Scale (NPRS-NP) [3] and Oswestry 
Disability Index (ODI-NP) [392] were assessed at baseline.  PSFS-NP and 
NPRS-NP were re-administered at a 2-week follow-up along with a Nepali 7-
item Global Rating of Change (GRoC-NP) [3] as an external anchor for 
computing measurement error and responsiveness [336]. Participants with the 
GRoC score=4 was categorized as the “stable” group, and scores between 5 
and 7 were categorized as “improved” group (GRoC=5, slight improvement; 
GRoC=6, medium improvement; and GRoC=7, large improvement).  All 
measures were administered verbally to allow the inclusion of participants 
with lower levels of literacy. The details of the measures used are presented in 
Table 6.1. Data were analysed using Statistical Package for Social Sciences 
(SPSS) version 24. The level of significance was considered at P<0.05.  
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Table 6.1 Nepali versions of Patient-Reported Outcome Measures (PROMs) 
used in the Study. 
  
Reliability  
Internal consistency was reported using Cronbach’s alpha, with ≥ 0.90 
indicating excellent internal consistency [365]. Two-week test-retest reliability 
was computed for the stable group using a two-way random effect model 
(with absolute agreement) Intraclass Correlation Coefficient (ICC2,1). ICC 
value higher than 0.75 indicates excellent test-retest reliability [365]. We used 
the Bland-Altman plot to report the limits of agreement [395]. Standard error 
Name  Item  Scale  Construct 
assessed 
Scoring  Measurement 
properties 




Mean of item scores. 
Range, 0-10. Lower 
scores indicate 
greater disability. 
 -  




Mean of 3 item scores 
(current, best, and 
worst in past 24 h). 
Range, 0-10. Higher 
scores indicate 
greater pain intensity.  
0= No pain 
10= Maximum pain 
ICC= 0.81; SDC90 = 
1.13; MIC= 1.17; 
Concurrent validity 
(with GRoC, r) = 
0.45. 
 





Sum of item 
scores/number of 
items rated × 100. 




0.72; ICC= 0.87. 












Four means no 
change. Scores higher 
than 4 means greater 
improvement and 
scores lower than 4 
means greater 
worsening in health 
status.  
7= A lot of 
improvement  6= 
Medium improvement 
5= Slight improvement 
4= No change 
3= Slightly worse 
2= Moderately worse 
1= A lot worse 
MIC: 1 point 
change.14, 19 
Abbreviations:  ICC, Intraclass Correlation Coefficient;  GRoC, Global Rating of Change; MIC, 
Minimum Important Change; NPRS, Numerical Pain Rating Scale; ODI, Oswestry Disability Index;  
PSFS, Patient Specific Functional Scale; SDC, Smallest Detectable Change. 
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of measurement (SEM) was calculated as SDchange (1 - ICC)1/2 (where SDchange 
= SD(baseline - final) [336].  We computed individual level smallest detectable 
change at 90% CI (SDC90) as z x √2 x SEM (z = 1.64 estimating 90% CI) in line 
with the original English version [332]. We hypothesized that PSFS-NP would 
demonstrate excellent internal consistency and test-retest reliability, and 
SDC90 between 1.0 and 2.5 as previously reported [390].   
Validity 
 Construct validity of the PSFS-NP was examined by testing the 
hypotheses that (1) PSFSchange (PSFSbaseline – PSFSfinal) score changed 
significantly within the improved group using a one-sample t-test, and (2) 
PSFSchange scores differed significantly between the stable and improved 
groups using independent samples t-test [396]. Construct validity was further 
tested by comparing PSFSbaseline scores with the ODIbaseline scores for the sub-
group with low back pain, and with NPRSbaseline scores for the total sample. 
We hypothesized a moderate significant negative correlation.  
Responsiveness 
 I correlated PSFSchange scores with GRoC-NP and NPRSchange 
(NPRSbaseline – NPRSfinal) scores for the total sample. We hypothesized that 
PSFSchange would correlate strongly (significantly and positively) with GRoC-
NP, but moderately (significantly and negatively) with the NPRSchange scores. 
I considered correlation coefficients (r) less than 0.30 as weak, values between 
0.30 – 0.49 as moderate, and values 0.50 or larger as strong correlations [397]. 
 The Receiver Operating Characteristic (ROC) curves were also plotted 
to assess the responsiveness of PSFS-NP using GRoC-NP as an external 
anchor [336]. The ROC curves were plotted for the PSFSchange for the stable 
group compared with the improved group.  Secondary analyses assessed (1) 
stable versus small improvement group, (2) stable versus medium 
improvement group, and (3) stable versus large improvement group. The 
Area under the curve (AUC) was used to indicate the ability of PSFS-NP to 
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differentiate between stable and improved groups.  The value of AUC closer 
to 1 indicates better agreement with the GRoC [336].  Minimum important 
change (MIC) values were also calculated [336]. We hypothesized that the 
MIC values would range between 1 and 4 typically reported in a previous 
systematic review [390]. 
RESULTS 
In Phase 1, the translation of PSFS to Nepali was successfully completed. 
The summary of the translation history is summarised in Figure 6.1. PSFS-NP 
can be found in Appendix 6 and at www.jospt.org.  
In Phase 2, 104 adults with musculoskeletal pain (75 Hospital, 29 
community) consented to participate in the study; 100% completed both the 
baseline and final assessments at a mean interval of 11.5 (SD 3.5) days (range, 
6 – 18 days).  The participant characteristics are described in Table 6.2. Thirty-
six participants (35%) with complete follow-up data were classified as 
“stable”, 64 (61%) as “improved”, and four (4%) as “worsened” based on the 
GRoC scores as per a priori definition. Forty-five of 48 participants (94%) in 
the low back pain subgroup completed ODI-NP. 
Table 6.2 Description of the participants. 
Variables Frequency (%) Mean (SD) 
Age (years):  Mean (SD)  41.2 (13.5) 
Sex   
 Male  32 (31%)  
 Female 72 (69%)  
 Total 104 (100%)  
Ethnicity   
 Newar 34 (33%)  
 Brahmin  23 (22%)  
 Chettri 16 (15%)  
 Others  31 (30%)  
Education    
 No school 41 (39%)  
 Primary  11 (11%)  
Chapter 6: THE PATIENT-SPECIFIC FUNCTIONAL SCALE 
122 
Variables Frequency (%) Mean (SD) 
 Secondary 17 (16%)  
 Higher secondary 16 (15%)  
 Bachelor and above 19 (18%)  
Occupation    
 Agriculture and housework 28 (27%)  
 Household work only 22 (21%)  
 Agriculture only 8 (8%)  
 Sitting job (Office/ business) 8 (8%)  
 No work 6 (6%)  
 Others  32 (31%)  
Site of pain   
 Low back pain  48 (46%)  
 Knee pain  21 (20%)  
 Shoulder pain  13 (13%)  
 Neck  9 (9%)  
 Elbow pain  5 (5%)  
 Others  8 (8%)  
The total duration of pain (in months)  21.70 (34.00) 
Days between evaluations, d  11.50 (3.50) 
GRoC at follow-up   
 Worsened group (GRoC < 4)  4 (4%)  
 No improvement (GRoC = 4) 36 (35%)  
 Improved group (GRoC = 5 – 7)  64 (61%)  
    Small improvement (GRoC = 5)     30 (29%)  
    Medium improvement (GRoC = 6)     23 (22%)  
    Large improvement (GRoC = 7)     11 (11%)  
Average PSFS scores (0 - 10)   
 Baseline   3.70 (1.73) 
 Final   5.03 (2.27) 
 Change (baseline – final)  -1.32 (1.89) 
Average NPRS scores (0 - 10)   
 Baseline 104 4.27 (1.63) 
 Follow-up 104 3.36 (1.56) 
 Change (baseline – final) 104 0.90 (1.49) 
Abbreviations: SD, Standard Deviation; GRoC, Global Rating of Change; PSFS, Patient Specific 
Functional Scale; NPRS, Numerical Pain Rating Scale. 
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Reliability 
 PSFS-NP demonstrated reliability with acceptable internal consistency 
of 0.75 and excellent test-retest reliability of 0.89 (95% CI: 0.78, 0.94).  SEM and 
individual level SDC90 were 0.63 and 1.46 respectively. The Bland-Altman plot 
is shown in Figure 6.2. 
 
Figure 6.2 Bland Altman Plot for Nepali Patient-Specific Functional Scale. 
Note: Y-axis is the change of PSFS-NP scores between baseline and follow-up measurements 
and X-axis is the mean of PSFS-NP scores at the baseline and final measurements. The solid 
line is the mean change of score (d), and dotted lines are d ± Z x SDchange (where Z = 1.64 for 
90% confidence interval.)   
  
Construct validity  
 PSFS-NP demonstrated construct validity by t-tests: t(63) = 8.65, 
p<0.001 within the improved group; and t(98) = 5.21, p<0.001 between the 
stable and improved groups.  It was further supported by moderate 
correlations of PSFSbaseline with ODIbaseline (r = -0.47, P = 0.001) and NPRSbaseline 
(r = -0.32, P = 0.001).  
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Responsiveness  
 Responsiveness was supported by moderate correlation of PSFSchange 
with NPRSchange (r = -0.55, P < 0.001), and significant strong positive 
correlation of PSFSchange with GRoC-NP (r = 0.71, P < 0.001).  
 Four ROC curves for the PSFSchange scores were plotted (see Figure 6.3) 
for the four dichotomous groups based on GRoC scores as described in 
Chapter 5 for the further support of responsiveness.  
 
(a) Stable group versus improved group 
 
 
(b) small improvement 
 
 
(c) medium improvement 
 
 
(d) large improvement.  
Figure 6.3 Receiver Operating Characteristic (ROC) curves. 
 The AUCs with their CIs and the respective MICs are reported in Table 
6.3. 
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Table 6.3 Responsiveness of Nepali- Patient Specific Functional Scale. 
Analysis AUC (95% CI) MIC 
Primary analysis 
 (GRoC 4 vs GRoC 5-7) 
0.83 (0.74, 0.91) 2.00 
Small improvement 
 (GRoC 4 vs GRoC 5) 
0.72 (0.59, 0.84) 0.50 
Medium improvement 
 (GRoC 4 vs GRoC 6)  
0.89 (0.8, 0.98) 0.66 
Large improvement  
 (GRoC 4 vs GRoC 7) 
0.99 (0.97, 1.00) 2.00 
Abbreviations: AUC, Area Under the ROC Curve; CI, Confidence Interval; MIC, Minimum 
Important Change; GRoC, Global Rating of Change. 
 
DISCUSSION 
 The Nepali version of PSFS after translation in accordance with 
recommended guidelines demonstrated acceptable measurement properties 
as hypothesized. Although PSFS has been validated in many languages in a 
variety of clinical conditions, this study supports its validation in individuals 
with low literacy (50% study participants had only primary education or less) 
when administered verbally.   
Reliability  
 Test-retest reliability of PSFS-NP was excellent, in line with our a priori 
hypothesis. The 95% CI of ICC of PSFS-NP (0.78, 0.94) is consistent with 6/8 
studies included in a previous systematic review reporting measurement 
properties of PSFS in musculoskeletal conditions (ranging between 0.76 and 
0.97) [390]. Only one study reported a lower ICC (=0.76, for chronic lateral 
epicondylalgia), and one reported a higher ICC (=0.97, for low back pain). 
Similarly, the Japanese PSFS reported almost perfect 1-week reliability 
(ICC=0.98) [398]. Such high reliability could be because participants were 
informed of the baseline scores, which may have increased the reliability. 
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Likewise, SDC90 of PSFS-NP (=1.46) was also within the hypothesized range 
(1.0 - 2.5) [390] and equal to that reported for chronic low back pain [399].  
Construct validity  
 The PSFS-NP demonstrated its construct validity as hypothesized. 
First, the construct validity was established by a statistically significant mean 
difference within the improved group, and between the stable and improved 
groups, similar to a previous study [396]. Second, the PSFSbaseline 
demonstrated moderate correlation (r= -0.47) with ODIbaseline in our study, 
which is lower than previously reported correlations (r= 0.51-0.74) [332] with 
the Roland Morris Disability Questionnaire (RMDQ), which is also a measure 
of back-related disability like ODI. The strength of correlation of PSFS and 
ODI was only moderate, which could be because of verbal administrations of 
ODI, which likely affected responses to the item related to sex life. Culturally, 
Nepalese patients prefer to say, “sex life is absent” rather than “sex life is 
normal” when interviewed, which is evident by the lowest scores in this item.  
 Finally, the correlation of the baseline scores of the PSFS-NP and 
NPRS-NP was moderate as hypothesized. It is worth noting that neither 
GRoC nor NPRS directly assesses the construct of physical function; the 
findings relating to validity would have benefited from the use of scales that 
assess the construct of physical function specifically. However, due to a few 
available valid measures in Nepali during the time of the study, we were 
limited in the present study to investigate this only in people with low back 
pain, using the ODI-NP, which supported the construct validity. 
Nevertheless, we can confirm the construct validity of PSFS-NP because more 
than 75% of our a priori hypotheses were achieved, as proposed by Terwee 
and colleagues [400].   
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Responsiveness  
 Responsiveness was confirmed by the correlations of PSFSchange and 
GRoC, which were strong as hypothesized, because both of these assessed 
change of physical function and overall change respectively. As physical 
function is a prime concern of patients with musculoskeletal pain conditions, 
participants’ overall reporting of change (assessed by GRoC) could have 
reflected their consideration of change in physical function (captured by 
PSFSchange) [398, 401].  
Minimum important change 
 The MIC value (2.00) of the PSFS-NP in the current study lies within 
the range reported previously, as hypothesized [390]. The MIC values 
obtained in our study are consistent with those reported previously for 
chronic low back pain [399, 401] using the same method using the ROC 
curves. The stepwise increase of MIC for small, medium, and large change for 
PSFS-NP (0.50, 0.66, and 2.00 respectively) supports its construct validity. Our 
method of estimating the MIC for small, medium, and large change 
separately provides a conservative estimate of MIC, i.e. calculation of the MIC 
using cut-points for medium (or lesser) change, or large (or lesser) change, 
would result in lower estimates for MIC than our discrete group method.  
Strengths and limitatations 
 Although the current study is robust in terms of its methodology and 
complies with COSMIN recommendations [346], the results should be 
interpreted with consideration of its limitations. First, the findings related to 
the reliability of the PSFS-NP are based on a relatively small number of 
individuals in the stable group (N = 36). Larger sample sizes may provide 
greater certainty for reliability coefficients. Second, as the findings on 
responsiveness are based on the short duration of follow-up (6-18 days), 
which is shorter than many studies, the magnitude of change may be smaller 
than other studies. This disadvantage of a shorter follow up period is offset by 
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the advantage that shorter recall time for GRoC in the current study would 
likely have reduced the recall bias [402]. Finally, the findings of this study are 
limited to individuals with musculoskeletal pain, and may not be generalized 
to other health conditions, for example, cardiopulmonary or neurological 
conditions. Future research may consider the usefulness of PSFS in other 
health conditions [390].  
 The findings of our research have important clinical and research 
implications. As the assessment of physical function is recommended in core-
outcome sets [7,10], the availability of a validated PSFS-NP will facilitate its 
use in the assessment of physical function in musculoskeletal conditions in 
Nepal in both research and clinical practice.  
CONCLUSIONS 
 The Nepali version of PSFS is a reliable, valid and responsive measure 
for the assessment of physical function in adult Nepalese with 
musculoskeletal pain.  Clinicians should consider a change of score lower 
than 1.5 on 0-10 PSFS-NP as measurement error and a score change of 2 
points as a meaningful change of physical function for Nepalese with 
musculoskeletal pain. It can be used in clinical practice and research in adult 
Nepalese with musculosketal pain. The measurement properties of the PSFS 
in other clinical samples (neurological or cardiopulmonary disorders) or 
populations (e.g., paediatrics) should further be explored.  
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CHAPTER 7  
The Pain Catastrophizing Scale 
 
 
CHAPTER 7 : THE PAIN 
CATASTROPHIZING SCALE 
[Sharma S, Thibault P, Abbott JH, Jensen MP: Clinimetric properties of the Nepali version of the Pain 
Catastrophizing Scale in individuals with chronic pain. J Pain Res 2018, 11:265-276.] 
***
INTRODUCTION 
Pain catastrophizing — which has been defined as an exaggerated 
negative cognitive response related to pain [265] — has been shown to be 
associated with a broad array of important quality of life domains such as 
pain intensity, pain interference and psychological function in individuals 
with chronic pain from different cultures [403, 404].  Catastrophizing is 
responsive to a variety of pain treatments [405-408] and has been found to 
mediate the effects of many of these [405, 409]. Thus, catastrophizing remains 
an important psychosocial domain to assess in patients with chronic pain. The 
most common measure of pain catastrophizing is the 13-item Pain 
Catastrophizing Scale (PCS).   
The PCS has three subscales assessing pain-related rumination, 
magnification, and helplessness [265, 410]. This 3-factor structure has been 
confirmed in other English-speaking samples [266, 410], although research 
has shown that 2-factor solutions show better fit in some samples [411, 412], 
Non-English translations have also been shown to yield both 2- and 3-factors 
[413-419]. However, given the strong associations among the factors, 
researchers tend to use the total PCS score more often than the subscale scores 
[405, 406, 408].  
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The original English version of the PCS and its translated versions are 
psychometrically robust. The total score of PCS has repeatedly been shown to 
be reliable as evidenced by good to excellent internal consistency [266, 403, 
404, 414-417, 420, 421], and excellent test-retest reliability [403, 414, 417, 420-
422]. Standard error of measurement (SEM) and smallest detectable change 
(SDC) of the PCS ranges from 1.6 and 4.6 points [414, 415, 421, 422], and 8.8 
and 12.8 points (of a total 52 points) [414, 415, 417, 421] respectively. 
Construct validity of the PCS is supported via moderate to strong correlations 
(i.e., r ≥ 0.30) with measures of depression [403, 414, 416, 417], anxiety [265, 
403, 414, 417], and pain intensity [265, 266, 403, 411, 414, 416, 417]. 
The PCS has been translated into a number of different languages 
(https://eprovide.mapi-trust.org/instruments/pain-catastrophizing-
scale#languages). The availability of translated measures is critical to facilitate 
research examining the role that language and culture may play in how 
catastrophizing is related to patient function.  Thus, the aim of this study was 
to translate the PCS into another language — this time, Nepali (PCS-NP) — 
and assess its measurement properties. Consistent with the extant research, 
we hypothesized that the PCS-NP would demonstrate either a 2- or 3-factor 
structure [265, 412] and that the factors would be strongly associated with one 
another, supporting the use of the PCS total score in this population. We 
further hypothesized that the PCS-NP scales would demonstrate: (1) good to 
excellent internal consistencies (i.e., Cronbach’s alphas ≥ 0.70) [365, 403, 414-
417, 420, 421, 423]; (2) excellent 2-week test-retest reliability (i.e., ICC  ≥ 0.75) 
[365, 414, 415, 417, 420-422]; (3) SEM between 1.6 and 4.6 [414, 415, 421, 422]; 
(4) a SDC from 8.8 and 12.8 [414, 415, 417, 421]; and (5) construct validity via 
moderate to strong correlations (i.e., r ≥ 0.30) with measures of  depression, 
anxiety and pain intensity [403, 414, 416, 417]. 
METHODS 
We first translated the PCS to Nepali (PCS-NP) and performed 
cognitive debriefing of the instructions, items and to item response options to 
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ensure that the items were culturally appropriate in 30 individuals with 
musculoskeletal pain.  Next, we evaluated the measurement properties of the 
PCS-NP in two independent samples. Ethical approval of the research was 
obtained from the Institutional Review Committee of the Kathmandu 
University School of Medical Sciences (ethics approval numbers: 105/14 and 
75/15), and the study complies with ethical guidelines of the Declaration of 
Helsinki. Written informed consent was obtained from all the research 
participants before data collection. Those participants who could not read or 
provide a written signature provided verbal consent, and a witness signed on 
their behalf. The data were collected from January 2016 to May 2017.  
Translation procedure 
Translation of PCS to Nepali was performed using standard guidelines 
[96].  First, we obtained permission from the developer (Prof. Michael 
Sullivan) to translate the PCS to Nepali.  Then, two forward translators 
translated the PCS into Nepali. The two forward translated versions were 
synthesized to a single forward translated (FT) version. The FT was then 
back-translated into English by three independent Native English speakers. 
An expert committee meeting was held, which comprised of language 
experts, translators (who were available for a face-to-face meeting), and 
research methodologist. Any discrepancies were discussed and the Nepali 
version of the PCS that is simple and comprehensible was finalised during the 
meeting. The primary aim of the meeting was to retain a comprehensible 
Nepali version of the PCS with semantic, idiomatic, and conceptual 
equivalence. Translators remotely located were contacted via emails and 
Skype, and any important suggestions were noted. The final Nepali version 
was back-translated to English, which was sent to my supervisor (MPJ) for 
review.  
The resultant version was tested on 30 individuals with either acute or 
persistent musculoskeletal pain for cognitive debriefing. Minor changes were 
made in sentence structure, and simpler words replaced difficult words so 
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that most participants could understand the final Nepali version of the PCS 
(PCS-NP). The final Nepali version, its back translation, and translation 
history were sent to the developer, who reviewed and approved it.  The 
Nepali version is licensed and distributed by Mapi Research Trust, and 
researchers intending to use PCS-NP should contact Mapi Research Trust for 
its use (https://eprovide.mapi-trust.org/instruments/pain-catastrophizing-
scale). Translation history is summarized in Figure 7.1.  
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Figure 7.1 Translation history. 
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  Participants  
Two independent adult samples (age ≥ 18) of Nepali-speaking 
individuals with chronic pain (pain lasting for longer than three months) 
were recruited. The first sample included individuals with chronic pain (N = 
144) recruited from Dhulikhel Hospital, a tertiary care hospital (n = 44; 
consecutive patients) and a community (n = 100; by door-to-door survey) in 
rural Nepal with pain intensity ≥ 4/10 on a 0-10 numerical pain rating scale 
(NPRS); 0 = “No pain” and 10 = “Maximum Pain”. The second sample, also 
consisted of individuals with chronic pain (N= 275) who were required to 
report ≥ 3/10 pain on an NPRS, was recruited mostly from the community (n 
= 252).  The reminder (n = 23) of the sample was recruited from the same 
hospital as that used to recruit the first sample. All the participants in both 
samples provided data via interview. 
Measures  
Pain Catastrophising Scale (PCS). The PCS is a 13-item scale assessing 
negative cognitive responses related to pain. Participants are asked to rate the 
frequency of their catastrophizing thoughts using a 5-point Likert scale 
ranging from 0 (“Not at all”) to 4 (“All the time”) [265].  The total score ranges 
from 0 to 52. Higher scores indicate higher catastrophizing. The original scale 
has three subscales assessing rumination, magnification, and helplessness.  
Participants in the first sample were administered the PCS-NP once, and 
participants in the second sample were administered the PCS-NP twice (two 
weeks apart), with 244 (90%) of the original sample providing retest data.  A 
summary of the measures used in the study is provided in Table 7.1 and 
described in more detail below.  
Table 7.1 Patient-Reported Outcome Measures (PROMs) used. 
Scale Study Item Scale Construct assessed 
PCS-NP EFA, CFA 13 0-4, Ordinal Pain Catastrophizing 
BDI-NP [424]  EFA 21 0-3, Ordinal Depression 
BAI-NP [425] EFA 21 0-3, Ordinal Anxiety 
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Scale Study Item Scale Construct assessed 
GRoC-NP [3] CFA 7 1-7, Ordinal Global rating of change 
PROMIS pain 
intensity [233] 
CFA 1 1-5, Ordinal Average pain intensity 
Abbreviations: PCS-NP, Nepali version of Pain Catastrophizing Scale; BDI-NP, Nepali version of 
Beck Depression Inventory; BAI-NP, Nepali version of Beck Anxiety Inventory; GRoC-NP, Nepali 
version of Global Rating of Change; PROMIS= Patient-Reported Outcomes Measurement 
Information System; EFA, Exploratory Factor Analysis; CFA, Confirmatory Factor Analysis.  
 
Beck Anxiety Inventory (BAI). The 21-item BAI was used to assess 
perceived anxiety in the first sample [426]. Each item is scored on a 4-point 
Likert scale ranging from 0 to 3 where 0= “Not at all” and 3= “Severely, I could 
barely stand it”. The total score can range from 0 to 63, with higher scores 
indicating more anxiety. The Nepali version of BAI — the version used in this 
study — has been shown to be reliable (Cronbach’s alpha= 0.89 [425]; ICC= 
0.88 [427]). The BAI demonstrated excellent internal consistency (Cronbach’s 
alpha = 0.90) in the current sample. 
Beck Depression Inventory (BDI). The 21-item BDI was used to assess 
depression in the first sample [428].  Each item on the scale has four unique 
response options designed for that item. The severity of depression symptoms 
is rated on these 4-point scales, ranging from 0 to 3. The total score can range 
from 0 to 63, with higher scores indicating more depression. The Nepali 
version of BDI is a reliable measure (Cronbach’s alpha = 0.90 [424]; ICC= 0.84 
[427]) and demonstrated excellent internal consistency (Cronbach’s alpha = 
0.90) in the current sample.  
PROMIS pain intensity. The Patient-Reported Outcome Measurement 
Information System (PROMIS) average pain intensity over the past 7 days 
was assessed in the second sample on a 5-point Likert scale where 1= “No 
pain”, and 5= “Very severe pain”; with higher scores indicating more intense 
pain (http://www.healthmeasures.net). Test-retest reliability (ICC) of the 
Nepali version of the PROMIS pain intensity scale is 0.71 in the current 
second sample. 
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Global Rating of Change (GRoC). The Nepali version of GRoC was 
used to assess the global impression of perceived change in their chronic pain-
related problems in the second sample on a 7-point Likert scale ranging from 
1 to 7 [3, 4, 333]. The middle score, “4” represents “No change”; scores greater 
than “4” indicate improvement and scores less than “4” indicate worsening. 
The GRoC was used to categorize the sample to “improved” and “stable” 
group, considering one-point change as a significant improvement [333]. We 
classified participants with a GRoC score of 4 as “stable”, and participants 
with GRoC scores of 5-7 as “improved”.  Using this classification, participants 
in the stable group were used for computing the test-retest reliability, SEM, 
SDC, and limits of agreement statistics [394]. 
Other measures. The demographics information collected included 
age, sex, religion, ethnicity, education, and occupation.  Additionally, the total 
duration of chronic pain was recorded in months, and pain site was assessed 
using a pain diagram.  
Statistical analyses 
The conduct and reporting of the measurement properties were guided 
by the COSMIN recommendations.  
Factor analyses 
 We performed an exploratory factor analysis (EFA) in the first sample 
(hereafter referred to as the EFA sample) using maximum likelihood for factor 
extraction. Factor rotation was performed using oblique rotation (Direct 
Oblimin; delta= 0), allowing the factors to correlate with each other.  Next, we 
performed a series of confirmatory factor analyses (CFAs) in the second 
sample (hereafter referred to as the CFA sample) to compare the results of the 
EFA from the first sample with (1) a 1-factor solution including all the 13 
items as a single factor, (2) the 2-factor solution obtained from the largest 
English speaking sample published [411], and (3) the original 3-factor solution 
found by Sullivan and colleagues [265] using AMOS for SPSS 24.  Model fit 
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was evaluated using the chi-square goodness-of-fit index, the ratio of chi-
square value to degree of freedom, the root mean square error of 
approximation (RMSEA), comparative fit index (CFI), and parsimony 
goodness-of-fit index (PGFI). A better fit is indicated by (1) chi-square value 
and the ratio of chi-square to degree of freedom values closer to zero, (2) 
lower values of RMSEA, (3) larger values of CFI, and (4) larger value of PGFI 
which indicates more parsimonious fit [429].   
Reliability  
 To evaluate reliability, I assessed internal consistency, test-retest 
reliability, SEM, SDC, and created Bland-Altman Plots.  I computed the 
internal consistencies of the PCS-NP scales for both samples, using 
Cronbach’s alpha. I considered values of Cronbach’s alpha less than 0.70 as 
inadequate, values from 0.70 to 0.79 as adequate, values from 0.80 to 0.89 as 
good, and values 0.90 or larger as excellent [365]. Two-week test-retest 
reliability (random-effect model) was evaluated using the intraclass 
correlation coefficient (ICC2,1) agreement in the stable group (GRoC = 4).  We 
considered ICC values of between 0.40 and 0.59 as fair, values between 0.60 
and 0.74 as good, and values equal to or greater than 0.75 as excellent [365].   
 To further evaluate reliability, we also computed the SEM, which is an 
indication of how repeated administration of a measure tends to be 
distributed around the “true” score.  SEM is important to consider because 
two measurements obtained at different times will not yield exactly the same 
score, either because of the variation in the participants being assessed, 
because of the variation in the measurement process, or both [430]. Thus, it is 
possible that a measure may have large test-retest reliability, which indicates 
excellent reliability but may also have a large measurement error. Therefore, 
the SEM compliments test-retest reliability and is a recommended parameter 
to assess and report in studies related to measurement properties [345]. 
Larger scores indicate large variability and smaller scores indicate less 
variability.  
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I calculated SEM using the formula, SEM = SDchange x √(1 - ICC) [338] 
where SDchange is the standard deviation for the mean change of PCS-NP 
scores.  Using the SEM value, I further calculated SDC95% of the PCS-NP using 
the formula, SDC95% = 1.96 x √2 x SEM [338, 345]. A Bland-Altman plot was 
created to complement the measurement error and indicates the levels of 
agreement between the baseline and follow-up assessment [344, 345, 395]. The 
plot was drawn with change of PCS-NP scores from baseline to follow-up (Y-
axis) versus mean score of PCS-NP between baseline and follow-up 
assessments (X-axis). Limits of agreement with 95% confidence interval 
(LOA95%) were computed by using the formula [mean difference ± 1.96 × 
SDchange] [395, 431]. 
Validity 
 I evaluated the construct validity of the PCS-NP scales to test the a 
priori hypotheses presented in the Introduction section by computing Pearson 
Correlation Coefficients between the PCS-NP scale scores and scores from 
Nepali versions of BDI, BAI administered to participants in the EFA sample 
and PROMIS pain intensity short form 3a measure administered to CFA 
sample. I considered correlation coefficients (r) less than 0.30 as weak, values 
between 0.30 – 0.49 as moderate, and values 0.50 or larger as strong 
correlations [397]. I excluded the participants for all analyses if there were any 
missing values on the PCS items.  
RESULTS 
 The PCS-NP succeeded in retaining the semantic, idiomatic, and 
conceptual equivalence. Scores of PCS-NP were normally distributed in both 
the EFA and CFA samples. A total of 0.7% (n=1) and 2.6% (n= 7) in EFA and 
CFA samples respectively scored 0/52 total score, and 0.7% (n=1) and 1.1% 
(n=2) in EFA and CFA samples respectively scored 52/52 total score. 
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Demographic characteristics 
The majority of study participants were women (65% and 73% in the 
EFA and CFS samples, respectively) and were Hindu in religion (92% and 
85%). Almost half the participants in both the samples had pain in multiple 
body parts (42% and 47%), followed by pain in the low back and pelvis (22% 
and 18%), and pain in the knee(s) (21% and 19%) respectively. All the 
participants in the EFA sample were individuals with chronic 
musculoskeletal pain; however, 4% of the CFA sample had a chronic 
headache. The descriptive information for the two samples is presented in 
Table 7.2. 
Table 7.2 Description of the study participants. 
 EFA sample CFA sample  
 (N = 143) (N= 272) 
Variable  N (%) or Mean (SD) N (%) or Mean (SD)  
Site of pain, N (%)      
  Multiple sites  60 (42%) 128 (47%)  
  Low back and pelvis  32 (22%) 50 (18%) 
  Knee  30 (21%) 52 (19%) 
  Other sites  18 (13%) 42 (16%) 
Duration of pain (months)  
  Mean (SD)   51.10 (76.42) 51.26 (65.72)   
Age (years) 
   Mean (SD) 47.06 (14.50) 46.30 (15.65)  
Sex, N (%)     
  Men 50 (35%)  73 (27%)  
  Women 93 (65%)  199 (73%) 
Religion, N (%)     
  Hindu    132 (92%) 230 (85%) 
  Buddhist 5 (4%)  35 (13%) 
  Others 6 (4%)                                   7 (3%) 
Race/Ethnicity, N (%)     
  Chettri   59 (41%) 16 (6%) 
  Brahmin 40 (28%) 87 (32%) 
  Newar 19 (13%) 144 (53%) 
  Others  25 (18%) 25 (9%) 
Education, N (%)     
  No school 45 (31%) 41 (15%) 
  Primary school  42 (30%) 53 (20%) 
  Secondary school  35 (24%) 60 (22%) 
  Higher secondary and above 21 (15%) 118 (43%) 
Occupation, N (%)     
  Not working 7 (5%)  37 (14%) 
  Agriculture 49 (34%) 43 (16%) 
  Household work  39 (27%) 55 (20%) 
  Business  15 (10%) 57 (21%) 
  Office worker 11 (8%)  39 (14%) 
  Other     22 (15%)  41 (29%) 
 
Chapter 7: THE PAIN CATASTROPHIZING SCALE 
141 
Of 144 participants in the EFA sample and 275 participants in the CFA 
sample who were administered PCS-NP at the baseline assessment, there 
were missing items in the data completed by one and three participants 
respectively in the two samples. We excluded the participants with missing 
items in all analyses from EFA and CFA samples; thus, there were N=143 
participants in the EFA sample and N=272 participants in the CFA sample for 
all analyses.  
Factor analyses 
 Results of EFA on the EFA sample (N=143) using maximum likelihood 
with Oblimin rotation for factor extraction and the Kaiser criterion (i.e., 
eigenvalues greater than 1.0) to determine the number of factors, indicated a 
two-factor solution. As can be seen in the pattern matrix from the EFA 
analysis (Table 7.3), Factor 1 comprised of items 2, 3, 4, 5, 9, 12, 13 and Factor 
2 comprised of items 1, 6, 7, 8, 10, 11. Given the items that loaded on each 
factor, we labeled Factor 1 “Helplessness” and Factor 2 “Pain Focus.” 






Brief description of the items Factor 
1 2 
3 H Never get any better .78 .06 
5 H Can’t stand it .73 .03 
12 H Nothing I can do .73 .10 
4 H It’s awful .72 -.07 
2 H Can’t go on .62 -.13 
9 R Can’t keep out of mind .56 -.24 
13 M Something serious may happen .53 -.16 
11 R Want the pain to stop -.10 -.85 
8  R Want the pain to go away .03 -.73 
10 R Thinking how much it hurts .28 -.55 
1 H Worrying whether the pain will end .37 -.39 
7 M Thinking of painful experiences .25 -.37 
6 M Afraid if the pain may get worse .28 -.34 
Abbreviations: H, Helplessness; R, Rumination; M, Magnification. 
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These two factors explained 50% of the variance in the items (see 
Figure 7.2). The two factors, however, were very strongly associated with one 
another (r = 0.91). The 2-factor solution found in the first sample 
demonstrated an acceptable fit in the CFA sample (see Table 7.4).  In 
addition, the 1-factor, another 2-factor extracted by Chibnall and Tait [411], 
and the 3-factor extracted by Sullivan and colleagues [265] also had an 
adequate fit, comparable to the 2-factor solution extracted from the EFA 
sample. Attempts to improve each of these models further by allowing up to 
two pairs of error terms to correlate resulted in only modest improvements in 
the fit of each model (Table 7.4).   
 
Chapter 7: THE PAIN CATASTROPHIZING SCALE 
143 
 
Figure 7.2 Path diagram after CFAs, two-factor model and one-factor model 
with adjustment for the covariance of error terms in CFA sample (N=272). 
Abbreviations. CFAs, confirmatory factor analyses; PCS, Pain Catastrophizing Scale. 
Table 7.4 Results of the confirmatory factor analyses for the Nepalese Pain 
Catastrophizing Scale (PCS-NP) in the CFA sample (N=272). 
Models and modifications X2 (df) X2/df RMSEA CFI     PGFI 
One-factor model 
  No Modifications 229 (65) 3.53     0.097 0.913  0.628 
  With modifications 190 (63) 3.01 0.086 0.933 0.622 
Two-factor model a  
  No modifications 190 (64)  2.97 0.085  0.933 0.632 
  With modifications 166 (62)  2.67 0.079  0.945 0.620  
Two-factor model b 
  No modifications 207 (64) 3.23 0.091 0.924 0.626 
  With modifications 171 (62) 2.76 0.081 0.942 0.617 
Three-factor model c 
  No modifications 200 (62)  3.23 0.091 0.927 0.608 
  With modifications 180 (60) 3.00 0.086 0.936 0.596 
a Two-factor model based on results from the EFA sample (N = 143).  
b Two-factor model based on Chibnall and Tait (2005) [411]. 
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c Three-factor model based on Sullivan et al. (1995) [265]. 
Abbreviations. CFA; PCS-NP, Nepali version of Pain Catastrophizing Scale; Confirmatory Factor 
Analysis; X2, Chi-Square; df, degree of freedom; RMSEA, Root Mean Square Error of Approximation; 
CFI, Comparative Fit Index; PGFI, Parsimony Goodness-of-fit Index. 
Reliability  
 Results of the analyses evaluating the reliability of the PCS-NP total 
and two subscale scores (computed using the results of the factor analyses as 
a guide) are presented in Table 7.5. The PCS-NP demonstrated good to 
excellent internal consistency (range: 0.83 – 0.93) in both samples.  Two-week 
test-retest reliability on the stable group was excellent 0.90 (95% CI: 0.85, 0.93).  
SEM and SDC for the total score of PCS-NP were 2.52 and 6.98 respectively.  
LOA95%  ranged from -15.17 to 16.02 for the total PCS-NP scores. LOA95% of the 
sub-scales are presented in Table 7.5. Bland-Altman Plot, which shows the 
limits of agreement for the total PCS items and the two factors separately, 
presented as Figure 7.3.   
 
(a) Total PCS 
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(b) PCS Factor 1  
 
 
(c) PCS Factor 2 
 
Figure 7.3 Bland-Altman Plots. 
Note: Y-axis is the change in PCS-NP scores between baseline and follow-up measurements 
and X-axis is the mean of the PCS-NP scores at the baseline and final measurements. The red 
line is the mean change of score (¯d), and green lines are ¯d ± Z x SDchange (where Z = 1.96 
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for 95% confidence interval.) Abbreviations: GRoC, Global Rating of Change; PCS, Pain 
Catastrophizing Scale; PCS-NP, Nepali version of Pain Catastrophizing Scale. 
 
Table 7.5 Reliability of the Nepali- Pain Catastrophizing Scale. 
Sample N IC Test-rest (ICC) SEM SDC95% LOA95% 
EFA sample  143      
   PCS-NP total   0.91     
   PCS-NP factor 1  0.87     
   PCS-NP factor 2  0.83     
CFA sample 272      
   PCS-NP total   0.93     
   PCS-NP factor 1  0.89     
   PCS-NP factor 2  0.85     
CFA- Stable 
group 
122      
   PCS-NP total  0.90 0.90 (0.85, 0.93) 2.52 6.98 16.02, -15.17 
   PCS-NP factor 1  0.88 0.88 (0.83, 0.92) 1.67 4.62 9.29, -9.69 
   PCS-NP factor 2  0.89 0.89 (0.84, 0.92) 1.33 3.67 8.47, -7.22 
Abbreviations: IC, Internal consistency (Cronbach’s alpha); ICC, Intraclass Correlation 
Coefficient (with 95% CI) for 2-week test-retest reliability; SEM, Standard Error of 
Measurement; SDC95%, Smallest Detectable Change for 95% Confidence Interval; LOA95%, 
Limits of agreement at 95% confidence interval.  
  
Validity 
 Both the total score and subscales scores were positively, moderately 
and significantly associated with the instruments assessing depression, 
anxiety and pain intensity as hypothesised. The results of hypotheses testing 
for the construct validity of PCS-NP total scores and subscales are presented 
in Table 7.6. 
Table 7.6. The validity of the Nepali- Pain Catastrophizing Scale. 
 
  Construct validity (r) 
Sample N BDI BAI PROMIS 
EFA sample 143    
   PCS-NP total   0.56** 0.55**  
   PCS-NP factor 1  0.55** 0.52**  
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   PCS-NP factor 2  0.49** 0.49**  
CFA sample  272    
   PCS-NP total     0.35** 
   PCS-NP factor 1    0.33** 
   PCS-NP factor 2    0.33** 
*P < .05; **P < .01. 
Abbreviations: BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; PROMIS, 1-5 Verbal 
Rating PROMIS Pain Intensity Scale for average pain in the past 7 days.  
 
DISCUSSION 
 The PCS-NP was successfully translated and adapted to Nepali and 
validated in Nepalese with chronic pain. The findings support its reliability 
and validity. Specifically, we extracted a 2-factor solution (Factor 1= 
Helplessness, and Factor 2= Pain Focus) from the EFA in the EFA sample, and 
confirmed this solution by CFA in an independent sample.  The reliability of 
the PCS-NP total score and two subscale scores was supported by excellent 
internal consistencies and test-retest reliability over a two-week period.  
Construct validity was supported via moderate to strong associations with 
measures assessing depression, anxiety, and pain intensity, as hypothesized.   
Factor analysis  
The factor analysis of the PCS-NP items yielded two factors in our 
sample.  Although three factors are more common [403, 414-416, 418, 420, 422, 
432], two factors sometimes emerge [411, 412, 419, 433] in different samples of 
individuals with chronic pain.  The differences in the factor structure of these 
items across different samples may be related to cultural differences in how 
catastrophizing thoughts relate to each other (and possibly impact function) 
in different countries.  In our sample, “Helplessness” was largely retained as a 
unique factor.  But distinct “Rumination” and “Magnification” factors did not 
emerge as they had in the original English version of the PCS [434] or many 
other samples (e.g., [403, 414-416, 418, 420, 422, 432]).  Instead, the second 
factor appeared to reflect thoughts related to a focus on the pain. 
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At the same time, the two factors that emerged in this study were 
strongly associated with each other, suggesting that they may both be 
assessing the same overarching construct. This conclusion is also supported 
by a similar pattern of associations between the two PCS-NP subscale scores 
and the criterion variables.  Many other studies have also shown strong 
between-factor associations in both 2-factor [411, 412, 419] and 3-factor 
models [404]. Also, of note, even though there is a large degree of overlap in 
how the PCS items load onto different factors across studies, rarely if ever do 
the exact same PCS items load on the same 2- or 3-factors in any pair of 
studies (e.g., [404, 411, 412, 414, 417]).  As a group, these findings support the 
conclusions that (1) the PCS items tend to reflect more than one (but strongly 
inter-correlated) subdomains of catastrophizing, (2) the specific subdomains 
reflected in the items vary to some degree across different populations, and 
(3) there exists a single overarching domain assessed by the PCS that is 
reliable and consistent across populations.  Practically, these findings indicate 
that the PCS total score (but not necessarily the subdomain scores) may be 
most appropriate for cross-cultural research.    
Reliability  
The internal consistencies of the PCS-NP total score in this study (alpha 
range= 0.90 – 0.93) lie within the ranges previously reported.  They are higher 
than the original English and the Catalan versions (alphas = 0.87 in both) [333, 
416], and Hindi version (alpha= 0.76) [422]; similar to those found in samples 
that speak other languages such as Malay, Korean, Chinese, Italian, and 
German (alpha range= 0.90- 0.93) [403, 404, 414, 417, 420], and less than those 
found in a sample of patients from South Africa (alpha= 0.97-0.98) [421].  
Similarly, we found that the 2-week test-retest reliability of the PCS-NP 
was excellent in our test-retest sample, consistent with our a priori hypothesis. 
Two weeks is considered optimal for the assessment of the reproducibility of 
a measure because it is long enough to limit potential recall bias, and short 
enough also limit real change [344]. Additionally, it is important to compute 
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test-retest reliability in the sample reporting that did change in their pain 
problem. Thus, in the current study, we assessed test-retest reliability in those 
participants who reported “no change” in their pain problem using the GRoC 
as an external anchor [338].   
Numerous previous studies either assessed test-retest reliability in 
short periods (range, 1 day – 7 days) [415, 417, 420, 422], which may have 
been resulted in findings that have recall bias [344]; or assessed using longer 
epochs (3-4 weeks) [404, 415, 421]. To our knowledge, only two studies 
assessed the test-retest reliability of the PCS using a two-week time period, 
the results of which are comparable to our study [414, 416].  Additionally, we 
reported test-retest reliability in a stable sample who reported no change in 
their pain-related problems. Most of the studies evaluating the measurement 
properties of the PCS have not computed the test-retest reliability in a 
“stable” sample. This is especially true and problematic for those studies 
reporting longer follow-up for retest assessment [404, 415, 421]. The 
participants in these studies were more likely to have changed with respect to 
their pain problems (and catastrophizing scores). Thus, the reliability of the 
PCS may be under-estimated in these studies. Support for this possibility is 
found in one study which computed test-retest reliability in both a subsample 
of stable patients with low back pain as well as the total sample and found 
better temporal stability in the stable group (ICC= 0.92, n=34) versus the total 
group (ICC= 0.85, n=60) [415].   
Measurement error 
The measurement error parameters we found met our a priori 
hypothesis for SEM, but we found lower SDC values than previously 
reported. Both the SEM and SDC are dependent on the test-retest coefficient. 
As previously indicated, the reliability assessed is influenced by the sample 
chosen (i.e. stable sample versus total sample). Not many studies have 
reported measurement error parameters, which is now recommended by the 
COSMIN recommendations [345]. The value of SEM we found for the total 
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score (2.52) is larger than the Hindi version (SEM=1.60) [422] and smaller than 
other versions (SEM= 3.30- 4.60) [414, 415, 420, 421]. The SEM is influenced by 
the SD of change of PCS score (SDchange) and the ICC. The smaller SEM values 
in our study are likely related to our use of the stable group to compute test-
retest reliability and measurement error, as opposed to other studies that used 
total group to compute test-retest reliability and SEM.  Thus, we obtained 
smaller SDchange and larger ICC values, giving us a more precise value of SEM. 
The authors of the Hindi version study included the SD of the baseline 
measurement instead of the SDchange, which may have accounted for their very 
low SEM [422].   
The SDC value of 6.98/52 observed in our sample provides a cut-point 
for determining the reliability of changes in the PCS score. The SDC 
computed from our sample is smaller than those observed in other samples 
(range, 8.83 to 13) [414, 417]. This is due to the smaller variability in the 
catastrophizing scores (as represented by the standard deviation), and larger 
test-retest reliability coefficient (ICC) in our sample, relative to those in 
previous studies [414, 417]. The SDC statistic is useful as a guide to indicate 
whether or not a change in PCS score greater than measurement error; that is 
if the change represents “true” change and not just random error. For the 
PCS-NP, a change of 7/52 can be viewed as representing a true change in the 
total PCS score beyond measurement error.  
The results of LOA95% and Bland-Altman Plots [395] (Figure 7.3) 
provide further information regarding measurement error [338, 344]. The 
Bland-Altman Plots show agreement between test and retest scores for every 
study participant; that is, how far each participant deviates from the mean 
change score between the baseline and final measurements.  In the current 
study, LOA95% indicates that for 95% of participants, a measurement at 
follow-up assessment would be between 15.17 points less and 16.02 points 
greater (out of a total of 52 points) than the baseline measurement.  
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Validity 
 The validity of PCS-NP is supported by (1)  its comprehensibility and 
negligible missing items, (2) structural validity interpreted by factor analyses, 
(3) cross-cultural validity by adherence to high standards of translation 
guidelines [435], and (4) construct validity by testing a priori hypotheses. We 
adapted and adhered to translation and cross-cultural adaptation guidelines 
by Beaton and colleagues [435], which assured high standards in translation 
methodology. Importantly, we confirmed the construct validity of the PCS-
NP based on our a priori hypotheses that PCS-NP would correlate moderately 
to strongly and significantly with the comparator instruments.  Association of 
PCS-NP with measure of depression in the current sample (r = 0.56) is within 
the range previously reported (r = 0.40- 0.61) [403, 414-417, 420]. It is larger 
than those reported by the Chinese (r = 0.40) [2], similar to Korean (r = 0.53) 
[14]  but smaller than Catalan (r = 0.61, BDI) [416] versions. Like the 
association with depression, PCS-NP in the current sample showed moderate 
positive associations with the measures of anxiety and lies in the range that is 
previously reported (r = 0.53 - 0.82) [403, 414, 415, 417, 420]. Similarly, the 
association of PCS-NP with a measure of pain intensity is moderate, which 
also lies within the range previously reported (r = 0.25 - 0.45) [403, 414-417, 
420-422]. As the a priori hypotheses regarding expected correlations of the 
PCS-NP with other variables were met in the current study, the construct 
validity of the PCS-NP is supported.  
Strengths and limitations 
One strength of the study is that I conducted and reported the 
manuscript using the COSMIN recommendations as a guide [344, 345]. As per 
the COSMIN recommendations, I used an adequate sample size (>100)  and 
confirmed participants’ stability during the interim period by the use of 
GRoC. However, the study also has a limitation, which should be considered 
when interpreting the results.  I did not evaluate the responsiveness of the 
PCS-NP to change. Future research to evaluate the responsiveness of the PCS-
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NP, as well as to better understand the meaning of change in the PCS-NP 
scores (e.g., the change that represents a minimum important change) would 
be useful.  
CONCLUSIONS 
To conclude, here we developed a comprehensible, culturally 
appropriate, valid and reliable Nepali version of the PCS for the use in 
Nepalese with chronic musculoskeletal pain or headache. The availability of 
this measure will facilitate more cross-cultural comparative studies studying 
the role of catastrophizing in chronic pain.  For the clinical use of the PCS-NP 
clinicians should consider PCS change score of 7 or more like a true change 
beyond the measurement error. Future research should evaluate the  
responsiveness and minimum important change scores in the PCS-NP that are 
meaningful to patients, in order to be better able to understand the clinical 
significance of the PCS-NP. The PCS-NP can be used to assess the levels of 
pain catastrophizing in adult Nepalese with chronic pain.  
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Resilience has been defined as an individual’s ability to recover or 
“bounce back” from stressful events [436]. Resilience is gaining popularity as 
a domain for understanding variability in adjustment to chronic pain.  It has 
been shown to be associated with physical disability and psychological 
function, including catastrophizing, anxiety and depression [436-438]. Those 
with higher resilience scores are more able to recover from painful states and 
use fewer analgesics than those with lower resilience scores [439, 440]. 
Resilience is commonly assessed in chronic pain research using the Connor 
Davidson Resilience Scale (CD-RISC).  
The CD-RISC has three versions: the full 25-item [334], abbreviated 10-
item (CD-RISC-10) [441] and brief 2-item (CD-RISC-2) [442] versions. The CD-
RISC-10 was derived using exploratory and confirmatory factor analyses 
(EFA and CFA) and has been shown to have stronger validity than the full 
version [441].  Factor solutions of the original English version and translations 
have predominantly extracted one-factor solutions [441, 443-446]. The CD-
RISC-10 has demonstrated good internal consistency [443, 445-447] and good 
to excellent test-retest reliability over two to six weeks [443, 446, 447]. Validity 
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has been supported via moderate negative associations with catastrophizing, 
anxiety and depression [446]. 
The CD-RISC-2 is made up of two items that constitute the CD-RISC-
10.  The two items included in the 2-item version were recommended by the 
developers as the two items that best represent the resilience construct; they 
were “I am able to adapt when changes occur” and “I tend to bounce back 
after illness, injury or other hardships” [448].  The CD-RISC-2 total score 
correlates strongly with the full-version of CD-RISC [442] and has previously 
shown to have acceptable internal consistency [442, 449] and good one-week 
test-retest reliability [448].  Its validity is supported via moderate negative 
associations with measures of depression and anxiety [449].  
The CD-RISC-10 has been translated into many languages [444-446, 
450-452]. Translation and validation of the CD-RISC-10 and CD-RISC-2 into 
Nepalese will allow for a deeper understanding of resilience as an important 
domain in individuals in this unique population where the description of pain 
differs from populations from western cultures; for example, many more 
Nepalese than individuals from western cultures describe their pain using 
metaphors and use pain descriptors which are difficult to translate into 
English [211]. 
The aims of this study were to translate, cross-culturally adapt, and 
evaluate the measurement properties of the 10- and 2-item Nepali versions of 
CD-RISC in individuals with chronic pain.  We hypothesized that the Nepali 
CD-RISC-10 would demonstrate (1) a single-factor solution in two 
independent samples; (2) at least good internal consistency (Cronbach’s alpha 
≥ 0.70 [443-447]); (3) good to excellent 2-week test-retest reliability (ICC ≥ 0.70 
e.g., [443, 446, 447]); and moderate negative correlations (i.e., r ~ -0.30) with 
pain catastrophizing [446].  We further hypothesized that the CD-RISC-2-NP 
would demonstrate (1) acceptable internal consistency, (2) good test-retest 
reliability [448], and (3)  construct validity via moderate negative correlations 
(i.e., r ~ -0.30) with measures of anxiety and depression [446, 449]. We further 
hypothesized that the Nepali versions of CD-RISC-2 and CD-RISC-10 would 
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(1) strongly correlate with each other, and (2) negatively correlate with the 
measure of pain intensity. Finally, we evaluated the standard error of 
measurement (SEM), the smallest detectable change (SDC), and limits of 
agreement of both scales.  
METHODS 
We first translated the CD-RISC-10 and CD-RISC-2 into Nepali and 
evaluated the measurement properties of these scales in two independent 
samples of individuals with chronic pain. 
Translation procedures 
Translation of CD-RISC-10 into Nepali was performed using standard 
patient-reported outcome measure translation guidelines [96]. After forward 
translations, synthesis of forward translations, and backward translation of 
the Nepali version of CD-RISC was completed, all the versions of the 
translations were evaluated by an expert committee, which consisted of the 
translators, researchers (SS, AP, MPJ), and Nepali language experts. Expert 
committee discussion aimed to retain the semantic, idiomatic, and conceptual 
equivalence whenever possible. After consensus among this expert committee 
members, a Nepali version of CD-RISC was finalised.  
This Nepali version was pre-tested on 30 individuals with 
musculoskeletal pain selected to be representative of different ages, both 
sexes, and different education levels.  After the completion of the Nepali 
translation, participants were asked to describe the meaning of each item. 
Feedback collected was used to improve the readability and ease of item 
understanding.  Minor changes were made on 3 items to improve semantic 
and conceptual equivalence. The final version was reviewed and approved by 
Jonathan Davidson, one of the developers of the scale. Details of the 
translation history are presented in Figure 8.1.  
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Figure 8.1 Translation history. 
Evaluation of measurement properties 
The planned analyses and reporting of measurement properties were 
guided by COSMIN (COnsensus-based Standards for the selection of health 
status Measurement INstruments) recommendations [344, 345]. To evaluate 
the measurement properties of CD-RISC-NP, we used data from two samples. 
Ethical approval was obtained from the Institutional Review Committee of 
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Kathmandu University School of Medical Sciences, Nepal (reference number 
75/15).  Written informed consent was obtained from every participant before 
the collection of data. The participants who were unable to read or write in 
Nepali provided verbal consent, and a witness signed the consent form on 
their behalf.  The data were collected from January 2016 to May 2017. 
 Participants 
To evaluate the measurement properties of CD-RISC-NP measures, we 
used the two samples that were also used to evaluate the measurement 
properties of the Nepali version of the Pain Catastrophizing Scale [6] 
described in Chapter 7.  However, although there is a significant overlap in 
the participants between the previous study [6] and the current study, not the 
same participants completed both measures in both studies.  
The first sample in the current study consisted of 265 individuals with 
chronic pain recruited from a tertiary care hospital (n = 22) or the community 
(n = 243) in Nepal.  This sample was further divided into two subgroups (n = 
131 and n = 134) for the planned exploratory and confirmatory factor analyses 
(EFA and CFA) of the CD-RISC-10-NP, hereafter called the EFA sample and 
CFA sample, respectively.  The CD-RISC-10-NP, the 7-point Global Rating of 
Change (GRoC), the 3-item Patient-Reported Outcome Measurement 
Information System (PROMIS) pain intensity scale short-form 3a, and the 13-
item Pain Catastrophizing Scale (PCS) were administered to this sample. Two 
hundred and twenty nine (86%) of these individuals were re-administered the 
CD-RISC-10-NP after two weeks. Test-retest reliability was computed on a 
subgroup (N= 113) who endorsed the “no change” item on the GRoC scale 
over this time period. 
The second sample consisted of 140 individuals with chronic 
musculoskeletal pain recruited from community (n=100) and the same 
tertiary hospital (n=40). Nepali versions of the 21-item Beck Depression 
Inventory (BDI), 21-item Beck Anxiety Inventory (BAI), and PCS were 
administered concurrently with CD-RISC-2 to this sample. 




  The Nepali version of 10-item and 2-item CD-RISC were administered 
to samples 1 and 2, respectively [442].  Each of the CD-RISC-10-NP items is 
rated on a 5-point Likert scale ranging from 0 = “Not true at all” to 4 = “True 
nearly all the time.” The two-item scale sums to a possible high score of 8, and 
the 10-item scale sums a possible high score of 40. Higher scores indicate 
more resilience.   
Depression 
The Nepali version of the 21- item Beck Depression Inventory (BDI) 
was used to assess depression.  With the BDI, respondents are asked to 
indicate the severity of depressive symptoms using 4-point scales ranging 
from 0 to 3. Each 4-point scale response is specific to individual items. Total 
scores can range from 0 to 63, with higher scores indicating more depression.  
The Nepali version of BDI has excellent measurement properties (Cronbach’s 
alpha = 0.90 and two week test-retest reliability = 0.84) [424, 427].  The BDI 
evidenced excellent internal consistency (Cronbach’s alpha = 0.90) in the 
second chronic pain sample of the current study (n=140).  
Anxiety 
The Nepali version of the 21-item Beck Anxiety Inventory (BAI) was 
used to assess anxiety.  With the BAI, participants are asked to rate each item 
on a 4-point Likert scale ranging from 0 (“Not at all”) to 3 (“Severely, I could 
barely stand it”), with possible total scores ranging from 0 to 63.  Higher scores 
indicate greater anxiety.  The Nepali version of BAI has shown to have good 
internal consistency (Cronbach’s alpha = 0.89) [425]. The internal consistency 
of BAI in the second chronic pain sample of the current study (n=140) was 
also good (Cronbach’s alpha = 0.89).  
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Catastrophizing  
Catastrophizing was measured using the Nepali version of the 13-item 
Pain Catastrophizing Scale (PCS). Participants are asked to rate the frequency 
of their catastrophizing thoughts using a 5-point Likert scale ranging from 0 
(“Not at all”) to 4 (“All the time”) [453]. Higher scores indicate higher 
catastrophizing.  The Nepali version of PCS has been found to have excellent 
internal consistency (Cronbach’s alpha= 0.90 – 0.93) and test-retest reliability 
(ICC= 0.90) [6]. In the current samples, which as indicated previously, largely 
but not completely overlap with the those used to validate the PCS-NP [23], 
the PCS evidenced excellent internal consistencies (Cronbach’s alphas = 0.91 
and 0.93, in the first (n = 265) and second (n = 140) chronic pain samples, 
respectively). 
Pain intensity 
 A Nepali version of the PROMIS pain intensity version 1.0 short form 
3a scale was used to assess the pain intensity over the past week. It asks three 
questions regarding pain intensity: current pain intensity, worst pain, and 
average pain. Each item is scored on a 5-point Likert scale from 1 (“Had no 
pain”) to 5 (“Very severe”) [454]. A T-score representing characteristic pain 
intensity was calculated using response pattern scoring as recommended by 
PROMIS [454].  
Global Rating of Change 
 A Nepali version of the Global Rating of Change (GRoC) scale was 
used to assess the global rating of change in chronic pain-related problems in 
sample 1 [3, 333].  It is a 7-point Likert scale ranging from 1 to 7. The mid-
point 4 represents “No change”; higher scores indicate improvement and 
lower scores indicate worsening. The GRoC score = 4 was used to categorize 
the participants as “stable” or unchanged, and those who scored score >5 as 
“improved,” similar to previous studies [3, 6, 333].  We considered a one-
point change as a significant improvement in the GRoC scores [3, 4, 333]. The 
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GRoC classification was used to help interpret a number of measurement 
properties of the CD-RISC-10-NP and CD-RISC-2-NP (i.e., test-retest 
reliability, SEM, SDC, and limits of agreement statistics).  That is, we limited 
analyses for computing these statistics to those participants who reported no 
change in their GroC scores (i.e., GRoC = 4) [338]. 
Data analysis 
All the data were analysed using SPSS version 24 except confirmatory 
factor analysis which was performed in AMOS for SPSS version 24. As 
indicated previously, the reporting of the measurement properties was 
guided by COSMIN recommendations [344]. 
Sample description 
 Descriptive statistics for the demographic variables (means and 
standard deviations for continuous variables, numbers, and percentages for 
categorical variables) were computed to describe the sample. 
Factor analyses 
 I first performed an exploratory factor analysis (EFA) using maximum 
likelihood as the method of factor extraction, and factor rotation was 
performed using Direct Oblimin (delta= 0) allowing factors to correlate with 
each other in the EFA sample. I then performed a series of confirmatory factor 
analyses (CFAs) in the CFA sample.  Model fit was evaluated using the chi-
square goodness-of-fit index, the ratio of chi-square value to the degree of 
freedom, the root mean square error of approximation (RMSEA), comparative 
fit index (CFI), and parsimony goodness-of-fit index (PGFI). We determined 
that a model had a good fit if (1) the chi-square value and the ratio of chi-
square to degree-of-freedom values were relatively close to zero, (2) the 
RMSEA value was low and close to 0, (3) the CFI was large and close to 1, and 
(4) the PGFI value was large and close to 1 [429].   
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Reliability 
 We computed internal consistencies for both versions of CDRISC-NP 
scales; using Cronbach’s alpha for CD-RISC-10-NP and Spearman-Brown 
Coefficient for the CD-RISC-2-NP [455].  We considered internal consistencies 
between 0.70 and 0.79 as adequate, 0.80 and 0.89 as good, and values 0.90 or 
larger as excellent [365].  Two-week test-retest reliability was evaluated using 
the intraclass correlation coefficient (ICC) in the stable group who endorsed 
no change in response to the GRoC.  We considered ICC values of .75 or more 
as excellent [365].   
 SEM is another reliability parameter recommended by the COSMIN 
recommendations to describe measurement error which compliments the 
temporal stability of a scale [345]. Larger scores of SEM indicate large 
variability and indicate more error, and smaller scores indicate minimal 
variability and suggest high precision. We calculated the SEM using the 
formula, SEM = SDchange x √(1 - ICC) [338] where SDchange is the standard 
deviation for the mean change score of CD-RISC-NP.  We then computed 
SDC95% for the CD-RISC-NP scales using the formula, SDC95% = 1.96 x √2 x 
SEM [338, 345].  Finally, we created two Bland-Altman plots to indicate the 
levels of agreement of CD-RISC-NP scorings between the baseline and follow-
up assessments for CD-RISC-2-NP and CDRISC-10-NP separately [344, 395].  
The plot was drawn using change in CD-RISC-NP scores between baseline 
and follow-up in the Y-axis, and mean score of CD-RISC-NP between baseline 
and follow-up assessments in the X-axis.  
Validity 
 We evaluated the construct validity of the CD-RISC-NP scales by 
computing the correlations of the baseline data of CD-RISC-NP scales with 
the baseline scores of Nepali versions of BDI, BAI, PCS administered in the 
EFA sample and PROMIS-PI administered to CFA sample, using Pearson 
correlation coefficients.  
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 We also performed concurrent validity of CD-RISC-2-NP scale by 
evaluating its correlation with CD-RISC-10-NP, and hypothesized that CD-
RISC-2-NP to have concurrent validity if the correlation coefficient was 0.70 
or more [400].  
RESULTS 
Translation of CD-RISC-10 into Nepali 
The Nepali version of CD-RISC-NP was easy to understand and 
retained its original meaning. Cultural adaptations were made on three of the 
CD-RISC-10 items (i.e., items, 1, 3, and 4) to retain the semantic, idiomatic, 
and conceptual equivalence. The cultural adaptations are presented in Figure 
8.2 below.  
 
Figure 8.2 Key cross-cultural adaptation of the Nepali CD-RISC-10 items 
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CD-RISC Scores 
The CD-RISC-2-NP and CD-RISC-10-NP scores were normally 
distributed in all the three samples at all assessment points. The means and 
SDs of the CD-RISC-2-NP and CD-RISC-10-NP scores are presented in Table 
8.1. A total of 83% (n=109/131) and 81% (n=106/131) in EFA sample and 95% 
(n=128/134) and 92% (n=123/134) completed follow-up assessments in the 
CFA sample for CD-RISC-2 and CD-RISC-10, respectively.  
Total CD-RISC-2 score of 0/8 was reported by 0.4% of the participants 
in sample 1 (N= 265; EFA and CFA sample combined), and 1% (n=1) 
participants in sample 2 (N=140); and 8/8 score was reported by 10% (n=26) 
of participants in sample 1, and 16% (n=23) of participants in the sample 2. 
Likewise, CD-RISC-10 score of 0/40 was reported by 0.4% (n=1) and 5% 
(n=13) of participants in sample 1.  
Handling missing items 
In sample 1, there was a missing response for item 3 CD-RISC-10 for 
one participant, and a missing response to items 6 and 8 for another 
participant.  There were no missing responses to the CD-RISC-2-NP items. 
Both the participants with missing items were excluded from all analyses 
involving the CD-RISC-10.  
Demographic characteristics 
The majority of the study participants were Hindu in religion (76% or 
more across samples) and were women (65% or more across samples).  The 
plurality of participants (43% - 48% across samples) reported that they had 
chronic pain in more than one site. Of those reporting pain in one site, the 
most common sites were the low back and pelvis (16% - 22% across samples) 
and pain in the knees (19% - 21% across samples). Additional descriptive 
information for the study samples are presented in Table 8.1.  
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Table 8.1 Description of the study participants and the CD-RISC scores. 
                                                        EFA sample (N=131)     CFA sample (N=134)      Sample 2 (N=140) 
                                                        N (%) or Mean (SD)         N (%) or Mean (SD)    N (%) or Mean (SD) 
Recruitment, N (%) 
   Community 109 (83%) 134 (100%) 100 (71%) 
   Hospital  22 (17%) 0 (0%) 40 (29%) 
The primary site of pain, N (%)  
  Multiple sites  60 (46%) 65 (48%) 60 (43%) 
  Low back and pelvis 21 (16%) 25 (19%) 31 (22%) 
  Knee  25 (19%) 28 (21%) 29 (21%) 
  Headache 6 (5%) 5 (4%) 0 (0%) 
  Neck  4 (3%) 0 (0%) 3 (2%) 
  Upper back 4 (3%) 0 (0%) 3 (2%) 
  Elbow 3 (2%) 1 (1%) 1 (1%) 
  Ankle and foot 3 (2%) 4 (3%) 1 (1%) 
  Shoulder 1 (1%) 1 (1%) 9 (6%) 
  Other sites  4 (3%) 5 (3%) 3 (2%) 
Duration of pain in months,  
  Mean (SD) 41.67 (56.19) 61.56 (74.14) 52.09 (76.94) 
Follow-up assessment epoch in days,  
  Mean (SD) 10.62 (1.42) 10.27 (1.82) - 
Age in years, Mean (SD) 44.92 (17.20) 47.91 (13.81) 47.27 (14.54) 
Sex, N (%)   
  Men 37 (28%) 33 (25%) 50 (36%) 
  Women 94 (72%)  101 (75%) 90 (64%) 
Religion, N (%) 
  Hindu  123 (94%) 102 (76%) 130 (93%) 
  Buddhist 6 (5%) 27 (20%) 4 (3%) 
  Others 2 (1%) 5 (4%) 6 (4%) 
Race/Ethnicity, N (%) 
  Chettri  10 (8%) 6 (4%) 59 (42%) 
  Brahmin 71 (54%) 13 (10%) 38 (27%) 
  Newar 40 (30%) 101 (75%) 19 (14%) 
  Others  10 (8%) 14 (11%) 11 (8%) 
Education, N (%) 
  No school 25 (19%) 15 (11%) 44 (31%) 
  Primary school  32 (24%) 20 (15%) 42 (30%) 
  Secondary school  23 (18%) 34 (25%) 34 (24%) 
  Higher secondary  31 (24%) 5 (19%) 5 (4%) 
  Bachelor and over  20 (15%) 40 (30%) 15 (11%) 
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                                                        EFA sample (N=131)     CFA sample (N=134)      Sample 2 (N=140) 
                                                        N (%) or Mean (SD)         N (%) or Mean (SD)    N (%) or Mean (SD) 
Primary occupation, N (%) 
  Unemployed 21 (16%) 0 (0%) 6 (4%) 
  Agriculture 37 (28%) 15 (11%) 48 (34%) 
  Homemaker  18 (14%) 36 (27%) 39 (28%) 
  Business  20 (15%) 37 (28%) 15 (11%) 
  Office worker 14 (11%) 24 (20%) 10 (7%) 
  Other 21 (16%) 22 (14%) 22 (16%) 
CD-RISC-2 score, Mean (SD) 
    Initial assessment  5.21 (1.67) 5.47 (1.68) 5.43 (1.94) 
    Final assessment  5.20 (1.77) 5.54 (1.69)  - 
CD-RISC-10 score, Mean (SD)  
    Initial assessment  27.05 (7.03) 28.54 (7.62)  - 
    Final assessment 26.25 (8.32) 27.72 (7.91)  - 
Factor analyses results 
The results of the EFA supported a single factor (first two eigenvalues 
were 4.98 and 0.90) for the CD-RISC-10-NP. This factor solution was 
confirmed via CFA in the CFA sample, which demonstrated a good fit. The 
covariance of error terms improved the fit index (Table 8.2). The path 
diagram of the CFA is presented in Figure 8.3.  
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Figure 8.3 Path diagram after confirmatory factor analysis of CD-RISC-10 and 
covariance of error terms. 
Abbreviations: CDRISC, Connor Davidson Resilience Scale; CD-RISC-10, 10-item Connor 
Davidson Resilience Scale.  
 
Table 8.2 Confirmatory factor analysis of the CD-RISC-10-NP. 
Model X2 (df) X2/df RMSEA CFI PGFI 
One-factor model     48.49 (35) 1.82 0.054 0.978 0.593  
One-factor model 
with Modification a 
34.33 (34) 1.01 0.009 0.999 0.588 
a Confirmatory factor analysis results after covariance of error terms e4 and e10. 
 
Reliability 
The results of the reliability analyses for both the CD-RISC-10-
NP and CD-RISC-2-NP are presented in Table 8.3. As can be seen, 
internal consistencies of CD-RISC-10-NP ranged between 0.87 and 
0.90; and between 0.48 and 0.70 for CD-RISC-2-NP. The two-week test-
retest reliability (ICC) of CD-RISC-10-NP in the stable group (GRoC = 
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4) was 0.89 and 0.71 for the CD-RISC-2-NP. The SEM and SDC for 
both the 2-item and 10-item CD-RISC are presented in Table 8.3.   
   
Table 8.3 Reliability of the CD-RISC-10-NP and CDRISC-2-NP. 
Sample N IC Test-retest 
ICC (95% CI) 
SEM SDC95% 
CD-RISC-10      
   Total sample        265 .89    
   EFA sample  131 .88    
   CFA sample 134 .87    
   Stable group       113 .90 .89 (.86, .92)       2.42 6.72 
CD-RISC-2      
   Total sample          265 .55    
   EFA sample  131 .62    
   CFA sample 134 .48    
   Stable group       119 .70 .71 (.58, .80) 0.86 2.38 
Sample 3 140 .60    
Abbreviations: CD-RISC-10, 10-item Connor Davidson Resilience Scale; CD-RISC-2, 2-
item Connor Davidson Resilience Scale; IC, Internal consistency (Cronbach’s alpha for 
the CD-RISC-10 and Spearman-Brown correlation coefficient for the CD-RISC-2); SEM, 
Standard Error of Measurement (SEM = SDchange x √(1-ICC)); SDC95%, Smallest 
Detectable Change  for 95% Confidence Interval (SDC95% = Z x √2 x SEM); ICC, 
Intraclass Correlation Coefficient.  
 
 The Bland-Altman Plots demonstrating the limits of agreement are 
presented in Figure 8.4 which shows a graphical representation of the 
systematic and random errors of test-retest measurement scores for the 10-
item and 2-item CD-RISC assessed in the stable group.  The central red lines 
represent the systematic error, and the green dotted lines represent random 
errors of test-retest scores.  





Figure 8.4 Bland-Altman Plots. 
Note: Y-axis is the change of CD-RISC scores between baseline and follow-up 
measurements and X-axis is the mean of the CD-RISC scores at the baseline and final 
measurement. The solid line is the mean change of score (d̄), and dotted lines are d̄ ± 
Z x SDchange (where Z = 1.96 for 95% confidence interval.)   
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Validity 
Construct validity of CD-RISC-10-NP was supported by 
significant moderate negative correlations with the PCS, (rs = .30 - .45, 
Ps <0.001); the CD-RISC-2-NP showed weak to moderate associations 
with the PCS (rs = .23 - .35, P < 0.001).  The validity of CD-RISC-2-NP 
was supported by a moderate negative correlation with depression and 
weak and negative association with anxiety. Finally, CD-RISC-2-NP 
and CD-RISC-10-NP were weakly to moderately associated with the 
measure of pain intensity. The CD-RISC-2-NP demonstrated 
concurrent validity by strong positive association (r= 0.75) with its 
longer version, CD-RISC-10-NP. The construct validity correlation 
coefficients are presented in Table 8.4.  
Table 8.4 Construct validity. 
Sample N PCS BDI BAI PROMIS 
  Total sample       265 -.35**   -.27** 
   EFA sample  131 -.45**   -.37** 
   CFA sample 134 -.30**   -.23** 
   Stable group       113 -.36**   -.19** 
   Total sample       265 -.30**   -.27** 
   EFA sample  131 -.35**   -.38** 
   CFA sample 134 -.23**   -.17* 
   Stable group       119 -.24**   -.23** 
Sample 3 140 -.43** - .31** -.27**  
*P < .05; **P < .01. 
Abbreviations: CD-RISC-10, 10-item Connor Davidson Resilience Scale; CD-RISC-2, 2-item Connor 
Davidson Resilience Scale; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; NRS, 
Numerical Pain Rating Scale; PROMIS, PROMIS pain intensity scale short form 3a. 
 
DISCUSSION 
 The translation and cross-cultural adaptation of CD-RISC-10-NP 
yielded a comprehensible, reliable and valid Nepali version consistent with 
the study hypotheses.  
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Factor analyses 
The findings support a single-factor solution for the CD-RISC-10-NP, 
consistent with both the original English version [441] and translations [443-
446] of this scale.  To our knowledge, only the Nigerian version of the CD-
RISC-10 [450] has shown a two-factor solution, albeit with a very strong 
correlation between the two factors (r = 0.82).   
Reliability  
The internal consistency of the CD-RISC-10-NP in our sample was 
similar to those previously reported [441, 444-446].  However, the internal 
consistency of the brief version (CD-RISC-2-NP) here was lower than those 
previously reported [442, 449].  The internal consistencies of CD-RISC-2-NP 
tend to be lower than that of CD-RISC-10-NP across all populations [441, 
442, 445, 446, 449]. This could be due, in part, to the strategy chosen to 
develop the CD-RISC-2.  That is, the two items of the CD-RISC-2 were 
chosen from the original 25 CD-RISC items to capture their view of the 
meaning of resilience, without the guidance of empirical tests [448]. The use 
of such tests, including Item Response Theory or Rasch analyses, could 
potentially yield a 2-item version of the CD-RISC that has greater reliability. 
Additional work to develop alternative brief versions of the CD-RISC with 
greater reliability appears warranted.  
We found a high 2-week test-retest reliability for the CD-RISC-10-
NP, similar to the 6- and 2-week test-retest reliability coefficients 
previously reported in two studies [443, 446], and higher than (but still 
adequate) 2-week test-retest reliability coefficient (0.71) reported in a third 
study [447].  In the current study, we assessed test-retest reliability only in 
a group of participants who reported no global changes in pain (i.e., a 
stable group). This is a recommended method for the reporting of the 
temporal stability of patient-reported outcome measures [338, 344].  The 
use of a stable group is important because resilience scores could 
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potentially change after an intervention [448] or as after facing adversities 
in life. 
Our study presents novel findings regarding the measurement errors 
(SEM and SDC) of the CD-RISC scales. It is important to consider both of 
these when interpreting results of a measure to be used in longitudinal 
research, because not every scale score change represents a true (reliable) 
change.  The SDC is the amount of change beyond measurement error, and 
thus represents the amount of change that can be considered reliable. Our 
findings suggest that changes in the CD-RISC-10-NP and CD-RISC-2-NP of 
6.72 (scale 0-40) and 2.38 (scale 0-8) represent true changes; values below 
these are more likely to be due to measurement errors than values above 
these cutoff values.  The Bland-Altman Plot [395] results (Figure 8.4) 
provides visual information regarding the limits of agreement; that is, how 
far the retest scores deviate from the test scores, indicating general 
agreement between the two assessment points. 
Validity  
Both the 2-item and 10-item CD-RISC-NP demonstrated construct 
validity via moderate negative associations with measures of pain 
catastrophizing and pain intensity. The validity of the 2-item scale was 
supported via its moderate but significant negative association with 
measures of pain catastrophizing and depression and weak but still 
significant negative association with a measure of anxiety. These findings are 
consistent with previous research, and support the validity of the 10-item 
Nepalese version of the scale [446, 449].  Less, but still adequate, support for 
the validity of the CD-RISC-2-NP was found, via its weak negative 
association with anxiety in our sample. To our knowledge, only one study 
has previously evaluated the association of CD-RISC-2 with anxiety, which 
showed a moderate correlation [449].  
The CD-RISC-2-NP demonstrated its concurrent validity by a strong 
association with the CD-RISC-10-NP.  The magnitude of association found 
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here was similar to that found in a previous study (r= 0.77; [449]), although it 
was somewhat lower than that found in another study (r= 0.88; [442]). It is 
important to remember that the two items for the CDRISC-2-NP scale were 
the items extracted from the CDRISC-10-NP. For this reason, the concurrent 
validity of the CDRISC-2-NP should be considered tentative until the results 
are replicated in a separate sample by concurrently administering both 2- 
and 10-item versions of the CDRISC.  
Strengths and limitations  
An important strength of the current study is that I followed the 
standard translation guidelines for the translation and cross-cultural 
adaptation of health-related PROMs [96]. COSMIN recommendations for 
the reporting of measurement properties of the 2-item and 10-item CD-
RISC-NP scales [344, 345], the current reference standard for reporting 
measurement properties. The measurement properties of CD-RISC-NP 
measures were tested in three different samples (including the analyses for 
factor structure), with Ns > 100 for each sample, which is minimum 
recommended for the assessment of measurement properties. Test-retest 
reliability was also assessed in more than 100 participants (as recommended 
by COSMIN [344, 345]) who reported little change in their pain problem, as 
assessed by the GRoC [338]. Finally, I also evaluated the SEM and SDC of 
CD-RISC-NP, which I believe is the first time these important statistics have 
been reported for the CD-RISC-2 and CD-RISC-10 measures.   
Although the study has important strengths in terms of sample size, 
methodology, and rigour, the study’s limitations should also be considered 
when interpreting the findings. One limitation is that the back translation of 
the measure was performed by a single back-translator; translation and 
cross-cultural adaptation guidelines described by Beaton and colleagues 
[96] recommend that two or more translators perform the back translations. 
This weakness might be mitigated by the fact that translation guidelines 
indicate that the use of a single back translator is acceptable [252]. As the 
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items of the CD-RISC are fairly straightforward, translation was relatively 
simple and I found only few issues during the cognitive testing of the items.  
Moreover, the few issues that emerged were minor and relatively easy to 
resolve (see Figure 8.3).  The adequacy of this approach was also supported 
by the strong measurement properties of the resulting scales.  Still, the use 
of two or more back translators would have been ideal.  
A second important limitation of the study is that I used a GRoC 
scale that asked participants to rate global change in pain-related problems 
to categorize participants as “unchanged” in order to evaluate test-retest 
reliability of the CD-RISC-NP scales.  Although, asking participants to rate 
their change in “resilience” would have been ideal to categorize participants 
into stable or improved group, using global scores to assess test-retest 
reliability is a common practice (e.g., [338, 362, 363]). The excellent 
reliability scores in the present study are consistent with the idea that the 
participants may have considered resilience into account when rating 
overall change. Future studies may evaluate relationships between patient’s 
“global rating of change” and “change in resilience” scores, to explore if 
they are related, or conduct temporal stability of resilience measures using 
the change of the resilience scores instead of GRoC.  
Third, the GRoC score asks participants to recall the change in pain-
related problems since the baseline assessment, which may introduce recall 
bias.  However, the duration of reassessment of only approximately 10 days 
likely limited recall bias, and is less than the recommended duration of two 
weeks for the assessment of test-retest reliability [344].   
Fourth, we assessed the measurement properties of CD-RISC-NP in 
adult Nepalese with chronic, predominantly musculoskeletal pain only.  
The findings, therefore, do not necessarily generalise to other populations 
or who have other clinical conditions, for example, paediatric populations 
and those with psychological or psychiatric conditions.  Future research is 
required to evaluate the validity of CD-RISC-NP measures in these 
populations.   
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Finally, we did not evaluate the responsiveness of the CD-RISC-NP 
scales.  It would have been ideal to evaluate the minimum important 
change score of the CD-RISC-NP, which could be used as reference to 
evaluate clinical improvement. Future studies may evaluate responsiveness 
to determine the utility of the CD-RISC-NP scales as outcome measures 
would be useful. 
CONCLUSIONS  
In summary, the 10-item CD-RISC-NP scales evidenced good 
measurement properties; the findings support the use of this measure in 
research studying resilience in Nepalese adults with chronic, predominantly 
musculoskeletal pain.  The results provide less support for the reliability and 
validity of the 2-item CD-RISC-NP, but indicate that it could be used in 
studies using larger samples (e.g., survey studies).  Further testing of 
measurement properties of the 2-item version scale is also warranted. 
Research is needed to better understand the causal influence of resilience on 
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INTRODUCTION 
Low back pain is a highly prevalent health condition worldwide [63, 
456]. It is also is the leading cause of disability in both low- and high-income 
countries, and is associated with large direct (health care) and indirect costs 
[63, 68, 81, 456]. Low back pain is the leading cause of disability in Nepal with 
prevalence ranging from 51% to 91% [1, 134, 457], which is expected to 
increase in the next decade [81]. It is also alarming that the number of spine 
surgeries for spinal pain has been increasing in Nepal over the years [458], 
despite lack of evidence supporting efficacy for this treatment [459, 460]. 
Therefore, the timely use of interventions that are evidence-informed, 
effective, and inexpensive are urgently required.   
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Interventions for the management of low back pain 
Many interventions have been investigated for the management of low 
back pain. These include surgery [461, 462], pharmacotherapy [463-468], 
exercises [469-471], advice for self-management including advice to remain 
physically active [462], and psychological therapies [472, 473].  As alluded to 
earlier, biomedically-focused interventions such as surgery and 
pharmacotherapy are not recommended for a non-specific low back pain as 
the evidence does not support their effectiveness [465-468].  Moreover, they 
are associated with significant risks for adverse events and are costly [31].   
Clinical practice guidelines for low back pain recommend self-
management including reassurance, education, and advice to remain active as 
the first line of care that should be provided to all the patients with low back 
pain. Superficial heat and manual therapy (massage/manipulative therapy) 
are recommended for acute low back pain as the second-line treatment, 
whereas exercise and psychological therapies are recommended for chronic 
low back pain [109, 474, 475].   
Pain education for low back pain 
Patient education for low back pain is of two types: biomedical 
education and pain biology education [476]. The first refers to educating 
patients about vertebral anatomy and pathoanatomy of the spine, which has 
been shown to be ineffective and may even have negative effects on low back 
pain outcomes [476].  On the other hand, the second type of education – pain 
biology education (hereafter called as “pain education”) has shown to have 
positive effects on both pain and disability [477, 478]. Pain education is a 
structured education programme with specific aims and objectives [479]. This 
intervention has a list of target key concepts to be delivered and includes the 
curriculum contents to deliver the key concepts using up-to-date pain science 
knowledge, stories, and metaphors.   
It has been previously hypothesized that this type of education 
programme utilizing metaphors and stories may be an effective intervention 
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in Nepalese with chronic pain [211]. However, the pain education materials 
that are developed in western cultures are not necessarily valid and equally 
effective in reducing pain and disability in non-western cultures. Therefore, 
when developing pain education materials in a newer language or culture, 
(significant) cultural adaptations of the education materials may be required 
to make it suitable for the target population, as culturally inappropriate 
education may not produce desirable results.   
Therefore, in order to evaluate the effectiveness of pain education in 
patients with non-specific low back pain from Nepal, culturally appropriate 
pain education materials should first be developed for Nepal, specifically.  
However, it is possible that the adaptations made could potentially reduce its 
effectiveness. Thus, before testing the adapted pain education in a full clinical 
trial, a feasibility study is needed in order to determine if a full clinical trial 
based on the adapted intervention is warranted, or if additional modifications 
may be needed prior to performing the full trial.   
Why the feasibility trial? 
We propose a feasibility trial because: (1) the intervention (i.e., pain 
education) will need significant cultural adaptation, although it has been 
evaluated for efficacy previously in other languages and cultures [118, 324, 
480, 481]; (2) the adapted intervention has never been investigated for its 
efficacy or effectiveness before; (3) the population in question (individuals 
with extremely low socioeconomic status and educational attainment in 
Nepal) is unique; and (4) a high-quality clinical trial in patients with low back 
pain has not been conducted in Nepal, to our knowledge, and we therefore do 
not know if a full trial is feasible. The findings from the proposed feasibility 
study will inform the planning and design of a full trial, if the results indicate 
that a full trial is warranted.  
The results of the full trial will have significant clinical implications for 
the management of low back pain in Nepal, and similar cultures, providing 
empirical evidence if pain education is a viable treatment option for the 
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management of low back pain, and if it is effective in reducing pain, 
disability, and emotional distress.   
Aims and objectives 
The primary aim of this feasibility randomised study is to evaluate the 
feasibility of a full randomised clinical trial for assessing the effects of pain 
education as an intervention for patients with low back pain of any duration 
in a physiotherapy facility in Nepal after developing culturally-appropriate, 
evidence-based pain education materials. The primary objectives of the study 
are related to feasibility of randomised clinical trial, specifically: (1) 
willingness to participate in a randomised controlled trial, (2) feasibility of 
assessor blinding, (3) eligibility and recruitment rates, (4) acceptability of 
screening procedures and random allocation, (5) possible contamination 
between the groups, (6) intervention credibility for patients with low back 
pain, (7) intervention adherence, (8) treatment satisfaction, and (9) difficulty 
in understanding the intervention being provided.  
METHODS 
Study Design and setting 
This is a feasibility clinical trial that aimed to determine if a definitive 
randomised clinical trial (RCT) can be successfully conducted using the 
procedures and protocol of this feasibility study, or if modifications of the 
feasibility study protocol are needed prior to conducting the full trial. The 
study findings will inform the design of the full trial, if a full trial is deemed 
feasible [482].   
The definition of a feasibility study highlights the question, “Can this 
study be done?”  I used the SPIRIT statement [483], the CONSORT statement 
extension to pilot and feasibility randomised trial [482] in the planning and 
reporting this study.  
The study was an assessor-blinded, two-arm, feasibility RCT.  Ethical 
approvals were obtained from the Nepal Health Research Council (NHRC, 
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reference number: 422/2017) and the University of Otago Human Ethics 
Committee (reference number: H17/157). The study was then registered in 
Clinicaltrials.gov (trial registration number: NCT03387228) on January 2, 
2018. The study was conducted in the Sahara Physiotherapy Hospital, 
Kathmandu, Nepal from February to April 2018. The protocol of the study 
was submitted for publication prior to data collection and subsequently 
published [7].  
Overview of the study 
I advertised the trial using social media. All patients with low back 
pain presenting at the study site were also invited to participate. I, with the 
help of a research assistant, screened the interested candidates for eligibility 
(described later under "Participants" sub-heading). Eligible patients with non-
specific low back pain were then enrolled in the trial. I randomly assigned 
patients to one of the two study groups (see details of randomisation process 
below). All the participants in the experimental group received pain 
education and those in the control group received guideline-based 
physiotherapy treatment. A blinded research assistant assessed all 
participants at baseline, and one week following the treatment.  Details 
describing the schedule of enrolment, interventions, and assessment are 
presented in Table 9.1, in the manner recommended by the SPIRIT checklist 
[483].  
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Table 9.1 Schedule of enrolment, assessment, and interventions. 
  Study period 
Enrolment Allocation Post allocation Final 
Assessment 










 Eligibility screening X     
Explain study procedure/ 
provide participant 
information sheets 
X     
Informed consent X     












 Experimental intervention 
(PEG) 
   X   




















information (age, sex, 
address, occupation, 
religion, ethnicity) 






Pain history (site of pain, 
duration of pain, 
continuous or intermittent 
pain, aggravating and 
relieving factors) 
  X   















Willingness to participate in 
an RCT.  
X     
Acceptability of random 
allocation  
X     
Acceptability of intervention X     
*Feasibility of blinding the 
assessor 
    X 
Eligibility and recruitment 
rates 
X      
*Acceptability of screening 
procedures 
    W 
Contamination      X 
Credibility of interventions   X  X 
Adherence to intervention     X 
Treatment satisfaction     X 
Difficulty in understanding 
the interventions 

















PROMIS Pain Interference    X  X 
PROMIS Pain Intensity   X  X 
Quality of Life   X  X 
PROMIS Sleep Disturbance    X  X 
PROMIS Depression   X  X 
GRoC   -  X 
PCS   X  X 
CD-RISC-10    X  X 
Note: *Assessed by the therapist providing intervention; all other outcomes are assessed by the 
blinded outcome assessor.  
Abbreviations: -T1, Enrolment time; T0, Allocation time; T1, Baseline assessment (before treatment); 
T2, During treatment; T3, One week post-treatment; RCT, Randomised Clinical Trial; PROMIS, 
Patient-Reported Outcome Measurement Information System; GRoC, Global Rating of Change; 
PCS, Pain Catastrophizing Scale; CD-RISC-10, 10-item Connor-Davidson Resilience Scale. W= 
assessment at the end of every week on Fridays. 
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Development of pain education in Nepali 
I developed the pain education resources in Nepali, based on the 
“Explain Pain” principles (NOIgroup publishing, Adelaide, Australia) [115, 
479]. Figure 9.1 lists the development process, which included five steps.  
In the first step, SS developed a context and culture-specific pain 
education curriculum according to the process set out in Moseley and Butler 
[479]. The curriculum was reviewed by the authors of that guide (A/P David 
Butler, a co-author of this study - GLM, and another Explain Pain expert, Tim 
Cocks). I identified four key concepts (described below), with one additional 
optional concept if time permitted to deliver pain education. The final 
curriculum, including the key concepts to deliver, details of contents, and 
methods of delivery was published in the protocol paper [7] and also 
included as Appendix 7.   
In the second step, I created a pain education handbook using original 
patient stories from Nepal, some contents from Explain Pain [115, 479] and 
clinical practice guidelines on low back pain [109, 474, 475]. I compiled pain 
stories from Nepal to help explain each target concept [7]. I kept the Nepalese 
adaptations as simple as possible so that patients with low to no formal 
education could understand.  
In the third step, four Nepalese with a medical (n=2) or non-medical 
(n=2) background reviewed the material. I subsequently revised the content 
as per their feedback. In the fourth step, I pilot tested the pain education 
handbook with six patients with chronic low back pain. The main aim of this 
was to assess its readability, relevance of patient stories, and whether the new 
pictures created for the handbook delivered their intended meanings. I 
revised the texts again based on patients' feedback, but the pictures required 
no changes. Finally, three native Nepali-speaking persons proof-read the 
handbook and a final version was completed.  
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Figure 9.1 Steps in the development of pain education handbook 
Participants 
Patients with non-specific low back pain seeking rehabilitative services 
at Sahara Physiotherapy Hospital were invited to participate. Interested 
patients were screened by a research assistant (physiotherapist by training) 
involved in the study.  
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Inclusion Criteria  
 Nonspecific low back pain (low back pain other than those excluded, 
see exclusion criteria below) of any duration with pain primarily localized 
between T12 and gluteal folds, in patients aged 18 years or older, with 
average pain intensity reported as moderate, severe, or very severe on a 
PROMIS five-point PROMIS Pain Intensity Short-form Scale [484] over the 
past week, and who is a Nepalese, and is able to understand and speak 
Nepali fluently were included.  
Exclusion Criteria  
 Participants with likely specific causes of low back pain were excluded 
using a triage procedure as suggested by Bardin and colleagues [485]. This 
includes participants with nerve root compromise as assessed using physical 
examination, history of prolonged use of corticosteroid, history of 
malignancy, a recent history of fever or chills, history of other diseases 
associated with compromise in the immune system, history of recent spinal 
surgery or dental procedures, a recent history of trauma to the spine or a 
fracture of a spine, history of bladder and bowel dysfunction, history of 
perineal or saddle anaesthesia, and history of weakness of lower extremity or 
loss of sensation in the lower extremity. Additionally, current pregnancy, and 
history of diagnosed mental health conditions that would limit adherence to 
the trial procedures were excluded.  
 Sample Size 
For a feasibility study, it is inappropriate to calculate sample size based 
on desired statistical power to detect a treatment effect [486], because, the 
primary aim of the study is to assess if a full trial can or should be conducted. 
Feasibility outcomes are descriptive in nature; inferential statistics regarding 
treatment effects, although reported later in this chapter, are not important. 
To achieve the primary objectives related to feasibility outcomes, the research 
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team estimated that 40 participants would be adequate [487]. Twenty patients 
were randomly allocated to each treatment condition.  
Participant screening and recruitment 
Consecutive participants with non-specific low back pain were invited 
to participate in this study. The study purpose and procedures were 
described to the potential participants.  This included information about the 
benefits and potential harms of the intervention, the time required for the 
completion of the study, follow-up duration, the voluntariness of 
participation, the cost of participation, and the rights to withdraw from the 
study at any point. A study information sheet that I prepared for this study 
was also provided to all potential participants.   
If the potential participants are interested to participate, a trained 
research assistant assisted me to screen for eligibility. Participants found 
eligible then provided informed consent.  For those who could not sign, a 
witness signed on their behalf as per the ethics guidelines provided by the 
NHRC.  We did not exclude uneducated patients who could not sign an 
informed consent in order to increase the inclusion of uneducated or low 
education group, given that 31% of people in Nepal who are five years old or 
more cannot read and write [69]. Additionally, exploration of the feasibility of 
pain education in those with no schooling or low educational attainment is 
important in order to inform clinical practice.  
Participants were informed that they will receive one of the two 
treatments randomly. It was highlighted that both of the treatment options 
are thought to be effective for low back pain, and that the goal of the future 
definitive RCT is to compare the interventions, however, the current study 
will more specifically evaluate the feasibility of such a study.   
Group Allocation, Randomisation, and Blinding 
A senior author and the primary supervisor of the study, who is not 
involved in the recruitment process, generated a random number sequence in 
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random blocks of 4 and 6 using www.random.org. Allocation concealment 
was performed using opaque, sealed envelopes. I allocated the participants to 
one of the two groups based on the random sequence that was generated. The 
two study groups were: (1) Group 1: Pain education group (PEG), and (2) 
Group 2: Control group (CG). 
Interventions 
I used the TIDieR (Template for Intervention Description and 
Replication) Checklist to plan and report the study interventions [488, 489]. I 
along with study therapists followed the manuals of standard operating 
procedures (MSOPs) when delivering interventions in both groups. This was 
done to ensure treatment uniformity and fidelity. It was not possible to blind 
the treating therapists based on the design of the study.  
Participants in the intervention group (PEG) received detailed pain 
education as described in the next paragraph, and those in the control group 
(CG) received evidence-based physiotherapy treatment. After the completion 
of the post-treatment assessment at the end of one week, all study participants 
received the regular treatment provided at the recruitment site. Participants in 
both groups were encouraged not to seek other medical care for low back 
pain during the 1-week study period, unless they have to. If they do 
undertake other forms of treatment, they were requested to report this during 
the follow-up assessment, and was recorded.  
The Pain education group  
I delivered the pain education intervention for the PEG group. To be 
able to do so, I received extensive training in Explain Pain via NOIgroup 
(Adelaide, Australia) and one-on-one mentoring with pain education experts. 
I first asked two questions to the patients in the PEG:  
(1) “Is there anything in particular that you would like to learn about your 
low back pain, or pain in general?”, and  
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(2) “Do you know what caused your low back pain? Can you please explain 
the cause of your low back pain from what you have understood, or what you have 
been told?”  
I allocated up to 15 minutes to address, with evidence-informed 
answers, any questions participants had and to clarify any misconceptions the 
patients had regarding their low back pain. I used the rest of the session 
(summing to about 60 minutes) to deliver information regarding the target 
concepts.  
Four key target concepts:  
(1) Pain is normal and almost everyone experiences it at different times 
during their life.  
(2) The body sends danger signals (i.e., not necessarily information about 
physical damage, but the danger of potential physical damage), and 
the brain decides whether to produce pain.  
(3) Learning about pain changes pain, and anything previously associated 
with it (e.g., past learning, social factors, environmental cues) can 
influence current pain.  
(4) The body can learn to experience pain and become more 
overprotective over time.  
I delivered one additional target concept “pain and tissue damage are 
poorly related” if there was time available after addressing the four key 
concepts. During the pain education session, I also provided the patients with 
strategies for graded-exposure to painful or difficult activities to increase their 
physical activity.   
Control group (CG) 
CG treatment consisted of guideline-based physiotherapy 
interventions that I extracted from recent clinical practice guidelines on low 
back pain [109, 490, 491]. Criteria for the CG treatment component required 
that it be:  
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(1) a first-line recommended treatment, or;  
(2) a second-line recommended treatment to make the total duration of the 
session be one hour (to match PEG treatment time);  
(3) feasible to be delivered during the first clinical contact; and  
(4) one that is routinely delivered in, and can be competently delivered by, 
physiotherapists at the recruitment centre.  
Given these criteria, the CG treatment condition included the following 
interventions.  
(1) brief education to reassure the patient, advice to remain active and 
remain at or return to work (if the participant had been working prior to 
pain onset), general education about the favourable prognosis of low back 
pain that it will generally get better in two to six weeks, and advice to 
avoid bed rest and lumbar corsets (10 - 15 minutes) [109, 490, 491];  
(2) superficial heat (10 - 15 minutes) [109, 491];  
(3) back massage (10 minutes) [109, 490]; and  
(4) static cycling to promote physical activity (remaining time; between 20 – 
30 minutes) [109, 490, 491].  
 
Although treatment in CG involved communication between the 
treating therapist and patients, this communication was strictly limited to 
providing either (1) brief education as described above, or (2) active listening. 
Key concepts delivered in the PEG were strictly not provided to the patients 
in this group.   
Home treatment  
We also prescribed a home programme for both groups. This included 
a leaflet providing brief education on self-management of low back pain, with 
pictures to remind the participants to remain physically active, education 
regarding positive prognosis, advice to walk for 30 minutes daily (with rest if 
required) and to avoid bed rest or lumbar corsets. 
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In addition to the leaflet that was provided to the control group, 
participants in the PEG received the pain education handbook which was 
developed for this study. We suggested to participants that they read the 
booklet at least once during the following week. If the patients could not read, 
they were advised to request a family member to read the pain education 
handbook to them. Adherence to both exercise (e.g., walking), and reading 
the pain education handbook at home was recorded, by self-report, one-week 
post-treatment. Participants in both treatment groups were required to pay 
the same fee for physiotherapy services as usual for non-trial patients. This 
payment was identical for both interventions. 
Outcome Measures  
Demographic data were collected as per the recommendations of the 
NIH task force on research standards for chronic low back pain [492].  
Primary outcome measures 
The primary outcomes were related to feasibility: recruitment, 
retention, and treatment adherence of participants, feasibility and blinding of 
outcome assessments, outcomes related to treatment delivery, credibility of, 
and satisfaction with, treatment.  
Recruitment-related feasibility outcomes were assessed by recording 
the numbers of potential participants who were eligible and recruitment rates.  
Participation-related feasibility outcomes were (1) rates of willingness 
to participate in an RCT and (2) acceptability of random allocation to a 
treatment group.  
Assessment-related feasibility outcomes were (1) feasibility of 
assessor blinding procedures and (2) acceptability of screening procedures.  
Finally, the treatment-related feasibility outcomes were (1) possible 
contamination between the groups, (2) the credibility and acceptability of the 
interventions, (3) adherence to the interventions, (4) treatment satisfaction, (5) 
difficulty in understanding the treatment, and (6) adverse events related to 
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the interventions.  Details of these feasibility outcome measures are presented 
in Table 9.2.
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Table 9.2 Feasibility outcomes. 
SN Objectives  Measures to assess specific objectives Statistical analysis 
1 Willingness to 
participate in a 
randomised 
controlled trial 
Consecutive participants presenting at the centre were invited to 
participate in the study. They were asked if they were willing to 
participate in the study. The reasons for refusal were recorded.  
The total number of participants willing to 
participate in the study with percentage was 
recorded. The reasons for non-willingness were 
collated and reported.  
2 Feasibility of blinding 
the assessor 
Assessed by asking the assessor if she received any information regarding 
patients’ group allocation. Further, the way how this information was 
received was recorded. Assessor’s guess regarding group assignment 
was recorded for each participant, and each response was coded as 
“correct” or “incorrect” guess. 
The frequency of “Yes” were counted and 
reported as a percentage. Frequency of correct 
guesses was computed and compared between 
the groups. Finally, reasons for guesses were 
recorded and reported.   
3 Eligibility and 
recruitment rates 
The total number of participants invited, screened, found eligible, and 
recruited was recorded. The reasons for exclusion were recorded. 
Consent rates were also recorded.  
Eligibility rate, recruitment rate, and consent rate 
were reported as percentages.  
4 Acceptability of 
screening 
procedures 
Any difficulties or challenges in screening and recruiting the participants were 
recorded. Further, the outcome assessor’s recommendations for overcoming 
any challenges were recorded. Time taken to complete the questionnaires 
were also recorded.   
The frequency of difficulties or challenges were 
counted, difficulties or challenges noted and 
reported with the assessor’s recommendations 
to overcome those challenges.  
5 Acceptability of 
random allocation 
to a treatment 
group 
Acceptability of random allocation to one of the two treatment groups is 
acceptable by the participants were recorded as “Acceptable”, “Not 
acceptable”, or “No preference”.  
The frequency and percentage of acceptability 




between the groups 
Participants were asked if: 
1. They talked to other participants in this study about the intervention 
they are receiving, and if the attitude towards the intervention was 
changed after talking to participant(s) in the other group,  
2.  The participants are aware of the intervention that participants in the 
other group are receiving,  
3.  The participants in the other group are aware of the intervention you 
are receiving.  
The positive responses were computed for the 
first three questions for each group separately. 
Frequency of how many patients in control 
group had access to pain education materials 
was recorded and reported as percentage.  
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Participants in the control group were asked if he or she read the pain 
education booklet or any videos related to PEG. 
7 Credibility and 
acceptability of the 
interventions 
Treatment credibility was assessed using five questions adapted from 
Borkovec and Nau. The questions were modified to fit ‘Pain education’ 
and ‘Control group’ as treatments for patients with LBP and was 
administered to all the participants in both conditions. One, important 
cultural adaptation for the scoring made was changing the numerical 
scale proposed by Borkovec and Nau to a Verbal Rating Scale, because 
Numerical Rating Scales have shown to be have greater errors in 
Nepalese with musculoskeletal pain based on my previous research, 
especially in those who are older and have low educational 
attainment. Responses for each of the five questions will be recorded on a 
Likert scale where, 0=‘Not at all’, 1=‘A little bit’, 2=‘Somewhat’, 3=‘Quite a 
bit’, 4=‘Very much’. The total scores ranged between 0 and 20. Higher 
scores indicate greater credibility of the intervention. The questions are: 
1. How logical does the treatment provided seem to you for the 
management of low back pain? 
2. How confident would you be that this treatment would be successful in 
reducing pain? 
3. How confident would you be in recommending this treatment to a friend 
or family who also has LBP? 
4. If you were having low back pain again, would you be willing to 
undergo such treatment? 
5. How successful do you feel this treatment would be in reducing pain in 
other parts of the body, for example, knee pain? 
All the questions were asked at baseline and at 1 week following 
treatment. 
The means of the total scores on the credibility 
scale were computed separately for each 
treatment arm. Between-group differences in 
credibility were evaluated using a t-test.  
8 Adherence to the 
intervention 
Adherence to home treatment was assessed during the post-treatment 
assessment by recording “Yes” or “No” response to “Did you follow 
home advice?”; and “how many days did you perform the home 
exercises?”. The latter was recorded as the number of days. Any 
deviation from the prescribed home treatment programme was recorded.  
The treatment adherence was recorded in the 
number of days and reported for both 
treatment arms separately. Deviation from the 
treatment protocol was reported.  
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9 Satisfaction of 
treatment 
Patient Global Assessment of Treatment Satisfaction (PGATS) scale was 
used to assess treatment satisfaction. Responses were recorded on a 5-
point categorical scale (0 = ‘‘Very dissatisfied’’; 1 = ‘‘Dissatisfied’’; 2 = 
‘‘Neutral or no preference’’; 3 = ‘‘Satisfied’’; 4 = ‘‘Very satisfied’’). Total scores 
of treatment satisfaction range from 0 and 4, with higher scores 
indicating greater treatment satisfaction.   
Mean scores for treatment satisfaction were 
computed for each treatment arm separately.  
Between-group difference was evaluated using 
a t-test.  
10 Difficulty in 
understanding the 
information 
provided by the 
physiotherapist. 
Difficulty in understanding the information provided by the 
physiotherapist was asked with responses recorded on a 5-point Likert 
Scale, where 1= “Very easy”, 2= “Easy”, 3= “Neither easy nor difficult”, 4= 
“Difficult”, 5= “Very difficult”. Scores range from 1 and 5, with higher 
scores indicating more difficulty in understanding.  
The differences in the difficulty in understanding 
the information provided were compared 
between the two groups.   
11 Adverse events Any adverse events after treatment were recorded as written verbatim.  The number of adverse events was computed for 
each treatment condition separately.  The 
responses were collated.   
 
Chapter 9: THE PEN-LBP FEASIBILITY TRIAL 
193 
Secondary outcome measures 
All but one secondary outcome measures have been shown to be reliable 
and valid in Nepali populations. The two-item measure on quality of life, 
although not validated at the time of study, was included as a secondary 
outcome because it is a recommended domain for assessment by a recent core-
outcome set in clinical trials on low back pain [95]. Comprehensibility was 
assured before using it in the study. We hypothesised that it will show adequate 
validity in the Nepalese sample. The study related to the validity of this scale is 
underway, which is expected to complete before the start of the definitive trial.  
A trained research assistant, physiotherapist by training, interviewed all 
the study participants to complete all questionnaires in order to make the study 
procedures consistent, and to allow for the inclusion of participants with little or 
no education. The assessor was blind to the group assignment. Secondary 
measures include the four Patient-Reported Outcome Measurement Information 
System (PROMIS) short-form measures assessing Pain Interference [493], Pain 
Intensity [493], Sleep Disturbance [493], and Depression [493], as well as the 13-
item Pain Catastrophizing Scale (PCS) [6], Connor-Davidson Resilience Scale 
(CD-RISC) [5], Global Rating of Change (GRoC) [3, 4], and a two-item quality of 
life (QOL) scale. All the items in each PROMIS measure were summed to obtain 
raw scores for each scale. The raw scores of each measure were then converted to 
T-scores, with a mean of 50 and SD of 10 using the steps illustrated in the 
PROMIS website (www.assessmentcenter.net). Details of the measures with their 
measurement properties are presented in Table 9.3.   
All secondary outcome measures that were selected in this study are 
verbal rating scales. Although, as described in Chapters 5 and 6, I translated, 
cross-culturally adapted and validated two numerical scales (the NPRS and the 
PSFS) into Nepali, we found that Nepalese, especially, older adults and those 
with lower educational levels struggle to understand these scales. Most 
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importantly, in a separate study, we also found that Nepalese do not prefer 
numerical scales as much as other scales such as Verbal Rating Scales or Faces 
Rating Scale-Revised, and have more error rates [133]. For these reasons, the 
NPRS and the PSFS cross-culturally adapted in Chapters 5 and 6 were replaced 
by PROMIS scales to assess the domains of pain intensity and physical function 
(or physical disability in terms of pain interference) which are non-numerical and 
have good to excellent measurement properties [493].” 
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short form 6b 
Pain interference 6 5 point, 
Ordinal 
Responses are scored as a T-score that can 
range from 0-100, with a mean of 50 and 
SD of 10 in the normative sample. 
 Cronbach alpha= 0.85 and Intraclass correlation 
coefficient (ICC) = 0.80 chronic pain sample 








The total PCS score can range from 0 to 
52, with higher scores indicating greater 
pain catastrophizing.  
 Cronbach alphas= 0.85- 0.93,  
 ICC= 0.89- 0.90,  
 Positive moderate correlations with measures of 
pain intensity, depression, and anxiety in a 
chronic pain sample from Nepal.  
Global rating of 






Overall improvement were rated with 4 = 
“No change”. Scores greater than 4 
indicate greater improvement and 
scores lower than 4 indicate a perceived 
worsening in the health condition. 




Quality of life 2 5-point, 
Ordinal 
Respondents were asked to rate their 
general quality of life and general 
health by responding to the questions 
on a 5 point Likert Scale. Total scores 
range from 0 to 10 with greater score 
indicating better quality of life.  
Not available during the time of protocol writing 
the manuscript. Internal consistency between 
the two items of the QOL scale in the current 




Pain intensity 3 5-point, 
Ordinal 
Responses were scored as a T-score that 
can range from 0-100, with a mean of 50 
and SD of 10 in the normative sample.  




short form 8b   
Sleep disturbance  8  5-point, 
Ordinal  
Responses were scored as a T-score that 
can range from 0-100, with a mean of 50 
and SD of 10 in the normative sample. 
ICC= 0.78.  
Good internal consistency of 7-items (Cronbach’s 
alpha = 0.89) [493]. 






short form 8b 
Depression 8 5-point, 
Ordinal  
Responses were scored as a T-score that 
can range from 0-100, with a mean of 50 
and SD of 10 in the normative sample. 
 Cronbach’s alpha= 0.93. 





Resilience  10 4-point, 
Ordinal 
Responses were summed such that total 
scores range from 0 to 40, with higher 
scores indicating more resilience.   
 
 Cronbach’s alpha= 0.87- 0.90.  
 ICC=0.89.  
 Standard error of measurement= 2.42 points. 
 Minimum detectable change= 6.72 points. 
 Significant negative and moderate association 
with the PCS in a chronic pain sample from 
Nepal [5].  
- Use of pain 
medications 
and other pain 
treatments 
- - Names, and dosage of pain medication 
intake were recorded.  Medications 
were categorized into analgesic type 
(opioids, NSAIDs, sedatives, and anti-
seizure medications). Other pain 
treatments received were also recorded 
and classified (e.g., electrotherapy).  The 
number of days each treatment of these 
treatments received were recorded.  
 No validity data for self-reported analgesic or 
pain treatment use in Nepali patients available 
at the time of manuscript writing.  
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The risk of adverse events in both groups is very low. Participants 
were asked to choose home exercises or physical activity (such as walking) 
based on a level that is comfortable. Participants were asked to reduce the 
duration and/or pace of exercises if they feel the initial level is high [494]. 
Participants were asked to record any adverse events that occur, and report 
these to the researcher. Adverse events in both groups were recorded and 
compared between the groups.  
Additional measures 
Additional questionnaires administered to obtain data were related to 
(1) socio-demographic information (age, sex, education level, employment 
status, income, religion and ethnicity); (2) pain history, including duration of 
pain, aggravating and relieving factors, other associated comorbidities; and 
(3) pain location using pain drawings. Other information such as resources 
required to conduct the trial (e.g., cost), time required to complete the 
recruitment of desired number of participants were also be recorded with the 
total duration of home exercises in each group [495].  
Criteria for feasibility  
The results of this feasibility trial will indicate if the study as designed 
is feasible which will inform the decision of progressing to a full trial with the 
recommendations.  The decision was based on the criteria used before [496]. 
One of the following as the decision to continue with the full trial:  
(1) do not proceed to a full trial if any pre-planned changes may not help 
improve the feasibility;  
(2) modify the protocol further before conducting a full trial;  
(3) continue with the full trial using the same procedures used in the 
feasibility trial without modifications, however, monitor the study 
procedures closely; and  
(4) continue without modifications, as it is in the feasibility trial, close 
monitoring is not required.  
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The criteria for the feasibility are presented in Table 9.4 below. 
 





Full trial is not possible as designed  Proceed to a full trial without 












Close monitoring is 
not required if… 
Blinding of 
assessor 







Identify ways to 
improve assessor 
blinding based on 
the responses or 
feedback provided 
by the assessors.  
70-90% blinding 
is found. 
<10% incorrect guess 






Identify reasons for 
low participation 
rates or declining 
participation.  
Possible strategies 
could be changing 
the study site, 
increasing the 




for participation.  
2-3 participants 
recruited 
every week.  



















<15% total drop-outs 












Reduce the number 
of outcome 
measures.  
Identify and use 








<10% missing data 









the groups.  
Identify reasons for 
contamination and 


















Develop a new CG 
for the PEN trial, 
and pilot test to 
ensure that its 
credibility rating is 
< .50 SD different 
from PEG. 
- The credibility scores 
of the two 
conditions are w/i 










Identify reasons for 
not attending the 
treatment session 
in order to increase 
attendance in the 
full trial.  















Full trial is not possible as designed  Proceed to a full trial without 












Close monitoring is 
not required if… 














intervention a little 
more challenging 
if more than half 
participants report 
1-3 out of 5 in the 
difficulty scale, by 
increasing the 
depth of the 
education, by 
adding more pain 
biology education 
content. Whereas, 
if more than half 
participants report 





complexity in a 




level of difficulty.  
- ≥50% participants in 
the experimental 
group rate pain 
education as a 
“difficult” 
intervention (4 out 
of 5 in the 
difficulty scale). 
This is the 
preferred difficulty 
level because we 
want pain 
education 
intervention to be 
difficult enough to 
challenge 
participants – but 
not too easy or 
very difficult.  
Statistical methods 
Baseline characteristics for demographic and clinical data of the 
participants were reported using descriptive statistics. The plans for analysis 
of primary outcome measures are presented in Table 9.2. 
We planned the exploratory analysis of between-group differences in 
the secondary outcome measures using two-group t-tests, with the 
understanding that the current study was not powered to detect statistically 
significant between-group differences in the secondary outcomes. Rather, 
analyses of between group differences were computed primarily for 
descriptive purposes in order to inform decisions regarding the selection of 
measures for a possible future full clinical trial. The scores of the PROMIS 
measures were transferred into the template provided by 
www.assessmentcenter.net, which computed the total raw scores, T-scores 
and standard errors. The assessment centre automatically handles missing 
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items when performing the analysis. For other measures, missing items were 
imputed using the mean of the items for that patient. The details of the 
measures with the measurement properties are outlined in Table 9.3.  
RESULTS 
Data were collected from February to April 2018, with mean (SD; 
range) duration to follow-up of 7.63 (1.08; 7 – 11) days. Recruitment was 
stopped after achieving the desired sample size of 40. Twenty participants 
were randomised to each treatment arm as planned.  
Sample characteristics 
Fourteen participants (70%) in each treatment arm were recruited from 
the hospital. The majority of participants in each group were men, married, 
and Hindu. Baseline demographic characteristics were comparable between 
the groups. However, baseline scores on the secondary outcomes were 
somewhat different in the two groups such that scores on the domains that 
indicate negative aspects (pain intensity, pain interference, pain 
catastrophizing, sleep disturbance, and depression) were higher and scores on 
the domains indicating positive aspects of health (resilience and quality of 
life) were lower in the PEG than the control group. Details of the baseline 
sample characteristics are presented in Table 9.5.  
Table 9.5 Baseline characteristics of the two study groups. 
Variable                                    PEG (n=20)                            CG (n=20) 
                                                  N (%) or mean (SD)         N (%) or mean (SD) 
Recruitment, N (%) 
   Advertisement 6 (30%) 6 (30%)   
   Hospital  14 (70%)    14 (70%)  
Sex, N (%)   
  Men 15 (75%) 13 (65%)  
  Women 5 (25%)  7 (35%)  
Marital status 
  Married 16 (80%) 15 (75%) 
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  Single 4 (20%) 3 (15%) 
  Separated or widowed 0 (0%) 2 (10%)  
Religion, N (%) 
  Hindu  19 (95%) 16 (80%)  
  Buddhist 1 (5%) 3 (15%)  
  Others 0 (0%) 1 (5%)  
Race/Ethnicity, N (%) 
  Chettri  6 (30%) 5 (25%)  
  Brahmin 4 (20%) 9 (45%)  
  Newar 4 (20%) 2 (10%)  
  Others  6 (30%) 4 (20%)  
Education, N (%) 
  No school 3 (15%) 2 (10%)  
  Primary school (<5 years) 3 (15%) 1 (5%)  
  Up to high school (6-12 years) 5 (25%) 8 (40%)  
  Bachelor degree and over 9 (45%) 9 (45%)  
Primary occupation, N (%) 
  Business or office work 13 (65%) 7 (35%) 
  Unemployed 0 (0%) 5 (25%)  
  Homemaker  2 (10%) 3 (15%)  
  Currently Sick leave for LBP 1 (5%)    1 (5%)    
  Other  4 (20%) 2 (10%)  
Smoking history    
  Never smoked  10 (50%) 12 (60%) 
  Currently smoker  8 (40%) 5 (25%) 
  Have quit smoking  2 (10%) 3 (15%) 
Have left work for more than  
1 month due to LBP 
  Yes  4 (20%)    4 (20%) 
   No  16 (80%) 16 (80%) 
Medications used for LBP 
  NSAIDs 3 (15%) 6 (30%) 
  Pregabalin  2 (10%) 3 (15%) 
  Vitamin B12  3 (15%)  1 (5%) 
  Gabapentin  1 (5%) 0 (0%) 
  Opioids  1 (5%) 0 (0%) 
  Antidepressant  1 (5%)  0 (0%) 
Secondary outcomes 
  Pain intensity* 54.38 (3.48) 52.72 (2.45) 
  Pain interference*  62.28 (6.62) 58.92 (7.69) 
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  Sleep disturbance* 51.84 (7.68) 45.63 (8.71) 
  Depression* 56.99 (8.08) 53.60 (11.25) 
  Quality of life 5.70 (1.22) 6.10 (1.21) 
  Pain Catastrophizing 22.70 (10.99) 20.50 (12.56) 
  Resilience 26.95 (9.14) 28.60 (8.08) 
Abbreviations: PEG, Pain Education Group; CG, Control Group; LBP, Low Back Pain; 




One item (item #10) in the baseline assessment of the PCS and one item 
in the follow-up assessment of CDRISC (item #8) were missing for one 
participant. Missing values were replaced by the mean score of each measure 
for that participant. One item in the baseline depression scale was missing for 
one participant, which was imputed by the PROMIS assessment centre during 
the analysis.  
Primary (feasibility) outcomes 
Results related to feasibility outcomes are presented in Table 9.6, and 
summary results on feasibility criteria are presented in Table 9.7.  
Table 9.6 Feasibility results for the two study groups 
Feasibility outcomes PEG 














1 (5%) 1 (5%) - No difference in attrition rates 
between groups. 
Assessor’s correct guess 
for group allocation 
12 (60%) 11 (55%) - Assessor correctly guessed the 
group allocation slightly more 










No contamination between 
groups. 
1. Have you talked to 
other participants about 
the intervention? 
0 (0%) 0 (0%) - 
2. If yes, was your 
attitude/ intervention 
changed? 
0 (0%) 0 (0%) - 
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Feasibility outcomes PEG 












3. Are you aware of the 
intervention that 
participants in the other 
group are receiving? 
0 (0%) 0 (0%) - 
4. Are participants in the 
other group aware of 
the type of intervention 
you are receiving? 
0 (0%) 0 (0%) - 
5. For the control group: 
Did you read the pain 
education booklet 
provided to the 
experimental group? 




   Similar credibility scores 
between groups. 














Adherence to treatment  
(number of days) 
   Participants were adherent to 
the treatment in both groups, 
with significantly more 
adherence reported by the CG 
participants.  
Followed advice (n=19)  17 (89%) 18 (95%) - 
Performed home 








Number of patients who 
received other treatments 
(total) 
5 (26%) 7 (37%) -  
Slightly more CG participants 
received regular physiotherapy 
at the centre, massage or 
acupuncture, and NSAIDs.  
Regular physiotherapy 
at the centre* 
4 (21%) 5 (26%) - 
Massage or acupuncture  1 (5%) 2 (10%) - 
Number of NSAIDs per 
week used at follow-up 
2 5  -3 






- Treatment time is very similar 
between the two treatment 
conditions, and consistent with 
the planned treatment duration 
of treatment.  






Satisfaction of treatment scores 
were similar between groups 
with slightly higher satisfaction 
reported by the PEG 
participants but insignificant.  






Majority of the participants 
(75%) reported both treatments 
as easy, with slightly higher 
difficulty scores reported by the 
PEG participants but 
insignificant.  
  Very easy 0 (0%) 1 (5%)  
  Easy  15 (75%) 15 (75%)  
  Neither easy nor difficult 3 (15%) 2 (10%)  
  Difficult  1 (5%) 1 (5%)  
  Very difficult  0 (0%) 0 (0%)  
Abbreviations: PEG, Pain Education Group; CG, Control Group; NSAIDS, Non-steroidal anti-
inflammatory drugs. 
*Mostly included electrotherapy treatment.  
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Table 9.7 Were the feasibility criteria met? 
Criteria  Feasibility 
criteria met? 
Recommendations for full trial 
Blinding of assessor Yes Treatment providers should try to keep the 
treatment duration close to or equal to one hour to 
avoid any guesses of group allocation between the 
treatment groups. 
Recruitment rate  Yes Incorporating advertisement to recruit the patients 
was a good idea, which should be considered in 
the full trial. 
Attrition rate (in both 
arms) 
Yes Phone call reminders for the follow-up assessment 
helped reduce the drop-outs and which should be 
considered in the future trial.  
Feasibility of outcome 
assessment 
Yes 1. Practice administration of the outcome measures 
on real patients who are older and have lesser 
education before the actual recruitment by 
learning ways to keep patients focused on the 
questions being asked,  
2. Keep the relatives and friends of the patients 
separate from the participant during screening 
and assessment.  
3. Self-administration of the questionnaires for 
participants who can read and write could 
improve the efficiency of completing the 
screening and data collection forms.  
4. Separate the pain-related questionnaires and 
general questionnaires during administration.  
Contamination of 
intervention 
Yes The appointment time for follow-up helps avoid 
contamination.  
Credibility of treatment  Yes The credibility scores of the two treatment conditions 
were within 0.50 SD of each other therefore no 
changes in the treatment conditions are required.  
Adherence to treatment  Yes 
 
Not many patients read the handbook provided to 
them. Creating interesting short audios or videos 
with the key messages may help improve the 
adherence to home advice.   
The difficulty level of the 
intervention 
 
No The complexity of the pain education content may be 
increased by providing more complex 
neurophysiological knowledge to the patients. 
However, this may demand longer duration of 
treatment time, and or compromise the 
effectiveness of the intervention, and may require 
pre-testing of the changed intervention before 
using it in the full trial.  
 
Recruitment-related feasibility outcomes  
Seventy candidates were invited to participate in the study. Twenty-
eight participants (70%) were recruited from the data collection centre; 12 
(30%) from community advertisements. Fifty-seven percent of invited 
candidates participated. Of those who did not, 27 (90%) declined participation 
and 3 (10%) did not meet inclusion criteria.   Forty out of 43 candidates (93%) 
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screened were eligible to participate. All 40 participants (100%) who met the 
inclusion criteria provided written informed consent and were randomised to 
one of the study arms. One participant in each group was lost to follow-up. 
The reasons for all exclusions and losses to follow-up are outlined in the 
participant flow diagram (Figure 9.2).  
 
Figure 9.2 Participant flow. 
 
Participant-related feasibility outcomes  
Willingness to participate in a randomised trial. The main reasons for 
unwillingness to participate were: (1) wanting to receive comprehensive 
physiotherapy treatment as an in-patient (n = 8), (2) not wanting to pay for 
treatment (n = 6), (3) not having time to participate in the study and complete 
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the post-treatment assessment at one week (n = 6), and (4) wanting to receive 
electrotherapy treatment for one week because it was recommended by their 
physician.  
Acceptability of random allocation to a treatment group.  Random 
allocation of the treatment was acceptable to 57 out of 70 individuals (81%). 
Of the 13 participants who did not accept random allocation, five (7%) wanted 
to receive electrotherapy treatment specifically, and eight (11%) wanted to be 
admitted at the centre to receive comprehensive physiotherapy treatment 
(including electrotherapy) twice a day for a week as advised by their treating 
physician or physiotherapists. 
Outcomes assessment-related feasibility outcomes  
Feasibility of blinding the assessor.  The assessor did not receive any 
definitive information about participants’ group allocation for any of the 
participants during the study. The assessor’s guess was correct for 12 
participants (60%) in the PEG condition, and for 11 participants (55%) in the 
CG condition. On questioning, the assessor identified some clues that may 
have influenced a correct guess: (1) “duration of treatment time” (see below) 
(n = 5; 3 correct and 2 incorrect guesses), (2) patients’ reporting the treatment 
as “interesting” (n = 2; both incorrect guesses), and (3) the treating therapist’s 
description of the treatment as interactive (n = 1; correct guess).  
Acceptability of screening procedures by the assessor.  Mean (SD; 
range) time taken to complete the screening process (including the time to 
sign the consent) was 7 (6; 6 – 45) minutes. Mean (SD; range) time taken to 
complete all the forms during the baseline assessment was 20 (5; 12 – 35) 
minutes. 
The screener reported that the screening procedures were acceptable, 
but there were two problems. First, the duration of screening was occasionally 
too long, for example when patients told stories about their pain rather than 
keeping answers focused on the questions that were asked, or an 
accompanying friend kept responding on the patient’s behalf. Second, 
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interspersing assessments unrelated to pain (e.g. CDRISC, sleep disturbance, 
depression, and quality of life) between assessments related to pain (e.g., pain 
intensity, pain interference) made it difficult for some participants to switch 
focus between the pain and general domains.  As a result, some participants 
kept answering about pain when the questions asked about other domains 
such as sleep or depression.  
Treatment-related feasibility outcomes  
Contamination. There were no detected instances of contamination 
between the two groups. Table 9.6 presents the results of the five separate 
contamination questions.  
Credibility and acceptability of the interventions. The credibility 
scores of the two conditions at one-week assessment and average treatment 
time were similar (Table 9.6). Both interventions were acceptable to all the 
participants. However, patients in the PEG often expected some form of 
physiotherapy interventions in addition to education. For example, one 
patient, assigned to the PEG condition, had severe pain and stated that he 
wanted a physical treatment for his back pain. Similarly, most of the patients 
in the control group mostly expected back-specific exercises and or 
electrotherapy treatment over the painful sites. One comment from a 
participant after completing cycling was “Okay, this was exercise for my general 
health. What exercise should I perform for my back pain?” Similarly, many 
participants in the CG were keen to receive pain education intervention, 
which they did (n = 15) after post-treatment assessment at one week.  
Adherence to intervention and treatment satisfaction. Adherence to 
intervention and treatment satisfaction were similar in both groups (Table 
9.6). Twelve out of 38 patients who completed the post-treatment assessment 
at one week (32%; 5 in the PEG and 7 in the CG) wished to receive their 
regular physiotherapy treatment (mostly electrotherapy) at the centre 
between the two assessment time-points; these participants did receive this 
treatment as requested.  
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Difficulty in understanding the treatment. In both groups, 15 
participants (75%) reported that the treatment was “easy” to understand 
(Table 9.6). This result contravened our a priori cutoff point for this criterion 
of 50% (see Table 9.7). 
Adverse events. One participant in the CG reported lower extremity 
pain after cycling for 20 minutes. The increase in her leg pain lasted for two 
days and then subsided. None of the other participants reported any other 
adverse events associated with the treatments.  
Results of secondary outcomes.  We found significant within-group 
improvements from pre- to post-treatment in all the secondary outcomes, 
except resilience for the PEG participants. In the CG group, we found pre- to 
post-treatment improvements in pain interference, depression, and 
catastrophizing. We found between-group differences in favor of PEG for 
pain intensity and pain catastrophizing (Table 9.8).
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Table 9.8 Results of secondary outcome measures. 
Measures Pain education group Control group Between-group 
Baseline Mean 
(SD) 
Follow-up Change (95% CI) Baseline 
mean (SD) 
Follow-up Change (95% CI) t Difference 
Pain intensity† 54.38 (3.48) 49.14 (3.77) 5.28*** (2.91, 7.65) 52.72 (2.45) 50.95 (6.54) 1.72 (-0.82, 4.26) 2.16 3.56* (0.21, 6.91) 
Pain interference† 62.28 (6.62) 57.67 (5.80) 4.47** (1.91, 7.04) 58.94 (7.69) 56.13 (8.24) 3.03* (0.69, 5.36) 0.88 1.45 (-1.90, 4.79) 
Sleep disturbance† 51.84 (7.68) 43.74 (5.31) 7.62** (3.50, 11.74) 45.63 (8.71) 42.25 (8.41) 3.49 (-0.12, 7.10) 1.58 4.13 (-1.16, 9.42) 
Depression† 56.99 (8.08) 48.25 (8.36) 8.89*** (5.28, 12.50) 53.60 (11.25) 49.49 (10.29) 4.61* (0.69, 8.54) 1.68 4.27 (-0.88, 9.42) 
Quality of life  5.70 (1.22) 6.42 (0.77) -0.79* (-1.42, -.15) 6.10 (1.21) 6.58 (1.22) -0.47 (-1.04, 0.09) -0.78 -0.32 (-1.13, 0.50) 
Pain 
catastrophizing 
22.70 (11.00) 11.16 (7.59) 11.63*** (7.19, 16.07) 20.50 (12.56) 16.10 (12.16) 5.47** (1.79, 9.16) 2.24 6.16* (0.59, 11.72) 
Resilience  26.95 (9.14) 28.61 (5.55) -1.39 (-4.19, 1.41) 28.60 (8.08) 27.00 (8.08) 1.95 (-2.02, 5.92) -1.43 -3.34 (-8.07, 1.40) 
Global rating of 
change 
- 5.16 (0.69) - - 5.37 (0.64) - -0.95 -0.21 (-0.66, 0.24) 
*Significant at P < 0.05; **Significant at P <0.01; ***Significant at P < 0.001 
†T-scores are reported.  
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Other findings 
The standard low back pain treatment protocol at the data collection 
centre typically included non-guideline-based care such as advice to rest, 
advice against physical activity, admission for bed rest and intensive passive 
therapies (mostly electrotherapy). Such a care pathway contrasts with the 
recommendations and treatments presented in both groups. We found it 
challenging to alter the physiotherapists’ usual practice.  
Related to this, all of the physiotherapists who provided the control 
group treatment reported being dissatisfied with not being able to provide 
interventions they would normally provide, many of which were treatments 
that patients also wanted to receive, such as spine-specific exercises and 
manual therapies. Moreover, five of the physiotherapists who were initially 
trained in guideline-based care before the initiation of the study left the 
treatment centre during the trial recruitment period. They were replaced by 
four physiotherapists who therefore had not been trained in guideline-based 
care as part of this study.  
DISCUSSION 
We aimed to determine whether or not it would be feasible to 
undertake a full RCT within the Nepalese health care system and to identify 
any modifications that may be needed before doing so. Seven of the eight a 
priori feasibility criteria were met, which suggests that a clinical trial to 
evaluate the effectiveness of pain education and evidence-based 
physiotherapy treatment in Nepal is feasible. This feasibility trial also 
provided important additional information that informs the design of the full 
trial. 
 Primary feasibility outcomes 
The recruitment rate exceeded our target of four participants enrolled 
every week. We used advertisements in social media, and we suspect that 
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recruitment was aided by patient-to-patient word of mouth as the trial 
progressed. This, and the finding that our attrition rate (5%) was well below 
our a priori maximum rate of 20% (which is thought to lead to serious threats 
to validity [498]), was surprising considering that most patients in both 
groups did not receive the care they expected to receive.  This is encouraging 
because it suggests that a broader education strategy, to prepare potential 
patients for an alternative approach to their problem before including them in 
a trial, is probably not required. 
Although screening and data collection procedures were generally 
acceptable to the assessor, the assessor provided important recommendations 
to improve overall screening and data collection. For example, extended 
assessment sessions might be avoided by upskilling the assessors in dealing 
with patients, who are often elderly and uneducated and who tend to tell 
stories about their pain rather than provide direct answers to the questions 
being asked. An important caveat here, however, is the potentially critical role 
that this extra time and attention — particularly insofar as it is dedicated to 
listening to patient stories — may have had in subsequent engagement and 
participation, particularly against the backdrop of unexpected care. The 
patients’ stories in fact provide a context and meaning of their health 
problems [499], which may be a therapeutic intervention in itself, and are 
important to establish a good doctor-patient relationship [500]. Clearly, the 
cost-benefit relationship of time-limited assessment is likely to be 
individually-specific and nuanced.  
The advantages and disadvantages of interviewing patients without 
their friends or family members present are also worthy of consideration. 
There were instances when excluding an accompanying family member 
would have reduced the data collection time, and possibly improved the 
accuracy of the answers. However, the relationships patients have with those 
around them play an important role in the experience of pain [501, 502] and 
what people do about it [501]; exclusion of important others at a critical time 
may also disengage the patient or instill other barriers to their participation in 
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the project. A final pragmatic modification to improve assessment would be 
to organise pain-related and pain-unrelated questions into different sections 
of the data collection protocol, so as to avoid patients being confused 
regarding the domains being assessed.   
Blinding appeared to be successful and contamination appeared to be 
avoided. Most controlled trials do not adequately examine assessor blinding 
[503], even though it is widely considered a very important component of 
good study design [504]. We were able to blind the assessor here because we 
could provide a separate office space that was isolated from the treatment 
area. We were also able to schedule appointments to avoid contact with 
assessors that would unblind them to the group. Our inclusion of participant-
reported items to evaluate contamination is not routinely included in 
feasibility or full clinical trials – the common approach, is to implement 
strategies to minimize the risk a priori but not investigate it post hoc. However, 
in settings such as that involved here, where the community is well connected 
and word of mouth appears to be a significant recruitment pathway, we 
considered it important to also examine potential contamination post-hoc. 
Limiting the number of patient recruitments performed in a single day to two 
may also have helped avoid contamination, but to see no evidence of 
contamination was surprising. 
Treatment credibility and satisfaction were high for both groups (even 
though the participants did not receive the treatment they expected). That 
most participants in the pain education group found the material “easy” or 
“very easy”, was surprising and contrary to an a priori feasibility criterion. 
Our protocol [7] stipulated a response to this outcome requiring that the 
material presented to be viewed as "difficult" before proceeding to full trial. 
Whether we should increase the difficulty by increasing the number of 
concepts covered, or going more fully into the four concepts we chose, or 
both, will require some pilot testing. Contrary to my original idea of having 
the intervention "difficult" to understand would challenge patients current 
understanding of pain and contribute to improvement in pain (analogous to 
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overload principle of exercise prescription), in retrospect, I now believe that 
having the educational interventions simple and easy to understand was a 
strength of the education programme which may be desirable to improve  
treatment effectiveness. That secondary outcome data findings suggesting a 
beneficial effect in the PEG condition appears to support making such a 
change may not be required. 
Secondary outcomes 
Mean improvements over time were observed for 7/8 outcomes in the 
PEG condition and 4/8 outcomes in the CG condition. Although assessment 
of the effectiveness of the interventions on the secondary outcomes was not a 
primary aim of this study, significant between-group differences were found, 
in favor of PEG, and the apparent effect was substantial on two key target 
outcomes - pain intensity and pain catastrophizing (Table 9.8). However, the 
consistently larger improvements in all of the other outcomes for the PEG 
condition, relative to the CG condition, suggests the possibility of wide 
benefits of pain education as compared to guideline care, in Nepal. It should 
be remembered that these are secondary outcomes, not corrected for multiple 
analyses, and therefore at risk of false-positive results. However, these results 
add pertinence to the feasibility results - a full-scale clinical trial appears 
warranted.   
Recommendations  
Although the findings suggest that a clinical trial evaluating the 
effectiveness of a Nepali pain education programme is feasible within Nepali 
primary and tertiary care, and some improvements could be made. First, to 
improve the compliance of the physiotherapists with the control group 
treatment - guideline-based care - and adherence of patients to that care, the 
control group treatment condition may need to be modified. Ideally, this 
modification would be made so that the control treatment was consistent with 
the evidence-based practice paradigm as much as possible; for example, by 
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giving participating patients and their therapists the ability to choose 
treatments that are mostly consistent with guideline recommendations for 
low back pain treatment. For example, the guideline-based treatment could 
have two components: (1) mandatory first-line care recommended by the 
guidelines (education and reassurance, promotion of physical activity, early 
return to work, advice about the positive prognosis for back pain), in addition 
to (2) a more pragmatic approach to low back pain treatment. This second 
component may include any form of exercise (treadmill, static cycling or 
back-specific motor control or movement exercises), manual therapy 
(massage, mobilization, or manipulation, based on therapist’s preference), or 
electrotherapy treatment, according to the therapist and patient preference (as 
per recommendations of evidence-based care [505]), as long as it is safe and 
does not extend treatment time to beyond one hour. We should also consider 
the fidelity assessment of the interventions provided by the therapist to be 
certain that per-protocol treatment is being provided in each treatment arm.  
A final modification would be the addition of economic analysis. 
Nepalese individuals are often poor and the Nepalese public health system is 
resource-poor. Not surprisingly, the cost was a barrier to participation for 9% 
of potential participants.  Pain education intervention appears to be a less 
resource-intensive alternative to current practice and could be delivered 
outside of the public health system, in community settings, although the costs 
and time of physiotherapist would be no different from guideline-based care 
as delivered in a physiotherapy department. Pain education might require 
more training of therapists, although training in guideline-based care may be 
necessary too. As such, a full trial would benefit from the addition of a full 
economic evaluation.  
Strengths and limitations  
The current study has a number of strengths: we used active guideline-
based care as the comparator group; we successfully blinded the assessor and 
analyst, and assessed both blinding and contamination; outcomes were 
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consistent with NIH recommendations on research standards for chronic low 
back pain [492] and core outcome sets for low back pain research [90], and we 
submitted our protocol for publication before data collection and remained 
transparent in all reporting [506].   
To our knowledge, this is the first study to examine the feasibility of a 
clinical trial on low back pain in Nepal. Conducting a feasibility study is an 
important step before conducting a full clinical trial [496], especially in a 
setting where a clinical trial has never been conducted, which lacks 
recommendations from previous experiences for such a study. For example, 
we had planned a full clinical trial in 2016 [507] but were unable to recruit 
participants because the clinicians were too busy to collect data and provide 
interventions as per protocol, and we encountered difficulty ensuring access 
to an assessor blinded to group allocation because of multiple responsibilities 
of the clinicians. These are feasibility problems that would have been revealed 
in a preliminary feasibility study [496]. 
The current study also has a number of important limitations. Our 
follow-up was shorter than we would use in a full clinical trial. The short 
follow-up duration was chosen because a one-week assessment was sufficient 
to answer the feasibility-related questions, but whether or not long-term 
follow-ups are feasible in this setting and population remains to be 
demonstrated. We did not assess treatment fidelity in the current study, 
because we did not have the resources to do so. That the current practice in 
the low back pain management at the study site was very different from 
clinical practice guidelines made it harder for the physiotherapists to comply 
with guideline-based care. Another limitation was that we did not include 
any measure of physical activity as a secondary outcome, despite improved 
physical activity being one aim of pain education. In a definitive trial, we may 
consider using a measure to assess physical activity such as the International 
Physical Activity Questionnaire [508], or an objective measure of physical 
activity, such as Actigraphy [509]. Finally, the experimental group treatment 
was provided by the primary author of the study, who may have 
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inadvertently communicated more enthusiasm for the experimental group 
treatment than the therapists providing the control group treatment; this may 
have influenced the study findings. A full clinical trial would ideally include a 
number of therapists who would be trained to deliver both treatments, as one 
way to control for the therapist effects. This could also improve the 
generalizability of the study findings.   
Summary and conclusions 
We conclude that a clinical trial to evaluate the effectiveness of pain 
education and evidence-based physiotherapy treatment in Nepal is feasible 
and warranted, although some minor modifications are required.   
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The overarching aim of this thesis was to identify knowledge gaps in 
pain research in Nepal and to begin a programme of research that would 
address these knowledge gaps. I identified a number of important key 
knowledge gaps in the extant research literature in Chapter 2. The primary 
gaps that required urgent attention were related to the biopsychosocial 
assessment and management of pain. This informed subsequent chapters 
which described research to address these gaps, and included (1) research to 
cross-cultural adapt of five PROMs of important pain-related domains, (2) the 
development of pain education resources for biopsychosocial management of 
pain in Nepal, and (3) the design and conduct of a feasibility trial to evaluate 
if a definitive trial on pain education in Nepal is feasible.  
I found that each of the five PROMs that were translated and cross-
culturally adapted into Nepali was reliable and valid, that patients with low 
back pain in Nepal accepted pain education as a credible intervention, and 
that a randomised controlled trial to evaluate its effectiveness in Nepal is 
feasible. In addition to these studies, I also conducted a systematic review to 
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determine if between-country and between-language differences in chronic 
pain beliefs, coping, and catastrophizing existed. The results of this review 
indicated that these differences did exist in 50% or more cases based on low- 
to moderate-quality evidence. Below I provide a summary of the key points 
and considerations derived from each study in the same sequence as they 
were presented in the thesis.  
State of pain research in Nepal  
The scoping review summarised the published literature on pain in 
Nepal up to December 2018. The primary findings were: (1) a biomedical 
focus on pain assessment and management is common; (2) pain conditions 
such as musculoskeletal pain, back pain, headache, and dysmenorrhoea are 
very common conditions in the population; (3) patient-reported outcomes in 
adults with musculoskeletal pain are recently being translated and validated; 
and (4) areas of research redundancies were noted (for example, analgesia for 
post-surgical pain, imaging for non-specific pain conditions). Knowledge 
gaps were identified which included an absence of epidemiological studies on 
pain conditions other than headache, outcome measurement studies in 
populations other than adults with musculoskeletal pain (e.g., paediatric 
pain), and biopsychosocial assessment and management of pain. The scoping 
review of pain research in Nepal allowed for the identification of most 
research studies published in Nepal, including studies that are not necessarily 
discoverable using the usual international databases (e.g., PubMed, CINAHL, 
or Embase). Although this approach has not yet been adopted by other 
researchers in other countries, it would be interesting and potentially useful 
to replicate the review in other developing countries to determine if similar 
knowledge and knowledge gaps emerge. Based on the findings from such 
reviews, it may be possible to make research recommendations from a more 
international perspective. 
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Potential facilitators to pain research in Nepal 
Pain research in Nepal only began to proliferate after 2011 (83% of 
studies published since 2012), which potentially had various facilitators. The 
establishment of Nepalese scientific journals published by medical societies 
and colleges in Nepal may have facilitated the increase in pain research 
published by Nepalese scientists in local journals [142, 149, 151, 153, 157, 161, 
167, 169, 172, 177, 178, 181, 203]. On the other hand, international 
collaborations may have facilitated the publication of pain research authored 
by Nepalese authors in international journals indexed in international 
databases such as PubMed [3, 5, 6, 133, 160, 199, 211, 220, 228, 234]. The 
increase in the volume of research in Nepal in the last decade is similar to the 
global increase in pain research. Although some facilitators seem to exist, 
several barriers still limit pain research in Nepal. 
Barriers to pain research in developing countries  
Several barriers to conducting research in both developed and 
developing countries have been identified by previous researchers [510, 511]. 
These include lack of research knowledge and skills, absence of dedicated 
research team with research commitments, lack of research training, lack of 
research funding, barriers to access databases, and systems-level regulatory 
barriers [510, 511]. Although barriers specific to pain research in Nepal have 
not been empirically examined, it would be reasonable to expect that the 
barriers listed above also apply to Nepal. One additional barrier of 
conducting these studies, I also found that lack of overall understanding of, 
and the need of research in general among the general Nepalese population 
(and health professionals) is a major barrier for participant recruitment.  
Strategies to facilitate pain research 
In addition to strategies to improve the quality pain research and 
reduce research redundancies in Nepal discussed in Chapter 2, several 
strategies could be adopted to improve pain research in Nepal and other 
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developing countries. As discussed above, the availability of local journals to 
provide a platform for local scientists to publish scholarly work has provided 
a platform for the proliferation of pain research in Nepal; the quantity of 
published work is not desirable without acceptable quality. One potential 
strategy would be to provide undergraduate, postgraduate, and post-doctoral 
research training in a well-established pain research group. This could 
provide dedicated research time and resources to local pain research trainees, 
and also provide a first-hand learning experience from the world leaders in 
pain research.  
Collaborations with more experienced researchers (both local and 
international) can improve both the quality and quantity of research by 
helping trainees identify the most important research questions and using the 
state-of-science research methods to answer these questions. Similarly, 
conducting and promoting regular international pain conferences (example 
by Nepalese Association for the Study of Pain) and pain research training 
(similar to one conducted by North American Pain School 
(https://northamericanpainschool.com/) could assist in improving the 
quality of pain research within the country.  
Another way of facilitating pain research would be to allocate grants 
for (pain) research by Ministry of Health and Population at different levels, 
including grants to pre-doctoral students, early-career reseachers, 
intermediate-career researchers, and late-career researchers, similar to those 
provided by other funding agencies such as National Health and Medical 
Research Council, Australia; Medical Research Council, UK; and National 
Institutes of Health, USA. These and other international funding agencies 
could also potentially support pain research in Nepal. Similarly, seed funding 
or start-up funding from the universities and medical colleges within Nepal 
to faculty members could potentially kick-start pain research in the area of 
their interest.  
Lastly, in line with the barrier of lack of understanding of research 
among general public and health professionals, the value of research may be 
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introduced early in secondary school. Other strategies would aware general 
members of the public on the value of good research on television and 
newspaper may help people of Nepal to understand why research is 
important in the first place. All of these can help nurture more high-quality 
pain research in Nepal that addresses important questions that could 
ultimately help to reduce the pain and suffering of individuals in Nepal with 
chronic pain.  
Strategies to uptake pain knowledge 
 Although conducting local research to generate evidence is important, 
it is only useful when this evidence is locally uptaken and implemented in 
practice. To do this well, curriculums of health professionals should be 
upgraded to incorporate (1) recommended contemporary pain curricula, for 
example, by the IASP [512], and (2) evidence-based practice knowledge and 
skills. Locally conducted pain camps such as one conducted by the IASP or 
other regular workshops targeting pain clinicians could help them to uptake 
high-quality evidence in their practice.  
Culture and pain  
Chapter 3 presented the results of a comprehensive systematic review 
of the literature exploring the between-country and between-language 
differences in pain beliefs, coping, and catastrophizing in adults with chronic 
pain. As can be seen in the protocol of this review that was registered in the 
PROSPERO registry (registration: CRD42017082449), the original aim of the 
review was to assess the role of culture in pain beliefs, coping, and 
catastrophizing. For this study, I chose “country” and “language” as proxies 
for (or operational definitions of) “culture”. “Country” has been used as a 
proxy for culture by many other researchers, as it is thought to reflect some 
commonalities of the more complex construct of culture [282, 283, 327, 513-
516].  
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However, as noted in the paper, we later changed the language used in 
the review to make it a paper examining between-country and between-
language differences and not between-culture differences. This was done 
because I and my co-authors, after the reviewers' feedback, determined that 
“culture” is a concept that is influenced by a large number of factors in 
addition to just the country a person lives in or the language that one speaks. 
In fact, there are many cultural differences between groups who all live in the 
same country and who even speak the same language. Thus, we concluded, 
as have others [319] that "country" (and language) are not adequate proxy 
indications of culture. 
Although this review did not meet my initial intended goal of 
exploring the role of culture in chronic pain beliefs, coping, and 
catastrophizing, it did provide important new information that could inform 
a way forward in this area. For example, it became clear that pain researchers 
need to agree on a common definition of culture and the best ways to assess 
culture in the context of pain, in order to study the role of culture in chronic 
pain. This important step will advance research related to culture and pain.  
In the meantime, and until a consensus definition of culture is created 
by researchers in this area, research to examine the impact of “culture” 
continues to be needed. In Nepal, there are a variety of different groups of 
people with cultural differences. These may be reflected by groups classified 
with respect to race and ethnicity, socioeconomic status, education level, age 
(e.g., age cohort), and religion. Future research is needed to help determine 
how each of these culturally-related factors — both individually and as a 
group — influences pain and an individuals’ response to pain. The findings 
from such “culture”-focused research could help inform the development or 
adaptations of treatment interventions there may be more effective when or if 
they take these differences into account. Similarly, identifying the cultural 
predictors of better treatment outcomes when adapting pain interventions 
from one country or language to another may help clinicians identify the key 
domains they should take into account when providing treatment.  
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Outcome measures 
I initially translated and cross-culturally adapted the NPRS and the 
PSFS into Nepali with an aim to use it in future studies including the PEN-
LBP feasibility trial, because these measures are the recommended scales to 
assess pain intensity in the chronic pain and low back pain studies [88, 90]. 
However, even though we found that NPRS was a reliable, valid, and 
responsive measure to assess pain intensity in people with musculoskeletal 
pain in Nepal among those who could complete the measures, only a small 
subset of the sample screened was able to complete the NPRS.  
Specifically, and in the studies presented in Chapters 5 and 6, the 
participants struggled to complete the NPRS (and the PSFS which also has 
numerical rating responses). However, many more individuals were able to 
complete the GROC which has verbal rating options. This finding provided 
the important information that in general Nepalese are not able to respond to 
numerical rating scales, which limits the use of the NPRS and the PSFS in the 
wider population in Nepal.  
Another study we conducted in Nepal supported this conclusion [133]. 
In this study, we found that numerical rating scales had the maximum errors 
associated with the completion and were the least preferred among other 
scales administered (a visual analogue scale, a verbal rating scale, and the 
Faces Rating Scale-Revised) [133]. The Faces Rating Scale-Revised, on the 
other hand, was the most preferred and with the least errors followed by the 
verbal rating scale.  
However, one important limitation of the Faces Rating Scale is that it 
cannot be administered via telephone interview. With these considerations in 
mind, we replaced the use of the NPRS by PROMIS pain intensity short form 
3a scale and the PSFS by the PROMIS pain interference short form scale 7b for 
the PEN-LBP trial in order to maximize our ability to obtain complete data 
from the participants in the PEN-LBP trial. These instruments have been 
should to be reliable and valid in Nepalese with chronic pain.  
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Pain education  
To make it possible to perform research evaluating whether pain 
education could effectively reduce disability due to the number one cause of 
disability in Nepal — low back pain – it was necessary to develop pain 
education resources in Nepali (see Chapter 9). This effort appeared to be 
successful. Given that it also appears feasible to evaluate the beneficial effects 
of these resources (see discussion of the PEN-LBP feasibility trial in the next 
section), an important next step will be to evaluate the benefits of these 
materials in individuals in Nepal with low back pain. 
However, I am also mindful that pain education is not the only 
strategy that could reduce the burden of low back pain. Although pain 
education is an important aspect of pain management and is recommended 
by clinical practice guidelines [82, 109, 517], recent evidence shows that pain 
education alone may not be adequate to reduce pain and disability for 
example, in acute low back pain [126] despite improving pain beliefs. 
Moreover, behavioural changes that are needed for long-term adjustment to 
chronic pain [473] may not occur after a single session of pain education [126]. 
The follow-up treatment sessions should reinforce the education provided 
and facilitate behavioural changes including encouragement to exercise.  
Similarly, identifying the key target concepts that patients find most 
helpful for their recovery should help to prioritize the most important target 
concepts that could be the focus of pain education. These could then be used 
in mass media campaigns to change beliefs about pain and its management at 
the population levels, which may reduce the consumption of low-value care.  
PEN-LBP feasibility trial 
The PEN-LBP feasibility trial was designed to assess if (1) pain 
education programme was accepted as a credible treatment for low back pain 
and (2) a high-quality randomized controlled trial evaluating the effectiveness 
of pain education programme is feasible in Nepal. I found that pain education 
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was accepted as a credible treatment for low back pain and that conducting a 
full trial is feasible in the Nepalese healthcare system.  I also achieved the aim 
of gaining insight into important consideration for a full definitive clinical 
trial in Nepal.  
Strategies used in the feasibility trial that worked  
As this was a first clinical trial of pain education and guideline-based 
care treatment on individuals with low back pain, we were not certain that we 
could achieve the sample size recruitment goals in the anticipated time frame 
and if important aspects of a clinical trial could be maintained. We adopted 
several strategies to achieve the proposed aims. First, we met our anticipated 
recruitment rate only after using social media advertisements and requesting 
referrals from other centres after slow recruitment in the first few weeks. This 
also led to patient-to-patient word of mouth referral to participate in the trial 
which improved the recruitment rate per week. Advertising the trial both to 
patients themselves via social media and to other clinicians should be 
adopted in the future definite trial or any other clinical trials of similar nature.  
The second strategy was related to improving attrition rates. It was 
facilitated by phone call reminders by a research staff. Another strategy that 
would work and save time would be to use automated text services to remind 
participants of the follow-up appointments. A similar strategy could also help 
patients’ adherence to advice for home (reading handouts and physical 
activities). Third, strategies that helped maintain assessor blinding was 
related to good coordination between the intervention providers and the 
blinded assessor. Although these clinicians met each other in the hospital 
premises and during lunch breaks which may have led to a discussion of 
patients recruited for the study which could lead to serious threats to the 
assessor blinding, this was not the case. If feasible, the patient assessment 
should be performed in a separate site to the treatment site to facilitate 
assessor blinding. In our trial, separate office space for assessment and 
treatment helped this. 
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Fourth, scheduled follow-up day and time and separate office space for 
the delivery of the experimental and the control group treatments helped 
avoid contamination between the two treatment arms. Next, the therapists 
providing interventions to the patients in the control group were not trained 
in “Explaining Pain” which also helped avoid contamination. Contrarily, 
based on the protocol, I was supposed to deliver intervention only to the 
experimental group, however, I also delivered interventions to a few 
participants in the control group because many clinicians trained for the trial 
left their job at the centre, and very few who remained were busy when the 
trial participants were needed to be treated. Despite all attempts to prevent 
contamination, we cannot assure treatment fidelity because we did not 
formally record it. The full clinical trial should systematically record 
treatment fidelity as recommended [518, 519] which will provide objective 
information on treatment contamination.   
Implications of the thesis  
The findings of the thesis have important implications for pain policy, 
research, and clinical practice in Nepal, and perhaps other developing 
countries as well.  
Policy implications  
 Health systems strengthening approaches. In a recent Viewpoint 
article [10], I highlighted that health system strengthening approaches are 
necessary to tackle the burden of pain in low- and middle-income countries 
including Nepal. Such an approach has several components. First, we should 
utilise public health approaches to fight the burden of pain. One good 
example of this is a mass media campaign [127]. These campaigns are 
potentially a cost-effective way to help individuals in the population obtain 
accurate (and adaptive) information about chronic pain and its management. 
They may, therefore, be particularly relevant in resource-limited settings.  
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In addition, with increasing access to digital technologies and social 
media in countries such as Nepal, utilizing these technologies could be 
another way to (1) promote evidence-informed high-value care to people with 
or without pain at the population level, and (2) debunk the myths related to 
pain management. For example, advice on self-management and improving 
physical activities should be promoted, whereas, popular but ineffective and 
potentially harmful treatments such as bed rest and paracetamol for low back 
pain should be discouraged in these campaigns [82]. Although evidence 
regarding the efficacy of mass media campaigns is inconsistent [520-524], 
there is no available evidence regarding the efficacy of such approaches in 
low- to middle-income countries and eastern cultures. Research that would 
evaluate the efficacy of these approaches – including research that identifies 
the most effective strategies – is warranted.  
A second important strategy that could help to address the burden of 
chronic pain would be to develop a health workforce that has up to date 
evidence-based knowledge regarding pain and its treatment. This should 
include healthcare providers in all settings, including primary care settings 
and community-based rehabilitation facilities. Educated health care providers 
could then deliver high-value care (maximum benefits with minimum harm 
and costs) to people with different pain conditions.  
A third strategy to reduce the burden of chronic pain in Nepal would 
be to improve access to rehabilitation services that have demonstrated efficacy 
[525-528]. Such evidence-based approaches could be integrated as a 
component of universal health coverage.  
A fourth approach – this one to help increase our knowledge regarding 
the prevalence and impact of chronic pain – would be to collect data 
regarding the workforce and population burden of pain by incorporating 
questions related to pain in national health surveys (see an example in the 
Solomon Islands [529]). This information, especially if it were collected on a 
regular basis over time, could be used to help determine the overall efficacy of 
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changes in health policy as well as community-wide media and education 
campaigns on the incidence and impact of chronic pain. 
Fifth, there is an urgent need to reform the health financial models to 
support high-value care in pain management [10, 530]. Although making 
changes in health systems so that they take into account high-value pain care 
can be challenging, incorporating evidence-based care with existing or 
emerging policies that are currently being developed for healthy ageing, 
prevention, and management of non-communicable diseases may make this 
easier. For example, incorporating health system strengthening approaches 
for pain care would likely support the health of individuals as they age [10].  
Reconsidering research priorities. Formulating an appropriate 
research priority agenda countrywide is necessary to ensure that resources, 
including funding, are directed appropriately at any particular time. 
Although communicable diseases such as cholera, tuberculosis, malaria, and 
HIV continue to be significant problems in developing countries [531-534], it 
is also time to consider pain as a research agenda in these countries. For 
example, the Nepal Health Research Council should consider the significant 
(and growing) burden of pain in Nepal and its impact on general health, 
socioeconomic status, overall productivity, and healthy ageing seriously. 
Increasing our knowledge about pain and its impact in Nepal should be 
prioritised as an important research agenda along with other important non-
communicable diseases such as cardiovascular conditions, diabetes, and 
cancer. Such identification of pain as a research priority area may trigger the 
proliferation of (high quality) research and research funding, thereby 
addressing important research questions.  
Research implications 
The findings from the studies that were conducted as a part of this 
thesis also have important research implications. First, as alluded to 
previously, Chapter 2 provides a rationale for including pain as a priority 
research agenda in Nepal. Second, the thesis findings also highlight the 
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potential effects that culture has on psychological domains in chronic pain. 
These effects warrant additional study. Third, the thesis findings also 
highlight the fact that it is feasible to incorporate valid and reliable outcome 
measures in clinical research in Nepal. Doing so will facilitate the collection of 
valid and reliable data in this area. Fourth, the thesis findings indicate that it 
is feasible to conduct high-quality clinical trials in Nepal, providing that there 
are adequate resources (e.g., physical space, research staff to deliver 
interventions and collect data) available. Finally, this study also provides a 
model of research to generate research priority agenda for other clinical 
conditions or to develop a research agenda for pain (or other conditions) in 
other developing countries.  
Clinical implications 
Clinicians should incorporate valid, reliable, and responsive outcome 
measures in their clinical practice to assess important biopsychosocial 
domains of pain. The measures that are translated into Nepali cross-culturally 
adapted and validated show reasonable evidence that these could be used in 
routine clinical care to track the levels of pain, psychological distress, and an 
overall improvement in health conditions. Similarly, clinicians treating 
musculoskeletal pain including low back pain should use high-value care 
(such as promoting physical activity, return to work, and self-management) as 
per guideline recommendations [82, 109, 110] and discard low-value care 
(such as bed rest and electrotherapy in low back pain) for routine use in 
clinical practice. 
Overall significance  
The thesis consisted of series of studies that (1) summarised the list of 
important pain research agenda for Nepal; (2) informed the between-country 
and between-language differences in psychological domains in chronic pain, 
and may help move the field of culture and pain forward; (3) can help 
improve biopsychosocial assessment and treatment of pain in Nepal; and (4) 
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can serve as a model for improving the assessment and pain management in 
other non-western or developing countries.  
Recommendations 
A number of key recommendations for future research can be made 
based on the thesis findings. First, based on the scoping review findings, 
future pain research should focus on epidemiological aspects of 
musculoskeletal pain; other pain conditions not yet studied or 
underrepresented complex regional pain syndromes, pediatric pain, and 
cancer pain; PROMs in pediatric pain conditions; and psychosocial 
management of pain. Second, Chapter 2 urges scientists in the field to develop 
a consensus-based definition of culture in the context of pain research. The 
availability of such a definition – and the measure or measures of culture that 
would emerge from such a definition – would facilitate more cross-cultural 
studies on pain. I would expect such a definition to have multiple facets or 
sub-domains (for example, country of origin and or residence, language 
people speak, income, education, occupation, age, and religion). With an 
assessment of each of these factors, analyses could be performed that could 
help us to understand which of these factors are most closely associated with 
pain beliefs and coping, using multivariate analyses. The cultural factor(s) 
that emerge as significant predictors could then help us to understand which 
aspect(s) of culture have the greatest roles in adjustment to chronic pain. Such 
research would also advance our understanding of the role of culture in 
chronic pain and may further contribute to the cross-cultural adaptation of 
interventions developed in one country/language into another. A systematic 
review of qualitative studies to assess the role of culture in chronic pain may 
also further our understanding of the role of culture in chronic pain.  
Third, outcome instruments developed in or translated to Nepali and 
cross-culturally validated should be used in clinical practice and research so 
that they provide information on biopsychosocial aspects of pain where the 
treatment could be targeted. Whether or not these instruments are reliable or 
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valid in other populations (e.g., pediatric populations, elderly populations) 
should be evaluated in future research.  
Fourth, studies focusing on the local adaptations of guideline-based 
care for various pain conditions in Nepali and their implementation is 
necessary to respond to the increasing burden of pain in Nepal. This will also 
help us identify barriers and facilitators of adapting guideline-based care in 
Nepal and ways to overcome the barriers.  
Finally, definitive clinical trials to evaluate the effectiveness and cost-
effectiveness of pain education in various forms (individualized and group 
therapy, or public health campaigns) and guideline-based care for various 
pain conditions will inform local clinical practice.  
Overall strengths and limitations  
Strengths  
We adapted contemporary recommended standards for conducting 
these studies: PRISMA guidelines and its extension for scoping reviews for 
the conduct and reporting of the scoping and systematic reviews [138, 286]; 
COSMIN guidelines for the conduct and reporting of cross-cultural 
adaptation and validation studies [345]; and SPIRIT checklist and CONSORT 
statement extension for pilot and feasibility trials for the conduct and 
reporting of the PEN-LBP feasibility trial [483, 535]. We also recruited an 
optimal number of participants to conduct each of these studies to address the 
specific aims.  
Limitations 
 Although we used the recommended standards to conduct the studies 
for this thesis, the studies reported here also have some important limitations. 
First, the scoping review as a review design suffers a limitation of not being 
able to provide evidence on the quality of evidence retrieved. Quality of 
evidence is not a concern that a scoping review addresses as it mainly aims to 
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identify the scope of research in a particular area of health research (i.e. the 
current knowledge), identify the knowledge gaps, and provide 
recommendations for the future research [137, 138]. The questions asked by 
scoping reviews are more general, unlike systematic reviews which ask more 
specific questions that aim to solve controversies in the literature and provide 
more definitive answers to the review question, therefore, quality appraisal of 
the literature is central to systematic reviews [286].  
Second, although we performed a comprehensive literature search for 
the systematic review between-country and language differences in chronic 
pain-related beliefs, coping, and catastrophizing, we were only able to 
retrieve a limited number of studies for the review; research in this area is still 
in its early stages.  As a result, we were unable to pool the findings from these 
studies for a meta-analysis. This warrants caution regarding any conclusions 
that are drawn from the review with respect to between-country differences 
in chronic pain beliefs, coping, and catastrophizing. Clearly, more high-
quality research in this area is needed to understand the role that an 
individual’s country plays with respect to how that person responds to pain 
and pain treatments.  
 Third, the PROMs that were translated and cross-culturally adapted 
into Nepali were validated in adults with pain. Therefore, these measures 
should not be assumed to be valid or reliable in paediatric populations. Some 
additional adaptations may be required for the younger populations to 
understand and complete the instruments. 
Finally, conclusions on the effectiveness of the pain education 
programme should not be made from the PEN-LBP feasibility trial, because, 
the study was not powered to detect the between-group differences. The 
study sample size was only adequate to answer the questions related to the 
feasibility outcomes.  
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Conclusions 
This thesis included a series of papers that describe the findings from a 
program of research that has an overarching aim to improve pain assessment 
and management in Nepal. Based on the findings of papers related to this 
thesis, I conclude that: (1) two factors that are a part of culture but do not 
themselves adequately define culture, appear to play some role in the 
people’s pain-related beliefs, coping, and catastrophizing; (2) translated and 
cross-culturally adapted patient-reported outcome measures are reliable and 
valid for use in individuals with musculoskeletal pain conditions; (3) a newly 
developed Nepalese pain education programme was accepted as a treatment 
for patients with low back pain in Nepal; and (4) conducting a high-quality 
clinical trial evaluating the effectiveness of this intervention is feasible in the 







































Appendix 1 Search strategies used for the scoping review 
Search strategy for Medline 
1 pain.ab,kw,sh,ti. 512451   
2 analgesia.ab,kw,sh,ti. 59225   
3 nepal.mp. or NEPAL/ 8209   
4 nepal.ab,ti. 6516   
5 kathmandu.ab,ti. 1130   
6 PAIN/ 126582   
7 Chronic Pain/ 10725   
8 Musculoskeletal Pain/ 2498   
9 Osteoarthritis/ 34437   
10 Low Back Pain/ 19603   
11 Neck Pain/ 6239   
12 Shoulder Pain/ 4299   
13 neuropathic pain.mp. or Neuralgia/ 20605   
14 Reflex Sympathetic Dystrophy/ or Complex Regional Pain Syndromes/ or 
Temporomandibular Joint Dysfunction Syndrome/ or Causalgia/ 
 
Limit: Humans 
Total articles: 214 
 
Search strategy for SCOPUS 
( ( TITLE-ABS-KEY ( Nepal  OR  Kathmandu ) )  AND  ( TITLE-ABS-
KEY ( pain  OR  "Chronic Pain"  OR  "Musculoskeletal 
Pain"  OR  headache  OR  osteoarthritis  OR  "Low Back Pain"  OR  "Cancer 
pain"  OR  "Neck Pain"  OR  "Shoulder Pain"  OR  "neuropathic 
pain"  OR  radiculopathy  OR  sciatica ) ) )  AND NOT  ( TITLE-ABS-
KEY ( animal  OR  dog  OR  swine  OR  pig  OR  rat  OR  mice  OR  mouse  OR
  rabbit  OR  dengue  OR  tuberculosis  OR  typhoid  OR  hepatitis  OR  encaph
alitis  OR  typhus  OR  giardia  OR  diarrhoea  OR  cholera  OR  hernia  OR  "h
elicobacter 
pylori"  OR  leishmaniasis  OR  appendicitis  OR  cholelithiasis ) )  AND  ( LIM
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IT-TO ( EXACTKEYWORD ,  "Human" )  OR  LIMIT-
TO ( EXACTKEYWORD ,  "Article" ) )  
 
Total articles: 431 
 
Search strategy for Embase 
1 pain assessment/ or pain/ or chronic pain/ or musculoskeletal pain/ or 
myofascial pain/ 426926   
2 low back pain/ 53522   
3 neck pain/ 20913   
4 shoulder pain/ 14677   
5 osteoarthritis/ 84835   
6 neuropathic pain/ 28725   
7 cancer pain/ 19036   
8 headache/ 204368   
9 nepal.mp. or Nepal/ 11748   
10 (Nepal or kathmandu).ab,ti. 10048   
11 9 or 10 11919   
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 762807   
13 11 and 12 299   
14 limit 13 to human 286  
Total articles: 286 
 
Search strategy for Cochrane 
 




MeSH: musculoskeletal pain, osteoarthritis, shoulder pain, neck pain, back 
pain, cancer pain, neuralgia.  
 
Total articles: 2 articles.  
 
Search strategy for Google Scholar 
 




Total: 208 articles (date 2018/12/04) 
 
Search strategy for NepJOL 
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237 
Title: (Pain OR analgesia OR nociception OR osteoarthritis OR headache OR 
radiculopathy OR sciatica OR neuralgia OR "musculoskeletal disorder*") 
NOT India 
 
Total article: 94 
 
Abstract: (Pain OR analgesi* OR nociception OR osteoarthritis OR headache 
OR radiculopathy OR sciatica OR neuralgia OR "musculoskeletal disorder*) 
NOT India 
https://www.nepjol.info/index.php/index/search/search   
Total articles: 665 (revised on 2018.12.04) 
 
 
Total number of articles screened: 1388. 
 





Appendix 2. Results of scoping review  
Appendix 2.1. Evidence on medical management  
Author 
Year  
Journal Primary aim of 
the study  
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60 Adults Group 1: 42 
(7) years;  













VAS  Gabapentin increased 
duration of analgesia, 
and pain intensity was 
significantly less in the 


















100 Adult  45 (9) years 100% Randomise
d clinical 
trial 













Not specified  Mean duration for 
request of first analgesia 
post-operatively was 
significantly less in 
intervention group (362 
minutes) than control 
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Pain after lower 
limb surgeries  
60 Adult  Group 1:  43 
(12) years;  
Group 2:  46 
(11) years 
Group 1:  
60%;  








Group 1:  
Bupivacaine  + 
Butorphanol 2 
mg;  
Group 2:  
Bupivacaine  + 
Tramadol 100 
mg 
VAS  The onset of analgesia 
was faster with 
butorphanol but the 
duration of analgesia 
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50 mg IA tramadol 
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300 Adults Group 1:  25 
(2) years;  












VAS Postoperative analgesia 
was significantly greater 

































Group 1: Ibuprofen 600 
mg; Group 2: 
Acetazolamide 85 mg, or 
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block (FICB) and 
femoral nerve 
block (FNB) in 
reducing pain 
associated 








30 Adults  Group 1: 54 
(8); 





Group 1: Fascia 
iliaca block 







block with 15 




VAS Fascia iliaca 
compartment block 
provides better 
analgesia than femoral 





















40 Adults Group 1: 44 
(16) years;  










al plane (TAP) 
block with 20 
ml of 0.5% 
bupivacaine; 
Group 2: TAP 
block with 20 
ml of 0.9% 
isotonic saline 
VAS Pain intensity at 0, 30 
min and 24 hours were 
similar between the two 
groups. Group A had 
significantly less pain at 
































(0=no pain and 
10 = worst pain 
that can be 
imagined) 
There was rapid and 
marked decrease of VAS 
score or pain in 
tramadol group as 
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years;  













Group 1: 400 mg 
of ibuprofen 
(IBU);  




10-cm VAS. No differences in mean 
VAS scores between the 
two groups were noted 

















 Acute anterior 
shoulder 
dislocation. 









VAS (0-10) Manual reduction of 
anterior shoulder 
dislocation is a safe and 
effective but also 
reduces hospital stay 














caudal route  








VAS for pain 
intensity,  
slrt  
Most patients had pain 
relief after 12 weeks 
with no severe 
complication. VAS 
scores changed 
significantly on 35th day 
(17.89 + 25.23) than on 
the day of presentation 






ists of Nepal 
Report a case of 
an acute discitis 










Diagnosis of Acute 
Infective Discitis made 
on Day 2 after MRI 
when pain did not 
resolve with tramadol, 
tizanidine and 
alprazolam. Antibiotics 
started on Day 3 and 
patient discharged 
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Duration of complete 
analgesia and the time 
to request for additional 
analgesics was longer in 
test group than in 






















29 Adults 55 (9) years 
 
 








2ml of methyl 
prednisolone,  
repeated at 2 
to 3 weekly 
intervals (a 
max of 3 
injections) 
until pain was 
2 or less on the 
VAS.   
VAS and CMS Sub-acromial 
methylprednisolone 
injections followed by 
physiotherapy exercises 
can provide statistically 
and clinically 
satisfactory pain relief 
and improvement of 
shoulder function at one 





































Meniscal pathology was 
found in 154 patients, 
synovial pathology in 14 
patients, ACL and PCL 
insufficiency in 18 
patients, chondral 
lesions in 25 patients, 
tight lateral structures in 
6 patients and loose 
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40 Adults 36 years 77% Randomise
d controlled 
trial 





and 20 ml of 
same 
concentration 
in 4 ports, 5 ml 
each at the 
end of 
surgery;  
Group 2: no 
treatment 
Vas  When VAS score was 
analysed in the two 
groups, the study group 
had less scores 
compared to control 
group though it was 
statistically not 
significant (p>0.05). The 
rescue analgesic 
requirement was 
significantly less in 





















60 Adults  Group 1: 40 
(13) years;  
Group 2:  








l instillation of 
0.25% 
bupivacaine 








30 ml of 0.25% 
bupivacaine  




Mean pain score was 
significantly less in 
magnesium sulphate 
group compared to sole 
bupivacaine group. The 
average time interval of 
first analgesia demand 
was also longer in 
magnesium sulphate 
plus bupivacaine  group 
compared to sole 
bupivacaine group 
(5.53±4.33) hours 
compared to 3.16±1.59 
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Pain Scale (VAS) 
87% patients in ESWT 
group improved at 6 
weeks while 53% 
improved in steroid 
injection group. At the 
end of 6 months, 5 
patients in DPM Group 
still had significant pain  
compared to 2 patients 









effectiveness of  
steroid injection 






100 Adults Group 1: 56 
(10) years; 





Group 1: 2 ml 
(80 mg) of 
methylprednis
olone and 3 ml 
of 1% 
Lignocaine; 
Group 2:  2 ml 
(80 mg) of 
methylprednis
olone and 3 ml 
of Distilled 








Even though steroid and 
physical exercises play 
important role in 
managing frozen 
shoulder, addition of 
lignocaine to 
steroid injection seems 
to be helpful. It relieves 





outcomes. Evaluation of 
long term benefits of 
lignocaine injection 
















80 Adults  Group 1:  41 
(12) years; 












VAS  1200 mg gabapentin 
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Women % Study 
design 
Intervention Measures used  Key findings related to 
study question(s) 
hours prior to 
surgery 
consumption with 



















57 Adults  Range 17 to 
91 years 















Epidural mixture of 
Bupivacaine-morphine 
in lower dose and 
concentration given as 
an intermittent 
bolus dosing via lumber 
epidural catheter is safe 
and very effective in 
relieving postoperative 
pain after major 
orthopaedic surgeries 









efficacy and to 
monitor side-
effects of low 
doses (0.5 mg 













117 Adults Group 1: 28 
(5) years;  
Group 2: 26 
(4) years;  



















and quality of 
analgesia, VAS 
Addition of a lower dose 
of epidural butorphanol 
with bupivacaine 
produces a significantly 
earlier onset, longer 
duration and better 
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and  pain  relief 
postoperatively  
with  ilioinguinal  
and  
iliohypogastric 
nerve  block  in  
patients  
undergoing  







60 Adults Group 1: 25 
(4) years;  
Group 2: 26 
(4) years 
100% Comparativ
e  study 
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The total postoperative 
tramadol consumption 
in the first 24hr post-
operatively was 
significantly less in the 
intervention group (125 
± 34.11mg) than 











causes of low 
back pain in the 
patients 
attending a pain 
management 
clinic 
Low back pain 97 Unclear Not available Not 
available 
Case series Epidural steroid 
injection 
VAS  Among the patients who 
received epidural 
 steroid, 50 (51%) had 
significant relief of the 
symptoms and signs, 
whereas 18 (19%) 
patients had moderate 
relief, 8 (8%) patients 
had no relief and follow 
















Labour pain 240 Adults Group 1: 24 
(4)  years;  












VAS The low back pain 
scores were significantly 
lower among the 
intervention group 
compared to the control 
group at 10, 45, 90 





Journal Primary aim of 
the study  








Women % Study 
design 



























45 Adults Group 1 42 
(11) years; 
Group 2: 38 
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block with 20 
ml of 0.25% 
bupivacaine;  
Group 2: Local 
infiltration of 
20 ml of 0.25% 
bupivacaine;  
Group 3: No 
bupivacaine.  
VAS Bilateral Transversus 
abdominis plane  
block was effective in 
reducing postoperative 
pain scores for 8 to 12 
hours postoperatively. 
This block was also 






Society of  
Anesthesiolog
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effect of adding 






dose of rescue 
analgesics used 
Post-operative 
pain in lower 
abdominal 
surgery 
90 Adults Group 1: 39 
(11) years; 
Group 2: 37 






Group 1: 9ml of 
0.5% 
bupivacaine 
plain with 1 










VAS  Addition of 
dexamethasone to 
bupivacaine  
for single shot epidural 
block almost doubled 
the duration of 
analgesia. Single shot 




provides effective post 
operative analgesia and 
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60 Paediatrics Group 1: 45 
(20) 
months; 




















FLACC scale Tramadol 1mg/kg as an 
adjuvant to 
 bupivacaine 0.25% for 
caudal analgesia in 
children is effective in 
increasing the duration 
of analgesia without an 











injection on low 
back pain 
Low back pain 
and sciatica 
52 Adults 37.9 yrs 
(range, 20 - 
65 yrs). 
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75 Adults 50 (39) years 36% Prospective 
study 
Group 1: 50 mg 
epidural 
pethidine (3 
ml) with 13 ml 
of 0.5% 
bupivacaine;  
Group 2: 5 mg (3 
ml) epidural 
morphine 
with 13 ml of 
 
The use of epidural 
Morphine and  
Midazolam in 
combination with 
Bupivacaine is the 
satisfactory method of 
post operative analgesia. 
When Midazolam is 
added, duration of 
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increased with decrease 
in incidence of nausea, 





















50 Paediatrics 7 years 0% Prospective 
controlled 
study 
Group 1: General 
anaesthesia 



















CHEOPS Combined penile nerve 
block in 
 combination with 
intravenous ketamine 
plus midazolam is the 
satisfactory method of 
post-operative pain 







Journal Primary aim of 
the study  








Women % Study 
design 
























100 Adults Group 1: 39 
(11) years;  




Group 1: 100 mg 
hydrocortison
e plus 100 mg 
bupivacaine in 
200 ml normal 
saline;  
Group 2: 100 mg 
bupivacaine in 
200 ml normal 
saline into the 
peritoneum 
VAS  Combination of 
hydrocortisone plus 
bupivacaine can relieve 
pain after laparoscopic 
cholecystectomy better 
compared to 










using a drug 
combination for 






































Significant pain relief 
was seen with the added 
intrathecal morphine 
but it also caused 
increased incidence of 
vomiting. Other serious 
effects were not seen. 
Morphine is effective in 
reducing post-operative 
pain but an effective 





















120 Adults  Group 1: 42 
(12) years; 

















VAS  Use of Dexamethasone 
and Pheniramine 
hydrogen maleate prior 
to surgical skin incision 
helps to reduce both 







Journal Primary aim of 
the study  








Women % Study 
design 










efficacy of bolus 











Group 1: bolus 
of magnesium 






boluses of 10 







three periods.  
VAS Patients in the 
magnesium groups 
received bolus epidural 
analgesia with Fentanyl 
8mcg, Bupivacaine 0.1%, 
and 
Magnesium 8mg in a 
volume of 8 ml after 
operation, when patient 
complained of pain and 
VAS score was more 
than 4. Patients in the 
control group received 
epidural analgesia with 
Fentanyl 8 mcg and 
Bupivacaine 0.1% in a 










tramadol and  
bupivacaine 







Group 1: 10 ml 
of 0.25% 
Bupivacaine;   






VAS, other vital 
parameters 
(Blood Pressure, 




with bupivacaine and 
tramadol provided 
better pain relief and 
reduced the total dose of 
bupivacaine in majority 
of the patients with no 
adverse effects on 
mother and foetus. As 






























dose of 0.3 
mg/kg if VAS 
was more than 
VAS at 0, 15, 30 





 The VAS decreased 
more than 20 mm at 15 
minutes in 27 (80%) 
patients.  
The relief was not 
dependent on age, 
gender, type of injury, 






Journal Primary aim of 
the study  








Women % Study 
design 
Intervention Measures used  Key findings related to 
study question(s) 




















90 Adults Group 1: 5 
(2) years; 
Group 2: 5 
(1) years; 







Group 1: 0.75 
ml/kg of 0.2% 
Ropivacaine in 
normal saline;  
Group 2: 0.75 





Group 3: 0.75 




FLACC scale Mean duration of 
analgesia was 
significantly longer in 
Group 2 (621.00 ± 142.73 
min) than in Group 3 
(507.74 ± 122.12 min) 
and Group 1 (380.07 ± 


















75 Adults Group 1: 32 
(10) years; 
Group 2: 34 
(11) years; 


























VAS (10 cm) Intrathecal morphine 
provides prolonged and 
better analgesic effect 
after abdominal and 
vaginal hysterectomy 
than butorphanol. 
However, side effects 
like nausea, vomiting, 
itching and urinary 






Journal Primary aim of 
the study  








Women % Study 
design 





















tizanidine to be 
















Wonca charts;  
visual body 
chart, and a 
pictorial scale 
(1= no pain and 
5= severe pain) 
Amitriptyline provided 
more effective in ETTH 
management than 
tizanidine. Social 
involvement and body 
pain also showed 
similar improvement 























84 Adults Group 1:  35 
(12) years;  



















gall bladder;  
Group 2: patient 
received 


















Journal Primary aim of 
the study  








Women % Study 
design 
























 Patients with 
low Vitamin-
D were given 
oral Vitamin-
D 60,000 IU 
for 6 months.  
VAS;  
Vitamin-D 
levels in blood 
Hypovitaminosis-D was 
seen in 1388 (82∙6%), of 
which 27∙5% had severe 
deficiency with Vitamin 
D levels <10ng/ml. 
Fibromyalgia overlap 
present in 25∙7%. After 6 
months of treatment, no 
improvement was seen 
in 196 patients (11∙6%) 
and all non-responders 
had fibromyalgia 
overlap. Vitamin-D level 
was checked again in 
non-responders and 
repeat vitamin-D levels 











































VAS Both the techniques are 





technique rendered the 
patients completely pain 
free at all times during 
first 24 hours 
Abbreviations. ACL, Anterior Cruciate Ligament; CHEOPS, Children’s Hospital Eastern Ontario Pain Scale; CMS, Constant Murley Score; FLACC, Face Legs Activity Cry Consolability; NRS, Numerical Rating 




Appendix 2.2. Evidence on surgical management. 
Author 
Year  
Journal Primary aim of 
the study  




Population Age Mean 
(SD) unless 
specified 


































, color doppler 
Cause of pain was not 
known for 47% of the 
cases. Other common 
cases were  
Epididymo-orchitis was 
found in 19.27% 
patients, and torsion of 













the treatment of 
lumbar disc 
prolapse 
Low back pain 
with disc 
prolapse 
120 Adults Median age 
37.14 (range: 
16-70 years) 







There were three 
instances of inadvertent 
dural tear without 
fascicle injury, and one 
instance of residual disc 
requiring reoperation. 
At 6 months, 97% had 
good to excellent (grade 
4, or 5) results reaching 
the premorbid states in 






























Group 2: nerve 
preservation  
NRS, PDI Excision of the 
iilioinguinal nerve does 
not reduce the incidence 

















40 Adults 65 years  58% Trial  Group 1: 
Hemiarthroplas
ty using Austin 
Moore’s;  
Group 2: Bipolar 
hemiarthroplast
y 







regarding pain and hip 







Journal Primary aim of 
the study  




Population Age Mean 
(SD) unless 
specified 
















Report a rare 




Sciatica as a 
result of 
Schwannoma  
1 Adult 69 years 100% A single 
case study 





MRI scan, and 
histopathological 
examination.  
MRI indicated presence 
of tumour alongside 







Study effects of 
drain on post-













 Group 1: Drain 
placed in sub-
hepatic space;  
Group 2: No 
drain. 
0-10 NRS* Postoperative mean pain 
score was similar at 6 
hours after surgery in 
both groups. 
Postoperative pain was 
higher in the drain 
group by more than two 
points on the average in 
VAS at 24 hours and 48 
hours. Length of 
hospital stay was more 
in the drainage group 
compared to non-





























and MVD of 
trigeminal 




All patients were 
advocated for 
cranial MRI 
before surgery.  
MVD for trigeminal 
nerve in younger 
patients 
who are refractory to 
medical treatment is one 
of the best treatment 
options which is safe 
and long term pain relief 
is achieved in majority 
of cases.  One patient 
came after 3 years of 
MVD with 







Journal Primary aim of 
the study  




Population Age Mean 
(SD) unless 
specified 
























63 Adults 42 (9) years 32% Retrospect
ive study 







health personal  
Being men, non-
alcoholic, having low 
level of education and  
numbness as a 
predominant symptom, 
disc herniation at L4-L5 
were significantly 
associated with better 
ODI at final follow-up. 
For ODI score 
interpretation, gender, 
smoking habit, presence 




whereas smoking and 
drinking habit, level of 
education, occupation, 
back pain and numbness 
as predominant pre-
operative symptom, 
types of disc in MRI 
were significantly 













(ENT head and 
neck surgery) 
61 Adults  Group 1: 30 
(13) years; 













VAS The early post-operative 
pain is less in ENT-Head 
and Neck surgery 
patients with skin 
incision by diathermy as 
compared to the patients 
with skin incision by 
scalpel. 
Abbreviations: NRS, Numerical Rating Scale; PDI, Patient Disability Index; ODI, Oswestry Disability Index; VAS, Visual Analogue Scale.  





Appendix 2. 3. Rehabilitation.  
Author 
Year  
Journal Primary aim of 
the study  




Population Age Mean 
(SD) unless 
specified 
Women % Study 
design 























200 Adults  Not available 30% Randomise
d clinical 
trial 
Group 1: Early 
ambulation;  
Group 2: Post-op 
bed rest for 24 
hours without 
pillows. 
Onset of spinal 
headache 
No significant different 
in onset of headache in 
the two groups (17 in 
experimental group and 
20 in control group). Bed 
rest may not be required 










posture in the 








112 Adults 40 (17) years 40% Prospective 
randomised 
study 
Group 1: No 
restriction to 
position after 
surgery; and  
Group 2: 24 
hours bed rest 
after spinal 
anaesthesia.  
0 -10 NRS Non-significant 
difference in the 
incidence of spinal 
headache between the 
two groups (22% in 
group A and 24% in 
group B).  
Sharma 
2018d [7] 
BMJ Open Determine 
feasibility to  

































Abbreviations: CDRISC, Connor-Davidson Resilience Scale; FABQ, Fear Avoidance Beliefs Questionnaire; GRoC = Global Rating of Change; LBP, Low Back Pain; NRS, Numerical Pain Scale; ODI = Oswestry 





Appendix 2.4. Prevalence and incidence of pain conditions. 
Author 
Year  
Journal Primary aim of the 
study  




Population Age Mean 
(SD) unless 
specified 

















dentist in Nepal 
Musculoskeleta
l pain  
103 Adults 30 (6) years 55% Cross-
sectional 
study 
Not specified. Prevalence of MSD during the past 12 
months were reported at the neck and 
lower back (52.4% each),  
shoulder (49.5%), upper back (41.7%), 






















The prevalence of TMD was 47.4% 





Prevalence of spinal 
and extremity pain.  
Musculoskeleta
l pain 





- 18% community adults had back or 







diagnoses and clinical 
features and 
demographic profile of 
chronic headache  
Chronic 
Headache ( > 
3months) 
168 Adult 29 (10) years 79% Cross-
Sectional 
NRS  Chronic headache accounted for 1% of 
total general outpatient visits. Patients 
did not fit into any diagnostic criteria 
in 51% cases. The headache was 
classified as chronic migraine in 20%, 
chronic tension type headache in 17% 
and chronic daily persistent headache 
in 12%. The mean score for pain 







prevalence of chronic 
pain in economically 
active population and 
its associated economic 
loss 
Chronic pain 1730 Adolescent 
and Adults 
15 - 64 years 52% Cross-
sectional 
study 
- Out of 1730 individuals interviewed, 
882 (50%) had pain of which 94% had 
chronic pain (826 of 1730, which is 
48% of total sample). 44% were 
musculoskeletal pain with Backache 
(26%), headache (20%) and abdominal 
pain due to acid peptic disease (12%). 






Journal Primary aim of the 
study  




Population Age Mean 
(SD) unless 
specified 














Estimate prevalence of 
occupational overuse 
syndromes and 





270 Adults  20 - 30 years:  
60.7%;  











Headache (63%; 12% severe), back 
pain (63%; 9% severe) and neck pain 
(57%; 4% severe), Finger pain (40%; 
1% severe), Shoulder pain (38%), 






Study the frequency 
and pattern of co-
morbid psychiatric 
illnesses amongst 














Comorbid psychiatric illness was 
present in 31 (65%) cases among 
which anxiety was the most common 
diagnosis (35%) followed by 








Identify work related 
physical ailments and 
discomforts dominate 








1 year to 17 
years 









73% of children experienced 
musculoskeletal pain in Bhaktapur 
district, and 56% in Sarlahi district. 
Working children were 8 times more 
likely to experience musculoskeletal 
pain compared to non-working 






Identify the frequency 
of the diagnosis of 
primary headache and 
its association with 
anxiety and depression 
Primary 
headache 
150 Adults  20-39 years 79% Cross- 
sectional 
study 
- 69% had migraine headache and 29% 
had tension-type headache and 2% 
had cluster headache. Comorbid 
psychiatric illness was present in 80 
(53%) cases among which Anxiety 
disorder was the most common (31%) 







Explore the an 
association between 
migraine and chronic 













Age- and gender standardized 
migraine prevalence increased from 
27.9% to 45.5% with altitude between 
0 and 2499 m and thereafter decreased 
to 37.9% at ≥2500 m. The likelihood of 
having migraine was greater (odds 
ratio, 1.5–2.2; P ≤ 0.007) at all higher 





Journal Primary aim of the 
study  




Population Age Mean 
(SD) unless 
specified 









The Journal of 
Headache and 
Pain  
Estimate burden of 
headache disorders in 
Nepal from a 
population-based 
survey 












assessed using 3 
point verbal 
scale - "not bad", 
"quite bad" and 
"very bad".  
85% of total participants reported 
headache in the last year. Mean 
headache frequency was 4 (SD 6) days 
per month. Those with headache had 
significantly poor quality life 
compared to those without headache. 
Total lost productive time due to 








treatments offered to 
people attending three 
rural health camps in 
Nepal 
All cases 





















Not specified. For adults, the most frequent 
complaints were stomach pain 20%, 









prevalence of backache 
among groups with 
long and normal 
working day 





Not specified. 62% of the participants had back pain.  
76% of individuals in long working 
day category, and 48% in normal 




The Journal of 
Headache and 
Pain 
Assess correlates of 
headache disorders.  
Headache 
disorders 













of the HADS to 
detect anxiety 
and depression. 
HADS-A and neuroticism was 
associated with any headache.  No 
associations were found between 
HADS-D and any headache type, or 
between tension type headache and 







associated with lost 
work days in nurses 
with back pain 





NPRS (0 -10) 65% nurses reported LBP. The average 
number of LWDs was 6.98 (SD = 5.33), 
and ranged from 0 to 14. Pain intensity 





Journal Primary aim of the 
study  




Population Age Mean 
(SD) unless 
specified 












prevalence of back 
pain and to identify 
predictors of back pain 
in the community.  





- The overall annual prevalence of LBP 
was 71%. The annual prevalence of 
back pain among males was 67.9% and 
females was 74.3%. The highest 
prevalence of back pain was found in 
the age group of 31-40 years.  
Older Age, marriage and occupation 
were related significantly to the 
occurrence of back pain. Farmers and 
housewives had greater prevalence of 
low back pain. The number of 
workdays lost was upto 5 days in 81% 
























a pilot study  
The lifetime prevalence of 
dysmenorrhea was 86.4%, while point 
prevalence was 75.6%. Among 
dysmenorrhoeic individuals; 36.9%, 
26.8% and 36.3% had mild, moderate, 
and severe pain respectively.  
Study showed no significant 
correlation of dysmenorrhea and its 
severity with family history, smoking 







Describe causes of 
neuropathic pain and 
commonly prescribed 
drugs in neuropathic 
pain management and 
the medication 
adherence pattern 









Not specified. 54% of patient had low back pain as 
cause of neuropathic pain, followed by 
peripheral neuropathy (14%), cervical 
radiculopathy (11%), and unknown 
causes (7%). Anticonvulsants were 
mostly prescribed (75%) followed by 
non-steroidal anti-inflammatory drugs 
(52%) and Methyl-cobalamin (48%). 
58% (n=49) patients were not adherent 









prevalence of low back 
pain among practicing 
dentists of Eastern 
Nepal 





ODI Prevalence of LBP in practicing dentist 
was 91% with 50% minimal pain, 37% 





Journal Primary aim of the 
study  




Population Age Mean 
(SD) unless 
specified 









Neurology Estimate prospectively 
the incidence of high-
altitude headache 
(HAH) and to 















IHS and AMS 
criteria. 
83% reported at least 1 HAH (median 
2, range 0 to 10). Those who 
developed HAH were younger, were 
women. Persons with headaches in 








incidence and risk of 
post dural puncture 











Not specified. The incidence of post-dural puncture 


















BPI, SALSA, and 
GHQ-12 
52% complained of pain, 35.3% had  
NP. Patients with NP suffered 
significantly higher intensity pain (p = 
0.023) and daily life interference (p = 
0.003) and were more likely to have 
moderate to extreme daily activity 
limitations (p = 0.005). 43% exhibited 
psychological distress, and 
medications only reduced moderate 








 Determine both 
prevalence of work 
related 
musculoskeletal 





50 Adults Mean 38.9 
years;  
















Thirty-five respondents (70%) 
reported having at least one 
musculoskeletal disorder. Twenty-
three (65.7%) surgeons had to miss 
their job at least once during last 12 
month of which nineteen (54.3%) 
missed them in last 7 days. Thirty-five 
(70%) surgeons had at least one MSD. 
Twenty-one (60%) of them complained 
of pain in lower back, 45% neck pain, 





Estimate prevalence of 
chronic pain 




WHO DAS, PCS, 
FSQ 
Nepalese showed a pain point 





Journal Primary aim of the 
study  




Population Age Mean 
(SD) unless 
specified 





Key findings related to study 
question(s) 
Abbreviations: AMS, Acute Mountain Sickness; FSQ, the Fibromyalgia Survey Questionnaire; GHQ-12, General Health Questionnaire-12; Hospital Anxiety and Depression Scale (HADS); HADS-A, HADS for 
Anxiety; HADS-D, HADS for Depression; HAH, High-Altitude Headache; ODI, HAM-A, Hamilton Rating Scales for Anxiety; HAM-D, Hamilton Rating Scales for Depression; HIS, International Headache 
Society; LBP, Low Back Pain; MSD, Musculoskeletal Disorders; NRS, Numerical Rating Scale; Oswestry Disability Index; PCS, Pain Catastrophizing Scale; SALSA, Screening of Activity Limitation and Safety 







Appendix 2.5. Studies on outcome measurement.  
Author 
Year  




Population Age Mean 
(SD) unless 
specified 
Women % Study 
design 










Translation of the ODI 
into Nepali, and assess its 
measurement properties. 
Low back pain 101 Adult 36. 6 (12.6) 
years 
45% Longitudi
nal study  
ODI ODI is reliable: Cronbach's alpha = 
0.72; test-retest reliability = 0.87 
Pathak 2018 
[133] 
Pain Reports (1) Identify which of 4 
commonly used pain 
scales is most preferred 
by Nepalese, (2) compare 
error rates, (3) determine 
whether preference and 
error rates are influenced 
by age or education level 
Musculoskeleta
l pain  




VAS, VRS  
FPS-R is the most preferred scale, 
followed by a VRS. The NRS and 
VAS were both least preferred and 
had higher rates of incorrect 






To evaluate the content 
validity of questionnaires 
used to assess pain 
quality in Nepalese with 








N/A Only the original McGill Pain 
Questionnaire was 
found to have content validity for 
assessing pain quality in patients 
from Nepal, although other 
existing pain quality measures 
could be adapted to be content 
valid by adding one or two 
additional 
descriptors, depending on the 




Quality of Life 
Outcomes 
To evaluate the 
measurement properties 
of a measurement scale 
(NRS and GRoC) 
Musculoskeleta
l pain 
104 Adults 41.2 (13.5) 69% Cross-
sectional 
study 
NRS, GRoC Significant cultural adaptations 
were required to obtain relevant 
Nepali versions of both the NRS 
and GRoC. The NRS-NP showed 
excellent test-retest reliability and a 
MDC of 1.13 points. NRS-NP 
demonstrated good construct 









Population Age Mean 
(SD) unless 
specified 
Women % Study 
design 





Quality of Life 
Outcomes 
To translate and 
culturally adapt 10- and 
2-item versions of the 
Connor Davidson 
Resilience Scale into 
Nepali and evaluate their 
measurement properties 
Chronic pain 405 Adults  46.7 (15.18) 
years 
70.33 Longitudi
nal study  
PCS; CDRISC The findings support the reliability 
and validity of the 10-item Nepali 
version of the CD-RISC, and use of 
the 2-item version in survey studies 





To translate and 
culturally adapt the Pain 
Catastrophizing Scale 
into Nepali 




PCS, BDI, BAI, 
NRS.  
PCS-NP was comprehensible and  
culturally acceptable. The PCS-NP 
scores evidenced excellent 
reliability and temporal stability, 
and demonstrated validity via 
moderate-to-strong associations 
with measures of depression, 








To translate and cross-
culturally validate the 
PSFS to Nepali 
Musculoskeleta
l pain 






The Nepali version of the PSFS 
showed good reliability. It 
demonstrated significant 
correlations with the Nepali 
versions of the ODI (r = –0.47, P = 







To assess measurement 
properties of 5 PROMIS 
measures to assess  
Chronic pain 275 Adults 46 (16) years 73 Longitudi
nal study 
N/A All measures were reliable (ICC of 
0.71 to 0.81). Correlations between 









estimate MIC of the 
validated Nepali versions 
of the PCS and the 10-
item and 2-item CDRISC 
Chronic pain  275 Adults  46 (16) years 73 Longitudi
nal study 
N/A The findings support the PCS and 
CDRISC as being associated but 
distinct. However, the low AUCs 
indicate that the Nepali versions of 
the PCS nor CDRISC are unable to 
discriminate between the improved 
and unimproved groups when 









Population Age Mean 
(SD) unless 
specified 
Women % Study 
design 
Measures used  Key findings related to study 
question(s) 
Abbreviations: APS, American Pain Society; AUC, Area Under the Curve; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CDRISC, Connor-Davidson Resilience Scale; FPS-R, Faces Pain Scale – 
Revised; GRoC, Global Rating of Change; ODI, Oswestry Disability Index; MIC, Minimal Important Change; NRS, Numerical Rating Scale; NRS-NP, Nepali version of NRS; PSFS, Patient-Specific Functional 
Scale; PCS, Pain Catastrophizing Scale; PROMIS, Patient-Reported Outcome Measurement Information System; VAS, Visual Analogue Scale; VRS, Verbal Rating Scale. 
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Appendix 2.6. Studies on diagnosis and imaging. 
Author 
Year  
Journal Primary aim of the 
study  






















Describe etiology of 
chronic pelvic pain in 
consecutive sample.  
Chronic pelvic 
pain 




Diagnostic findings were negative in 
29% of cases. Simple endometriosis was 
present in 56% cases, adhesion in 20%, 
pelvic congestion in 15%, pelvic 
inflammatory disease in 6%, chronic 








patterns in patients 













, color doppler 
Cause of pain was not known for 47% 
of the cases. Other common cases were 
Epididymo-orchitis was found in 19% 







Identify causes of 
chronic pelvic pain 
Chronic pelvic 
pain of at least 
6 months of 
duration 








62% had normal ultrasonography 
findings. 13% of patients had cystic 
ovaries and 11% had PID. Diagnostic 
laparoscopy detected abnormalities in 
45 (82%) of the patients with chronic 
pelvic pain. Pelvic adhesion was the 
most common etiology n=16 (29%), 
followed by PID (13%), 7% each of 









Evaluate the role of 
ultrasonography in 
patients presenting with 
scrotal pain. 
Scrotal pain 50 Adult  21-30 years:  
50%;  







Epididymitis with or without orchitis 
were seen in 40% patients, followed by 
cystic lesions of the epididymis (18%). 
Normal scan was seen in 14%. 
Malignancy as a cause of scrotal pain 







To classify important 
types of rheumatological 
disorders in patients 























Soft tissue rheumatism (40%), 
inflammatory arthritis (21%) and bone 
and cartilage diseases (21%), 
Connective tissue disorders were only 
5%, seronegative spondyloarthritis 3%, 
gout 4%, Rheumatoid arthritis 20%, 





Journal Primary aim of the 
study  














Key findings related to study 
question(s) 




knee, hand and hip were 10%. 
Lumbago, lumbar spondylolisthesis 
and spinal canal stenosis together 
comprised 14% of patients with low 
back pain. Cervical spondylosis and all 
types of shoulder joint pain syndromes 








implication of a CT scan 
for headache with non-
localizing sign 
Headache 136 Adults  Men: 44 






CT scan Positive scan report with significant 
findings was found only in 4% of cases. 
70% cases had no pathology in CT 
scans, while 29% had positive findings 







Map the etiology of 
recurrent abdominal 

















Organic causes were found in 41 (87%) 
children. Giardiasis was found to be the 
commonest (46%) organic cause, 
followed by idiopathic chronic 
constipation (34%) and urinary tract 








Evaluate the MRI 
findings of degenerative 












MRI Degenerative changes were present in 
94% participants. Disc bulge along with 
disc desiccation was the most common 
degenerative findings noted in 82%. 
Disc herniation was seen in 51%, neural 
foraminal stenosis in 60%, central spinal 
canal in 56% and nerve root 







Evaluate the occurrence 
of cervical degenerative 
disc pathologies in 
symptomatic patient 














MRI Degenerative disc disease in the form of 
disc desiccation, disc bulge, disc 
herniation was the most common 
finding in 76% patients. 14% had 





Journal Primary aim of the 
study  






















Evaluate all the CT scan 
findings in patients 
presenting with 
headache 












CT scan Only 10% showed some form of brain 
parenchymal pathology. Other 
associated findings were sinusitis in 28 
(11%), bone related in 10 (4%), and 





Identify causes of acute 
chest pain.  











The diagnosis of non-ischemic chest 
pain were made in 30 (20%) and Acute 










findings in young and 
elderly patients with 
low back pain and also 
correlate them with the 
clinical symptoms 














MRI One or more disc degeneration changes 
of the following were present in MRI of 
all the individuals. Disc desiccation 
change either focal or at multiple levels 
were more common in elderly (99%) 
than in young adults (90%) (p=0.02). 
Spinal canal stenosis was seen in almost 





To describe the pattern 
of clinical presentations 
















43% had a gastrointestinal cause, 29% 
had genitourinary cause, 10% had 
psychiatric cause. Among 
gastrointestinal cause, IBS was the 
commonest gastrointestinal cause of 








To describe the clinical 
profile  and  functional  
outcome  of  patients  
with  juvenile idiopathic 
arthritis 
Juvenile     
idiopathic     
arthritis   








and HLA B27. 
Polyarticular disease was the most 
common form of JIA, followed by 
oligoarticular, enthesitis-related and   
systemic-onset JIAs. Systemic 
complications were frequent in 
polyarticular JIA with fixed flexion 





Journal Primary aim of the 
study  
























of patients with 
mastalgia with 
treatments provided.  
Mastalgia 
(breast pain) 
221 Adult Not available 100% Cross-
sectional 
study 
Not available Overall 37% presented with cyclical 
mastalgia and 43% with noncyclical 
mastalgia. Non-hormonal therapy like 
reassurance, breast support, reduction 
in dietary fat intake, Vitamin E, Vitamin 







To find out the 
proportion of 
intracranial 
abnormalities in patients 
with chronic headache 
without neurologic 
abnormality with the 
use of CT 
Chronic 









CT Scan Of the 56 patients, 50 had normal CT 
(89%), 4 had minor abnormality (7.14%) 
that did not alter patient management 
and 2 had significant lesions (3.57%). 
This further corroborates the evidence 
that the ability of CT scan in detecting 
significant intracranial pathology is 







To determine the 
patterns of degenerative 
disc disease on MRI in 
patients with low 
backache. 














MRI The most common category was disc 
bulge note in 46.5% of cases. Nerve root 
compression was observed in 56% 
cases. 






Appendix 3. Search strategy used for the systematic review. 













































 Helpless*  











 Hoping  
 Pray* 
















Note: Texts in bold were the additional search terms used when repeating the 
search on November 21, 2019 on Medline.  
Limits: Adults >18 years; Humans 
 



















Appendix 7. Pain education curriculum for Nepalese with non-
specific low back pain. 
Learner or patient characteristics 
Learners are adult patients who present to the Physiotherapy 
Department in Kathmandu, Nepal for the management of their low back pain. 
This education was be delivered to patients with any duration of low back 
pain.  Every participant who understood and spoke Nepali could be the 
learner for the planned curriculum of pain education. These individuals may 
have a very low literacy level. Patients who have diagnosed psychiatric illness 
were excluded from this intervention.  
Deliverer or physiotherapist 
I delivered the pain education to all the participants in the study. The 
competency to deliver the intervention was supported by undertaking two 
“Explain Pain” courses in 2015 and 2017. Prof. G. Lorimer Moseley, one of the 
developers of the concept, supervised me for the delivery.  
Number of learners or patients 
A total of 40 learners participated in the study. All interventions were 
delivered individually to each participant. No other concurrent interventions 
were provided. However, patients were encouraged to perform physical 
activities at home for one week.  
Unique needs of the learners 
 These learners are from Nepal, many of them did not have any formal 
education, and education as the core component of treatment may be new to 
these patients. Thus, this group may be a challenging group to provide 
Explain Pain intervention. Therefore, the contents were simplified and 
adapted to their need to match their level of understanding, and culture.  
 Delivery methods 
The study physiotherapist delivered approximately an hour long 
session of one-on-one Explain Pain to every study participant. Every 
participant were provided with a take away education booklet, which 
included details of target concept, pictures and stories to strengthen their 
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education provided by the physiotherapist.  Participants read the booklet if 
they could read, or the family members read out for them if they cannot read 
themselves. All the participants provided with an additional audio-visual 
information on neurophysiology knowledge of pain, if they could operate 
these at home (or office) to reinforce the learning so that the participants hear 
this every day before the post treatment assessment at 1 week.  
Place 
A private room at a physiotherapy facility (Sahara Care Hospital) in 
Kathmandu, Nepal.   
Patient consideration 
 Physiotherapist extracted learner’s personal goal of treatment.  
Nepalese generally struggle to bring out their own goals in general, 
therefore this was a difficult task.  
 Involvement of family throughout the education session were 
encouraged if they accompanied the patients. Role of family members 
were highlighted in the education programme along with the 
prognosis of the individuals with low back pain.  
 All the participants were reminded to perform their home-based tasks 
(reading, listening/watching audio-visual support, and exercising) by 
a text message every day for five days a week.  
Aims 
The deliverer intended to: 
 Advise patient that educate is an important aspect of treatment of pain. 
 Provide contemporary knowledge about pain biology in relation to low 
back pain in an individual face-to-face teaching and learning 
environment.  
 Provide a comprehensive patient education by providing relevant 
information on graded exposure, pacing, and self-management.  
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 Use pictures, metaphors, and relevant stories related to pain to explain 
details and complexities related to pain.  
 
Objectives 
At the end of the session learner will: 
 Have contemporary knowledge of pain biology that is relevant to 
their low back pain.  
 Understand importance of pain knowledge as a therapy.   
 Use the pain knowledge in changing the danger messages into 
safety signals.  
 Use exercises to pave the track for recovery.  
Explain Pain Curriculum plan 
 
Part 1: Question and answer                [10 – 15 minutes] 
Physiotherapist first asked two questions to the learners.  
Question 1- “Is there anything in particular that you would like to learn about your 
low back pain, or pain in general?” 
 Physiotherapist answered to any questions that arose.  
Question 2- “Do you know what caused your low back pain? Can you please explain 
the cause of your low back pain from what you have understood, or what you have 
been told?” 
Physiotherapist addressed any misconceptions and acknowledged or 
appreciated healthy/sound understanding about their pain. Scan 
findings were discussed where appropriate.  
 
Part 2: Discuss the key concepts of pain biology.                   [40 minutes] 
1. Pain is normal and almost everyone gets it in life.  




3. Learning about pain changes pain; and anything associated with it can 
influence it.  
4. Body learns pain and becomes overprotective over time. 
5. Additional concept: Pain and tissue damage are poorly related. 
 
[see the table below for the details] 
Part 3: Do you want to learn ways to train your system?        [5 – 10 minutes] 
Teach 1 – 2 ways to train the system.  
End: Patients were asked if they had a cell phone. If yes, they were further 
asked if they wanted to receive a daily reminder to perform home-based 
tasks, and learn more about pain.  
 The phone number was recorded and daily information were sent 
when applicable.  
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Other ways of expressing the 
target concept 





Did the patient 
understand? 
Assessment 
1 Pain is normal 
and almost 
everyone gets 






 Everyone has some pain in 
lifetime so you are not 
alone.  
 Pain is normal. 
 Your low back pain is 
unique to you and real, and 
only you can control your 
pain.   
 There is no test for 
pain or love.  
 Emotional and 
physical pain are 
one. 
 Pain is always a 
conscious event. 
 Stories  
 Brief pain 
epidemiology 
 
 Pain should not 
be a reason to 
worry about, and 
stop you from 
enjoying life, and 
fulfilling life 
goals.  
 Ask- so who 
suffers pain or 
how many people 
suffer pain? 
 
Answer may be- 
almost everyone. 









 How danger signal travels 
in the body and how pain is 
perceived.  
 Brain is needed to create/ 
perceive pain.  
 Human body has danger 
sensors not pain sensors.  
 Pain depends on the 




 Pain is created in 
the brain. 
 Ask patient if they 
had pain when 
they did not have 
tissue injury (or 
use aggravating 
factors). 







 Use the 
earthquake 
story. 
 Have you ever 
experienced 
having an injury 
and no pain? 
 Have you ever 
experienced pain 
when there was 
no injury? 
 Use the scale 
protectometer to 
describe. 
 So what creates 
pain, or which part 













 Knowing about pain can 
reduce pain.  
 Education is analgesic.  
 Retraining your system can 
reduce sensitization.  
 
 Understanding 
your pain can  
reduce your pain.  
 Wrong 
understanding can 




 Hear other’s pain 
stories and 
analyse how it 








over time.    
10 
minutes 
 Out of many outputs of the 
brain, pain is only one 
protective output.  
 As pain persists, body 
systems can be over 
protective.  
 Multiple systems protect us 
from threats, and allow us 
to learn and heal.   
 You can train your body 
systems to be less 
protective.   












 Ask the patient 
what are the 
other symptoms 
they get with 
pain?  [Examples 




 Ask, do you 
understand this 
and think if this is 
logical?  
 
 Reinforce this by 
summarizing 









Pain and tissue 
damage are 
poorly related  
5 minutes  Pain is an unreliable 
indicator of tissue damage.  
 Pain and scans do not 
correlate.  
 
 Tissue stop 
hurting a long 
time before they 
heal.  
 Recent evidences 
regarding poor 
correlation 
between pain and 
scan reports.  
Bad scan 
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Pain in the Developing World
Review
State of clinical pain research inNepal: a systematic
scoping review
Saurab Sharmaa,b,*, Mark P. Jensenc, Anupa Pathakb, Sweekriti Sharmad,e, Mukesh Pokharelf, J. Haxby Abbottb
Abstract
Before determining the pain research priorities for a country, a comprehensive literature review of existing research is warranted.We aimed
to (1) identify and describe the extent and nature of pain research performed in Nepal, (2) identify existing knowledge and significant
knowledge gaps, and (3) provide recommendations for future studies. We conducted a systematic scoping review of the literature, in
accordance with recommended guidelines. We searched local and international databases to identify research conducted in Nepal on
individualswith a diagnosis of clinical pain conditions. Apair of independent reviewers screened the studies for inclusion.We identified 1396
records and included 116 studies. Most studies were published in Nepalese journals (75%) and were conducted in clinical settings (73%).
Postsurgical painwas themost commonly studied pain condition (33%), followedbymusculoskeletal pain (16%), headache (14%), and low
back pain (13%). The most common research topics, in order of frequency, were (1) medical management (40%), (2) pain prevalence/
incidence (21%), (3) diagnostic procedures (15%), (4) surgical management (8%), and (5) patient-reported outcome measurement (8%).
Research gaps andpotential areas of researchwastewere identified. Although a large number of research articles about pain inNepal have
been published, the majority of these have focused on the biomedical diagnosis and management of pain. Other topic areas (eg,
psychological and social aspects of pain) are under-represented. The findings may inform future research directions for maximizing the
knowledge that could be gained.
Keywords: Pain, Pain management, Chronic pain, Headache, Back pain, Musculoskeletal pain, Postoperative pain, Developing
countries, Nepal
1. Background
Given its high prevalence, costs, and impact on physical, mental,
and social function, and all aspects of quality of life,48 pain
remains a significant health problem worldwide.12 One-year
prevalence of chronic pain is more in developing countries (41%)
compared with developed countries (37%).47 The economic
burden of chronic pain is extremely high, with annual estimates of
the cost of treatment in the United States to be from US$ 560
billion and US$ 635 billion12 and about £1 billion in the United
Kingdom.47
Knowledge from pain research comes predominantly from
developed countries; pain research in developing coun-
tries—including Nepal—is relatively sparse. Currently, musculo-
skeletal pain conditions are the number one cause of disability in
Nepal with a 32% increase in the last 3 decades.9,11 Despite this,
pain is not currently viewed as a priority research area in Nepal. For
example, the Nepal Health Research Council’s (NHRC) research
priority agenda does not include pain research as one of its
priorities.21 However, recently, there have been promising signs
that research related to pain in Nepal is growing.17,25,30,32,36,38,45
Given the scarce resources for performing research in Nepal
in general, it is important that researchers should (1) avoid
duplicating research efforts and (2) address the research
questions that are most likely to be impactful. Thus, the
purpose of this review is to clarify the current state of pain
research in Nepal, identify the extent and nature of research
published, identify significant knowledge gaps, and provide
recommendations for future studies. To achieve these aims,
here, we included studies irrespective of study design that
focused on a range of topics, including research that evaluated
interventional procedures (eg, medical, surgical, and
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rehabilitation), epidemiological research, and outcome mea-
surement studies, among others. As a part of this review, we
also hoped to estimate the prevalence of pain conditions, to
identify the outcome measures used to assess pain and
related domains, and the treatment approaches used to treat
pain conditions in Nepal.
2. Methods
A scoping review was conducted using recent guidelines.26 The
study aims and methods were defined a priori. An extension of
Preferred Reporting Items for Systematic reviews and Meta-
Analysis (PRISMA) guidelines for scoping reviews was followed
for reporting the review.46
2.1. Study eligibility criteria
We included studies that (1) were conducted in Nepal; (2)
included participants who had a diagnosis of a clinical pain
condition (eg, low back pain, headache, chronic pain, musculo-
skeletal pain, neuropathic pain, postsurgical pain, pediatric pain,
cancer pain, etc) or included pain as the primary outcome (eg,
fracture management); and (3) used either qualitative or
quantitative research designs. We did not exclude studies based
on language of publication, year of publication, study design, or
age of study participants. However, we did exclude studies that
(1) included healthy volunteers and animals instead of human
participants; (2) were editorials or review articles; (3) included
participants who did not have a clear pain condition or diagnosis,
or had pain as only 1 symptom of another primary condition being
studied (eg, infectious diseases such as typhoid); or (4) were
conducted outside of Nepal.
2.2. Search strategy
We searched MEDLINE, Embase, Scopus, Cochrane library,
Google Scholar, and Nepal Journals Online (NepJOL, https://
www.nepjol.info/) from inception to November 2018. We also
searched the reference lists of included studies. We collated
articles in the Endnote software and removed duplicates. The
lead author (S.S.) developed the search strategy and amended it
after receiving feedback from all authors. We used a combination
of terms “pain” or “analgesia” and “Nepal” or their alternative
terms and adapted search strategies for each database. Details
of search terms and strategies used can be found as
supplementary file 1a (available at http://links.lww.com/
PR9/A54).
2.3. Data screening
A pair of authors (S.S. and Sw.S., and A.P. and M.P.)
independently screened the title and abstract of all the articles.
Disagreements about inclusion were resolved through discus-
sions. A third independent reviewer (S.S. or A.P.) who was not
a member of the original pair made a final decision in case
consensuswas not reached.We then performed the screening of
the full-text articles that required further reading. Next, we
performed data charting (see below).
2.4. Data charting process
Data chartingwas performed using an Excel spreadsheet created
by S.S. The form was pretested on 10 studies by first 5 study
authors and finalized. One of 4 authors (A.P., M.P., S.S., and
Sw.S.) then extracted data from the included studies, and
a second author confirmed that the datawere extracted correctly.
If included studies were authored or coauthored by one of the
Figure 1. Flow diagram.
2 S. Sharma et al.·4 (2019) e788 PAIN Reports®
authors of this review, a review author who was not the author of
the study extracted the data. Any discrepancies were discussed
with S.S., and the final decision was made through consensus.
Based on the results from all the studies included, the lead author
(S.S.) classified the studies into key themes to organize the
presentation and discussion.
2.5. Data items
Weextracted data related to (1) the year of publication, (2) place of
data collection/research, (3) source of publication (local or
international journal, PubMed indexed or not indexed journal),
(4) study design (qualitative study, clinical trial, study protocol,
observational design, case series, or case studies), (5) study
setting (clinical, community, or mixed), (6) population studied
(headache pain, musculoskeletal pain, postoperative pain, and
low back pain), (7) participant characteristics (age and sex), (8)
measures used, (9) treatment delivered, and (10) key findings.
2.6. Synthesis of results
We computed the frequency for publication types, setting
(community or hospital), study design, type of pain condition,
age categories, and scope of the study. We then classified the
results based on the broader themes of pain research, for
example, interventional studies (medical or surgical management
and rehabilitation), epidemiological studies, outcome measure-
ment studies, and diagnostic studies.
3. Results
A total of 1414 articles were identified, of which 116 studies were
included in the review (Fig. 1). A complete list of included studies
is presented in the supplementary file 1b (available at http://links.
lww.com/PR9/A54).
3.1. Characteristics of sources of evidence
Eighty-seven studies (75%) were published in Nepalese journals.
Eighty-five studies (73%) were conducted in clinical settings and
8 (7%) in community settings. The most common study design
was cross-sectional design (40%), followed by randomized
controlled trials (35%). The most commonly studied pain
condition was postsurgical pain (33%), followed by musculoskel-
etal pain (16%), headache (14%), and low back pain (13%). The
majority of studies were conducted in adults (76%), followed by
studies that included both adolescents and adults together (9%).
Only 3% of the studies were conducted with children only.
Detailed characteristics of included studies are presented in
Table 1.
3.2. Themes of identified studies
A total of 40% studies focused onmedical management, followed
by studies on prevalence/incidence of pain conditions (21%),
diagnostic studies (15%), and surgical management and out-
come measurement (8% each; see Fig. 2 and the Tables in
supplementary file 2, available at http://links.lww.com/PR9/A54).
3.2.1. Interventional studies
A total 29 of 46 studies (63%) studied postoperative analgesia.
Four studies (9%) tested the effectiveness of steroid injections
and 3 the effectiveness of epidural steroids for back pain. The
most commonly studied postoperative pain management drug
was bupivacaine (n 5 17), followed by morphine (n 5 9) and
tramadol (n5 6). Nine studies (8%) evaluated the role of surgical
procedures in pain. Only 3 studies studied rehabilitation
interventions, 2 of which studied effect of posture on post-
lumbar puncture headache, and 1 was a protocol of a feasibility
trial.14,15,29
3.2.2. Prevalence and incidence of pain conditions
Estimates of prevalence or incidence of musculoskeletal con-
ditions were most commonly studied (n5 9 studies), followed by
headache disorders (n5 8), chronic pain (n5 2), and neuropathic
pain (n 5 2).
Prevalence of any pain condition in a community sample was
50%, 94% of which were chronic pain.3 Prevalence of low back
pain ranged from 52% to 91%, and musculoskeletal pain ranged
from 35% to 70%. In a large population level survey of 2100
individuals, 85% of the participants reported headache in the last
year.20 Details are summarized in Table 2.
Table 1
Characteristics of sources of evidence.
Study characteristic domain Frequency
(n 5 116)
Percentage
Pain types and or sites
Postsurgical pain 38 33
MSK pain (excluding low back pain) 18 16
Headache pain of different origins 16 14
Low back pain 15 13
Chronic pain (general) 6 5
Neuropathic pain 6 5
Pelvic pain 3 3
Labour pain 3 3
Scrotal or penile pain 2 2
Orofacial pain 2 2
Abdominal pain 2 2
Mixed pain (MSK and abdominal pain) 1 1
Pain due to infection 1 1
Widespread pain 1 1
Cancer-related pain 1 1
Chest pain 1 1
Pain after trauma 1 1
Age categories
Adults (18 y and older) 88 76
Adolescent and adults (10 y and older) 11 9
All ages 5 4
Pediatrics 3 3
Pediatrics and adolescent




Cross-sectional study 46 40
Randomized trial 41 35
Case study or case series 14 12
Longitudinal study 12 10
Trial protocol 1 1
Qualitative study 1 1
Nonrandomized comparative study 1 1
Setting
Hospital/clinical setting 85 73
Mixed sample 11 9
Community 8 7
Workplace or university sample 6 5
Base camp (mountains) or trekking route 3 3
Health camps* 2 2
Online survey 1 1
* Health professionals’ visit in rural community for the diagnosis and treatment of health conditions.
MSK, musculoskeletal.
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3.2.3. Outcome measurement studies
Nine studies focused on outcome measurement1,25,31–35,37,39
with 7 examining the psychometric properties of patient-reported
measures in pain population.
3.2.4. Diagnostic imaging and investigation studies
Of 17 diagnostic studies identified, 3 used computed tomography
scan in diagnosis of headache disorders10,22,43 and 3 used
a magnetic resonance imaging for diagnosis of low back
pain.13,24,44
3.2.5. Cost of pain treatment
One community survey on a sample of 882 participants in Eastern
Nepal reported the cost of chronic pain treatment, with the
participants reporting that they spent an average of 8.4% of their
total income for chronic pain treatment.3
4. Discussion
This systematic scoping review of research related to pain in
Nepal identified 116 articles. Most studies evaluated the efficacy
of biomedical interventions or studied pain prevalence. These
findings indicate a predominance of the biomedical model of pain
in Nepal. The review also identified some areas of research
redundancy and critical knowledge gaps, which have both
research and clinical implications for Nepal, and also perhaps
for other similar developing countries.
4.1. Areas of research redundancy
Most published studies asked similar (and sometimes even the
same) research question(s) in identifying optimal medical
management of postoperative pain, effect of posture on spinal
headache, or use of imaging for diagnosis of a nonspecific pain
conditions. This suggests a potential problemof awaste of limited
research resources. Also, the focus on imaging research
represents a potential ethical problem, given that diagnostic
imaging is rarely recommended for chronic pain management.
4.2. Knowledge gaps
The findings highlight several gaps in the topic areas of pain
research in Nepal. First, no studies were identified that sought to
estimate the incidence or prevalence of a number of important
pain conditions, or pain in specific populations, including
pediatric pain, cancer pain, and pain in ageing populations. Also,
the studies that estimated the prevalence of pain conditions were
usually limited to very specific regions of the country and had
small samples. Large population-level studies to estimate
prevalence and incidence of various pain conditions would
provide better estimates of disease burden. Third, research
studies to cross-culturally adapt patient-reported outcome
measures were limited to adult populations and patients with
chronic pain or musculoskeletal pain. Cross-cultural adaptation
of patient-reported outcome measures in other pain populations
is needed to advance research in these areas. Finally, there were
very few studies that focused on biopsychosocial assessment
and pain management.
4.3. Recommendations for research
4.3.1. Limiting redundant research
Several approaches could be adapted to limit redundant research.
First, researchers should perform comprehensive reviews of the
literature before conducting any clinical trial. If meta-analyses of
intervention studies have not been reported in the literature, this
would be a more valuable contribution than a redundant additional
trial. Second, associations and the national research authority
(NHRC, Nepal Medical Council, and Nepalese Association for the
Study of Pain in the context of Nepal) should consider encouraging
researchers to prospectively register clinical trials. Along these
lines, national journals should mandate clinical trial registration
before data collection for an article to beconsidered for publication,
consistent with the recommendations from International Commit-
tee of Medical Journal Editors.5
Figure 2. Study scope or purpose.
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4.3.2. Mobilizing research funding for pain research
Addressing the burgeoning pain problem in Nepal requires more
thoughtful use of limited research funds. Identifying pain as
a research priority is the first step. Funding should be directed
towards (1) developing additional culturally appropriate outcome
measures, (2) implementing clinical practice guidelines,
(3) evaluating the challenges for implementation of guidelines,
and (4) conducting effectiveness trials of population-level
interventions, including the analysis of cost-effectiveness.
4.3.3. Administering scales and outcome measures
Researchers should consider using valid, reliable, and responsive
instruments with reference to core-outcome sets for clinical trials.4,6
When a desirable instrument is unavailable in a local language, a first
step would be to cross-culturally adapt and validate the needed
instrument(s) using recommended guidelines.2,7
4.4. Recommendations for practice
Overall, clinical assessment and treatment of pain should align
more with contemporary clinical practice guidelines. The re-
spective regulatory authorities and pain society should reinforce
the use of treatment guidelines among their members.
4.4.1. Preventing overdiagnosis and overtreatment of pain
conditions
Clinicians should stop routinely using expensive and some-
times invasive diagnostic procedures, including imaging, for
nonspecific pain conditions.8,28,42 These diagnostic procedures
can have significant costs and have limited benefits.40 The
“Choosing Wisely” Campaign (www.choosingwisely.org) could
help clinicians and consumers in appropriate use of diagnostic
tests and interventions in Nepal.
Invasive interventions, including surgeries and injections which
continue to be provided for the management of pain conditions in
Nepal, have significant risks and have been shown to have limited
benefits.16,18,19,23,27,41 Thus, some of these treatments should
be avoided until further better evidence supports their safety and
efficacy.
4.5. Study strengths and limitations
We adapted recommended guidelines for conducting and
reporting a scoping review26,46 and performed comprehensive
literature searches. However, we did not search the grey literature
(other than Google Scholar). A systematic review of the research
literature that included a critical appraisal of methodological
quality of pain research conducted in Nepal would provide an
overview of quality of research conducted in the country.
5. Conclusions
Most articles identified focused on the biomedical diagnosis and
treatment of pain, suggesting a biomedical focus of pain research
and clinical practice in Nepal. Pain diagnosis and management
should be in line with clinical practice guidelines, include more
comprehensive contemporary biopsychosocial approaches, and
a pain research priority agenda should be supported at the
national level.
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Abstract
Objective. To evaluate the extent to which pain-related beliefs, appraisals, coping, and catastrophizing differ between
countries, language groups, and country economy. Design. Systematic review. Methods. Two independent reviewers
searched 15 databases without restriction for date or language of publication. Studies comparing pain beliefs/
appraisals, coping, or catastrophizing across two or more countries or language groups in adults with chronic pain
(pain for longer than three months) were included. Two independent reviewers extracted data and performed the
quality appraisal. Study quality was rated as low, moderate, or high using a 10-item modified STROBE checklist.
Effect sizes were reported as small (0.20–0.49), medium (0.50–0.79), or large (0.80). Results. We retrieved 1,365
articles, read 42 potential full texts, and included 10 (four moderate-quality, six low-quality) studies. A total of 6,797
adults with chronic pain (33% with chronic low back pain) were included from 16 countries. Meta-analysis was not
performed because of heterogeneity in the studies. A total of 103 effect sizes were computed for individual studies,
some of which indicated between-country differences in pain beliefs, coping, and catastrophizing. Of these, the ma-
jority of effect sizes for pain beliefs/appraisal (60%; eight large, eight medium, and eight small), for coping (60%;
seven large, 11 medium, and 16 small), and for catastrophizing (50%; two medium, one small) evidenced statistically
significant between-country differences, although study quality was low to moderate. Conclusions. In 50% or more of
the studies, mean scores in the measures of pain beliefs and appraisals, coping responses, and catastrophizing
were significantly different between people from different countries.
Key Words: Culture; Chronic Pain; Coping; Pain Beliefs; Musculoskeletal Pain; Catastrophizing; Low Back Pain
Introduction
Chronic pain is a significant problem worldwide, influ-
enced by a complex interaction between biological,
psychological, and social factors [1]. The one-year preva-
lence of chronic pain ranges from 37% to 41% in devel-
oped and developing countries [2], with substantial
VC 2020 American Academy of Pain Medicine.
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percentages having constant pain and moderate to severe
pain [3]. Chronic pain imposes an enormous emotional
and financial burden both at individual and societal lev-
els [4], and psychological factors contribute to this.
One such factor is pain beliefs. Pain beliefs can be de-
fined as cognitions or thoughts related to the pain prob-
lem [5] (such as beliefs about the cause of pain, its
meaning, or appropriate treatments for pain [6–9]). Such
beliefs can be personally held, culturally shared, or both
[10]. Another factor, coping, is defined as cognitive and
behavorial responses intended to manage stressful events
such as chronic pain [5,11]. Pain-related beliefs and cop-
ing are often classified as adaptive (i.e., beliefs thought to
lead to positive outcomes and adjustment) or maladap-
tive (i.e., beliefs thought to contribute to negative out-
comes and poor adjustment) [10,12]. However, it is
likely that adaptiveness varies with context—what is
maladaptive in one context might be adaptive in another.
Moreover, this classification disregards the cultural ap-
propriateness of behavior such as seeking others’ emo-
tional support vs keeping problems to oneself [13,14].
A third psychological factor—catastrophizing—can be
defined as an exaggerated negative orientation toward
pain [15]. Because catastrophizing is often significantly
associated with greater pain intensity, pain interference,
depressed mood, and anxiety [15–17], it is generally
viewed as a maladaptive (coping) response to pain [18].
However, although catastrophizing is viewed in the West
as maladaptive because it contributes to a depressive-
thinking bias, in other cultures it could be viewed as mal-
adaptive for different reasons; for example, it may reflect
a lack of acceptance of (divinely determined) fate.
Cultural factors may therefore influence pain beliefs/
appraisal, coping responses, and catastrophizing [19–
22]—all of which are targeted by psychologically based
treatments [23–30]. However, “culture” is notoriously
difficult to define and operationalize. Variables such as
ethnicity, gender, nationality, and language group are
commonly used as proxy measures of culture in research
studies because these variables are thought to reflect cul-
tural differences [13,31–33]. Consistent with this, previ-
ous systematic reviews related to culture have studied
racial and ethnic differences [19,34] and religiosity and
spirituality [35].
Regardless of how culture is defined, however, it
remains important to understand the associations be-
tween variables thought to reflect culture—variables
such as country of origin and language—because these
variables have the potential to influence the acceptability
and efficacy of treatments that target pain beliefs, coping,
and catastrophizing for change. The findings from
research in this area could help us understand the extent
to which pain treatments may need to be adapted to
make them most appropriate to new populations who
may live in different countries or speak different lan-
guages than those for whom the interventions were first
developed [13].
One recently published review—registered in the
PROSPERO registry two months after the current review
was registered—sought to provide a summary of the state
of knowledge in this area [34]. These investigators
reviewed research studies examining differences in pain-
related beliefs, cognitions, and behaviors as a function of
race, ethnicity, and culture in samples of individuals with
chronic musculoskeletal pain. However, this review was
limited in that 1) it only included studies whose partici-
pants had chronic musculoskeletal pain and not other
chronic pain problems and 2) the search was limited to
only two databases. The current study sought to address
these limitations by including studies whose participants
had any chronic pain problem and by searching 15 data-
bases. As a result, we were able to identify five additional
studies not included in the previously published review.
The primary aim of this systematic review was to in-
crease our understanding of the role of country of origin
and language spoken on pain beliefs/appraisals, pain cop-
ing, and pain catastrophizing in individuals with chronic
pain. We hypothesized that people living in two different
countries or people living within a country but speaking
different languages would endorse different levels of
pain-related beliefs/appraisals, ways of coping with their
chronic pain, and extents of pain catastrophizing [1]. We
also aimed to explore differences in pain beliefs/apprais-
als, coping, and catastrophizing between countries’ in-
come levels.
Methods
Review Protocol and Registration
We followed the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) check-
list and Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) guidelines for both the conduct
and reporting of this systematic review [36,37]. The re-
view was prospectively registered in the PROSPERO reg-
istry (CRD42017082449).
Eligibility Criteria
We included studies if they 1) compared pain-related
beliefs/appraisals, coping, and catastrophizing in differ-
ent countries or groups within one country that speak
different languages, or both, in a single study; 2) included
quantitative scales of pain beliefs/appraisals, pain coping,
and/or pain catastrophizing; 3) were an observational
study (cohort, case–control, and cross-sectional studies)
or a multicountry clinical trial with information on pain
beliefs/appraisal, coping, or catastrophizing separately
for the two countries; and 4) included adults (age
18 years or older) with chronic pain (defined as pain last-
ing for longer than three months), irrespective of etiology
(e.g., cancer, trauma, infection, nerve damage, musculo-
skeletal problems, surgery-related, other systemic illness)
or body part (e.g., headache, neck pain, low back pain,
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upper or lower extremity pain). There were no restric-
tions in the language and date of publication. We ex-
cluded studies if 1) the sample included individuals
younger than age 18 years; 2) the study did not report a
quantitative scale of pain beliefs/appraisal, coping, or
catastrophizing; and 3) the study was a review, editorial,
or qualitative research.
Information Sources and Search Strategies
We adapted several search strategies to identify relevant
publications. First, we searched 15 databases or search
engines for articles to include in the review; namely
MEDLINE, Embase, Cochrane Central Register of
Controlled Clinical Trials, PsycINFO, CINAHL, Web of
Science, Scopus, PubMed, Physiotherapy Evidence
Database (PEDro), Google Scholar, Applied Social
Sciences Index and Abstracts (ASSIA) via PROQUEST,
International Bibliography for Social Sciences (IBSS) via
PROQUEST, Literatura Latino Americana em Ciências
da Saude (LILACS), opengrey.eu, and OpenSIGLE.
Second, we searched unpublished literature in the largest
and most widely used clinical trial registry platform,
ClinicalTrials.gov. Finally, we screened the titles in the
reference list of included studies in order to identify
articles there were not identified by the database search.
We searched databases for articles published before
January 15, 2019. We used the search terms 1) chronic
pain AND 2) country, language, and socioeconomic sta-
tus AND 3) belief OR coping OR catastrophizing, as
well as their synonyms in various combinations. We re-
peated the search again on November 21, 2019, with ad-
ditional search terms to incorporate “language” and
“socioeconomic status,” but did not retrieve any addi-
tional eligible papers. The detailed search strategy for
MEDLINE can be found in the Supplementary Data; we
customized search strategies for each database.
Domains of Interest
We were interested in studies reporting pain-related
beliefs (or appraisal), coping, or catastrophizing in two
or more countries, or in two or more language groups
within the same country. The following are commonly
used self-report questionnaires for the assessment of
pain-related beliefs or appraisal, coping, and catastroph-
izing and were used in the included studies.
Pain Beliefs and Appraisals
The Survey of Pain Attitudes (SOPA) is commonly used
to assess pain beliefs in pain research [6,7]. It assesses
seven belief domains, namely 1) belief in one’s control
over pain (Pain Control), 2) belief that one is disabled by
pain (Disability), 3) belief in a medical cure for pain
(Medical Cure), 4) belief that others should be solicitous
in response to pain (Solicitude), 5) belief that medications
are appropriate for pain management (Medications), 6)
belief that emotions influence pain (Emotions), and 7)
belief that pain is a signal of harm, and that therefore ac-
tivity should be avoided (Harm) [7]. Internal consisten-
cies of its subscales have been shown to be acceptable to
good, with Cronbach’s alphas ranging from 0.70 to 0.84
for its 57-item and 35-item versions, with an exception
for the Harm subscale (alpha ¼ 0.66) [38]. A one-item
version of the SOPA was created to increase clinical and
research utility based on its strength of association with
the parent subscale [7]. The single items have demon-
strated their construct validity similar to those of their
full version by moderate correlations, with scales assess-
ing depression, pain intensity, and physical disability [7].
Goubert and colleagues developed the Low Back Pain
Beliefs Questionnaire (LBPBQ) using items from different
scales assessing pain beliefs [21]. It assesses six domains
of back pain beliefs related to harm, limited physical ac-
tivity, belief in a medical cure, caution, lack of self-
control, and belief in pain medication. The internal con-
sistencies of the LBPBQ subscales have not been reported.
The Tampa Scale for Kinesiophobia (TSK) and the
Fear-Avoidance Beliefs Questionnaire (FABQ) are the most
common questionnaires to assess fear of movement, which
is considered an important pain-related belief. The factor
structure of the TSK is inconsistent, with reports of support
for both a four- and a two-factor structure; therefore, we
recorded and reported on the findings for the total score
only [39]. There are two versions of the TSK, a 17-item
and an 11-item version. The FABQ assesses fear-based
avoidance of physical activities and fear-based avoidance
of work [40]. The internal consistencies of the TSK scales
(both versions) have been reported to range from 0.79 and
0.89 for the total scores [41–43]. The internal consistencies
of the FABQ subscales have been shown to range from
0.77 to 0.88 [40].
The Revised Illness Perception Questionnaire (IPQ-R)
assesses individuals’ perceptions about their illness using
a self-report in a variety of clinical conditions including
chronic pain [44]. The first section asks questions related
to 14 symptoms (if present) that are related to the illness
(chronic pain in this study). The IPQ-R assesses seven ill-
ness perception domains labeled identity, consequences,
timeline acute/chronic, timeline cyclical, coherence, and
emotional dimension. Internal consistencies of the sub-
scales range from 0.77 to 0.88 [44].
Finally, the Pain Self-Efficacy Questionnaire (PSEQ) is
a questionnaire related to pain appraisal that assesses
pain-related self-efficacy beliefs by asking how confident
the person is about engaging in a variety of activities de-
spite pain [45,46]. The internal consistency of the origi-
nal English version of the scale was reported to be 0.92
[46]. Pain appraisal was assessed using the PSEQ under
the broad category of pain beliefs for the purpose of the
review.
Pain Coping
Pain-related coping is most commonly assessed using the
Coping Strategies Questionnaire (CSQ) [47] or one of the
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versions of the Chronic Pain Coping Inventory (CPCI)
[7,48,49]. The CSQ and CPCI items assess a variety of
pain coping responses such as guarding, resting, asking
for assistance, relaxing, task persistence, exercising/
stretching, seeking support, coping self-statements, di-
verting attention, reinterpreting pain sensations, ignoring
pain, praying and hoping, increasing behavioral activi-
ties, and catastrophizing [7,47–49]. Although these ques-
tionnaires assess multiple domains, the scales from these
questionnaires that are most consistently associated with
patient function and/or treatment outcome are those that
assess catastrophizing [50,51], guarding and resting
[48,50,51], task persistence [48], and asking for assis-
tance [50,51]. Other domains that are sometimes associ-
ated (but less consistently or strongly) with function
include exercising/stretching, seeking support, and pray-
ing and hoping [48,50,51]. The internal consistencies of
the subscales of the CSQ are generally acceptable (alpha
range ¼ 0.71–0.85), except for increasing pain behaviors
(alpha ¼ 0.28) [47]. Similarly, the internal consistencies
of the CPCI subscales range from 0.70 to 0.93 [48].
Pain Catastrophizing
Pain catastrophizing is another domain sometimes con-
sidered a pain belief and sometimes considered a pain
coping mechanism. For the purpose of this review, we
are classifying pain catastrophizing as an independent
domain from pain beliefs and coping. As described previ-
ously, it is commonly assessed by the Catastrophizing
subscale of the Coping Strategies Questionnaire (internal
consistency ¼ 0.78) [47]. It is also assessed using the Pain
Catastrophizing Scale (PCS; internal consistency ¼ 0.87)
[15] and the Catastrophizing subscale of the Pain-
Related Self-Statements Scale (PRSS; internal consistency
¼ 0.88) [52].
Study Selection and Data Management
We transferred references from the search into EndNote
X8 (Clarivate Analytics) and deduplicated. Two study
authors (SS and JHA/AFV) independently screened each
of the titles and abstracts for eligibility on an Excel
spreadsheet. We obtained copies of those that appeared
to possibly satisfy inclusion criteria as full papers. Two
study authors (SS and AFV) then independently read the
full text of these articles and decided on the final list of
eligible studies. Any discrepancies were resolved by dis-
cussion and consensus with a third reviewer (MPJ) when
necessary. Exclusion of the studies was recorded with
reasons. Two authors (SS and AFV) then independently
extracted data from the included studies. Any differences
were resolved by discussion and consensus, and in the
event that a consensus was not achieved, a third senior
author (MPJ) was consulted, who made the final deci-
sion. The reviewers were not blind to the authorship of
the study. In case the screeners or data extractors were
the authors of the included study, screening and data
extraction were completed by an author who is not an
author of the included studies.
Data Extraction
We extracted the following data from each article into an
Excel spreadsheet: authors, year of publication, countries
of study, chronic pain diagnosis, language of data collec-
tion, and sample sizes from the countries or language
groups. Demographic characteristics of the samples
(mean and SD of participants’ age and percentage of fe-
male participants) were also extracted when reported.
Data (mean and SD) on pain-related beliefs/appraisals,
coping, and catastrophizing were extracted for the total
scores or subscales (see below for details), as appropriate
and available; if not available, authors were contacted to
obtain the data.
For pain beliefs, we extracted data related to beliefs
about 1) control over pain, 2) being disabled by pain, 3)
medical cure for pain, 4) solicitude from others, 5) medi-
cations being appropriate for pain management, 6) emo-
tional influence on pain, and 7) pain as a sign of harm
from the SOPA scales. We extracted fear and avoidance
beliefs about physical activity and work from the FABQ.
We extracted beliefs about fear of movement/re-injury
and low back pain beliefs from the total scores on the
TSK and the LBPBQ, respectively. Data related to pain-
related self-efficacy or appraisals were extracted from the
total scores of the PSEQ. For pain coping, we extracted
the means and SDs for scales assessing guarding, resting,
asking for assistance, relaxing, task persistence, exercis-
ing/stretching, seeking support, coping self-statements,
diverting attention, reinterpreting pain sensations, ignor-
ing pain, praying and hoping, and increasing behavioral
activities from the CPCI and CSQ. Finally, we extracted
the means and SDs of pain catastrophizing (i.e., CSQ
Catastrophizing scale, PRSS Catastrophizing scale, and
PCS).
Quality Assessment
We adapted the risk of bias tool based on the STROBE
checklist [53] and the Cochrane Collaboration risk of
bias tool [54] used by Catley and colleagues [55] to assess
the quality of the studies. The a priori items we planned
to use as reported in the PROSPERO registry consisted of
nine-item scale. Each item was scored as “yes” ¼ 1, “no”
¼ 0, and “unclear” ¼ ?. However, we subsequently re-
vised this to add one question (item #8 assessing the va-
lidity and reliability of the original scale), because after
pretesting data extraction from the first few papers, we
found studies using modified scales without reports of
their reliability or validity, and we determined that this
potential source of bias should be assessed and incorpo-
rated in the quality ratings. Thus, the final risk of bias
tool we used was a 10-item checklist with one question
on detection bias (diagnosis of chronic pain); two ques-
tions each on selection bias (if the cases were consecutive
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or randomly selected and if the demographic characteris-
tics of the participants were similar between groups), sta-
tistical methods (sample size calculation and assessment
of confounders), and reporting bias (flow of participants
reported and dealing with missing items); and three items
on validity and reliability of the scales used (validity and
reliability of the original scales or in the language in
which they were developed, appropriate cross-cultural
validity methods used if translated into a new language,
and reliability of the scales in the population and lan-
guage of interest). Total scores on quality assessment
were computed for each study, where higher scores indi-
cated better study quality. We then classified the quality
scores into low (<50%), medium (50–80%), and high
(>80%) [56,57]. Two study authors (SS and AFV) inde-
pendently assessed the methodological quality for each
study, resolving any discrepancies by consensus and con-
sulting a third author (MPJ) if consensus could not be
reached. We did not exclude any articles based on meth-
odological quality.
Data Analysis Plan
To test for possible between-country and -language
group differences in pain-related beliefs, appraisal, cop-
ing, and catastrophizing, we compared the mean scores
of the scales assessing these domains across languages
and countries. Additionally, we also compared the mean
scores based on the income levels of the countries based
on the World Bank country classifications indicating the
socioeconomic aspects of the country. We planned to
conduct meta-analyses if two or more studies reported
the same variable (pain beliefs, appraisals, coping, or cat-
astrophizing) in two of the same languages, countries, or
economic regions based on the World Bank country clas-
sifications, and if the studies were deemed sufficiently ho-
mogenous (I2 < 50%) [54].
For the language-group within-country differences
(Comparison 1) and between-country differences
(Comparison 2) in pain beliefs, coping responses, and
catastrophizing, we computed effect sizes using standard-
ized mean differences (SMDs) for any differences be-
tween participants between pairs of countries (or who
spoke two different languages within the same country)
for each study for each domain separately using means
and SDs. We pooled the results of two or more samples
(languages or chronic pain conditions) from the same
country to perform pairwise comparison between coun-
tries for Comparison 2. If the individual studies included
more than one language or country, then the SMDs for
all possible pairwise comparisons were computed. We
used Hedge’s g to compute SMDs, a recommended
method when group sizes are dissimilar [58]. It uses pool-
ing of “weighted” standard deviations. Effect sizes
(Hedge’s g) of 0.20 were considered small, 0.50 as me-
dium, and 0.80 as large [59]. All data are presented as ef-
fect estimates with 95% confidence intervals (CIs). A
result is deeemed statistically significant when the upper
and lower bounds of the CI do not cross 0 [58]. The
results of the Comparison 1 and Comparison 2 analyses
were collated, interpreted, and presented as per the rec-
ommendations of the Cochrane Collaboration [54]. For
the reporting of the results for between-country and -lan-
guage differences in pain beliefs, coping, and catastroph-
izing, we summarized the direction of effect, size of the
effect (ES), consistency of the effect across the studies,
and quality of evidence.
We further compared pain beliefs/appraisals, pain
coping, and pain catastrophizing scores by economic re-
gion (World Bank classification; Comparison 3) if indi-
vidual studies included data from two or more economic
regions. We pooled the results from two or more coun-
tries that represented the same economic region in a sin-
gle study. We reported results as SMDs (using Hedge’s g)
as in the primary analysis.
Addressing Missing Data
If a particular study did not report complete data (e.g.,
SD), we e-mailed the authors with a request to provide
data. A second e-mail was sent to the study authors after
about three weeks if they did not respond to the first. A
third and final reminder e-mail was sent to the authors
two weeks after the second e-mail.
Results
We identified and screened 1,365 potential articles
through the database search. We read the full texts of 42
of these, and nine met the criteria for inclusion. One ad-
ditional article was identified as a citation in a key study.
Figure 1 presents the PRISMA flow diagram and
describes the number of studies excluded (with reasons),
number of duplicates, and the total number of studies in-
cluded. We contacted the authors of four studies and re-
ceived data for our analysis from the authors of three
studies [21,22,60].
Description of the Included Studies
All 10 studies included in the review were observational.
Six scales were used to assess pain beliefs or appraisals
(the LBPBQ, FABQ, TSK, SOPA-brief, IPQ-R, and
PSEQ), two were used to assess pain-related coping (the
CSQ and CPCI), and three were used to assess pain-
related catastrophizing (the CSQ Catastrophizing sub-
scale, PCS, and PRSS Catastrophizing scale).
The 10 studies used data from participants in 16 dif-
ferent countries. One used data from individuals with
chronic pain from Asia (Singapore), two each from
Australia (Australia), Africa (Ivory Coast, Morocco,
South Africa, or Tunisia), and South America (Brazil).
Similarly, four studies included data from individuals liv-
ing in North America (either the United States or
Canada), and seven of the studies used data collected
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from participants from Europe (Belgium, Denmark,
France, the Netherlands, Portugal, Spain, or Sweden).
The majority of countries represented were high-
income countries (N¼ 11; Australia, Belgium, Canada,
Denmark, France, the Netherlands, Portugal, Singapore,
Spain, Sweden, and the United States), followed by lower
middle-income countries (N¼ 3; Tunisia, Ivory Coast,
and Morocco) and upper middle-income countries
(N¼ 2; Brazil and South Africa). No countries were rep-
resented by the low-income country category. The char-
acteristics of the individual included studies, with year of
publication, countries, and languages studied, scales
used, diagnosis of chronic pain, study participants’ mean
age, SD, and percentage of female participants, are pre-
sented in Table 1. We identified two studies by Roelofs
et al. [64,65] presenting data from samples that were
largely (but not completely) overlapping, which had the
aims of evaluating the psychometric properties of two
versions of the TSK scale (TSK-11 and TSK-17). We de-
cided to include both of these studies in the review for
the qualitative synthesis of the results, which allowed us
to determine if different versions of the same scale
resulted in similar or different conclusions regarding fear
of movement/re-injury beliefs between countries. All the
studies and samples used the questionnaires in their first
language or official language of the country (e.g., English
is the official language of Singapore).
Participants
The reviewed studies included 6,797 individuals with
chronic pain (excluding the study by Roelofs 2007 [64],
which included the same participants plus a few addi-
tional participants in a subsequent 2011 study [65]). The
most commonly studied diagnoses were chronic low
back pain (N¼ 4 studies: 2,224 participants
[21,60,62,65]); followed by chronic musculoskeletal pain
(N¼ 2 studies: 1,526 participants [20,65]); chronic pain
in general (N¼ 2 studies: 823 participants [22,67]); and
fibromyalgia (N¼ 3 studies: 809 participants
[63,65,66]). Nine of 10 included studies recruited clinical
samples. The exception was a study by Goubert and col-
leagues that used a postal survey design to assess a sam-
ple representative of the population in Belgium [21].
The reports that were identified and included in this
review were not sufficiently homogeneous to allow data
pooling for a meta-analysis, because no two studies that
met the criteria used comparable scales in the same two
countries or languages. Therefore, we performed a narra-
tive synthesis of the results without a meta-analysis.
Records identified through 
database search 
























Additional records identified 
through other sources 
(n = 2) 
Records after duplicates removed 
(n = 479) 
Records screened 
(n = 479) 
Records excluded 
(n = 437) 
Full-text articles 
assessed for eligibility 
(n = 42) 
Full-text articles 
excluded (n = 32): 
•  Did not compare two 
countries or languages 
= 14 
•  Not an observational 
or an experimental 
study = 10 
•  Participants did not 
have chronic pain = 4 
•  Duplicate conference 
abstracts = 2 
•  Did not report a 
measure of pain 
beliefs, coping, or 
catastrophizing = 1 
•  Full text not retrieved = 1
Studies included in 
qualitative synthesis 
(n = 10) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
Figure 1. PRISMA flow diagram.
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Methodological Quality of Studies
We rated four studies as being of moderate quality and the
remaining six as being of low quality (Table 2). No studies
were classified as being of high quality. Only three of 10
studies (30%) included a representative sample of consec-
utive participants, and in only one study (10%) were the
demographic characteristics of the study participants simi-
lar between the comparison groups. Seven studies (70%)
defined chronic pain as pain lasting for at least three
months, consistent with the International Association for
the Study of Pain definition of chronic pain, and nine stud-
ies (90%) either estimated a priori the sample size for the
study or included at least 30 participants in each group.
Only one study (10%) controlled for confounders (age,
sex, socioeconomic status of the study participants). Two
studies (20%) reported the flow of participants and how
the missing data were handled. Seven studies (70%) used
reliable and valid scales (i.e., in the original language they
were developed in), and eight studies (80%) met the crite-
ria for cross-cultural adaptation of scales used. Half of the
studies (50%) reported the internal consistency of the
(multi-item) scales as being at least marginally adequate
(i.e., internal consistency of at least 0.60 in the current
sample or clear evidence of its reliability in the population
of interest in a previous study).
Deviation from the Original Study Protocol
Our original goal for this review was to evaluate the role
of culture in pain beliefs, coping, and catastrophizing,
operationalizing culture (as previous researchers have) as
indicated by differences in country, differences in lan-
guage spoken, or differences in the socioeconomic status
of the included countries. However, after we registered
the study, we changed our views regarding the appropri-
ateness of these variables as proxy measures of culture
[68]. Thus, and although this did not affect the analyses
performed, it did change how we discussed the findings;
that is, we now discuss them as directly relating to differ-
ences as a function of country, the country’s economy, or
language, as opposed to as differences relating to culture.
The second deviation from our original protocol was that
we omitted the planned analysis to examine between-
continent differences in pain beliefs, coping, and cata-
strophizing, because of changes in conceptualization of
the review during its execution that made these contrasts
uninterpretable (Supplementary Data). The third devia-
tion was related to a quality assessment tool, as described
earlier.
Differences in Pain-Related Beliefs
Nine of the 10 included studies (90%) used at least one
questionnaire to assess pain beliefs or pain appraisal. The
results were collated from three studies [21,64,65] for
Comparison 1, eight studies [21,22,60,62,64–67] for
Comparison 2, and two studies [62,67] for Comparison
3. Overall, we found that 24 of 40 (60%) between-group
comparisons were statistically significant (eight large,
medium, and small SMDs each). The results indicate that
between-country, between–economic region differences
in pain beliefs exist (Table 3). However, we found no sta-
tistically significant differences in pain beliefs in people
living in the same country but speaking different lan-
guages based on three low-quality reports [21,64,65].
Overall, fear avoidance beliefs (or fear of movement
beliefs) were the most commonly studied pain beliefs,
with 52% statistically significant between-group effects
(12 of 23 ESs; five large, one medium, and six small) indi-
cating the presence of between-country and between-eco-
nomic region differences in fear avoidance beliefs.
Similarly, six of eight illness perception beliefs related to
fibromyalgia (75%) were statistically different between
patients with fibromyalgia in Spain and the Netherlands,
based on one moderate-quality study [66]. Patients from
Spain endorsed more illness belief domains related to
negative outcomes (e.g., identity, consequences, and cy-
clic timeline), whereas patients from the Netherlands en-
dorsed statistically significantly more domains associated
with positive outcomes (e.g., personal and treatment con-
trol and illness coherence). See Table 3 for detailed
results.
Differences in Pain-Related Coping
Only three (30%) studies included at least one question-
naire assessing pain coping [20,22,62]. Samples were
recruited from seven countries that met the criteria for
analysis for Comparisons 2 and 3. Only one study was
included for Comparison 3 [62], and no studies met the
criteria for Comparison 1. Thirty-four of 57 SMDs
(60%) computed for differences in pain coping indicated
that pain coping endorsement is significantly different be-
tween countries (Table 4). We found that seven, 11, and
16 of these statistically significant ES were large, me-
dium, and small, respectively.
The most commonly observed between-country statis-
tically significant difference in coping was for seeking so-
cial support (87%; seven of eight ESs; one large, two
medium, and four small), followed by 86% each (six of
seven ESs) for praying and hoping (three large, two me-
dium, and one small ESs), and diverting attention (one
large, one medium, and four small ESs). These coping
strategies were endorsed more often by patients with
chronic pain from lower middle-income African coun-
tries (Tunisia, Ivory Coast, and Morocco) than a high-
income European country: France. Similarly, guarding
and resting was statistically significant in two of two
comparisons, with samples from the United States en-
dorsing more guarding and resting than samples from
Portugal or Singapore.
On the other hand, there was no statistically signifi-
cant difference in ignoring pain between the same three
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African countries and France (six of six SMDs), whereas
we found a small ES in ignoring pain between samples
from the United States and Portugal. The results of the
pooled estimates of coping strategies listed in the CSQ
from the three lower-middle income African countries
compared with a high-income European country (France)
showed that the former group endorsed statistically sig-
nificantly more praying and hoping (large ES), seeking
social support (medium ES), diverting attention (medium
ES), and reinterpreting pain sensations (small ES) com-
pared with the latter.
Differences in Pain Catastrophizing
Four of the 10 included studies (40%) assessed pain cata-
strophizing in six countries [20,60,63,67]. Findings from
three studies were used for Comparison 2, whereas find-
ings from one study were used to perform Comparisons 1
and 3. Three of six SMDs (two medium and one small ES)
indicated that pain catastrophizing reporting is different
across countries/economic regions. Of the medium ES,
patients with chronic musculoskeletal pain from the
United States endorsed more pain catastrophizing (SMD
¼ 0.79) than patients with chronic musculoskeletal pain
Table 3. Standardized mean differences in pain beliefs across countries and languages
Study Comparisons (Groups) Domain/Subdomain Hedge’s g (Size) 95% CI Effect Direction*
Genet, 2009 [62] 2 (FRA vs CIV) Fear avoidance (PA) –1.14 (L) –1.48 to –0.80 CIV > FRA
Fear avoidance (work) –1.25 (L) –1.59 to –0.91 CIV > FRA
2 (FRA vs TUN) Fear avoidance (PA) –0.30 –0.60 to 0.01 FRA ¼ TUN
Fear avoidance (work) –0.02 –0.32 to 0.29 FRA ¼ TUN
2 (FRA vs MAR) Fear avoidance (PA) –0.27 –0.66 to 0.12 FRA ¼MAR
Fear avoidance (work) 0.28 –0.11 to 0.67 FRA ¼MAR
2 (CIV vs TUN) Fear avoidance (PA) –0.02 –0.33 to 0.29 CIV ¼ TUN
Fear avoidance (work) 1.17 (L) 0.84 to 1.51 CIV > TUN
2 (CIV vs MAR) Fear avoidance (PA) 0.83 (L) 0.42 to 1.24 CIV > MAR
Fear avoidance (work) 1.40 (L) 0.96 to 1.83 CIV > MAR
2 (TUN vs MAR) Fear avoidance (PA) 0.21 –0.18 to 0.60 TUN ¼MAR
Fear avoidance (work) 0.28 –0.11 to 0.67 TUN ¼MAR
3(HIC vs LMIC) Fear avoidance (PA) –0.26 (S) –0.52 to –0.00 LMIC > HIC
Fear avoidance (work) –0.34 (S) –0.60 to –0.08 LMIC > HIC
Goubert, 2004 [21] 1 (Dutch vs French - BEL) LBP beliefs –0.10 –0.25 to 0.05 French ¼ Dutch (BEL)
Kent, 2014 [60] (AUS vs DNK) Fear avoidance (PA) –0.19 –0.42 to 0.04 AUS ¼ DNK
Roelofs, 2007 [64]† 1 (English vs French-CAN) Fear of movement (TSK-11) –0.19 –0.37 to 0.01 French ¼ English (CAN)
2 (CAN vs SWE) Fear of movement (TSK-11) 0.62 (M) 0.48 to 0.76 CAN > SWE
2 (CAN vs NLD) Fear of movement (TSK-11) 0.30 (S) 0.20 to 0.39 CAN > NLD
2 (SWE vs NLD) Fear of movement (TSK-11) –0.13 –0.25 to –0.02 NLD > SWE
Roelofs, 2011 [65]† 1 (English vs French-CAN) Fear of movement (TSK-17) 0.04 –0.14 to 0.22 French ¼ English (CAN)
2 (CAN vs SWE) Fear of movement (TSK-17) 0.38 (S) 0.23 to 0.53 CAN > SWE
2 (CAN vs NLD) Fear of movement (TSK-17) 0.44 (S) 0.33 to 0.56 CAN > NLD
2 (SWE vs NLD) Fear of movement (TSK-17) 0.23 (S) 0.12 to 0.35 SWE > NLD
Ruiz-Montero,
2015 [66]
2 (ESP vs NLD) IP Identity 1.10 (L) 0.85 to 1.35 ESP > NLD
IP Timeline –0.04 –0.27 to 0.19 ESP ¼ NLD
IP Consequences 0.66 (M) 0.43 to 0.90 ESP > NLD
IP Cyclic Timeline –0.21 –0.44 to 0.02 ESP ¼ NLD
IP Personal Control –0.46 (S) –0.70 to –0.23 NLD > ESP
IP Treatment Control –0.80 (L) –1.04 to –0.56 NLD > ESP
IP Illness Coherence –0.58 (M) –0.81 to –0.34 NLD > ESP
IP Emotional Representation 0.92 (L) 0.68 to 1.16 ESP > NLD
Sarda, 2009 [67] 2, 3 (AUS/HIC vs BRA/UMIC) Pain self-efficacy beliefs (PSEQ) –0.52 (M) –0.68 to –0.36 BRA/UMIC > AUS/HIC
Thong, 2017 [22] 2 (USA vs SGP) SOPA Control 0.10 –0.18 to 0.38 USA ¼ SGP
SOPA Medical Cure –0.57 (M) –0.85 to –0.29 SGP > USA
SOPA Disability 0.66 (M) 0.37 to 0.94 USA > SGP
SOPA Solicitude –0.36 (S) –0.64 to –0.08 SGP > USA
SOPA Medication –0.62 (M) –0.90 to –0.37 SGP > USA
SOPA Emotions 0.17 –0.10 to 0.45 USA ¼ SGP
SOPA Harm –0.57 (M) –0.85 to –0.29 SGP > USA
Size of effect: L ¼ large; M ¼ medium; S ¼ small. Large effect sizes are bolded.
AUS ¼ Australia; BEL ¼ Belgium; BRA ¼ Brazil; CAN ¼ Canada; CI ¼ confidence interval; CIV; Ivory Coast; d ¼ effect size; DNK ¼ Denmark; ESP ¼ Spain;
FRA ¼ France; HIC ¼ high-income country; IP ¼ illness perception; LBP ¼ low back pain; MAR ¼ Morocco; NLD ¼ the Netherlands; PA ¼ physical activity;
SGP ¼ Singapore; SOPA ¼ Survey of Pain Attitudes; SWE ¼ Sweden; TUN ¼ Tunisia; UMIC ¼ upper middle-income country; USA ¼ United States of America;
ZAF ¼ South Africa.
*Use of “>” indicates significant differences, when the effect does not cross 0.
†Results of mean and SD from two samples within Canada and four samples within the Netherlands were combined.
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Table 4. Standardized mean differences in pain coping across countries
Study
Comparisons
(Groups) Scales/Subdomain Hedge’s g (Size) 95% CI Effect Direction
Ferreira-Valente,
2011 [20]
2 (USA vs PRT) CPCI Guarding 0.74 (M) 0.54 to 0.94 USA > PRT
CPCI Resting 0.96 (L) 0.76 to 1.17 USA > PRT
CPCI Asking for Assistance –0.07 –0.27 to 0.13 USA ¼ PRT
CPCI Relaxation –0.15 –0.35 to 0.05 USA ¼ PRT
CPCI Task Persistence –0.50 (M) –0.70 to –0.30 PRT > USA
CPCI Self-Statements –0.05 –0.25 to 0.14 USA ¼ PRT
CPCI Exercise/Stretch –0.34 (S) –0.54 to –0.14 PRT > USA
CPCI Seeking Social Support –0.20 (S) –0.40 to –0.00 PRT > USA
CSQ Diverting Attention 0.35 (S) 0.15 to 0.55 USA > PRT
CSQ Ignoring Pain 0.35 (S) 0.15 to 0.55 USA > PRT
CSQ Reinterpreting Pain Sensations –0.12 –0.32 to 0.08 USA ¼ PRT
CSQ Praying and Hoping 0.44 (S) 0.24 to 0.64 USA > PRT
CSQ Increase Behavioral Activities –0.25 (S) –0.45 to –0.05 PRT > USA
Genet, 2009 [62] 2 (FRA vs CIV) CSQ Seeking Social Support –0.94 (L) –1.27 to –0.61 CIV > FRA
CSQ Diverting Attention –0.95 (L) –1.28 to –0.62 CIV > FRA
CSQ Ignoring Pain –0.10 –0.41 to 0.21 FRA ¼ CIV
CSQ Reinterpreting Pain Sensations –0.32 (S) –0.63 to –0.00 CIV > FRA
CSQ Praying and Hoping –2.20 (L) –2.59 to –1.80 CIV > FRA
CSQ Increase Behavioral Activities –0.56 (M) –0.88 to –0.24 CIV > FRA
2 (FRA vs TUN) CSQ Seeking Social Support –0.32 (S) –0.63 to –0.02 TUN > FRA
CSQ Diverting Attention –0.50 (M) –0.81 to –0.19 TUN > FRA
CSQ Ignoring Pain –0.27 –0.57 to 0.03 FRA ¼ TUN
CSQ Reinterpreting Pain Sensations –0.49 (S) –0.80 to –0.18 TUN > FRA
CSQ Praying and Hoping –1.45 (L) –1.79 to –1.11 TUN > FRA
CSQ Increase Behavioral Activities 0.05 –0.25 to 0.35 FRA ¼ TUN
2 (FRA vs MAR) CSQ Seeking Social Support –0.39 (S) –0.78 to –0.00 MAR > FRA
CSQ Diverting Attention –0.46 (S) –0.85 to –0.06 MAR > FRA
CSQ Ignoring Pain –0.14 –0.53 to 0.25 FRA ¼MAR
CSQ Reinterpreting Pain Sensations –0.53 (M) –0.93 to –0.13 MAR > FRA
CSQ Praying and Hoping –1.27 (L) –1.70 to –0.85 MAR > FRA
CSQ Increase Behavioral Activities 0.38 –0.01 to 0.77 FRA ¼MAR
2 (CIV vs TUN) CSQ Seeking Social Support 0.59 (M) 0.27 to 0.91 CIV > TUN
CSQ Diverting Attention 0.38 (S) 0.07 to 0.70 CIV > TUN
CSQ Ignoring Pain –0.17 –0.49 to 0.14 CIV ¼ TUN
CSQ Reinterpreting Pain Sensations –0.20 –0.51 to 0.11 CIV ¼ TUN
CSQ Praying and Hoping 0.55 (M) 0.23 to 0.86 CIV > TUN
CSQ Increase Behavioral Activities 0.60 (M) 0.28 to 0.92 CIV > TUN
2 (CIV vs MAR) CSQ Seeking Social Support 0.49 (S) 0.09 to 0.89 CIV > MAR
CSQ Diverting Attention 0.49 (S) 0.09 to 0.90 CIV > MAR
CSQ Ignoring Pain –0.04 –0.43 to 0.36 CIV ¼MAR
CSQ Reinterpreting Pain Sensations –0.23 –0.63 to 0.17 CIV ¼MAR
CSQ Praying and Hoping 0.68 (M) 0.28 to 1.09 CIV > MAR
CSQ Increase Behavioral Activities 1.02 (L) 0.60 to 1.44 CIV > MAR
2 (TUN vs MAR) CSQ Seeking Social Support –0.08 –0.47 to 0.31 TUN ¼MAR
CSQ Diverting Attention 0.05 –0.34 to 0.44 TUN ¼MAR
CSQ Ignoring Pain 0.14 –0.25 to 0.53 TUN ¼MAR
CSQ Reinterpreting Pain Sensations –0.03 –0.42 to 0.36 TUN ¼MAR
CSQ Praying and Hoping 0.10 –0.29 to 0.49 TUN ¼MAR
CSQ Increase Behavioral Activities 0.32 –0.07 to 0.71 TUN ¼MAR
3 (HIC vs LMIC) CSQ Seeking Social Support –0.55 (M) –0.81 to –0.29 LMIC > HIC
CSQ Diverting Attention –0.65 (M) –0.92 to –0.39 LMIC > HIC
CSQ Ignoring Pain –0.17 –0.43 to 0.08 LMIC ¼ HIC
CSQ Reinterpreting Pain Sensations –0.43 (S) –0.69 to –0.17 LMIC > HIC
CSQ Praying and Hoping –1.75 (L) –2.04 to –1.45 LMIC > HIC
CSQ Increase Behavioral Activities –0.03 –0.29 to 0.22 LMIC ¼ HIC
Thong, 2017 [22] 2 (USA vs SGP) CPCI Guarding 0.73 (M) 0.45 to 1.02 USA > SGP
CPCI Resting 0.42 (S) 0.14 to 0.70 USA > SGP
CPCI Asking for Assistance 0.49 (S) 0.21 to 0.77 USA > SGP
CPCI Relaxation 0.16 –0.12 to 0.44 USA ¼ SGP
CPCI Task Persistence –0.17 –0.45 to 0.10 USA ¼ SGP
CPCI Self-Statements 0.10 –0.18 to 0.37 USA ¼ SGP
CPCI Exercise/Stretching –0.04 –0.31 to 0.24 USA ¼ SGP
CPCI Seeking Social Support 0.50 (M) 0.22 to 0.78 USA > SGP
Size of effect: L ¼ large; M ¼ medium; S ¼ small. Large effect sizes are bolded.
CI ¼ confidence interval; CIV; Ivory Coast; CPCI ¼ Chronic Pain Coping Inventory; CSQ ¼ Coping Strategies Questionnaire; d ¼ effect size; FRA ¼ France; HIC ¼
high-income country; LMIC¼ lower middle-income country; MAR¼Morocco; PRT ¼ Portugal; SGP ¼ Singapore; TUN ¼ Tunisia; USA¼ United States of America.
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from Portugal [20]. Similarly, patients with chronic LBP
from Australia endorsed more pain catastrophizing (SMD
¼ 0.70) than those from Denmark [60]. Three nonsignifi-
cant differences concerned pain catastrophizing between
samples of individuals who spoke different languages
within South Africa (Table 5) [63].
Discussion
The primary aim of this systematic review was to deter-
mine if pain beliefs/appraisals, coping, and catastrophiz-
ing varied between countries or between language groups
within a country. The findings suggest that between-
country differences in pain beliefs/appraisals, coping, and
catastrophizing may exist for some pain-related domains,
but not for all. If between-country differences do exist,
the findings suggest that these are more likely to occur
for fear of movement and re-injury, some subscales of
pain coping (resting and guarding, seeking social support,
diverting attention, and praying and hoping), and pain
catastrophizing. However, as discussed later, these con-
clusions should be viewed as tentative at this point; addi-
tional studies using higher-quality methods are needed to
determine the reliability of the findings from the studies
reviewed here.
Differences in Pain-Related Beliefs
The findings from low- to moderate-quality evidence sug-
gest that differences in fear avoidance beliefs between
countries appear to exist. Specifically, the mean values
for fear avoidance beliefs in the Ivory Coast were greater
than in Tunisia, Morocco, and France; and Canadian
samples endorsed higher levels of fear avoidance beliefs
than samples from Sweden and the Netherlands. Several
factors could potentially explain the between-country dif-
ferences in patients’ observed fear avoidance beliefs, in-
cluding the pain treatments available in a country (a
function of historical, political, and economic influences)
and health professionals’ pain beliefs [69]. For example,
health professionals in some countries tend to advise
patients to rest in response to pain, rather than maintain
a steady level of activity. Advice to rest in response to
pain runs counter to evidence, and may foster fearful
beliefs in patients [70]. The factors that contribute to the
between-country differences in fear avoidance beliefs
should further be explored using higher-quality research
designs (discussed later).
Between-country differences in other types of pain
beliefs were fewer and less consistent than in fear avoid-
ance beliefs, in part because of the limited number of
studies on pain beliefs using the same questionnaire(s).
For example, three studies [22,66,67] compared differen-
ces in pain beliefs/appraisals using scales that assessed
somewhat different constructs (IPQ, PSEQ, SOPA),
which were therefore not pooled. Whether systematic dif-
ferences exist between pain beliefs other than fear avoid-
ance beliefs as a function of cultural difference will
require additional research.
Differences in Pain-Related Coping
We observed that individuals with chronic low back pain
from the three lower-middle income African countries
(Tunisia, Morocco, and Ivory Coast) endorsed more
praying and hoping (large effect size), seeking social sup-
port (medium effect size), and diverting attention (me-
dium effect size) as pain coping responses than
individuals from France. However, no significant differ-
ences were found in ignoring pain and increasing behav-
ioral activities between individuals from lower-middle
income African countries and individuals from France,
based on a single low-quality study [62]. The differences
identified in the studies reviewed here could be related to
either differences in ethnicity, religiosity, socioeconomic
status, or some combination of these or other factors.
Differences appeared in comparisons of guarding,
resting, and task persistence between samples of people
with chronic pain in the United States vs the samples
from Portugal and Singapore, but not in relaxation.
However, data used to compare coping responses in these
two studies were not collected concurrently but five to
10 years apart. Additionally, it is possible that the
between-country differences found could be in part due
to differences in the overall health care systems of the
countries, including the availability of more paid sick
Table 5. Standardized mean differences in pain catastrophizing across countries and languages
Study Comparisons, No. Scale Used Hedge’s g (Size) 95% CI Effect Direction
Ferreira-Valente,
2011 [20]
2 (USA vs PRT) CSQ Catastrophizing subscale 0.79 (M) 0.59 to 0.99 USA > PRT
Kent, 2014 [60] 2 (AUS vs DNK) Brief Catastrophizing Scale 0.70 (M) 0.47 to 0.94 (AUS > DNK)
Morris, 2012 [63] 1 (English vs Xhosa - ZAF) PCS 0.38 –0.19 to 0.95 English ¼ Xhosa
1 (English vs African - ZAF) PCS 0.11 –0.35 to 0.56 English ¼ African
1 (Xhosa vs African - ZAF) PCS –0.27 –0.82 to 0.27 Xhosa ¼ African
Sarda, 2009 [67] 2, 3 (AUS/HIC vs BRA/UMIC) PRSS Catastrophizing subscale 0.20 (S) 0.05 to 0.36 AUS/HIC > BRA/
UMIC
Size of effect: M ¼ medium; S ¼ small. Medium effect sizes are bolded.
AUS ¼ Australia; BRA ¼ Brazil; CI ¼ confidence interval; CSQ ¼ Coping Strategies Questionnaire; d ¼ effect size; DNK ¼ Denmark; HIC ¼ high-income
country; PCS ¼ Pain Catastrophizing Scale; PRSS ¼ Pain-Related Self-Statement Scale; PRT ¼ Portugal; UMIC ¼ upper middle-income country; USA ¼ United
States of America; ZAF ¼ South Africa.
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leave in the United States (especially compared with
Singapore), which in turn may promote more passive
forms of coping strategies such as resting and guarding.
This possibility could be tested by specific comparisons
between countries that control for or evaluate the effects
of measures of health care sick leave policy variables.
Differences in Pain Catastrophizing
We observed that pain catastrophizing was significantly
different across countries based on findings from three
studies. Specifically, a sample of people with chronic pain
from the United States endorsed higher levels of pain cata-
strophizing than the sample from Portugal [20], and those
from Australia endorsed more pain catastrophizing than
samples from Denmark [60] and Brazil [67]. However,
there were no significant differences in pain catastrophiz-
ing within different language-speaking groups within
South Africa [63], although the study was small. The small
number of studies limits any conclusions regarding pain
catastrophizing; additional studies from different countries
(and different language groups within a single study), ide-
ally using larger sample sizes, are needed.
Research Recommendations
The findings from the current review could help to guide
future research on group differences between countries
or between groups that speak different languages, or cul-
tural differences in general, in pain beliefs, coping
responses, and catastrophizing. Culture is a very complex
concept, which has not yet been satisfactorily defined or
operationalized in the context of pain research. At pre-
sent, for psychological domains such as pain beliefs/
appraisals, coping, and catastrophizing, studies that de-
scribe themselves as “cross-cultural” predominantly use
scales originally developed in Western countries. It is
challenging to determine if between-country differences
in scores from (translated) questionnaires that are rooted
in Western philosophy and psychology reflect differences
between respondents or nonequivalence of culture and/or
translation, especially when research participants are
recruited from a non-Western country. Bicultural
researchers with expertise in both qualitative and quanti-
tative methods could help develop appropriate and cul-
turally sound ways of assessment of pain-related domains
[71]. A meta-synthesis of existing qualitative studies in
this area may also further our understanding of the role
of culture (however defined) in chronic pain.
Ideally, cross-cultural comparison research would col-
lect data from individuals from different cultures concur-
rently rather than compare groups of patients using
preexisting data, use transparent sampling methods, and
pay attention to local norms of social desirability [72].
Similarly, researchers should consider conducting longitu-
dinal studies to explore how a coping strategy assessed at
one point in time predicts subsequent pain and function. A
study comparing the endorsement of certain pain coping
strategies between individuals from different countries or
who speak different languages using a cross-sectional de-
sign provides at best very limited information regarding
the relative efficacy of the coping response in the popula-
tion studied, because a coping strategy that is adaptive for
one individual in one situation (or from one country) is
not necessarily adaptive in another situation for the same
person, or a person from another country.
Given the current findings suggesting some between-
country differences in pain beliefs, coping, and cata-
strophizing, another recommendation is that a treatment
developed in and recommended for individuals from one
country or who speak one language should not necessar-
ily be assumed to be effective in individuals from another
country or who speak another language without evidence
of efficacy in the target population. There is a growing
trend to apply psychological interventions for chronic
pain that were developed in one country to individuals
from a different country [73–76]. However, before trying
to change beliefs or coping strategies in individuals from
a different country, it would be useful to first conduct re-
search to identify the effects of particular pain beliefs and
coping responses on pain and function in the target popu-
lation in that country.
Limitations
Although we adapted high-quality systematic review
methods recommended by the Cochrane Collaboration
and the PRISMA guidelines (searching 15 databases and
gray literature without limiting our search to language or
date of publication), it is important to recognize the
review’s limitations. First, the cross-country comparison
of pain beliefs, coping, and catastrophizing does not ade-
quately consider individual factors such as race/ethnicity,
socioeconomic status (occupation, education, and in-
come), religion, lifestyle factors (e.g., generally active vs
sedentary), individual access to health care, or country-
related factors such as the health care system (e.g., self-
funded vs publicly funded), worker compensation poli-
cies, and geography. We cannot confirm whether the
between-country differences identified are due to racial
differences [19], ethnic differences [34], or individuals’
access to health care, or one or more of many other fac-
tors that might influence beliefs or whether these could
explain, at least in part, the differences found. Further,
ethnic groups within a country can be so diverse that
grouping people together “simply on the basis of
country” obscures important differences. Similarly, im-
migrant individuals to a host country may not necessarily
hold views of other individuals who live in that country
and may or may not be partly or fully acculturated in dif-
ferent areas of life, and the level of acculturation could
potentially influence their pain beliefs or coping
responses, as well as the impact of those beliefs and cop-
ing responses on pain and function [77]. Differences un-
der investigation need to be clearly specified. Although
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some may consider between-country differences to be
cultural differences [33,78], others argue that “country”
is not a valid proxy for culture [68].
A second limitation is related to the stringent inclusion
criteria used for this review. For example, we chose to in-
clude studies based on their use of quantitative scales to
assess pain beliefs, coping, or catastrophizing. However,
the use of quantitative scales to assess psychological func-
tions has limitations that have been noted for decades
[79,80]. The widely accepted view is that it is possible to
quantify psychological domains using multiple-item
questions, such as those used in the studies reviewed
here. Either way, an additional way to address the role of
culture in cognitive and behavioral responses to pain
would be by qualitative studies across two or more coun-
tries, and comparison of emergent themes.
The third limitation of this and other systematic
reviews on this topic is the limited number and heteroge-
neity of eligible studies (i.e., they studied different patient
populations and used different scales to assess the same
domain), many of which were of low to moderate quality
for comparison purposes, as most were designed to 1)
evaluate measurement properties of patient-reported
questionnaires or 2) compare between-country differen-
ces using preexisting data sets [20,22]. Findings from ad-
equately powered quantitative and qualitative studies
specifically designed to evaluate the effects of countries,
and using the same set of measures and procedures con-
currently, would be important to be able draw firmer
conclusions.
Finally, the between-country similarities and differen-
ces in the scale scores (of pain beliefs/appraisal, coping,
and catastrophizing) identified in this review could have
been influenced by the different language versions of the
questionnaires used in eight of the 10 studies included.
To address this issue, future researchers should use cross-
culturally adapted scales that are valid and reliable in
both countries/language being compared whenever
possible.
Conclusions
Despite the review’s limitations, the findings indicate
that between-country differences appear to exist in a
number of pain beliefs/appraisals (specifically, fear
avoidance beliefs), pain coping responses (specifically,
use of resting, guarding, praying, and hoping), and pain
catastrophizing, whereas between-country differences do
not appear to exist for other pain beliefs or coping
responses.
The findings indicate that additional research on the
role of country (both country of origin and country
where an individual lives) in pain responses is warranted.
Such research should 1) use procedures specifically
designed to address this question including the collection
of data at the same time using measures that are known
to be culturally relevant (e.g., have the same underlying
meaning in the samples studied) and 2) use qualitative
approaches to evaluate pain-related beliefs/appraisals,
coping, and catastrophizing to identify similar and differ-
ent themes in the different samples.
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Translation, cross-cultural adaptation and
psychometric properties of the Nepali
versions of numerical pain rating scale and
global rating of change
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Abstract
Background: Pain intensity and patients’ impression of global improvement are widely used patient-reported
outcome measures (PROMs) in clinical practice and research. They are commonly assessed using the Numerical Pain
Rating Scale (NPRS) and Global Rating of Change (GROC) questionnaires. The GROC is essential as an anchor for
evaluating the psychometric properties of PROMs. Both of these PROMs are translated to many languages and have
shown excellent psychometric properties. Their availability in Nepali would facilitate pain research and cross-cultural
comparison of research findings. Therefore, the objectives of this study were to translate and cross-culturally adapt the
NPRS and GROC into Nepali and to assess the psychometric properties of the Nepali version of the NPRS (NPRS-NP).
Methods: After translating and cross-culturally adapting the NPRS and GROC into Nepali using recommended
guidelines, NPRS-NP was administered to 104 individuals with musculoskeletal pain twice. The Nepali version of the
GROC (GROC-NP) was administered at the follow-up for anchor-based assessment. (1) Test-retest reliability and
minimum detectable change (MDC) among the stable group, (2) construct validity (by single sample t-test within the
improved group and independent sample t-test between groups), and (3) concurrent validity were assessed. Receiver
operating characteristic (ROC) curves were plotted to determine the responsiveness of the NPRS-NP using the area
under the curve (AUC), and minimum important changes (MIC) for small, medium and large improvements.
Results: Significant cultural adaptations were required to obtain relevant Nepali versions of both the NPRS and GROC.
The NPRS-NP showed excellent test-retest reliability and a MDC of 1.13 points. NPRS-NP demonstrated a good
construct validity by significant within-group difference in mean of NPRS score- t(63)= 7.57, P < 0.001 and statistically
significant difference of mean score- t(98)= -4.24, P < .001 between the stable and improved groups. It demonstrated
moderate concurrent correlation with the GROC-NP; r = 0.43, P < 0.01. Responsiveness of the NPRS-NP was shown at
three levels with AUC = 0.68–0.82, and MIC = 1.17–1.33.
Conclusions: The NPRS and GROC were successfully translated and culturally adapted into Nepali. The
NPRS-NP demonstrated good reliability, validity and responsiveness in assessing musculoskeletal pain
intensity in a Nepali population.
Keywords: Outcome measure, Assessment, Pain, Global change, Pain assessment, Numerical rating scale,
Pain intensity, Pain measurement, Outcome measurement, Global impression of change
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Background
Outcome measurement is essential to monitoring and
improving the quality and effectiveness of health care
[1]. Assessment of pain intensity [2] and patients’ im-
pression of global improvement [3] are important “pa-
tient-centred” outcomes in both clinical practice and
research, as patients are asked to rate their own pain in-
tensity and global change in their health status [4, 5].
Further, assessment of patients’ impression of global im-
provement is recommended as an anchor for assessment
of the measurement properties of patient-reported out-
come measures (PROMs) [6].
Pain intensity is often the primary focus of treatment
[7], and is a preferred outcome of assessment in both
clinical practice and research for conditions such as can-
cer, rheumatic diseases, low back/ neck conditions and
post-operatively [8–11]. Pain intensity is routinely
assessed in clinical practice using the Numerical Pain
Rating Scale (NPRS) [12]. It has acceptable psychometric
properties. Out of many versions of numerical rating
scales, the 11-point NPRS is commonly preferred [4, 9].
The anchor at the left is 0, corresponding to “no pain”,
and the anchor at the right side means “worst possible
pain” or “maximum pain”. The NPRS is a very simple to
use measure, can be administered by patient self-report,
or verbally by face-to-face interview, or over a telephone,
and has wide applicability to a variety of pain-related
conditions [9, 13–15]. One of the advantages of this
measure is that it can also be used in individuals with
low literacy. It is used routinely in many countries and
languages [9].
The global rating of change (GROC) scale was de-
signed for use as an external anchor to determine min-
imal important change of health-related quality of life
measures [16]. The GROC scale is easy to administer, re-
quires minimal skills or training, has good reproducibil-
ity, and is sensitive to change [1, 17]. While scores
correlate with pain, disability and quality-of-life mea-
sures, the open nature of the question allows the patient
to take into account other factors that he or she may
consider important in his or her clinical situation [3]. It
is a Likert scale with a mid-point representing “no
change”, a left anchor representing “very much worse”
and a right anchor representing “very much better” or
“recovered completely”. A variety of GROC scales have
been used in research including 15 points, 11 points and
7 points [3]. The originally proposed scale was the 15-
point scale [16], while in contemporary use 11-point and
7-point measures are recommended [3].
Use of outcome measures is limited in Nepal because
of low literacy levels, unavailability of measures in Nepali
and unawareness of need and usefulness of outcome
measures. Despite the acceptable validity and reliability
and wide applicability of NPRS and GROC measures,
neither the NPRS nor GROC are available in Nepali. Be-
fore PROMs can be used in clinical practice and re-
search, they should be translated, cross-culturally
adapted and validated in the language of the target
population [18]. For a measure to be acceptable to use,
it is important to know its measurement properties such
as reproducibility, validity and responsiveness to change
due to treatment or time [18, 19]. Translation of these
measures to Nepali using standard recommended
guidelines can improve their wide use in both research
and patient care in Nepal. Translation of GROC is par-
ticularly important to provide an external anchor that
researchers in future can use to investigate the clini-
metrics of other outcome measures in Nepal.
Therefore, the primary aim of this study was to trans-
late and cross-culturally adapt the NPRS and GROC in
accordance with internationally accepted guidelines [18].
Secondary objectives of the study were to evaluate, using
a GROC anchor-based approach, the psychometric
properties of the Nepali version of the NPRS (NPRS-
NP) including the: test-retest reliability, minimum de-
tectable change (MDC), construct and concurrent valid-
ity, and the minimum important change (MIC). We
hypothesized that translation of the NPRS and GROC to
Nepali will provide outcome measure instruments with
acceptable psychometric properties.
Methods
The study protocol was approved by Institutional Review
Committee of Kathmandu University School of Medical
Sciences, Dhulikhel, Nepal, and complies with the prin-
ciples outlined in the Declaration of Helsinki. Every par-
ticipant provided a written informed consent prior to
the start of the study. In the event participants were un-
able to sign the consent form themselves, a witness
signed for them. The conduct and reporting of this re-
search was guided by the guidelines proposed by Beaton
and colleagues in 2000 for the process of cross-cultural
adaptation of self-report measures [18] and by the
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) guidelines [20].
Participants
To be eligible to participate in the study, participants
were required to be: (1) over 18 years, (2) a citizen of
Nepal, (3) able to understand and speak Nepali fluently,
(4) say numbers from 0 to 10 in order, and (5) currently
experiencing musculoskeletal pain. Exclusion criteria in-
cluded: any past surgeries related to the current pain; re-
cent history of trauma; presence of red flags suggesting
the presence of tumor and infection; and diagnosed psy-
chiatric illnesses. A sample more than 100 is considered
adequate in order to assess the psychometric properties
of a patient-reported outcome measure [20], therefore,
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we recruited 104 individuals with musculoskeletal pain
who consented to participate in the study and completed
all the measures. Of these, 75 (72%) were recruited from
the Physiotherapy Out-patient Department of Dhulikhel
Hospital and 29 (28%) from the surrounding commu-
nity. This gave a representative mix of rural and semi-
urban participants. We recruited participants between
October 2015 and April 2016.
The study was conducted in two phases: Phase 1 - the
translation and cross-cultural adaptation of NPRS and
GROC to Nepali, including the pre-testing of the trans-
lated Nepali versions; and Phase 2 – investigation of the
psychometric properties of NPRS-NP.
Phase 1: Translation process
The translation of NPRS and GROC into Nepali
followed the standard guidelines for translation and
cross-cultural adaptation of patient-reported outcome
measures [18]. We chose to translate these measures
into Nepali because Nepali is the national language of
Nepal; it is the most common language spoken in Nepal,
with 45% Nepalese speak Nepali as the first language,
followed by “Maithili” (12%) [21]; and it is taught in
schools as a compulsory subject. The translation process
included:
Forward translations
Three native Nepali speakers (one physiotherapist, one
professional translator and one naïve non-medical pro-
fessional) independently translated the original English
versions of the NPRS and GROC to Nepali, resulting in
3 versions: T1, T2 and T3.
Synthesis
A single Nepali version (T4) was created following dis-
cussion and consensus among the three translators and
the principal investigator (SS).
Back-translations
T4 was then back-translated independently by three na-
tive English speakers unaware of the purpose of the
translation and blind to the original English version
resulting in 3 versions: T5, T6 and T7. Inconsistencies
were discussed among the back translators and a single
synthesized version was produced.
Expert committee meeting
An expert committee was formed which consisted of the
researchers, translators, methodologist, and a language
expert (professional translator). Discussions were under-
taken to resolve any discrepancies in the translations
that did not reflect the original English version. A final
Nepali version (T8) was approved after significant
(cross-cultural) modifications on both the measures (see
the Results section below). Questionable words or
phrases in the Nepali version were replaced with alterna-
tive Nepali wordings which the committee considered to
be reasonable cultural adaptations that maintained the
meaning of the English version but were not a direct lit-
eral translation. In some instances two options were put
forward to be evaluated during the pre-testing of the
translation process to obtain the most appropriate op-
tion. Translators who were not available to attend the
meeting in person were contacted to confirm that all
parties were in agreement. From these discussions pre-
final versions of the NPRS and GROC were created
(TNP). All translated versions (with the final back trans-
lated English version) were then sent to a senior re-
searcher (JHA) for final comments and approval.
Pre-testing
The approved TNP versions of NPRS and GROC were
then pre-tested on 30 individuals with self-reported
musculoskeletal pain. This sample selected was repre-
sentative of population age, sex and education level.
During the pre-testing, participants were interviewed to
complete the TNP versions of NPRS and GROC. The
participants were asked if they understood the actual
meaning of the TNP upon completion. The participants
were also asked for their preference in any unresolved
alternative Nepali translations of word choices put for-
ward by the expert committee, and majority preferences
were adopted. In response to participants’ feedback,
minor corrections were made to improve the sentence
structure of the instructions to make it easier for the
participants to understand, and the final Nepali versions
of NPRS and GROC were finalised (NPRS-NP and
GROC-NP respectively).
Phase 2: NPRS-NP psychometric testing procedure
A longitudinal single-arm cohort design was adopted to
assess the test-retest reliability, minimal detectable
change (MDC) and minimal important change (MIC) of
the NPRS-NP. Data were collected at two time points, at
an initial assessment and between 1 and 2 weeks after at
a follow-up assessment. No information about the previ-
ous NPRS-NP scores were provided to the study partici-
pants at the follow-up assessment. The 7 – item Nepali
version of GROC (GROC-NP) was also administered in-
dependently at the follow-up to assess the participants’
perception of their global rating of change. The research
assistant (JP) administering the measures was trained by
the principal investigator (SS). All the research partici-
pants were interviewed in order to maintain the uni-
formity of the data collection and not to exclude
illiterate participants. To minimize loss to follow-up,
phone call interviews were conducted for any partici-
pants recruited from the hospital who could not attend
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subsequent follow-up appointments. To facilitate follow
up among the community participants, a research assist-
ant visited individuals at a time convenient to them.
Data analysis
Data were manually entered into Microsoft Excel and
later were transferred to Statistical Package for Social
Sciences (SPSS) version 24 for further analysis. Sociode-
mographic variables including age, sex, ethnicity, educa-
tion and occupation were reported using descriptive
statistics. Distribution of pain was reported as frequency
count and percentage by body part affected, and dur-
ation of pain (in months) was reported as mean and
standard deviation. To differentiate between the re-
sponders (Improved group) versus non-responders
(Stable group) and to report small, medium, and large
improvements (changes) in their NPRS-NP scores,
GROC-NP was used as an external anchor [3]. Partici-
pants who chose “same as before”, a score of ‘4’ on
GROC-NP were classified as the stable or unchanged
group, whereas the participants who chose “slight im-
provement” ‘5’, “moderate improvement” ‘6’ or “a lot of
improvement” ‘7’ were classified as responders [22].
Three sensitivity analyses were performed separately on
the groups that achieved small, medium and large im-
provements [12].
For both the initial measurement and final measure-
ment, average scores of NPRS-NP current, minimum,
and maximum pain intensities were reported. Change in
NPRS-NP scores was computed for individual partici-
pants by subtracting the NPRS-NP final measurement
from the baseline score.
Reliability
Test-retest reliability was evaluated for the stable group
by using Intraclass Correlation Coefficient (ICC). ICC
values closer to 1.0 indicate higher test-retest reliability
[6]. We hypothesized that the test-retest reliability would
be excellent for the stable group which will lie between
0.7–0.9 [23–25].
It has been suggested that ICC scores do not take into
account the scale of measurement and the size of error
that is clinically relevant [26]. Therefore, a complemen-
tary way of measuring reliability or limit of agreement
was also performed using ‘Bland-Altman Plots’, where
the difference between baseline and final NPRS-NP
values (in Y-axis) were plotted against the mean of
NPRS-NP scores at baseline and final measurement (in
X-axis) [26, 27].
Minimal detectable change (MDC) is the lowest esti-
mate of change of an outcome measure beyond random
measurement error [1]. MDC90 (MDC at the 90% confi-
dence margin) was calculated for the NPRS-NP using the
formula, MDC90 = z x √2 x SEM, where SEM is the
standard error of measurement and z = 1.64 (z score for
estimating a 90% confidence interval). We used square
root of 2, because a total of two measurements were done
for test-retest stability. Finally, we calculated SEM manu-
ally by using the formula, SEM= SD (1 - r)1/2 [1] where
SD is the standard deviation for the mean change of
NPRS-NP score from baseline to final measurement, and
r = reliability coefficient i.e. Intra-class Correlation Coeffi-
cient (ICC) of the stable group. We hypothesized that the
MDC90 value would lie between 0.5 and 2.5 [25, 28].
Validity
The construct validity of the NPRS-NP was examined
in two stages [1]. In the first stage, mean change of NPRS-
NP score was tested within the improved group by using a
one sample t-test. In the second stage, mean change
scores were tested between stable and improved groups
using independent samples t-test. It was hypothesized the
NPRS-NP would demonstrate construct validity with a
significant difference P < 0.05 in the NPRS-NP score
within the group that “improved” and in the NPRS-NP
scores between the stable group and the improved group.
The concurrent validity was evaluated by comparing the
difference of NPRS-NP scores at baseline and final meas-
urement with the score of the GROC-NP. We hypothe-
sized that NPRS-NP would moderately (but significantly
P < 0.05) correlate with GROC-NP score considering
Spearman correlation coefficients of 0.36 to 0.67 to be
moderate correlation [29].
Responsiveness
Responsiveness is the validity of an instrument for asses-
sing change over time. Responsiveness was evaluated in
five steps as recommended by de Vet and colleagues [6]:
(1) GROC-NP was used as the external anchor for the
construct of interest (for the assessment of pain intensity
using NPRS-NP), (2) individuals with musculoskeletal
pain were chosen as the population of interest as they
experience varying levels of pain intensity, (3) we consid-
ered that the AUC of 0.7 or more acceptable for the abil-
ity of NPRS-NP to differentiate between the groups that
improved (4) the changes in scores of NPRS-NP over
two time points were calculated with the independently
collected GROC scores, and (5) accuracy of the classifi-
cation between changes in NPRS-NP scores and the re-
sponder/ stable categories were assessed using a
Receiver Operator Characteristic (ROC) curve.
Area under this curve (AUC) indicates the accuracy of
NPRS-NP for differentiating between the group that im-
proved or remained stable. The value of AUC for the dif-
ference of NPRS-NP closer to “1” indicates better
agreement with the GROC-NP as an external anchor or
the gold standard where AUC = 0.5 means that NPRS-
NP cannot accurately differentiate between the group
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that improves and that does not beyond chance [30, 31].
Sensitivity analyses were conducted, with ROC curves
and values of AUC determined for the sub-groups which
demonstrated small improvement (GROC = 5), medium
improvement (GROC = 6) and large improvement
(GROC = 7). It was hypothesized that the AUC values
would be equal to or more than 0.7 in each instance.
Minimal important change (MIC) for NPRS-NP was
identified with reference to the patient reported score of
GROC-NP to differentiate the group that improved and
that did not, at three levels of meaningful change as de-
scribed above. Sensitivity and specificity values were also
recorded. We hypothesized that NPRS-NP would be
sensitive to change with MIC value between 1.1 and 3.5
as reported in the literature [12, 25, 28, 32, 33].
Results
Phase 1: Translation and cross-cultural adaptation
NPRS: An important change was made to the right an-
chor of the T4 version of NPRS-NP during the expert
committee meeting. The literal translation of “worst pain
possible” or “worst imaginable pain” did not convey the
original meaning in the Nepali language, it sounded
‘funny’. The expert committee’s proposal of two alterna-
tive anchors were more natural in Nepali and translated
back to English as “extreme pain” and “unbearable pain”.
Participants in the pre-testing phase when given the
choice of the three Nepali end anchor options gave a
unanimous preference for the two culturally adapted
phrases. Therefore, the Nepali translation of “worst pos-
sible pain” was discarded and translations of both “ex-
treme pain” and “intolerable pain” were retained. See
Additional file 1 for the final Nepali version of NPRS.
GROC: Initially, translation of the original 15 point
GROC [16] was attempted. The expert committee’s dis-
cussion however, highlighted that the Nepali translations
for each item of GROC were not reflective of the English
items as the meaning of the items could not be replaced
by Nepali words in the increasing order from 7 to 15
and decreasing order from 7 to 1, there were too many
subtle gradations. The committee decided to adopt the
7-point version of the GROC which is a recommended
version [3]. The 7-point measure is a numerical rating
scale with verbal descriptor for each item with the mid-
point “4” which means “no change”, the left anchor “1”
means “very much worse” and the right anchor “7”
means “recovered completely” or “very much better”. A
score more than or equal to 6 on the scale is considered
meaningful improvement [3, 34]. The most applicable
seven items from the 15-item GROC translations were
retained to comprise the 7-item Nepali version of the
GROC (GROC-NP) for pre-testing. During the pre-
testing, all the participants (N = 30) could identify num-
bers between 0 and 10, and could understand and
complete the scale without difficulty. Semantic equiva-
lence of the GROC-NP was assured. Only minor
changes were made in the sentence structure of the in-
struction during the pre-testing after the feedback from
the participants. See Additional file 2 for the final Nepali
version of GROC.
Phase 2: Psychometric properties of the NPRS-NP
All of the 104 participants (100%) completed the follow
up assessment. The baseline and the final assessments
for all the participants were performed with an average
interval of 11.5 (SD 3.5) days while the duration ranged
from 6 to 18 days.
Responders versus non-responders
Out of the 104 participants, 62% (n = 64) reported >4 on
the GROC-NP scale and therefore were classified as the
‘responders’ and considered the “improved group”.
Whereas 35% (n = 36) reported “no change” (4) on
GROC scale and were considered the stable group. Four
(4%) reported worsening (GROC < 4).
Demographic characteristics
Demographic information collected from the partici-
pants is presented in Table 1. The majority of the partic-
ipants were female, 69% (n = 72); and half the
participants had only attended a primary school or less.
More than half of the participants, 56% (n = 58) reported
an active lifestyle as they either worked at home or on
the fields as farmers.
Assessment of pain site and outcomes
Almost half the participants, 46% (n = 48) had low back
pain (LBP) and 20% (n = 22) had knee pain. Table 1 in-
cludes other sites of pain.
Reliability
The ICC statistic for the test-retest reliability of NPRS-
NP for the stable group (n = 36) at two week follow-up,
the SEM, and the MDC90 are presented on the Table 2.
Bland-Altman Plot drawn between (1) the differences
between the NPRS-NP scores in the baseline and final
measurements in the Y- axis, and (2) the mean of the
two scores in the X-axis is shown in Fig. 1.
Validity
Construct validity
The single sample t-test demonstrated a significant dif-
ference of mean NPRS-NP scores at baseline and follow-
up- t(63) = 7.57, P < 0.001 in the improved group. The
independent sample t-test also revealed a significant dif-
ference- t(98) = −4.24, P < 0.001 between the stable and
improved group.
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Concurrent validity
The mean change of the NPRS-NP scores demonstrated
significant correlation (r = 0.43, P < 0.001) with GROC-
NP scores for the total sample.
Responsiveness
The ROC curves for the differences of NPRS-NP scores
at baseline and final measurements between the im-
proved and stable group are shown in Fig. 2a. Secondary
analyses are shown in Fig. 2b–d for the; (1) small im-
provement group and stable group, (2) medium im-
provement group and stable group and, (3) large
improvement group and stable group. The values of
MIC for small and medium improvement was 1.17 and
1.33 for large improvement. The values of AUC, sensitiv-
ity and specificity are presented in the Table 3.
Discussion
We translated NPRS and GROC into Nepali with signifi-
cant cultural adaptations and that the NPRS-NP demon-
strated good to excellent psychometric properties as
hypothesized.
Translation and cross-cultural adaptation
Direct translation of an outcome measure developed for
one language or culture to another language may not re-
sult in a valid instrument [18, 35]. This study provides
clear evidence for the need of cross-cultural adaptation
after translation of a measure to the target language. For
example, “worst imaginable pain” or “pain as bad as you
can imagine” are widely used as the right anchor on a
NPRS [9] in many languages, and is recommended by
the Initiative on Methods, Measurement, and Pain As-
sessment in Clinical Trials (IMMPACT) [4]. In the
current study, translation of this anchor to Nepali was
attempted by three independent translators, however
none of the versions sounded “natural”. We proposed al-
ternative Nepali translations that mean “maximum pain”
and “intolerable pain” as these phrases as right anchor
which are simpler and easily understood. During the
pre-testing phase, individuals with musculoskeletal pain
were further interviewed and asked for their preference
among the three options of the right anchor proposed.
None of the participants chose the Nepali translation of
“worst imaginable pain”, so it was omitted from final
Nepali translation. A previous systematic review re-
ported that both “maximum pain” and “intolerable pain”
Table 1 Description of the participants with scores of numerical
pain rating scale and global rating of change
Variables Frequency (%) Mean (SD)











No school 41 (39%)
Primary 11 (11%)
Secondary 17 (16%)
Higher secondary 16 (15%)
Bachelor and above 19 (18%)
Occupation
Agriculture and house work 28 (27%)
House work only 22 (21%)
Agriculture only 8 (8%)
Sitting job (Office/ business) 8 (8%)
No work 6 (6%)
Others 32 (31%)
Site of pain
Low back pain 48 (46%)
Knee pain 21 (20%)
Shoulder pain 13 (13%)
Neck 9 (9%)
Elbow pain 5 (5%)
Others 8 (8%)
Total duration of pain (in months) 21.7 (34)
Time between evaluations (in days) 11.5 (3.5)
GROC-NP at follow-up
Worsened (GROC <4) 4 (4%)
Stable group (GROC = 4) 36 (35%)
Improved group (GROC = 5–7) 64 (61%)
Small improvement (GROC = 5) 30 (29%)
Medium improvement (GROC = 6) 23 (22%)
Large improvement (GROC = 7) 11 (11%)
NPRS scores
NPRS-NP baseline 104 4.27 (1.63)
NPRS-NP follow-up 104 3.36 (1.56)
NPRS-NP change 104 0.90 (1.49)
Abbreviations: GROC-NP Nepali version of global rating of change, NPRS-
NP Nepali version of numerical pain rating scale, SD standard deviation
Table 2 Reliability of Nepali- numerical pain rating scale
NPRS GROC
score
Sample (N) Test-retest reliability
as ICC (95% CI)
SEM MDC90
Stable group 4 36 0.81 (0.63, 0.90) 0.49 1.13
Abbreviations: NPRS numerical pain rating scale, GROC global rating of change,
ICC intraclass correlation coefficient, CI confidence interval, SEM standard error
of measurement, MDC90 minimum detectable change at 90% CI
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are used as the right anchor for the NPRS in languages
other than Nepali [9].
Further, we encountered difficulties attempting to
translate the original 15-item GROC scale developed by
Jaeschke and colleagues [16]. The ordinal gradations of
the 15-item scale could not be adequately translated, so
we produced a 7-item scale in the end. This 7-item scale
retained the ordinal property of the scale such that in-
crease of score from 4 to 7 reflect gradual improvement
in health status and decrease in score from 4 to 1 reflect
worsening of the condition. The 7-item scale is exten-
sively used in research [3, 36]. According to previous re-
search in LBP by Lauridsen and colleagues [36],
reduction in the number of items from 15 to 7 does not
appear to impact on the performance of the measure. In
that study, both the 7-item GROC and 15-item GROC
were administered, finding that the classification of im-
provement did not significantly change by the choice of
the GROC scale. They further reported that there were
no differences in the performance of the two versions of
GROC irrespective of how stringent the criteria was for
the improved group. The briefer scale should be easier
for the participants to complete because of the lesser
number of items. Moreover, the 7-item GROC is the
recommended scale to use for chronic pain trials by
IMMPACT [4].
Reliability
The finding of the current study supported our hypoth-
esis that NPRS would demonstrate an excellent test-
retest reliability (ICC = 0.81) for the stable group. The
test-retest reliability of NPRS-NP is comparable to other
studies investigating the clinimetric properties of the
NPRS [25, 28], but lower than the 48 h test-retest reli-
ability of the Arabic version (ICC = 0.89) [37]. We
followed up participants in the current study after one
to two weeks (mean 11.5 days with 3.5 days of SD), as
recommended in the literature for the test-retest reliabil-
ity, which is long enough to avoid recall bias [6]. The
duration of the follow-up in our study lies between the
duration reported in the previous studies i.e., interval of
2 to 4 days, and between 2 and 4 weeks in different
studies [25, 28, 37]. This shows that the reliability of
NPRS is similar or comparable irrespective of duration
of the follow-up. Similarly, the value of MDC90 of
NPRS-NP in the current study was 1.13, which was
found to be lower than that of the English version
(MDC = 2.1 and 2.5) [25, 28], and the Arabic version
(MDC = 1.96) [37].
Validity
As hypothesized, the NPRS-NP demonstrated good con-
struct validity. We found the NPRS-NP demonstrated a
significantly different scores within the group that im-
proved on the GROC anchor. This finding also supports
the discriminating property of the GROC-NP as an ex-
ternal anchor. Further support of the construct validity
of the NPRS-NP (also GROC-NP) was provided by the
between-group difference in the NPRS score change, be-
tween the stable and improved groups.
Fig. 1 Bland-Altman plot of Numerical Pain Rating Scale. Y-axis is the change of NPRS-NP scores between baseline and follow-up measurements
and X-axis is the mean of NPRS-NP scores at the baseline and final measurements. Solid line is the mean change of score (d̄); and green lines are
d̄ ± Z x SDchange (where Z = 1.64 for 90% confidence interval)
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Fig. 2 Receiver operating characteristic (ROC) curves. a Receiver Operating Characteristic (ROC) Curve for the stable group (GROC=4) versus
improved group (GROC=5-7). Area under this curve (AUC) indicates the accuracy of NPRS-NP for differentiating between the stable and improved
group with the value of AUC closer to “1” indicating better agreement with the GROC-NP as an external anchor. b Receiver Operating
Characteristic (ROC) Curve for small improvement group (GROC=5). Area under this curve (AUC) indicates the accuracy of NPRS-NP for
differentiating between the stable group and the group that had a small improvement with the value of AUC closer to “1” indicating better
agreement with the GROC-NP as an external anchor. c Receiver Operating Characteristic (ROC) Curve for the medium improvement group
(GROC=6). Area under this curve (AUC) indicates the accuracy of NPRS-NP for differentiating between the stable group and the group that had a
medium improvement with the value of AUC closer to “1” indicating better agreement with the GROC-NP as an external anchor. d Receiver
Operating Characteristic (ROC) Curve for the large improvement group (GROC=7). Area under this curve (AUC) indicates the accuracy of NPRS-NP
for differentiating between the stable group and the group that had a large improvement with the value of AUC closer to “1” indicating better
agreement with the GROC-NP as an external anchor
Table 3 Responsiveness of Nepali- numerical pain rating scale
AUC MIC Sensitivity Specificity
AUC 95% CI
Primary analysis (GROC 4 vs GROC 5–7) 0.74 0.64 0.84 1.17 0.53 0.89
Small improvement (GROC 4 vs GROC = 5) 0.75 0.64 0.87 1.17 0.57 0.89
Medium improvement (GROC 4 vs GROC = 6) 0.68 0.54 0.83 1.17 0.43 0.89
Large improvement (GROC 4 vs GROC = 7) 0.82 0.67 0.98 1.33 0.64 0.89
Abbreviations: AUC area under the curve, CI confidence interval, MIC minimum important change, GROC global rating of change
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The results also confirmed our hypothesis regarding
the concurrent validity of NPRS-NP, with NPRS change
scores moderately correlated with GROC-NP (r = 0.43),
which is within the range reported in the literature (rs =
0.26–0.57) [25, 28].
Responsiveness
The NPRS-NP was found to be sensitive to change with an
MIC ranging from 1.17 to 1.33 for small to large improve-
ments. The MIC in the current study meets the require-
ment of being greater than the MDC value for the NPRS-
NP which means that the value for important change ex-
ceeds measurement error, in contrast to the previous stud-
ies [25, 28]. The previous studies have found the MIC for
NPRS between 0.9 and 4.5 [12, 13, 25, 28, 32–34, 38], with
value closer to 2 as the most commonly accepted important
change for the patients with both acute and chronic pain
conditions [32, 33]. The MIC of NPRS-NP in the current
study is comparable to the previous research by Cleland
and colleagues (MIC 1.3) [25] and Mintken and colleagues
(MIC 1.1) [28] which reported MIC values for neck pain
and shoulder pain respectively. Higher MIC values (be-
tween 2.2 to 4.5) have also been reported in the studies on
LBP [34, 38]. The range of MIC estimates across small,
medium and large improvements is narrower than a previ-
ous report, which showed estimates for the NPRS of 1.5,
3.0 and 3.5, respectively [12]. Variations in the values of
MIC can be a result of variations in the method of assess-
ment of MIC [34, 39], the population sampled, and chron-
icity of the condition [34]. For example, van der Roer and
colleagues studied MIC in sub-acute and chronic LBP and
found that values of MIC were greater for chronic condi-
tions compared to sub-acute conditions for a number of
outcome measures (which also included NPRS) [34]. Fi-
nally, the findings on MIC of our study is slightly higher
than MIC on children and adolescent (MIC = 0.9–1.0), as
reported in a recent systematic review [13].
Strengths and limitations
The results of the current study are supported by a strong
methodology, demonstrated by; no loss to follow-up, two
independent measurement points at a mean interval of
11.5 days, and the external GROC measurement confirm-
ing the stable and improved groups. However, the study
also encounters a number of limitations. First, the COS-
MIN checklist rates the methodological quality of a study
on test-retest reliability as excellent if the sample is more
than 100 [40], a larger subset for each of the stable and
improved groups may have strengthened the results on re-
liability. We recommend the use of more than a single
measurement of pain intensity, including the assessment
of worst pain, best pain, average pain and current pain in
the clinical setting which is suggested to increase the reli-
ability of the pain intensity assessment [6].
Second, assessment of overall change using a GROC
scale is a standard practice in psychometrics study, GROC
score depends on overall change and not just pain inten-
sity. For the same reason, the COSMIN recommends to
ask patients' perception of improvement on the same con-
struct (i.e. pain intensity in this case) than their global im-
provement [6]. Considering this recommendation, the
construct validity of NPRS-NP was not entirely met. Fu-
ture research might test the psychometric properties of
NPRS by utilizing two versions of GROC i.e. one that asks
participants to rate their (1) global improvement and (2)
specific improvement in pain intensity to see if they yield
different psychometric properties of NPRS-NP.
Third, the sensitivity values of NPRS-NP ranged be-
tween 0.43 to 0.64, which indicate that the diagnostic abil-
ity of NPRS-NP to distinguish between the stable and
improved group should be reconsidered. De Vet and col-
leagues questioned the application of MIC at individual
level if the sensitivity and specificity of a measure are less
than 75% [6]. The reasons for the lower values of sensitiv-
ity of the NPRS-NP may be due to the difficulty in under-
standing the concept of the NPRS because the sample
included a large proportion of the participants with low
education level and varied ethnicity. Although the number
of participants who struggled to complete NPRS was not
documented, it was noted that repeated explanations had
to be given on the numerical nature of the NPRS-NP be-
fore some participants were able to complete the NPRS-
NP scale. Other participants did not rate the pain intensity
in a single number and reported their intensity of pain in
a range; for example 3–5 out of 10. In these cases, we con-
sistently recorded the higher number as the participant’s
response. In contrast to the difficulties in completing the
NPRS-NP, participants easily completed the GROC scale,
probably due to the descriptive nature of GROC which
has verbal descriptors in addition to a numeric scores. We
recommend that Nepalese should be asked for their pref-
erences for the choice of measure for assessment of pain
intensity in future research to assess if they prefer other
measures of pain assessment such as a verbal rating scale
or a faces pain rating scales over numerical rating scale,
due to this apparent difficulty with numerical rating.
Fourth, it is also worth noting that the sample used in
this study comprised of a variety of ethnic groups, which
could also raise a question whether differences in ethnicity
may have affected the study findings. As we included only
participants who could fluently speak and understand
Nepali, variation in ethnicity may be unlikely to have influ-
enced our results. Inclusion of individuals with lower edu-
cation and different ethnic groups could be considered a
strength of the study, as it improves the generalizability of
the study findings to the Nepalese population.
Finally, as the NPRS is considered an ordinal scale,
caution should be used with regard to treating it as a
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ratio scale like visual analogue scale (VAS); this is con-
sidered an important disadvantage of it as a measure for
assessment of pain intensity in research [41]. Neverthe-
less, researchers have argued that an outcome measure
with multiple items using a Likert scale can generally be
confidently treated as an interval scale [42]. Likewise, re-
search investigating the correlations of NPRS with VAS
have consistently found strong correlations both in the
adult (rs = 0.94–0.96) [43, 44] and pediatric populations
(rs = 0.74–0.96) [13].
Conclusions
The Nepali version of NPRS and GROC were success-
fully translated after cultural adaptations. NPRS-NP
demonstrated good reliability, validity, and ability to de-
tect change in pain intensity over time in Nepalese with
musculoskeletal pain.
Additional files
Additional file 1: The Nepali version of Numerical Pain Rating Scale
(NPRS). (PDF 345 kb)
Additional file 2: The Nepali version of Global Rating of Change (GROC-
NP). (PDF 342 kb)
Abbreviations
AUC: Area under the curve; CI: Confidence interval; COSMIN: COnsensus
Based Standards for the selection of health Measurement INstruments;
GROC: Global rating of change; GROC-NP: Nepali version of global rating of
change; ICC: Intraclass correlation coefficient; IMMPACT: Initiative on
methods, measurement, and pain assessment in clinical trials; LBP: Low back
pain; MDC: Minimum detectable change; MDC90: Minimum detectable
change at 90% confidence margin; MIC: Minimum important change;
NPRS: Numerical pain rating scale; NPRS-NP: Nepali version of numerical pain
rating scale; PROMs: Patient-reported outcome measures; ROC: Receiver
operating characteristic; SD: Standard deviation; SEM: Standard error of
measurement
Acknowledgements
Authors would like to acknowledge (1) all the translators who translated
NPRS and GROC measures into Nepali, and (2) all the research participants
who volunteered to participate in this study.
Funding
None declared.
Availability of data and materials
The dataset used and analysed during the current study are available from
the corresponding author on reasonable request.
Authors’ contributions
SS- Conception of the study, methodology, data acquisition, data analysis
and interpretation, preparation of the first manuscript draft, revisions of
manuscript drafts. JP – Data collection, data entry, revisions of manuscript
drafts. DR – Translation, revisions of the translations, feedback on the final
Nepali versions. JHA - Conception of the study, methodology, review of the
final translation, data analysis and interpretation, revisions of manuscript
drafts. All authors approved of the final manuscript draft for submission.
Ethics approval and consent to participate
Ethical approval for the current study was obtained from Institutional Review
Committee of Kathmandu University School of Medical Sciences, Dhulikhel
with ethical approval number: 74/15.
All the participants provided informed consent before the start of the study.
Those participants who could not sign, verbally provided consent to




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Physiotherapy, Kathmandu University School of Medical
Sciences, Dhulikhel, Kavre, Nepal. 2Centre for Musculoskeletal Outcomes
Research, Dunedin School of Medicine, University of Otago, Dunedin, New
Zealand. 3Scheer Memorial Hospital, Banepa, Nepal. 4University of Sydney,
Sydney, Australia.
Received: 2 August 2017 Accepted: 23 November 2017
References
1. Hefford C, Abbott JH, Baxter GD, Arnold R. Outcome measurement in
clinical practice: practical and theoretical issues for health related quality of
life (HRQOL) questionnaires. Phys Ther Rev. 2011;16:155–67.
2. Clement RC, Welander A, Stowell C, Cha TD, Chen JL, Davies M, Fairbank JC,
Foley KT, Gehrchen M, Hagg O, et al. A proposed set of metrics for
standardized outcome reporting in the management of low back pain. Acta
Orthop. 2015;86(5):523–33.
3. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of
strengths and weaknesses and considerations for design. J Man Manip Ther.
2009;17(3):163–70.
4. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz
NP, Kerns RD, Stucki G, Allen RR, Bellamy N, et al. Core outcome
measures for chronic pain clinical trials: IMMPACT recommendations.
Pain. 2005;113(1–2):9–19.
5. Fitzgerald GK, Hinman RS, Zeni J Jr, Risberg MA, Snyder-Mackler L, Bennell
KL. OARSI clinical trials recommendations: design and conduct of clinical
trials of rehabilitation interventions for osteoarthritis. Osteoarthr Cartil. 2015;
23(5):803–14.
6. De Vet HC, Terwee CB, Mokkink LB, Knol DL. Measurement in medicine: a
practical guide: Cambridge University Press; 2011. https://www.cambridge.
org/core/books/measurement-in-medicine/
8BD913A1DA0ECCBA951AC4C1F719BCC5.
7. Sullivan MD, Ballantyne J. Must we reduce pain intensity to reduce chronic
pain. Pain. 2015; epub ahead of print
8. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a
comparison of six methods. Pain. 1986;27(1):117–26.
9. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH,
Fainsinger R, Aass N, Kaasa S. Studies comparing numerical rating scales,
verbal rating scales, and visual analogue scales for assessment of pain
intensity in adults: a systematic literature review. J Pain Symptom Manag.
2011;41(6):1073–93.
10. Dijk JFMV, Wijck AJMV, Kappen TH, Peelen LM, Kalkman CJ, Schuurmans
MJ. Postoperative pain assessment based on numeric ratings is not the
same for patients and professionals: a cross-sectional study. Int J Nurs
Stud. 2012;49:65–71.
11. Aicher B, Peil H, Peil B, Diener HC. Pain measurement: visual analogue scale
(VAS) and verbal rating scale (VRS) in clinical trials with OTC analgesics in
headache. Cephalalgia. 2012;32(3):185–97.
12. Abbott JH, Schmitt J. Minimum important differences for the patient-
specific functional scale, 4 region-specific outcome measures, and the
numeric pain rating scale. J Orthop Sports Phys Ther. 2014;44(8):560–4.
13. Castarlenas E, Jensen MP, von Baeyer CL, Miro J. Psychometric properties of
the numerical rating scale to assess self-reported pain intensity in children
and adolescents: a systematic review. Clin J Pain. 2017;33(4):376–83.
Sharma et al. Health and Quality of Life Outcomes  (2017) 15:236 Page 10 of 11
14. Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M. Systematic
review of endometriosis pain assessment: how to choose a scale? Hum
Reprod Update. 2015;21(1):136–52.
15. Castarlenas E, de la Vega R, Jensen MP, Miro J. Self-report measures of hand
pain intensity: current evidence and recommendations. Hand Clin. 2016;
32(1):11–9.
16. Jaeschke R, Singer J, Guyatt GH. Measurement of health status.
Ascertaining the minimal clinically important difference. Control Clin
Trials. 1989;10(4):407–15.
17. Terwee CB, Roorda LD, Dekker J, Bierma-Zeinstra SM, Peat G, Jordan KP,
Croft P, de Vet HC. Mind the MIC: large variation among populations and
methods. J Clin Epidemiol. 2010;63(5):524–34.
18. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process
of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976).
2000;25(24):3186–91.
19. Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the
translation and cross-cultural validation of health status questionnaires. Eval
Health Prof. 2005;28(2):212–32.
20. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter
LM, de Vet HC. The COSMIN checklist for assessing the methodological
quality of studies on measurement properties of health status measurement
instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49.
21. Nepal Go: National Population and housing census 2011 (National Report).
In. Edited by Statistics CBo, vol. 1. Kathmandu: NHPC; 2012.
22. de Vet HCW, Terluin B, Knol DL, Roorda LD, Mokkink LB, Ostelo RWJG,
Hendriks EJM, Bouter LM, Terwee CB. Three ways to quantify uncertainty in
individually applied "minimally important change" values. J Clin Epidemiol.
2010;63(1):37–45.
23. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed
and standardized assessment instruments in psychology. Psychol Assess.
1994;6(4):284–90.
24. Taylor LJ, Herr K. Pain intensity assessment: a comparison of selected pain
intensity scales for use in cognitively intact and cognitively impaired African
American older adults. Pain Manag Nurs. 2003;4(2):87–95.
25. Cleland JA, Childs JD, Whitman JM. Psychometric properties of the neck
disability index and numeric pain rating scale in patients with mechanical
neck pain. Arch Phys Med Rehabil. 2008;89(1):69–74.
26. Bland JM, Altman DG. A note on the use of the intraclass correlation
coefficient in the evaluation of agreement between two methods of
measurement. Comput Biol Med. 1990;20(5):337–40.
27. Francq BG, Govaerts B. How to regress and predict in a bland-Altman plot?
Review and contribution based on tolerance intervals and correlated-errors-
in-variables models. Stat Med. 2016;35(14):2328–58.
28. Mintken PE, Glynn P, Cleland JA. Psychometric properties of the shortened
disabilities of the arm, shoulder, and hand questionnaire (QuickDASH) and
numeric pain rating scale in patients with shoulder pain. J Shoulder Elb
Surg. 2009;18(6):920–6.
29. Taylor R. Interpretation of the correlation coefficient: a basic review. Journal
of Diagnostic Medical Sonography. 1990;6(1):35–9.
30. Liang MH. Evaluating measurement responsiveness. J Rheumatol. 1995;22(6):
1191–2.
31. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health
status measures. Statistics and strategies for evaluation. Control Clin Trials.
1991;12(4 Suppl):142S–58S.
32. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance
of changes in chronic pain intensity measured on an 11-point numerical
pain rating scale. Pain. 2001;94(2):149–58.
33. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically
important difference in pain outcome measures. Pain. 2000;88(3):287–94.
34. van der Roer N, Ostelo RW, Bekkering GE, van Tulder MW, de Vet HC.
Minimal clinically important change for pain intensity, functional status, and
general health status in patients with nonspecific low back pain. Spine
(Phila Pa 1976). 2006;31(5):578–82.
35. Sharma S, Pathak A, Jensen MP. Words that describe chronic
musculoskeletal pain: implications for assessing pain quality across cultures.
J Pain Res. 2016;9:1057–66.
36. Lauridsen HH, Hartvigsen J, Korsholm L, Grunnet-Nilsson N, Manniche C. Choice
of external criteria in back pain research: does it matter? Recommendations
based on analysis of responsiveness. Pain. 2007;131(1–2):112–20.
37. Alghadir AH, Anwer S, Iqbal ZA. The psychometric properties of an Arabic
numeric pain rating scale for measuring osteoarthritis knee pain. Disabil
Rehabil. 2016;38(24):2392–7.
38. Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale
in patients with low back pain. Spine (Phila Pa 1976). 2005;30(11):1331–4.
39. Froud R, Abel G. Using ROC curves to choose minimally important change
thresholds when sensitivity and specificity are valued equally: the forgotten
lesson of pythagoras. Theoretical considerations and an example application
of change in health status. PLoS One. 2014;9(12):e114468.
40. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter
LM, de Vet HC. COSMIN checklist manual. Amsterdam: University Medical
Center; 2012.
41. Jensen MP, Karoly P: Handbook of pain assessment, 3rd edition edn. New
York: Guilford Press; 2011.
42. Norman G. Likert scales, levels of measurement and the "laws" of statistics.
Adv Health Sci Educ. 2010;15(5):625–32.
43. Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain
intensity rating scales. Pain. 2011;152(10):2399–404.
44. Bahreini M, Jalili M, Moradi-Lakeh M. A comparison of three self-report pain
scales in adults with acute pain. J Emerg Med. 2015;48(1):10–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sharma et al. Health and Quality of Life Outcomes  (2017) 15:236 Page 11 of 11
journal of orthopaedic & sports physical therapy | ahead of print | 1
[ research report ]
UU BACKGROUND: The Patient-Specific Functional 
Scale (PSFS) is among the most commonly used 
measures to assess physical function.
UU OBJECTIVES: We aimed to translate and cross-
culturally validate the PSFS to Nepali and further 
assess its psychometric properties.
UU METHODS: This longitudinal, single-arm cohort 
study translated and cross-culturally adapted 
the PSFS to Nepali (PSFS-NP) following recom-
mended guidelines. A sample of 104 Nepalese with 
musculoskeletal pain was recruited to evaluate 
the psychometric properties of the PSFS-NP. We 
assessed the internal consistency (Cronbach 
alpha), 2-week test-retest reliability (intraclass 
correlation coefficient [ICC3,2]), the smallest 
detectable change at the 90% confidence interval 
(CI), and construct validity. Concurrent validity 
was assessed against the Nepali versions of the 
Oswestry Disability Index, global rating of change, 
and numeric pain-rating scale. Receiver operating 
characteristic curves were plotted to measure 
responsiveness and area under the curve, and the 
minimum important change (MIC) was estimated.
UU RESULTS: The PSFS-NP showed good reliability, 
with a Cronbach alpha of .75, an ICC of 0.89 
(95% CI: 0.78, 0.94), and a smallest detectable 
change at the 90% CI of 1.46. It demonstrated 
significant correlations with the Nepali versions of 
the Oswestry Disability Index (r = –0.47, P = .001), 
global rating of change (r = 0.71, P<.001), and 
numeric pain-rating scale (r = –0.32 and –0.55, 
P<.001). Areas under the curve ranged from 0.72 
to 0.99. The MIC was 2.00 in the main analysis. 
Secondary analyses revealed MICs of 0.50, 0.66, 
and 2.00 for small, medium, and large improve-
ment, respectively.
UU CONCLUSION: The PSFS-NP is a reliable, 
valid, and responsive measure. It can be used 
in clinical practice and research in Nepalese 
with musculoskeletal pain. J Orthop Sports Phys 
Ther 2018;48(8):659-664. Epub 6 Apr 2018. 
doi:10.2519/jospt.2018.7925
UU KEY WORDS: clinimetrics, musculoskeletal 
pain, outcome measures, psychometric,  
responsiveness
T
he Patient-Specific Functional Scale (PSFS) is a patient-
reported outcome measure (PROM) in which patients identify 
the activities that are most important to them and rate their 
ability to perform these activities on a numerical scale from 
0 to 10, where higher scores indicate better physical function.20 The 
advantages of the PSFS over other measures of physical function or 
disability are that (1) it is brief, easy to understand, and comprehensive, 
comes across conditions and between 
studies.1,2,4,11,20
The validity of patient-specific scales 
for comparing across and between groups 
has been questioned; however, recent 
studies have shown that the PSFS is 
valid for use in group-level research and 
clinical data.2 Additionally, a systematic 
review published in 2012 reported that 
the psychometric properties of the PSFS 
were adequate in various musculoskel-
etal conditions.13 This scale is also more 
responsive than other longer measures of 
disability.9,20
Assessment of physical function is 
the primary focus of physical therapy 
interventions; however, this evalua-
tion is hampered in Nepal because of 
limited availability of PROMs to assess 
physical function. Although the Oswes-
try Disability Index (ODI) is validated 
in Nepali,3 administering this measure 
verbally can be challenging, given its 
length and inclusion of sensitive ques-
tions (eg, sex life). Making the PSFS 
available in Nepali would greatly fa-
cilitate assessment of physical function 
across a variety of musculoskeletal con-
ditions in both clinical practice and re-
search in Nepal. Accordingly, we aimed 
to translate and cross-culturally adapt 
the PSFS into Nepali (PSFS-NP), and 
to assess its clinimetric properties in 
Nepalese for the assessment of muscu-
loskeletal pain.
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Cross-cultural Adaptation and  
Validation of the Nepali Translation  
of the Patient-Specific Functional Scale
patients to be literate; and (4) it can 
be applied across a variety of condi-
tions and body regions, thus eliminat-
ing the need for multiple measures and 
enabling comparison of functional out-
and therefore can be completed in less 
time; (2) it is patient generated and 
considers activities important at an 
individual level; (3) it can be adminis-
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hort design was used, according 
to a methodology described in 
greater detail elsewhere.19 The study was 
conducted in 2 phases. Phase 1 involved 
the translation and cross-cultural adapta-
tion of the PSFS-NP using recommended 
guidelines.5 Refer to APPENDIX A (available 
at www.jospt.org) for the steps of the 
translation.
Phase 2 involved measurement of 
clinimetrics of the PSFS-NP. For this 
phase, adults experiencing muscu-
loskeletal pain and who could count 
numbers from 0 to 10 and could under-
stand and speak Nepali fluently were 
recruited from Dhulikhel Hospital and 
the community (rural and semi-urban). 
Participants were excluded if they had 
undergone any surgeries or had a recent 
history of trauma, a diagnosed psychi-
atric illness, or red flags suggestive of a 
tumor or infection. Ethical approval was 
obtained from the Institutional Review 
Committee of Kathmandu University 
School of Medical Sciences. The COn-
sensus‐based Standards for the selection 
of health Measurement INstruments 
(COSMIN) recommendations guided 
the methodology of the study.16
Sociodemographic characteristics, 
pain history, the PSFS-NP, and Nepali 
versions of the numeric pain-rating scale 
(NPRS-NP)19 and Oswestry Disability 
Index (ODI-NP)3 were assessed at base-
line. The PSFS-NP and NPRS-NP were 
readministered at a 2-week follow-up, 
along with a Nepali 7-item global rating 
of change (GROC-NP)19 as an external 
anchor for computation of measurement 
error and responsiveness.10 A GROC 
score of 4 was categorized as “stable,” and 
scores between 5 and 7 were categorized 
as “improved” (5, slight improvement; 6, 
medium improvement; 7, large improve-
ment). All measures were administered 
verbally to allow inclusion of participants 
with poor or no literacy. The details of the 
measures used are presented in TABLE 1. 
Data were analyzed using SPSS Version 
24 (IBM Corporation, Armonk, NY). The 
level of significance was set at P<.05.
Reliability
Internal consistency was reported using 
the Cronbach alpha, with a score of .90 
or greater indicating excellent internal 
consistency.7 Two-week test-retest reli-
ability was computed for the stable group 
using a 2-way mixed-effects model (with 
absolute agreement) and intraclass cor-
relation coefficient model 3,2 (ICC3,2). 
An ICC value higher than 0.75 indicates 
excellent test-retest reliability.7 We used 
a Bland-Altman plot to report limits 
of agreement.6 Standard error of mea-
surement (SEM) was calculated as SD 
change × (1 – ICC)1/2, where SD change 
equals SD (baseline – final).10 We com-
puted individual-level smallest detect-
able change (SDC) at the 90% confidence 
interval (CI) as z × √2 × SEM (z = 1.64 at 
the 90% CI). We hypothesized that the 
PSFS-NP would demonstrate excellent 
internal consistency and test-retest reli-
ability, and have an SDC90 between 1 and 
2.5, as previously reported.13
Validity
Construct validity of the PSFS-NP was 
examined by testing the hypotheses that 
(1) PSFS change score (PSFS baseline 
score – PSFS final score) would change 
significantly within the improved group 
using a 1-sample t test, and (2) PSFS 
change scores would differ significantly 
between the stable and improved groups 
using an independent-samples t test.12
Concurrent validity was evaluated by 
comparing PSFS baseline scores with 
the ODI baseline scores for the subgroup 
with low back pain (LBP), and with the 
NPRS baseline scores for the total sample. 
We hypothesized a moderate significant 
 
TABLE 1 Nepali Versions of PROMs Used in the Study
Abbreviations: GROC, global rating of change; ICC, intraclass correlation coefficient; MIC, minimum important change; NPRS, numeric pain-rating scale; 
ODI, Oswestry Disability Index; PROM, patient-reported outcome measure; PSFS, Patient-Specific Functional Scale; SDC, smallest detectable change.
PROM Items Scale Construct Assessed Scoring Psychometrics
PSFS 3 0-10, ordinal Physical function Mean of item scores (range, 0-10). Lower scores indicate greater 
disability
…
NPRS19 3 0-10, ordinal Pain intensity Mean of 3 item scores (current, best, and worst in past 24 h) (range, 
0-10). Higher scores indicate greater pain intensity
0 is no pain and 10 is maximum pain
ICC = 0.81; SDC90, 1.13; MIC, 
1.17; concurrent validity (with 
GROC), r = 0.45
ODI3 10 0-5, ordinal Physical function and pain Sum of item scores/number of items rated × 100 (range, 0-100). 
Higher scores indicate greater disability
Cronbach α = .72; ICC = 0.87




Single-item score (4 is no change). Scores higher than 4 mean 
greater improvement and scores lower than 4 mean greater 
worsening in health status
7 is a lot of improvement, 6 is medium improvement, 5 is slight 
improvement, 4 is no change, 3 is slightly worse, 2 is moderately 
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negative correlation. We also correlated 
PSFS change scores with GROC-NP and 
NPRS change (NPRS baseline – NPRS 
final) scores for the total sample. We hy-
pothesized that PSFS change would corre-
late strongly (significantly and positively) 
with the GROC-NP, but moderately (sig-
nificantly and negatively) with the NPRS 
change scores. We considered Pearson 
correlation coefficients of 0.30 to 0.70 as 
a moderate correlation, and greater than 
0.70 as a strong correlation.
Responsiveness
Receiver operating characteristic (ROC) 
curves were plotted to assess the re-
sponsiveness of the PSFS-NP, using the 
GROC-NP as an external anchor.10 The 
ROC curves were plotted for the PSFS 
change scores for the stable group com-
pared with the improved group. Second-
ary analyses assessed (1) stable group 
versus small improvement group, (2) 
stable group versus medium improve-
ment group, and (3) stable group versus 
large improvement group. Area under the 
curve (AUC) was calculated to indicate 
the capacity of the PSFS-NP to differen-
tiate between the stable and improved 
groups. Values of AUC closer to 1 indicate 
better agreement with the GROC.10 Min-
imum important change (MIC) values 
were also calculated.10 We hypothesized 
that MIC values would range from 1 to 




n phase 1, the translation of the 
PSFS to Nepali was successfully com-
pleted. The summary of the translation 
history is reported in APPENDIX A. The PS-
FS-NP can be found in APPENDIX B (avail-
able at www.jospt.org).
In phase 2, 104 adults with musculo-
skeletal pain (75 hospital, 29 community) 
consented to participate in the study. All 
participants completed both the baseline 
and final assessments at a mean ± SD 
interval of 11.5 ± 3.5 days (range, 6-18 
days). The participants’ characteristics 
are described in TABLE 2. Thirty-six par-
ticipants (35%) with complete follow-up 
data were classified as stable, 64 (62%) 
as improved, and 4 (4%) as “worsened” 
based on the GROC scores per a priori 
definition. Forty-five of 48 participants 
(94%) in the LBP subgroup completed 
the ODI-NP.
The PSFS-NP demonstrated accept-
able internal consistency of .75 and ex-
cellent test-retest reliability of 0.89 (95% 
CI: 0.78, 0.94). The SEM and individual-
level SDC90 were 0.63 and 1.46, respec-
tively. The Bland-Altman plot is shown 
in the FIGURE.
The PSFS-NP demonstrated construct 
validity by t tests: t63 = 8.65 (P<.001) 
within the improved group and t98 = 5.21 
(P<.001) between the stable and improved 
groups. Concurrent validity was supported 
by moderate correlations of PSFS base-
line score with ODI baseline score (r = 
–0.47, P = .001) and NPRS baseline score 
TABLE 2 Description of the Participants
Variable Value











No school 41 (39)
Primary (grades 1-5) 11 (11)
Secondary (grades 6-10) 17 (16)
Higher secondary (grades 11-12) 16 (15)
Bachelor and above 19 (18)
Occupation, n (%)
Agriculture and housework 28 (27)
Household work only 22 (21)
Agriculture only 8 (8)
Sitting job (office/business) 8 (8)
No work 6 (6)
Other 32 (31)

























0.0 2.0 4.0 6.0
PSFS Mean of Baseline and Final Scores
δ – z × SD of change
δ – z × SD of change
δ
Stable Group, GROC = 4
FIGURE. Bland-Altman plot for the PSFS-NP. The 
y-axis is the change in PSFS-NP scores between 
baseline and follow-up measurements, and the 
x-axis is the mean of PSFS-NP scores at baseline 
and at final measurement. The solid line is the mean 
change in score (δ), and dotted lines are δ ± z × 
SD change, where z = 1.64 at the 90% confidence 
interval. Abbreviation: PSFS-NP, Nepali version of 
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(r = –0.32, P = .001), a moderate corre-
lation of PSFS change score with NPRS 
change score (r = –0.55, P<.001), and a 
significant, strong positive correlation of 
PSFS change score with the GROC-NP 
(r = 0.71, P<.001). Four ROC curves for 
the PSFS change scores were plotted (see 
APPENDIX C, available at www.jospt.org) for 
the 4 groups based on GROC scores, as 
described in the Methods. The AUCs with 
their CIs and the respective MICs are re-
ported in TABLE 3.
DISCUSSION
T
he PSFS-NP, after translation 
in accordance with recommended 
guidelines, demonstrated acceptable 
clinimetric properties, as hypothesized. 
Although the PSFS has been validated 
in many languages in a variety of clinical 
conditions, this study supports its valida-
tion in individuals with low literacy (50% 
of this study’s participants had only pri-
mary education or less) when adminis-
tered verbally.
Test-retest reliability of the PSFS-NP 
was excellent, in line with our a priori hy-
pothesis. The 95% CI of the ICC of the PS-
FS-NP (0.78, 0.94) is consistent with 6 of 
8 studies included in a previous systematic 
review reporting clinimetric properties 
of the PSFS in musculoskeletal condi-
tions (ranging between 0.76 and 0.97).13 
Only 1 study reported a lower ICC (0.76, 
for chronic lateral epicondylalgia), and 
1 reported a higher ICC (0.97, for LBP). 
Similarly, the Japanese PSFS reported 
almost perfect 1-week reliability (ICC = 
0.98).17 Such high reliability could be be-
cause participants were informed of the 
baseline scores, which may have increased 
the reliability. Likewise, the SDC90 of the 
PSFS-NP (1.46) was also within the hy-
pothesized range (1.0-2.5)13 and equal to 
that reported for chronic LBP.15
Similarly, the PSFS-NP also dem-
onstrated validity as hypothesized. The 
construct validity was established by a 
statistically significant mean difference 
within the improved group, and between 
the stable and improved groups, as in a 
previous study.12
Concurrent validity was also con-
firmed, based on the a priori hypotheses 
of moderate to strong correlations with 
the criterion variables. First, the PSFS 
baseline scores demonstrated moder-
ate correlation (r = –0.47) with the ODI 
baseline scores in this study, which is a 
lower correlation than those previously 
reported (r = 0.51-0.74)20 with the Ro-
land-Morris Disability questionnaire, a 
measure of back-related disability similar 
to the ODI. The strength of correlation 
TABLE 2 Description of the Participants (continued)
Abbreviations: GROC, global rating of change; NPRS, numeric pain-rating scale; PSFS, Patient-
Specific Functional Scale.
*Values are mean ± SD.
Variable Value
Site of pain, n (%)






Total duration of pain, mo* 21.70 ± 34.00
Time between evaluations, d* 11.50 ± 3.50
GROC at follow-up, n (%)
Worsened group (<4) 4 (4)
No improvement (4) 36 (35)
Improved group (5-7) 64 (62)
Small improvement (5) 30 (29)
Medium improvement (6) 23 (22)
Large improvement (7) 11 (11)
Average PSFS score (0-10)*
Baseline 3.70 ± 1.73
Final 5.03 ± 2.27
Change (baseline – final) –1.32 ± 1.89
Average NPRS score (0-10)*
Baseline 4.27 ± 1.63
Follow-up 3.36 ± 1.56
Change (baseline – follow-up) 0.90 ± 1.49
TABLE 3
Responsiveness of the Nepali  
Patient-Specific Functional Scale
Abbreviations: AUC, area under the curve; GROC, global rating of change; MIC, minimum important 
change.
*Values in parentheses are 95% confidence interval.
AUC* MIC
Primary analysis (GROC 4 versus GROC 5-7) 0.83 (0.74, 0.91) 2.00
Small improvement (GROC 4 versus GROC 5) 0.72 (0.59, 0.84) 0.50
Medium improvement (GROC 4 versus GROC 6) 0.89 (0.80, 0.98) 0.66
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of the PSFS and ODI was only moderate, 
which may be because of the verbal ad-
ministrations of the ODI, which likely af-
fected responses to the item related to sex 
life. Culturally, Nepalese patients prefer 
to say that “sex life is absent” rather than 
“sex life is normal” when interviewed, 
which is evident by the lowest scores for 
this item.
Second, correlations of PSFS change 
and GROC scores were strong, as hypoth-
esized, because both assessed change (ie, 
physical function and overall change, 
respectively). As physical function is a 
prime concern of patients, their over-
all reporting of change (assessed by the 
GROC) could be highly influenced by 
change in physical function (assessed by 
the PSFS).8,17
Finally, as hypothesized, the correla-
tion of the PSFS-NP with the NPRS-NP 
was moderate. It is worth noting that 
neither the GROC nor NPRS directly as-
sesses the construct of physical function; 
the findings relating to validity would 
have benefited from use of scales that 
assess the construct of physical function 
specifically. However, due to few available 
valid measures in Nepali, we were limited 
in the present study to investigating this 
only in people with LBP, using the ODI-
NP, which supported concurrent validity. 
Nevertheless, we can confirm the con-
struct validity of the PSFS-NP, because, 
as proposed by Terwee and colleagues,21 
more than 75% of the a priori hypotheses 
were achieved.
The MIC value (2.00) of the PSFS-NP 
in the current study lies within the range 
reported previously, as hypothesized.13 
The MIC values obtained in this study 
are consistent with those reported previ-
ously for chronic LBP8,15 using the same 
method of assessment, by ROC curve. 
The stepwise increase of MICs for small, 
medium, and large change for the PSFS-
NP (0.50, 0.66, and 2.00, respectively) 
supports its construct validity. This meth-
od of estimating the MIC for small, medi-
um, and large change separately provides 
a conservative estimate of MIC; that is, 
calculation of the MIC using cut points 
for medium (or lesser) change or large (or 
lesser) change would result in lower esti-
mates for MIC than this discrete-groups 
method.
Although the current study is robust 
in terms of its methodology and complies 
with COSMIN recommendations,16 the 
results should be interpreted with consid-
eration of its limitations. First, the find-
ings related to reliability of the PSFS-NP 
are based on a relatively small number of 
individuals in the stable group (n = 36). 
A larger sample size may provide greater 
certainty for reliability coefficients.
Second, because the findings on re-
sponsiveness are based on a relatively 
short duration of follow-up (6-18 days, 
which is shorter than many studies), the 
magnitude of change may be smaller than 
that observed in other studies. This dis-
advantage of a shorter follow-up period is 
offset by the current study’s shorter recall 
time for the GROC, which likely reduced 
recall bias.18
Finally, the findings of this study are 
limited to individuals with musculoskel-
etal pain and so may not be generalized 
to other health conditions, such as car-
diopulmonary or neurological condi-
tions. Future research may consider the 
usefulness of the PSFS in other health 
conditions.13
The findings of this research have 
important clinical and research impli-
cations. As the assessment of physical 
function is recommended in core out-
come sets,7,10 the availability of a validat-
ed PSFS-NP will facilitate its use in the 
assessment of physical function in mus-
culoskeletal conditions in Nepal, in both 
research and clinical practice.
CONCLUSION
T
he Nepali version of the PSFS is 
a reliable, valid, and responsive 
measure for assessment of physical 
function in individuals with musculo-
skeletal pain. Clinicians should consider 
a change of score lower than 1.5 on the 
0-to-10 PSFS-NP as measurement error, 
and a score change of 2 points as a mean-
ingful change in function for people with 
musculoskeletal pain. U
KEY POINTS
FINDINGS: The Nepali translation of the 
Patient-Specific Functional Scale (PSFS) 
is a reliable, responsive, and valid measure 
for assessing physical function of Nepalese 
adults with musculoskeletal pain.
IMPLICATIONS: Clinicians and researchers 
should consider a change of 2 (out of 10) 
of the average score of 3 items as a clini-
cally meaningful change for patients 
with musculoskeletal pain. A score of 
1.46 (out of 10) is the smallest detect-
able change, and any change score less 
than this should be considered a mea-
surement error.
CAUTION: The validity of the PSFS was 
established in adult Nepalese with 
musculoskeletal pain with sufficient nu-
meracy to understand a numerical scale. 
The measure should not be considered 
valid or reliable in individuals with a 
lower level of numerical skill, or in other 
patient populations, such as patients 
with neurological, cardiopulmonary, or 
pediatric conditions.
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APPENDIX A
The original English version of the PSFS
Forward translation synthesis (T4)
Discrepancies between the 3 forward 
translations were resolved after 
discussion, which was facilitated by 
the lead author (S.S.)
Expert committee review
• Consisted of all the translators, researchers, methodologists, and original 
measure developer
• Remotely located experts were contacted via e-mails or Skype
• All the translations were reviewed, including the reports
• Prefinal version of the PSFS-NP was produced after consensus (T8)
Pretesting
• Prefinal version tested on 30 individuals with musculoskeletal pain 
representative of age, sex, and education
• Every participant was probed to inquire if he or she correctly identified 
the actual meaning of the instruction and the scale
• Questions were raised if any changes in the questionnaire would make it 
easier for participants  to understand
Approval of the PSFS-NP by the developer
• The final PSFS-NP was back translated to English and was sent to the 
developer (Dr Paul Stratford), with translation history, for his review
• The final translation was approved by Dr Stratford
• The PSFS-NP can be found as an online-only appendix at www.jospt.org
Creation of the final version of the PSFS-NP
• Minor changes were made in the sentence structure and choice of 
simpler words after the feedback by participants during pretesting
• Instructions to the clinicians and English words (eg, “history” and 
“physical examination”) were included within parentheses
• A scale was added for ease of explaining the numbers to patients, 
especially to those with lower education and older age    
• Tables were labeled clearly for clinicians, describing what to write in them
Forward translation 1 (T1) 
(by a nonmedical native 
Nepali translator)
Forward translation 2 (T2) 
(by a Nepali physical 
therapist)
Forward translation 3 (T3) 


























Note: All the back translations were performed independently by native English speakers blind to the original English version of the PSFS. 
FIGURE. Translation history of the Nepali version of the PSFS. Abbreviations: PSFS, Patient-Specific Functional 
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FIGURE. Receiver operating characteristic curves. (A) Stable group (GROC, 4) versus improved group (GROC, 5-7), (B) stable group (GROC, 4) versus small improvement 
group (GROC, 5), (C) stable group (GROC, 4) versus medium improvement group (GROC, 6), and (D) stable group (GROC, 4) versus large improvement group (GROC, 7). 
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Background: Pain catastrophizing is an exaggerated negative cognitive response related to pain. 
It is commonly assessed using the Pain Catastrophizing Scale (PCS). Translation and validation 
of the scale in a new language would facilitate cross-cultural comparisons of the role that pain 
catastrophizing plays in patient function.
Purpose: The aim of this study was to translate and culturally adapt the PCS into Nepali (Nepali 
version of PCS [PCS-NP]) and evaluate its clinimetric properties.
Methods: We translated, cross-culturally adapted, and performed an exploratory factor analy-
sis (EFA) of the PCS-NP in a sample of adults with chronic pain (N=143). We then confirmed 
the resulting factor model in a separate sample (N=272) and compared this model with 1-, 2-, 
and 3-factor models previously identified using confirmatory factor analyses (CFAs). We also 
computed internal consistencies, test–retest reliabilities, standard error of measurement (SEM), 
minimal detectable change (MDC), and limits of agreement with 95% confidence interval 
(LOA
95%
) of the PCS-NP scales. Concurrent validity with measures of depression, anxiety, and 
pain intensity was assessed by computing Pearson’s correlation coefficients.
Results: The PCS-NP was comprehensible and culturally acceptable. We extracted a two-factor 
solution using EFA and confirmed this model using CFAs in the second sample. Adequate fit 
was also found for a one-factor model and different two- and three-factor models based on prior 
studies. The PCS-NP scores evidenced excellent reliability and temporal stability, and demon-
strated validity via moderate-to-strong associations with measures of depression, anxiety, and 
pain intensity. The SEM and MDC for the PCS-NP total score were 2.52 and 7.86, respectively 
(range of PCS scores 0–52). LOA
95% 
was between -15.17 and +16.02 for the total PCS-NP scores.
Conclusion: The PCS-NP is a valid and reliable instrument to assess pain catastrophizing in 
Nepalese individuals with chronic pain.
Keywords: measurement error, outcome measure, Bland–Altman plot, reliability, measurement 
properties, pain assessment
Introduction
Pain catastrophizing, which has been defined as an exaggerated negative cognitive 
response related to pain,1 has been shown to be associated with a broad array of impor-
tant quality of life domains such as pain intensity, pain interference, and psychological 
function in individuals with chronic pain from different cultures.2,3 Catastrophizing is 
responsive to various pain treatments4–7 and has been found to mediate the effects of 
many of these.4,8 Thus, catastrophizing remains an important psychosocial domain to 
assess in patients with chronic pain. The most common measure of pain catastroph-
izing is the 13-item Pain Catastrophizing Scale (PCS).
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The PCS has three subscales assessing pain-related rumi-
nation, magnification, and helplessness.1,9 This three-factor 
structure has been confirmed in other English-speaking 
samples,9,10 although research has shown that two-factor 
solutions show better fit in some samples.11,12 Non-English 
translations have also been shown to yield both two and three 
factors.13–19 However, given the strong associations among 
the factors, researchers tend to use the total PCS score more 
often than the subscale scores.4,5,7
The original English version of the PCS and its translated 
versions are psychometrically robust. The total score of 
PCS has repeatedly been shown to be reliable as evidenced 
by good-to-excellent internal consistency2,3,10,14–17,20,21 and 
excellent test–retest reliability.2,14,17,20–22 Standard error of 
measurement (SEM) and minimal detectable change (MDC) 
of the PCS range from 1.6 to 4.614,15,21,22 and 8.8 to 12.8,14,15,17,21 
respectively. Concurrent validity of the PCS is supported via 
moderate-to-strong correlations (ie, r≥0.30) with measures of 
depression,2,14,16,17 anxiety,1,2,14,17 and pain intensity.1,2,10,11,14,16,17
The PCS has been translated into a number of differ-
ent languages (https://eprovide.mapi-trust.org/instruments/
pain-catastrophizing-scale#languages). The availability of 
translated measures is critical to facilitate research examining 
the role that language and culture may play in how catastroph-
izing is related to patient function. Thus, the aim of this study 
was to translate the PCS into another language – this time, 
Nepali (Nepali version of PCS [PCS-NP]) – and assess its 
clinimetric properties. Consistent with the extant research, 
we hypothesized that the PCS-NP would demonstrate either 
a two-factor structure or a three-factor structure1,12 and that 
the factors would be strongly associated with one another, 
supporting the use of the total scale in this population. We fur-
ther hypothesized that the PCS-NP scales would demonstrate 
1) good-to-excellent internal consistencies (ie, Cronbach’s 
a≥0.70),2,14–17,20,21,23,24 2) excellent 2-week test–retest stability 
(ie, intraclass correlation coefficient [ICC] ≥0.75),14,15,17,20–22,24 
3) SEM between 1.6 and 4.6,14,15,21,22 4) MDC between 8.8 
and 12.8,14,15,17,21 and 5) concurrent validity via moderate-to-
strong correlations (ie, r≥0.30) with measures of depression, 
anxiety, and pain intensity.2,14,16,17
Methods
We first translated the PCS to Nepali and performed cogni-
tive debriefing of the instructions and items to ensure that 
the items were culturally appropriate in 30 individuals with 
musculoskeletal pain. Next, we evaluated the clinimetrics of 
the PCS-NP in two independent samples. Ethical approval of 
the research was obtained from the Institutional Review Com-
mittee of the Kathmandu University School of Medical Sci-
ences, Dhulikhel, Nepal (reference number: 105/14), and the 
study complies with ethical guidelines of the Declaration of 
Helsinki. Written informed consent was obtained from all the 
research participants before data collection. Those participants 
who could not read or provide a written signature provided a 
verbal consent, and a witness signed on their behalf.
Translation procedure
Translation of PCS into Nepali was performed using standard 
guidelines.25 First, we obtained permission from the developer 
(Professor Michael Sullivan) to translate the PCS into Nepali. 
Then, two forward translators translated the PCS into Nepali. 
The two forward translated versions were synthesized to a 
single first translated (FT) version. The FT version was then 
back-translated into English by three independent native Eng-
lish speakers. An expert committee meeting was held, which 
comprised language experts, translators (who were available 
for a face-to-face meeting), and research methodologist. Any 
discrepancies were discussed, and Nepali version of the PCS 
that is simple and comprehensible was finalized during the 
meeting. Translators remotely located were contacted via 
e-mails and Skype, and any important suggestions were 
noted. The final Nepali version was back-translated into 
English, which was sent to the last author (MPJ) for review.
The resultant version was tested in a sample of 30 individu-
als with either acute musculoskeletal pain or persistent muscu-
loskeletal pain for cognitive debriefing. Minor changes were 
made in sentence structure, and simpler words replaced diffi-
cult words so that most participants could understand the final 
PCS-NP. The final Nepali version, its back-translation, and 
translation history were sent to the developer, who reviewed 
and approved it. The Nepali version is licensed and distributed 
by Mapi Research Trust, and researchers intending to use PCS-
NP should contact Mapi Research Trust for its use (https://epro 
vide.mapi-trust.org/instruments/pain-catastrophizing-scale). 
The translation history is summarized in Figure 1.
Clinimetric evaluation
Participants
Two independent adult (age ≥18 years) samples of Nepali-
speaking individuals with chronic pain (pain lasting for 
>3 months) were recruited. The first sample included indi-
viduals with chronic pain (N=144) recruited from a tertiary 
care hospital (n=44; consecutive patients) and a community 
(n=100; by door-to-door survey) in rural Nepal with pain 
intensity ≥4 out of 10 on a 0–10 numerical pain rating scale 
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Clinimetric properties of Nepali version of PCS
ond sample, also consisted of individuals with chronic pain 
(N=275) who were required to report ≥3 out of 10 pain on an 
NPRS, was recruited mostly from the community (n=252). 
The reminder (n=23) of the sample was recruited from the 
same hospital as that used to recruit the first sample. All the 
participants in both samples provided data via interview.
Measures
Participants in the first sample were administered the 
PCS-NP once, and participants in the second sample were 
administered the PCS-NP twice (2 weeks apart), with 244 
(90%) of original sample providing retest data. A summary 
of the measures used in the study is provided in Table 1 and 
described in more detail later.
Beck Anxiety Inventory (BAI)
The 21-item BAI was used to assess perceived anxiety in the 
first sample.26 Each item is scored on a 4-point Likert scale 
ranging from 0 to 3 where 0= “not at all” and 3= “severely, I 
could barely stand it”. Total score can range from 0 to 63, with 
higher scores indicating more anxiety. The Nepali version 
of BAI – the version used in this study – has been shown to 
Figure 1 Translation history of PCS-NP.
Note: aAll the back translators were performed independently by native English speakers blind to the original English version of the PCS.







The original English version of
PCS
FT 1
(translated by a nonmedical
native Nepali translator)
FT 2
(translated by a Nepali
physiotherapist)
FT synthesis
Discrepancies between the two forward
translations resolved after discussion
facilitated by the lead author (SS)
BT 1a BT 2a
Expert committee review
Pretesting
Creation of the final version of Nepali PCS-NP
Approval of the PCS-NP by the developer
PCS-NP was back-translated to English
All the written reports of the translation history was sent
to the developer for the review as a single Excel document
The translation history was reviewed by the developer
and was approved
PCS-NP was sent to www.mapi-trust.org
Changes on the grammar and sentence structure were made
using feedback by participants during the pretesting
Prefinal version tested on 30 individuals with
musculoskeletal pain
Every participant was probed to inquire if he/she correctly
identified the real meaning of the original English version
Asked if any changes in the questionnaire will make it easier
for them to understand
Consisted of all the translators, researchers, methodologists,
and original measure developer
Remotely located experts were contacted via e-mails or Skype
Reviewed all the translation version of the PCS and reports
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be reliable (Cronbach’s a=0.8927 and ICC =0.8828). The BAI 
demonstrated excellent internal consistency (Cronbach’s 
a=0.90) in the current sample.
Beck Depression Inventory (BDI)
The 21-item BDI was used to assess depression in the first 
sample.29 Each item in the scale has four unique response 
options designed for that item. Severity of depression symp-
toms is rated on the 4-point scale, ranging from 0 to 3. Total 
score can range from 0 to 63, with higher scores indicating 
more depression. The Nepali version of BDI is a reliable 
measure (Cronbach’s a=0.9030 and ICC =0.8428) and dem-
onstrated excellent internal consistency (Cronbach’s a=0.90) 
in the current sample.
Patient-Reported Outcomes Measurement Information 
System (PROMIS) pain intensity
The PROMIS average pain intensity over the past 7 days was 
assessed in the second sample on a 5-point Likert scale where 
1= “no pain”, and 5= “very severe pain”, with higher scores 
indicating more intense pain (http://www.healthmeasures.
net). Test–retest stability (ICC) of the Nepali version of PRO-
MIS pain intensity scale is 0.71 in the current second sample.
Global Rating of Change (GRoC)
The Nepali version of GRoC was used to assess global 
impression of perceived change in their chronic pain-related 
problems in the second sample on a 7-point Likert scale rang-
ing from 1 to 7.31–33 Score 4 represents “no change”, scores 
>4 indicate improvement, and scores <4 indicate worsening. 
The GRoC was used to categorize the sample to “improved” 
and “stable” groups, considering 1-point change as significant 
improvement.32,33 We classified participants with a GRoC 
score of 4 as stable and participants with GRoC scores of 
5–7 as improved. Using this classification, participants in the 
stable group were used for computing the test–retest stability, 
SEM, MDC, and limits of agreement statistics.34
Other measures
Demographics information collected included age, sex, 
religion, ethnicity, education, and occupation. Additionally, 
total duration of chronic pain was recorded in months and 
pain site was assessed using a pain diagram.
Statistical analyses
Factor analyses
We performed an exploratory factor analysis (EFA) in the 
first sample (hereafter referred to as the EFA sample) using 
maximum likelihood for factor extraction. Factor rotation was 
performed using oblique rotation (Direct Oblimin; delta =0), 
allowing the factors to correlate with each other. Next, we 
performed a series of confirmatory factor analyses (CFAs) in 
the second sample (hereafter referred to as the CFA sample) 
to compare the results of the EFA from the first sample with 
1) a one-factor solution including all the 13 items as a single 
factor, 2) the two-factor solution obtained from the largest 
English-speaking sample published,11 and 3) the original 
three-factor solution found by Sullivan et al1 using AMOS 
for Statistical Software for Social Sciences (SPSS) 24. Model 
fit was evaluated using the chi-square goodness-of-fit index, 
the ratio of chi-square value to degree of freedom, the root 
mean square error of approximation (RMSEA), comparative 
fit index (CFI), and parsimony goodness-of-fit index (PGFI). 
Better fit is indicated by 1) chi-square value and the ratio of 
chi-square to degree of freedom values closer to zero, 2) lower 
values of RMSEA, 3) larger values of CFI, and 4) larger value 
of PGFI, which indicates more parsimonious fit.35
Reliability
To evaluate reliability, we assessed internal consistency, 
test–retest stability, SEM, MDC, and created Bland–Altman 
Plots. We computed internal consistencies of the PCS-NP 
scales for both samples, using Cronbach’s a. We considered 
values of Cronbach’s a<0.70 as inadequate, values between 
0.70 and 0.79 as adequate, values between 0.80 and 0.89 as 
good, and values ≥0.90 as excellent.24 Two-week test–retest 
stability was evaluated using the ICC in the stable group 
(GRoC =4). We considered the values of ICC between 0.40 
and 0.59 as fair, values between 0.60 and 0.74 as good, and 
values ≥0.75 as excellent.24
To further evaluate reliability, we also computed the 
SEM, which is an indication of how repeated adminis-
tration of a measure tends to be distributed around the 
Table 1 Nepali versions of PROMs used in the study
Name Study Item Scale Construct assessed
PCS-NP EFA, CFA 13 0–4, ordinal Pain catastrophizing
BDI-NP30 EFA 21 0–3, ordinal Depression
BAI-NP27 EFA 21 0–3, ordinal Anxiety
GRoC-
NP31




CFA 1 1–5, ordinal Average pain intensity
Abbreviations: CFA, confirmatory factor analysis; EFA, exploratory factor 
analysis; BAI-NP, Nepali version of Beck Anxiety Inventory; BDI-NP, Nepali version 
of Beck Depression Inventory; GRoC-NP, Nepali version of Global Rating of 
Change; PCS-NP, Nepali version of Pain Catastrophizing Scale; PROMs, Patient-
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Clinimetric properties of Nepali version of PCS
“true” score. SEM is important to consider because two 
measurements obtained at different times will not yield 
exactly the same score, either because of the variation in 
the participants being assessed or because of the variation 
in the measurement process, or both.36 Thus, it is possible 
that a measure may have large test–retest stability indicating 
excellent reliability but may also have a large measurement 
error. Therefore, the SEM compliments test–retest stability 
and is a recommended parameter to assess and report in 
clinimetric studies.37 Larger scores indicate large variability, 
and smaller scores indicate minimal variability. We calcu-
lated SEM using the following formula: SEM = SD
change
 × 
√(1- ICC),38 where SD
change
 is the standard deviation for 
the mean change of PCS-NP scores. Using the SEM value, 
we further calculated MDC for 95% confidence interval 
(MDC
95%
) of the PCS-NP using the following formula: 
MDC
95%
 =1.96×√2× SEM.37,38 A Bland–Altman plot was 
created to complement the measurement error and indicates 
the levels of agreement between the baseline and follow-up 
assessments.38,39 The plot was drawn with change of PCS-
NP scores from baseline to follow-up (Y-axis) versus mean 
score of PCS-NP between baseline and follow-up assess-
ments (X-axis). Limits of agreement with 95% confidence 
interval (LOA
95%
) were computed by using the following 




We evaluated the concurrent validity of the PCS-NP scales 
by computing Pearson’s correlation coefficients between the 
PCS-NP scale scores and the scores from Nepali versions of 
BDI, BAI administered to participants in the EFA sample, and 
PROMIS pain intensity short-form 3a measure administered 
to CFA sample. We considered correlation coefficients (r) 
<0.30 as weak, coefficients between 0.30 and 0.49 as mod-
erate, and coefficients ≥0.50 as strong.42 We excluded the 
participants for all analysis if there were any missing values 
on the PCS items.
Results
The PCS-NP succeeded in retaining the semantic, idiomatic, 
experiential, and conceptual equivalence. The reporting of the 
clinimetric properties is guided by COSMIN recommenda-
tions.40 Scores of PCS-NP were normally distributed in both 
the EFA and CFA samples. A total of 0.7% (n=1) and 2.6% 
(n=7) in EFA and CFA samples, respectively, scored 0/52 
total score, and 0.7% (n=1) and 1.1% (n=2) in EFA and CFA 
samples, respectively, scored 52/52 total score.
Demographic characteristics
The majority of study participants were women (65% and 
73% in the EFA and CFA samples, respectively) and were 
Hindu in religion (92% and 85%). Almost half of the par-
ticipants in both the samples had pain in multiple body parts 
(42% and 47%), followed by pain in the low back and pelvis 
(22% and 18%) and knee(s) (21% and 19%), respectively. 
All the participants in the EFA sample were individuals 
with chronic musculoskeletal pain; however, 4% of the CFA 
sample had chronic headache. Descriptive information for 
the two samples is presented in Table 2.
Of the 144 participants in the EFA sample and 275 par-
ticipants in the CFA sample who were administered PCS-NP 
at the baseline assessment, there were missing items in the 
data completed by one and three participants, respectively, 
Table 2 Description of the study participants





Site of pain, N (%) 0.683
Multiple sites 60 (42) 128 (47)
Low back and pelvis 32 (22) 50 (18)
Knee 30 (21) 52 (19)
Other sites 18 (13) 42 (16)
Duration of pain (months), 
mean (SD) 
51.10 (76.42) 51.26 (65.72) 0.617
Age (years), mean (SD) 47.06 (14.50) 46.30 (15.65) 0.751
Sex, N (%) 0.085
Men 50 (35) 73 (27)
Women 93 (65) 199 (73)
Religion, N (%) 0.007
Hindu 132 (9) 230 (85)
Buddhist 5 (4) 35 (13)
Other 6 (4) 7 (3)
Race/ethnicity, N (%) <0.001
Chettri 59 (41) 16 (6)
Brahmin 40 (28) 87 (32)
Newar 19 (13) 144 (53)
Other 25 (18) 25 (9)
Education, N (%) <0.001
No school 45 (31) 41 (15)
Primary school 42 (30) 53 (20)
Secondary school 35 (24) 60 (22)
Higher secondary and 
above
21 (15) 118 (43)
Occupation, N (%) <0.001
Not working 7 (5) 37 (14)
Agriculture 49 (34) 43 (16)
Household work 39 (27) 55 (20)
Business 15 (10) 57 (21)
Office worker 11 (8) 39 (14)
Other 22 (15) 41 (29)
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in the two samples. We excluded the participants with miss-
ing items in all analyses from EFA and CFA samples; thus, 
there were N=143 participants in EFA sample and N=272 
participants in the CFA sample for all analyses.
Factor analyses
Results of EFA in the EFA sample (N=143) using maximum 
likelihood with Oblimin rotation for factor extraction and 
the Kaiser criterion (ie, eigenvalues >1.0) to determine the 
number of factors indicated a two-factor solution. As can be 
seen in the pattern matrix from the EFA analysis (Table 3), 
Factor 1 comprised items 2, 3, 4, 5, 9, 12, and 13 and Factor 
2 comprised items 1, 6, 7, 8, 10, and 11. Given the items that 
were loaded on each factor, we labeled Factor 1 “helpless-
ness” and Factor 2 “pain focus”.
These two factors explained 50% of variance in the items 
(Figure 2). The two factors, however, were very strongly 
associated with one another (r=0.91). The two-factor solu-
tion found in the first sample demonstrated an acceptable 
fit in the CFA sample (Table 4). In addition, the one-factor, 
another two-factor extracted by Chibnall and Tait,11 and the 
three-factor extracted by Sullivan et al1 also had adequate fit, 
comparable to the two-factor solution extracted from the EFA 
sample. Attempts to improve each of these models further by 
allowing up to two pairs of error terms to correlate resulted in 
only modest improvements in the fit of each model (Table 4).
Reliability
Results of the analyses evaluating the reliability of PCS-NP 
total score and two subscale scores (computed using the results 
of the factor analyses as a guide) are presented in Table 5. The 
PCS-NP demonstrated good-to-excellent internal consistency 
(range 0.83–0.93) in the two samples. Two-week test–retest 
reliability on the stable sample was excellent 0.90 (95% CI: 
0.85, 0.93). SEM and MDC for the total score of PCS-NP 
were 2.52 and 6.98, respectively. LOA
95% 
ranged from –15.17 
to 16.02 for the total PCS-NP scores. The LOA
95% 
of the sub-
scales is presented in Table 5. Bland–Altman plot, which 
shows the limits of agreement for the total PCS items and the 
two factors, separately, is presented as Figure 3.
Validity
Both the total score and subscale scores were positively, 
moderately, and significantly associated with the criterion 
variables assessing depression, anxiety, and pain intensity. 
Concurrent validity of PCS-NP total scores and subscales is 
presented in Table 6.
Table 3 Pattern matrix after maximum likelihood factor 





Brief description of item Factors
1 2
3 H Never get any better 0.78 0.06
5 H Can’t stand it 0.73 0.03
12 H Nothing I can do 0.73 0.10
4 H It’s awful 0.72 –0.07
2 H Can’t go on 0.62 –0.13
9 R Can’t keep out of mind 0.56 –0.24
13 M Something serious may happen 0.53 –0.16
11 R Want the pain to stop –0.10 –0.85
8 R Want the pain to go away 0.03 –0.73
10 R Thinking how much it hurts 0.28 –0.55
1 H Worrying whether pain will end 0.37 –0.39
7 M Thinking of painful experiences 0.25 –0.37
6 M Afraid if pain may get worse 0.28 –0.34
Note: Bold items were included in the factors 1 and 2 on the values of the factor 
loadings.
Abbreviations: H, helplessness; M, magnification; R, rumination.
Figure 2 Path diagram after CFAs, two-factor model (upper), and one-factor model 
(lower) with adjustment for covariance of error terms in CFA sample (N=272).


















































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Clinimetric properties of Nepali version of PCS
Discussion
The PCS-NP was successfully translated and adapted to 
Nepali and validated in Nepalese with chronic pain. The 
findings support its reliability and validity. Specifically, we 
extracted two-factor solution (Factor 1= helplessness and 
Factor 2= pain focus) from the EFA in the EFA sample and 
confirmed this solution by CFA in an independent sample. 
The reliability of the PCS-NP total score and two subscale 
scores was supported by excellent internal consistencies and 
test–retest stability over a 2-week period. Concurrent valid-
ity was supported via moderate-to-strong associations with 
measures assessing depression, anxiety, and pain intensity, 
as hypothesized.
Factor analysis
The factor analysis of the PCS-NP items yielded two 
factors in our sample. Although three factors are more 
 common,2,14–16,18,20,22,43 two factors sometimes emerge11,12,19,44 
in different samples of individuals with chronic pain. The 
differences in the factor structure of these items across 
different samples may be related to cultural differences 
in how catastrophizing thoughts relate to each other (and 
possibly impact function) in different countries. In our 
sample, helplessness was largely retained as a unique fac-
tor, but distinct “rumination” and “magnification” factors 
did not emerge as they had in the original English version 
of the PCS45 or many other samples.2,14–16,18,20,22,43 Instead, 
Table 4 Results of the confirmatory factor analyses for the PCS-NP in the CFA sample (N=272)
Model and modifications c2 (df) c2/df RMSEA CFI PGFI
1. One-factor model
a. No modifications 229 (65) 3.53 0.097 0.913 0.628
b. With modification 190 (63) 3.01 0.086 0.933 0.622
2. Two-factor modela 
a. No modifications 190 (64) 2.97 0.085 0.933 0.632
b. With modifications 166 (62) 2.67 0.079 0.945 0.620 
3. Two-factor modelb
a. No modifications 207 (64) 3.23 0.091 0.924 0.626
b. With modifications 171 (62) 2.76 0.081 0.942 0.617
4. Three-factor modelc
a. No modifications 200 (62) 3.23 0.091 0.927 0.608
b. With modifications 180 (60) 3.00 0.086 0.936 0.596
Notes: aTwo-factor model based on results from the EFA sample (N=143). bTwo-factor model based on Chibnall and Tait.11 cThree-factor model based on Sullivan et al.1 
Abbreviations: CFA, confirmatory factor analysis; CFI, Comparative Fit Index; df, degree of freedom; PCS-NP, Nepali version of Pain Catastrophizing Scale; PGFI, parsimony 
goodness-of-fit index; RMSEA, root mean square error of approximation.
Table 5 Reliability of the PCS-NP
Sample N IC Test–retest (ICC) SEM MDC95% LOA95%
EFA sample 143
PCS-NP total 0.91
PCS-NP Factor 1 0.87
PCS-NP Factor 2 0.83
CFA sample 272   
PCS-NP total 0.93   
PCS-NP Factor 1 0.89
PCS-NP Factor 2 0.85
CFA-stable group 122 
PCS-NP total 0.90 0.90 (0.85, 0.93) 2.52 6.98 16.02, –15.17
PCS-NP Factor 1 0.88 0.88 (0.83, 0.92) 1.67 4.62 9.29, –9.69
PCS-NP Factor 2 0.89 0.89 (0.84, 0.92)  1.33 3.67 8.47, –7.22
Abbreviations: CFA, confirmatory factor analysis; EFA, exploratory factor analysis; IC, internal consistency (Cronbach’s a); ICC, intraclass correlation coefficient (with 
95% CI) for 2-week test–retest stability; LOA95%, limits of agreement with 95% confidence interval; MDC95%, minimal detectable change for 95% confidence interval; PCS-NP, 
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Figure 3 Bland–Altman plots for total PCS (A), PCS Factor 1 (B), and PCS Factor 2 (C).
Note: Y-axis is the change in PCS-NP scores between baseline and follow-up measurements and X-axis is the mean of the PCS-NP scores at the baseline and final 
measurements. The red line is the mean change of score (d̄); and green lines are d̄ ± Z x SDchange (where Z = 1.96 for 95% confidence interval.)
Abbreviations: GRoC, Global Rating of Change; PCS, Pain Catastrophizing Scale; PCS-NP, Nepali version of Pain Catastrophizing Scale.
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Clinimetric properties of Nepali version of PCS
the second factor appeared to reflect thoughts related to a 
focus on pain.
At the same time, the two factors that emerged in this 
study were strongly associated with each other, suggesting 
that they may both be assessing the same overarching con-
struct. This conclusion is also supported by the similar pattern 
of associations between the two PCS-NP subscale scores and 
the criterion variables. Many other studies have also shown 
strong between-factor associations in both two-factor11,12,19 
and three-factor models.3 Also, of note, even though there 
is a large degree of overlap in how the PCS items load onto 
different factors across studies, rarely if ever do the exact 
same PCS items load on the same two- or three-factor mod-
els in any pair of studies.3,11,12,14,17 As a group, these findings 
support the conclusions that 1) the PCS items tend to reflect 
more than one (but strongly intercorrelated) subdomain of 
catastrophizing, 2) the specific subdomains reflected in the 
items vary to some degree across different populations, and 
3) there exists a single overarching domain assessed by the 
PCS that is reliable and consistent across populations. Practi-
cally, these findings indicate that the PCS total score (but not 
necessarily the subdomain scores) may be most appropriate 
for cross-cultural research.
Reliability
The internal consistencies of the PCS-NP total score in this 
study (a range =0.90–0.93) lie within the ranges previously 
reported. They are higher than the original English and the 
Catalan versions (a=0.87 in both)16,32 and Hindi version 
(a=0.76),22 similar to those found in samples who speak other 
languages such as Malay, Korean, Chinese, Italian, and Ger-
man (a range =0.90–0.93)2,3,14,17,20 and less than those found 
in a sample of patients from South Africa (a=0.97–0.98).21
Similarly, we found that the 2-week stability of the PCS-
NP was excellent in our test–retest sample, consistent with 
our a priori hypothesis. Two weeks is considered optimal for 
the assessment of reproducibility of a measure, because it 
is long enough to limit potential recall bias and also short 
enough to limit real change.40 Additionally, it is important 
to compute test–retest stability in the sample reporting that 
did they not perceive a change in their pain problem. Thus, 
in the current study, we assessed test–retest stability in those 
participants who reported no change in their pain problem 
using the GRoC as an external anchor.38 Numerous previous 
studies either assessed test–retest stability in short periods 
(range 1–7 days),15,17,20,22 which may have been resulted in 
findings that have recall bias,40 or assessed using longer 
epochs (3–4 weeks).3,15,21 To our knowledge, only two stud-
ies assessed the test–retest reliability of the PCS using a 
2-week time period, the results of which are comparable 
to our study.14,16 Additionally, we reported test–retest sta-
bility in a stable sample who reported no change in their 
pain-related problems. Most of the studies evaluating the 
psychometric properties of the PCS have not computed the 
test–retest reliability in a stable sample. This is especially 
true for those studies reporting longer follow-up for retest 
assessment.3,15,21 The participants in these studies were more 
likely to have changed with respect to their pain problem (and 
catastrophizing scores). Thus, the stability of the PCS may be 
underestimated in these studies. Support for this possibility 
is found in one study, which computed test–retest stabilities 
in both a subsample of stable patients with low back pain 
and the total sample and found better temporal stability in 
the stable group (ICC =0.92, n=34) versus the total group 
(ICC =0.85, n=60).15
Measurement error
The measurement error parameters we found met our a priori 
hypothesis for SEM, but we found lower MDC values than 
previously reported. Both the SEM and MDC are dependent 
on the test–retest coefficient. As previously indicated, the sta-
bility assessed is influenced by the sample chosen (ie, stable 
sample versus total sample). Not many studies have reported 
measurement error parameters, which are now recommended 
by the COSMIN checklist for clinimetric studies.37 The value 
of SEM we found for the total score (2.52) is larger than the 
Hindi version (SEM =1.60)22 and smaller than other versions 
(SEM =3.30–4.60).14,15,20,21 The SEM is influenced by the SD 
of change of PCS score (SD
change
) and the ICC (refer to the 
formula we used to calculate SEM in the “Methods” section). 
The smaller SEM values in our study are likely related to our 
Table 6 Validity of the PCS-NP
Sample N Concurrent validity (r)
BDI BAI PROMIS
EFA sample 143
PCS-NP total 0.56** 0.55**
PCS-NP Factor 1 0.55** 0.52**
PCS-NP Factor 2 0.49** 0.49**
CFA sample 272   
PCS-NP total 0.35**
PCS-NP Factor 1 0.33** 
PCS-NP Factor 2 0.33**
Notes: **P<0.01. PROMIS, 1–5 verbal rating PROMIS pain intensity scale for 
average pain in the past 7 days.
Abbreviations: BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; 
CFA, confirmatory factor analysis; EFA, exploratory factor analysis; PCS-NP, 
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use of the stable group to compute test–retest stability and 
measurement error, as opposed to other studies that used 
total group to compute test–retest stability and SEM. Thus, 
we obtained smaller SD
change
 and larger ICC values, giving 
us more precise value of SEM. The authors of the Hindi 
version study included the SD of the baseline measurement 
instead of the SD
change
, which may have accounted for their 
very low SEM.22
The MDC value of 6.98/52 observed in our sample pro-
vides a cut-point for determining the reliability of changes in 
the PCS score. The MDC computed from our sample is smaller 
than those observed in other samples (range 8.83–13).14,17 This 
is due to the smaller variability in the catastrophizing scores 
(as represented by the standard deviation) and larger test–
retest reliability coefficient (ICC) in our sample, relative to 
those in previous studies.14,17 The MDC statistics is useful as 
a guide to indicate whether or not a change in PCS score is 
greater than measurement error; that is, if the change repre-
sents true change and not just random error. For the PCS-NP, 
a change of 7/52 can be viewed as representing true change 
in the total PCS score beyond measurement error.
The results of LOA
95%
 and Bland–Altman plots39 
( Figure 3) provide further information regarding measure-
ment error.38,40 The Bland–Altman plots show agreement 
between test and retest scores for every study participant, that 
is, how far each participant deviates from the mean change 
score between the baseline and final measurements. In the 
current study, LOA
95%
 indicates that for 95% of participants, 
a measurement at follow-up assessment would be between 
15.17 points less and 16.02 points greater (out of a total of 
52 points) than the baseline measurement.
Validity
The validity of PCS-NP is supported by 1) its comprehen-
sibility and negligible missing items, 2) structural validity 
interpreted by factor analyses, 3) cross-cultural validity by 
adherence to high standards of translation guidelines,46 and 
4) concurrent validity by testing a priori hypotheses. We 
adapted and adhered to translation and cross-cultural adap-
tation guidelines by Beaton,46 which assured high standards 
in translation methodology. Importantly, we confirmed the 
concurrent validity of the PCS-NP based on our a priori 
hypotheses that PCS-NP would correlate moderately to 
strongly and significantly with the criterion variables. Asso-
ciation of PCS-NP with measure of depression in the cur-
rent sample (r=0.56) is within the range previously reported 
(r=0.40–0.61).2,14–17,20 It is larger than those reported by the 
Chinese (r=0.40),2 similar to Korean (r=0.53),14 but smaller 
than Catalan (r=0.61, BDI).16 As the association with depres-
sion, PCS-NP in the current sample showed moderate nega-
tive associations with the measures of anxiety and lies in 
the range that is previously reported (r=0.53–0.82).2,14,15,17,20 
Similarly, association of PCS-NP with measure of pain inten-
sity is moderate, which also lies within the range previously 
reported (r=0.25–0.45).2,14–17,20–22 As the a priori hypotheses 
regarding expected correlations of PCS-NP with criterion 
variables were met in the current study, concurrent validity 
of the PCS-NP is supported.
Strengths and limitations
One strength of the study is that it was conducted and reported 
using the COSMIN checklist as a guide.37,40 As per the COS-
MIN recommendations, we used an adequate sample size 
(>100) and we confirmed participants’ stability during the 
interim period by the use of GRoC. However, the study also 
has limitations, which should be considered when interpreting 
the results. One limitation is the use of cross-sectional design. 
Given that the correlations of the PCS-NP with the criterion 
variables presented are based on cross-sectional data, we are 
not able to draw any causal conclusions regarding the impact 
of catastrophizing on pain intensity, depression, or anxiety, 
or vice versa. Instead, the findings support the possibility that 
catastrophizing may play as large a role in patient functioning 
in Nepal as found in Western countries. This indicates that 
research examining the causal relationships in this population 
is warranted. Furthermore, the study design was not a clinical 
trial, in which catastrophizing was systematically manipulated. 
This would have allowed us to evaluate the responsiveness 
of the PCS-NP to treatment and link changes in the PCS-NP 
scores with treatment outcomes. Future research to evaluate 
the responsiveness of the PCS-NP to treatment, as well as 
to better understand the meaning of change in the PCS-NP 
scores (eg, the change that represents a minimum important 
change) would be useful. Finally, we did not assess divergent 
(discriminant) validity of the PCS-NP, which is another impor-
tant measure of construct validity. Research to evaluate this 
validity domain for the PCS-NP would be useful.
Summary and conclusion
Here, we developed a comprehensible, culturally appropriate, 
valid, and reliable PCS-NP for the use in Nepalese with chronic 
musculoskeletal pain or headache. The availability of this mea-
sure will facilitate more cross-cultural comparative study of 
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Clinimetric properties of Nepali version of PCS
For the clinical use of the PCS-NP, clinicians should consider 
PCS change score ≥7 as a true change beyond the measurement 
error. Future research should evaluate the discriminant validity 
of as well as the minimum important changes in the PCS-NP 
that is meaningful to patients, in order to better understand the 
validity and clinical significance of the PCS-NP.
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Measurement properties of the Nepali
version of the Connor Davidson resilience
scales in individuals with chronic pain
Saurab Sharma1,2* , Anupa Pathak1, J. Haxby Abbott2 and Mark P. Jensen3
Abstract
Background: Resilience is an individual’s ability to recover or “bounce back” from stressful events. It is commonly
identified as a protective factor against psychological dysfunctions in wide range of clinical conditions including
chronic pain. Resilience is commonly assessed using the Connor Davidson Resilience Scale (CD-RISC). Translation
and cross-cultural adaptation of the CD-RISC into Nepali will allow for a deeper understanding of resilience as an
important domain in health in Nepal, and will allow for cross-cultural comparison with other cultures. Therefore, the
aims of the study were to translate and culturally adapt 10- and 2-item versions of the CD-RISC into Nepali and
evaluate their psychometric properties.
Methods: After translating the measures, we performed exploratory and confirmatory factor analyses of the 10-item
version in two independent samples (ns = 131 and 134) of individuals with chronic pain. We then evaluated the
internal consistency, test-retest stability, and construct validity of the 10- and 2-item measures in these samples. We
also evaluated the internal consistency, and the construct and concurrent validity of the 2-item version in an
additional sample of 140 individuals.
Results: The results supported a single factor model for the 10-item measure; this measure also evidenced good to
excellent internal consistency and excellent test-retest stability. Construct validity was supported via moderate
associations with pain catastrophizing. The internal consistency of 2-item version was marginal, although construct
validity was supported via weak to moderate associations with measures of pain catastrophizing, depression and
anxiety, and concurrent validity was supported by strong association with the 10-item CD-RISC scale.
Conclusion: The findings support the reliability and validity of the 10-item Nepali version of the CD-RISC, and use
of the 2-item version in survey studies in individuals with chronic pain. The availability of these translated measures
will allow for cross-cultural comparisons of resilience in samples of individuals with chronic pain.
Keywords: Resilience, Clinimetric, Factor analysis, Reliability, Validity, Concurrent validity, Pain catastrophizing,
Depression, Anxiety, Musculoskeletal pain, Psychometrics
Background
Resilience has been defined as an individual’s ability to
recover or “bounce back” from stressful events [1]. Re-
silience is gaining popularity as a domain for under-
standing variability in adjustment to chronic pain. It has
been shown to be associated with physical disability and
psychological function, including catastrophizing,
anxiety and depression [1–3]. Those with higher resili-
ence scores are more able to recover from painful states
and use fewer analgesics than those with lower resilience
scores [4, 5]. Resilience is commonly assessed in chronic
pain research using the Connor Davidson Resilience
Scale (CD-RISC).
The CD-RISC has three versions: the full 25-item [6],
abbreviated 10-item (CD-RISC-10) [7] and brief 2-item
(CD-RISC-2) [8] versions. The CD-RISC-10 was derived
using exploratory and confirmatory factor analyses (EFA
and CFA) and has been shown to have stronger validity
than the full version [7]. Factor solutions of the original
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English version and translations have predominantly ex-
tracted one-factor solutions [7, 9–12]. The CD-RISC-10
has demonstrated good internal consistency [9, 11–13]
and good to excellent test-retest stability over 2 to 6 weeks
[9, 12, 13]. Validity has been supported via moderate asso-
ciations with catastrophizing, anxiety and depression [12].
The CD-RISC-2 is made up of two items that are also in
the CD-RISC-10. The CD-RISC-2 total score correlates
strongly with the full-version of CD-RISC [8] and has pre-
viously shown acceptable internal consistency [8, 14] and
good one-week test-retest reliability [15]. Its validity is
supported via moderate associations with measures of de-
pression and anxiety [14].
The CD-RISC-10 has been translated to many lan-
guages [10–12, 16–18], which facilitates cross-cultural
comparisons. Translation and validation of the CD-
RISC-10 and CD-RISC-2 into Nepalese will allow for a
deeper understanding of resilience as an important do-
main in individuals in this unique population where the
description of pain differs from populations from west-
ern cultures; for example, many more Nepalese than in-
dividuals from western cultures describe their pain using
metaphors, and use pain descriptors which are difficult
to translate into English [19].
The aims of this study were to develop and evaluate the
measurement properties (psychometrics properties) of the
10- and 2-item Nepali versions of CD-RISC in individuals
with chronic pain. We hypothesized that the Nepali CD-
RISC-10 would demonstrate (1) a single-factor solution in
two independent samples; (2) at least good internal
consistency (Cronbach’s alpha ≥0.70 [9–13]); (3) good to ex-
cellent 2-week test-retest stability (ICC ≥ 0.70 e.g., [9, 12,
13]); and moderate negative correlations (i.e., rs ~ − 0.30)
with pain catastrophizing [12]. We further hypothesized that
the CD-RISC-2-NP would demonstrate (1) acceptable in-
ternal consistency, (2) good test-retest reliability [15], and
(3) construct validity via moderate negative correlations (i.e.,
rs ~ − 0.30) with measures of anxiety and depression [12,
14]. We further hypothesized that the Nepali versions of
CD-RISC-2 and CD-RISC-10 would (1) strongly correlate
with each other, and (2) negatively correlate with the meas-
ure of pain intensity. Finally, we evaluated the standard
error of measurement (SEM), minimum detectable change
(MDC), and limits of agreement of both scales.
Methods
We first translated the CD-RISC-10 and CD-RISC-2 into
Nepali and evaluated the measurement properties of
these scales in two independent samples of individuals
with chronic pain.
Translation procedures
Translation of CD-RISC-10 into Nepali was performed
using standard patient-reported outcome measure
translation guidelines [20]. After forward translations,
synthesis of forward translations, and backward transla-
tion of the Nepali version of CD-RISC was completed,
all the versions of the translations were evaluated by an
expert committee, which consisted of the translators, re-
searchers (SS, AP, MPJ), and Nepali language experts.
After consensus among this expert committee members, a
Nepali version of CD-RISC was finalised for pre-testing.
This Nepali version was pre-tested on 30 individuals
with musculoskeletal pain selected to be representative
of different ages, both sexes, and different education
levels. After the completion of the Nepali CD-RISC, par-
ticipants were asked to describe the meaning of each
items. Feedback collected was used to improve the read-
ability and ease of item understanding. The final version
was reviewed and approved by Jonathan Davidson, one
of the developers of the scale. Details of the translation
history are presented in Fig. 1.
Evaluation of measurement properties
The planned analyses and reporting of measurement
properties was guided by COSMIN (COnsensus-based
Standards for the selection of health Measurement IN-
struments) checklist [21, 22]. To evaluate the measure-
ment properties of CD-RISC-NP, we used data from two
Fig. 1 Translation history of Nepali CD-RISC-10
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samples. Ethical approval was obtained from the Institu-
tional Review Committee of Kathmandu University School
of Medical Sciences, Nepal (reference number 75/15). Writ-
ten informed consent was obtained from every participant
before the collection of data. Participant who were unable
to read or write in Nepali provided verbal consent, and a
witness signed the consent form on their behalf.
Participants
To evaluate the measurement properties of CD-RISC-
NP measures, we used the two samples that were also
used to evaluate the psychometric properties of Nepali
version of the Pain Catastrophizing Scale (PCS) [23].
However, although there is significant overlap in the par-
ticipants between the previous study [23] and the
current study, not the same participants completed both
measures in both studies. The first sample in the current
study consisted of 265 individuals with chronic pain re-
cruited from a tertiary care hospital (n = 22) or the com-
munity (n = 243) in Nepal. This sample was further
divided into two subgroups (n = 131 and n = 134) for the
planned exploratory and confirmatory factor analyses
(EFA and CFA) of the CD-RISC-10-NP, hereafter called
the EFA sample and CFA sample, respectively. The CD-
RISC-10-NP, the 7-point Global Rating of Change
(GROC), the 3-item Patient-Reported Outcome Meas-
urement Information System (PROMIS) pain intensity
scale short-form 3a, and the 13-item PCS were adminis-
tered to this sample. Two hundred and twenty nine
(86%) of these individuals were re-administered the CD-
RISC-10-NP after 2 weeks. Test-retest reliability was
computed on a subgroup (N = 113) who endorsed “no
change” on the GROC scale over this time period.
The second sample consisted of 140 individuals with
chronic musculoskeletal pain recruited from community
(n = 100) and the same tertiary hospital (n = 40). Nepali
versions of 21-item Beck Depression Inventory (BDI), 21-
item Beck Anxiety Inventory (BAI), and PCS were admin-
istered concurrently with CD-RISC-2 to this sample.
Measures
Resilience
The Nepali version of 10-item and 2-item CD-RISC
were administered to samples 1 and 2, respectively [8].
Each of the CD-RISC-10-NP items is rated on a 5-point
Likert scale ranging from 0 = “Not true at all” to 4 =
“True nearly all the time.” The two item scale sums to a
possible high score of 8, and 10-item scale sums a pos-
sible high score of 40. Higher scores indicate more resili-
ence. The two items included in the 2-item version were
recommended by the developers as the two items that
best represent the resilience construct; they were “I am
able to adapt when changes occur” and “I tend to
bounce back after illness, injury or other hardships” [15].
Depression
The Nepali version of the 21- item Beck Depression In-
ventory (BDI) was used to assess depression. With the
BDI, respondents are asked to indicate the severity of
depressive symptoms using 4-point scales ranging from
0 to 3. Each 4-point scale response is specific to individ-
ual items. Total scores can range from 0 to 63, with
higher scores indicating more depression. The Nepali
version of BDI has excellent psychometric properties
(Cronbach’s alpha = 0.90 and two week test-retest
reliability = 0.84) [24, 25]. The BDI evidenced excellent
internal consistency (Cronbach’s alpha = 0.90) in the sec-
ond chronic pain sample of the current study (n = 140).
Anxiety
The Nepali version of 21-item Beck Anxiety Inventory
(BAI) was used to assess anxiety. With the BAI, partici-
pants are asked to rate each item on a 4-point Likert scale
ranging from 0 (“Not at all”) to 3 (“Severely, I could barely
stand it”), with possible total scores ranging from 0 to 63.
Higher scores indicate greater anxiety. The Nepali version
of BAI has shown to have excellent internal consistency
(Cronbach’s alpha = 0.89) [26]. Internal consistency of BAI
in the second chronic pain sample of the current study (n
= 140) was good (Cronbach’s alpha = 0.89).
Catastrophizing
Catastrophizing was measured using a Nepali version of the
13-item Pain Catastrophizing Scale (PCS). Participants are
asked to rate the frequency of their catastrophizing thoughts
using a 5-point Likert scale ranging from 0 (“Not at all”) to
4 (“All the time”) [27]. Higher scores indicate higher catastro-
phizing. The Nepali version of PCS has been found to have
excellent internal consistency (Cronbach’s alpha = 0.90–0.93)
and test-retest stability (ICC= 0.90) [23]. In the current sam-
ples, which as indicated previously, largely but not com-
pletely overlap with the those used to validate the PCS-NP
[23], the PCS evidenced excellent internal consistencies
(Cronbach’s alphas = 0.91 and 0.93, in the first (n= 265) and
second (n= 140) chronic pain samples, respectively).
Pain intensity
A Nepali version of the PROMIS pain intensity version 1.0
short form 3a scale was used to assess the pain intensity
over the past week. It asks three questions regarding pain
intensity: current pain intensity, worst pain, and average
pain. Each item is scored on a 5-point Likert scale from 1
(“Had no pain”) to 5 (“Very severe”) [28]. A T-score repre-
senting characteristic pain intensity was calculated using re-
sponse pattern scoring as recommended by PROMIS [28].
Global rating of change
A Nepali version of the Global Rating of Change (GRoC)
scale was used to assess the global rating of change in
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chronic pain-related problems in the sample 1 [29, 30].
It is a 7-point Likert scale ranging from 1 to 7. The mid-
point 4 represents “No change”; higher scores indicate
improvement and lower scores indicate worsening. The
GRoC score = 4 was used to categorize the participants
as “stable” or unchanged, and those who scored > 5 as
“Improved,” similar to previous studies [23, 29, 31]. We
considered a one-point change as significant improve-
ment in the GRoC scores [29–31]. The GRoC classifica-
tion was used to help interpret a number of
psychometric properties of the CD-RISC-10-NP and
CD-RISC-2-NP (i.e., test-retest stability, SEM, MDC,
and limits of agreement statistics). That is, we limited
analyses for computing these statistics to those
participants who reported no change in their GRoC
scores (i.e., GRoC = 4) [32].
Data analysis
All the data were analysed using SPSS version 24 except
confirmatory factor analysis which was performed in
AMOS for SPSS version 24. As indicated previously, the
reporting of the measurement properties was guided by
COSMIN recommendations [21].
Sample description
Descriptive statistics for the demographic variables
(means and standard deviations for continuous variables,
numbers and percentages for categorical variables) were
computed to describe the sample.
Factor analyses
We first performed an exploratory factor analysis (EFA)
using maximum likelihood as the method of factor ex-
traction, and factor rotation was performed using Direct
Oblimin (delta = 0) allowing factors to correlate with
each other in the EFA sample. We then performed a
series of confirmatory factor analyses (CFAs) in the CFA
sample. Model fit was evaluated using the chi-square
goodness-of-fit index, the ratio of chi-square value to
degree of freedom, the root mean square error of ap-
proximation (RMSEA), comparative fit index (CFI), and
parsimony goodness-of-fit index (PGFI). We determined
that a model had a good fit if (1) the chi-square value
and the ratio of chi-square to degree-of-freedom values
were relatively close to zero, (2) the RMSEA value was
low and close to 0, (3) the CFI was large and close to 1,
and (4) the PGFI value was large and close to 1 [33].
Reliability
We computed internal consistencies for both versions of
CDRISC-NP scales; using Cronbach’s alpha for CD-
RISC-10-NP and Spearman-Brown Coefficient for the
CD-RISC-2-NP [34]. We considered internal consisten-
cies between 0.70 and 0.79 as adequate, 0.80 and 0.89 as
good, and values 0.90 or larger as excellent [35]. Two-
week test-retest stability was evaluated using the intra-
class correlation coefficient (ICC) in the stable group
who endorsed no change in response to the GRoC. We
considered ICC values of .75 or more as excellent [35].
SEM is another reliability parameter recommended by
COSMIN checklist to describe measurement error which
compliments temporal stability of a scale [22]. Larger
scores of SEM indicate large variability and indicate more
error, and smaller scores indicate minimal variability and
suggest high precision. We calculated the SEM using the
formula, SEM= SDchange x √(1 - ICC) [32] where SDchange
is the standard deviation for the mean change score of
CD-RISC-NP. We then computed MDC95% for the CD-
RISC-NP scales using the formula, MDC95% = 1.96 x √2 x
SEM [22, 32]. Finally, we created two Bland-Altman plots
to indicate the levels of agreement of CD-RISC-NP scor-
ings between the baseline and follow-up assessments for
CDRISC-2-NP and CDRISC-10-NP separately [21, 36].
The plot was drawn using change in CDRISC-NP scores
between baseline and follow-up in the Y-axis, and mean
score of CDRISC-NP between baseline and follow-up as-
sessments in the X-axis.
Validity
We evaluated the construct validity of the CDRISC-NP
scales by computing the correlations of the baseline data
of CD-RISC-NP scales with the baseline scores of Nepali
versions of BDI, BAI, PCS administered in the EFA sam-
ple and PROMIS-PI administered to CFA sample, using
Pearson correlation coefficients.
We also performed concurrent validity of CD-RISC-
2-NP scale by evaluating its correlation with CD-
RISC-10-NP, and hypothesized that CD-RISC-2-NP to
have concurrent validity if the correlation coefficient
was 0.70 or more [37].
Results
Translation of CD-RISC-10 into Nepali
The Nepali version of CD-RISC-10 was easy to under-
stand, and retained its original meaning. Cultural adap-
tations were made on three of the CD-RISC-10 items (i.
e., items, 1, 3, and 4). The cultural adaptations are re-
ported in Appendix 1.
CD-RISC scores
The CD-RISC-2-NP and CD-RISC-10-NP scores were
normally distributed in all the three samples at all as-
sessment points. The means and SDs of the CD-RISC-2-
NP and CD-RISC-10-NP scores are presented in Table 1.
A total of 83% (n = 109/131) and 81% (n = 106/131) in
EFA sample and 95% (n = 128/134) and 92% (n = 123/
134) completed follow-up assessments in the CFA sam-
ple for CD-RISC-2 and CD-RISC-10, respectively.
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Table 1 Description of the study participants and the CD-RISC scores
Sample 1
EFA sample CFA sample Sample 2
(N = 131) (N = 134) (N = 140)
Variable N (%) or Mean (SD) N (%) or Mean (SD) N (%) or Mean (SD)
Recruitment, N (%)
Community 109 (83%) 134 (100%) 100 (71%)
Hospital 22 (17%) 0 (0%) 40 (29%)
Primary site of pain, N (%)
Multiple sites 60 (46%) 65 (48%) 60 (43%)
Low back and pelvis 21 (16%) 25 (19%) 31 (22%)
Knee 25 (19%) 28 (21%) 29 (21%)
Headache 6 (5%) 5 (4%) 0 (0%)
Neck 4 (3%) 0 (0%) 3 (2%)
Upper back 4 (3%) 0 (0%) 3 (2%)
Elbow 3 (2%) 1 (1%) 1 (1%)
Ankle and foot 3 (2%) 4 (3%) 1 (1%)
Shoulder 1 (1%) 1 (1%) 9 (6%)
Other sites 4 (3%) 5 (3%) 3 (2%)
Duration of pain in months,
Mean (SD) 41.67 (56.19) 61.56 (74.14) 52.09 (76.94)
Follow-up assessment epoch in days,
Mean (SD) 10.62 (1.42) 10.27 (1.82) –
Age in years, Mean (SD) 44.92 (17.20) 47.91 (13.81) 47.27 (14.54)
Sex, N (%)
Men 37 (28%) 33 (25%) 50 (36%)
Women 94 (72%) 101 (75%) 90 (64%)
Religion, N (%)
Hindu 123 (94%) 102 (76%) 130 (93%)
Buddhist 6 (5%) 27 (20%) 4 (3%)
Others 2 (1%) 5 (4%) 6 (4%)
Race/Ethnicity, N (%)
Chettri 10 (8%) 6 (4%) 59 (42%)
Brahmin 71 (54%) 13 (10%) 38 (27%)
Newar 40 (30%) 101 (75%) 19 (14%)
Others 10 (8%) 14 (11%) 11 (8%)
Education, N (%)
No school 25 (19%) 15 (11%) 44 (31%)
Primary school (<5 years) 32 (24%) 20 (15%) 42 (30%)
Secondary school (6-10 years) 23 (18%) 34 (25%) 34 (24%)
Higher secondary (11-12 years) 31 (24%) 25 (19%) 5 (4%)
Bachelor and over 20 (15%) 40 (30%) 15 (11%)
Primary occupation, a N (%)
Unemployed 21 (16%) 0 (0%) 6 (4%)
Agriculture 37 (28%) 15 (11%) 48 (34%)
Homemaker 18 (14%) 36 (27%) 39 (28%)
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Total CD-RISC-2 score of 0/8 was reported by 0.4% of
the participants in the sample 1 (N = 265; EFA and CFA
sample combined), and 1% (n = 1) participants in the
sample 2 (N = 140); and 8/8 score was reported by 10%
(n = 26) of participants in the sample 1, and 16% (n = 23)
of participants in the sample 2. Likewise, CD-RISC-10
score of 0/40 was reported by 0.4% (n = 1) and 5% (n =
13) of participants in sample 1.
Handling missing items
In sample 1, there was missing item 3 CD-RISC-10 re-
sponse for one participant, and a missing response to
items 6 and 8 for another. There were no missing re-
sponses to the CD-RISC-2-NP items. Both the partici-
pants with missing items were excluded from all
analyses involving the CD-RISC-10-NP.
Demographic characteristics
The majority of the study participants were Hindu in
religion (76% or more across samples) and were
women (65% or more across samples). The plurality
of participants (43% - 48% across samples) reported
that they had chronic pain in more than one site. Of
those reporting pain in one site, the most common
sites were the low back and pelvis (16% - 22% across
samples) and pain in the knees (19% - 21% across
samples). Additional descriptive information for the
study samples are presented in Table 1.
Factor analyses results
The results of the EFA supported a single factor (first
two eigenvalues were 4.98 and 0.90) for the CD-RISC-
10-NP. This factor solution was confirmed via CFA in
the CFA sample, which demonstrated a good fit. Covari-
ance of error terms improved the fit index (Table 2).
The path diagram of the CFA is presented in Fig. 2.
Reliability results
The results of the reliability analyses for both the
CD-RISC-10-NP and CD-RISC-2-NP are presented in
Table 3. As can be seen, internal consistencies of CD-
RISC-10-NP ranged between 0.87 and 0.90; and be-
tween 0.48 and 0.70 for CD-RISC-2-NP. The two-
week test-retest reliability (Intraclass Correlation Co-
efficient) of CD-RISC-10-NP in the stable group
(GRoC = 4) was 0.89; and 0.71 for the CD-RISC-2-NP.
The SEM and MDC for both the 2-item and 10-item
CD-RISC are presented in Table 3.
The Bland-Altman Plots demonstrating the limits of
agreement are presented in Fig. 3. Figure 3a and b show
graphical representations of the systematic and random
errors of test-retest measurement scores for the 10-item
and 2-item CD-RISC assessed in the stable group, re-
spectively. The central red lines represent the systematic
error, and the green dotted lines represent random er-
rors of test-retest scores.
Validity results
Construct validity of CD-RISC-10-NP was supported by
significant moderate negative correlations with the PCS,
(rs = .30–.45, Ps < 0.001); the CD-RISC-2-NP showed
weak to moderate associations with the PCS (rs = .23–.35,
P < 0.001). Validity of CD-RISC-2-NP was supported by a
moderate negative correlation with depression and weak
and negative association with anxiety. Finally, CD-RISC-2-
NP and CD-RISC-10-NP were negatively (weakly to mod-
erately) associated with the measure of pain intensity. The
CD-RISC-2-NP demonstrated concurrent validity by
strong positive association (r = 0.75) with its longer ver-
sion, CD-RISC-10-NP. The construct validity of the CD-
RISC-NP scales with their correlation coefficients with
comparator instruments are presented in Table 4.
Table 1 Description of the study participants and the CD-RISC scores (Continued)
Sample 1
EFA sample CFA sample Sample 2
(N = 131) (N = 134) (N = 140)
Variable N (%) or Mean (SD) N (%) or Mean (SD) N (%) or Mean (SD)
Business 20 (15%) 37 (28%) 15 (11%)
Office worker 14 (11%) 24 (20%) 10 (7%)
Other 21 (16%) 22 (14%) 22 (16%)
CDRISC-2 score, Mean (SD)
Initial assessment 5.21 (1.67) 5.47 (1.68) 5.43 (1.94)
Final assessment 5.20 (1.77) 5.54 (1.69) –
CDRISC-10 score, Mean (SD)
Initial assessment 27.05 (7.03) 28.54 (7.62) –
Final assessment 26.25 (8.32) 27.72 (7.91) –
a As reported by the study participants
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Discussion
The translation and cross-cultural adaptation of CD-
RISC-10-NP yielded a comprehensible, reliable and valid
Nepali version consistent with the study hypotheses.
Factor analyses
The findings support a single factor solution for the CD-
RISC-10-NP, consistent with both the original English ver-
sion [7] and translations [9–12] of this scale. To our
knowledge, only the Nigerian version of the CD-RISC-10
[16] has shown a two factor solution, albeit with a very
strong correlation between the two factors (r = 0.82).
Reliability
The internal consistency of the CD-RISC-10-NP in
our sample was similar to those previously reported
[7, 10–12]. However, the internal consistency of the
brief version (CD-RISC-2-NP) here was lower than
those previously reported [8, 14]. The internal
consistencies of CD-RISC-2-NP tends to be lower
than that of CD-RISC-10-NP across all populations
[7, 8, 11, 12, 14]. This could be due, in part, to the
strategy chosen to develop the CD-RISC-2. That is,
the two items of the CD-RISC-2 were chosen from
the original 25 CD-RISC items to capture the view of
the meaning of resilience, without the guidance of
empirical tests [15]. Use of such tests, including Item
Response Theory or Rasch analyses, could potentially
yield a brief version of the CD-RISC that has greater
reliability. Additional work to develop alternative brief
versions of the CD-RISC with greater reliability ap-
pears warranted.
We found a very high 2-week test-retest stability for the
CD-RISC-10-NP, similar to the 6- and 2-week test-retest
stability coefficients previously reported in two studies [9,
12], and higher than (but still adequate) 2-week test-retest
stability coefficient (0.71) reported in a third study [13]. In
the current study, we assessed test-retest stability only in a
group of participants who reported no global changes in
pain-related problems (i.e., a stable group). This is a rec-
ommended method for the reporting of the temporal sta-
bility of a patient-reported outcome measures [21, 32].
Use of a stable group is important, because resilience
scores could potentially change after an intervention [15]
or after facing adversities in life.
Our study presents novel findings regarding the measure-
ment errors (SEM and MDC) of the CD-RISC scales. It is
important to consider both of these when interpreting re-
sults of a measure to be used in longitudinal research,
because not every scale score change represents a true (reli-
able) change. The MDC is the amount of change beyond
measurement error, and thus represents the amount of
change that can be considered reliable. Our findings sug-
gest that changes in the CD-RISC-10-NP and CD-RISC-2-
NP of 6.72 (scale 0–40) and 2.38 (scale 0–8) represent true
changes; values below these are more likely to be due to
Table 2 Confirmatory factor analysis results for the 10-item Nepalese Connor Davidson Resilience Scale (CD-RISC-10-NP)
X2 (df) X2/df RMSEA CFI PGFI
One-factor model 48.49 (35) 1.82 0.054 0.978 0.593
One-factor model with Modificationa 34.33 (34) 1.01 0.009 0.999 0.588
a Confirmatory factor analysis results after covariance of error terms e4 and e10
Fig. 2 Path diagram after confirmatory factor analysis of CD-RISC-10 and covariance of error terms. Abbreviations: CDRISC, Connor Davidson Resilience
Scale; CD-RISC-10, 10-item Connor Davidson Resilience Scale
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measurement errors than values above these cutoffs. The
Bland-Altman Plot [36] results (Fig. 3) provides visual infor-
mation regarding the limits of agreement; that is, how far
the retest scores deviate from the test scores, indicating
general agreement between the two assessment points.
Validity
Both the 2-item and 10-item CD-RISC-NP demonstrated
construct validity via moderate associations with measures
of pain catastrophizing and negative associations (weak to
moderate) with pain intensity. The validity of the 2-item
scale was supported via its moderate negative associations
with measures of pain catastrophizing and depression, and
weak but still significant association with measure of anxiety.
These findings are consistent with previous research, and
support the validity of the 10-item Nepalese versions of the
scales [12, 14]. Less, but still adequate, support for the valid-
ity of the CD-RISC-2-NP was found, via its weak association
with anxiety in our sample. To our knowledge only one
study has previously evaluated the association of CD-RISC-2
with anxiety, which showed a moderate correlation [14].
The CD-RISC-2-NP demonstrated its concurrent val-
idity by a strong association with the CD-RISC-10-NP.
The magnitude of association found here was similar to
that found in a previous study (r = 0.77; [14]), although
it was somewhat lower that that found in another study
(r = 0.88; [8]).
Strengths and limitations
An important strength of the current study is that we
followed the standard translation guidelines for the
translation and cross-cultural adaptation of health-
related patient reported measures [20]. We also followed
COSMIN recommendations for the reporting of meas-
urement properties of the 2-item and 10-item CD-RISC-
NP scales [21, 22], which is the current reference stand-
ard for reporting measurement properties. The psycho-
metric properties of CD-RISC-NP measures were tested
in three different samples (including the analyses for fac-
tor structure), with Ns > 100 for each sample, which is
minimum recommended for the assessment of psycho-
metric properties. Test-retest stability was also assessed
in more than 100 participants (as recommended by
COSMIN [21, 22]) who reported little change in their
pain problem, as assessed by the GRoC [32]. Finally, we
also evaluated the SEM and MDC of CD-RISC-NP,
which we believe is the first time these important statis-
tics have been reported for the CD-RISC-2 and CD-
RISC-10 measures.
Table 3 Reliability of the Nepali versions of the 10- and 2-item
Connor Davidson Resilience Scales
Test-retest
Sample N IC ICC (95% CI) SEM MDC95%
CD-RISC-10
Total sample 265 .89
EFA sample 131 .88
CFA sample 134 .87
Stable group 113 .90 .89 (.86, .92) 2.42 6.72
CD-RISC-2
Total sample 265 .55
EFA sample 131 .62
CFA sample 134 .48
Stable group 119 .70 .71 (.58, .80) 0.86 2.38
Sample 3 140 .60
CD-RISC-10 10-item Connor Davidson Resilience Scale, CD-RISC-2 2-item Connor
Davidson Resilience Scale, IC Internal consistency (Cronbach’s alpha for the
CD-RISC-10 and Spearman-Brown correlation coefficient for the CD-RISC-2);
SEM Standard Error of Measurement (SEM = SDchange x √(1-ICC)); MDC95%,
Minimum Detectable Change for 95% Confidence Interval (MDC95% = Z x √2 x
SEM); ICC Intraclass Correlation Coefficient
Fig. 3 Bland-Altman Plot for CD-RISC-10 (a) and CD-RISC-2 (b). Note:
Y-axis is the change of CD-RISC scores between baseline and follow-up
measurements and X-axis is the mean of the CD-RISC scores at the
baseline and final measurement. Solid line is the mean change of score
(d̄); and dotted lines are d̄ ± Z x SDchange (where Z = 1.96 for 95%
confidence interval)
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Although the study has important strengths in terms
of sample size, methodology, and rigour, the study’s limi-
tations should also be considered when interpreting the
findings. One limitation is that the back translation of
the measure was performed by a single back-translator;
translation and cross-cultural adaptation guidelines de-
scribed by Beaton and colleagues [20] recommend that
two or more translators to perform the back transla-
tions. This weakness might be mitigated some by the
fact that translation guidelines indicate that use of a sin-
gle back translator is acceptable [38]. As the items of the
CD-RISC are fairly straightforward, translation was rela-
tively simple and we found few issues during the cogni-
tive testing of the items. Moreover, the few issues that
emerged were easy to resolve (see Appendix 1). The ad-
equacy of this approach was also supported by the
strong psychometric properties of the resulting scales.
Still, use of two or more back translators would have
been ideal.
A second important limitation of the study is that we
used a GRoC scale that asked participants to rate global
change in pain-related problems to categorize partici-
pants as “unchanged” in order to evaluate test-retest sta-
bility of the CD-RISC-NP scales. Although, asking
participants to rate their change in “resilience” would
have been ideal to categorize participants into stable or
improved groups, using "global" scores to assess test-
retest stability is a common practice (e.g., [32, 39, 40]).
The excellent reliability scores in the present study are
consistent with idea that the participants may have con-
sidered resilience into account when rating overall
change. Future studies may evaluate relationships be-
tween patient’s “global rating of change” and “change in
resilience” scores, to explore if they are related, or con-
duct temporal stability of resilience measures using
change of the resilience scores instead of GRoC.
Third, the GRoC score asks participants to recall the
change in pain-related problem since the baseline assess-
ment, which may introduce a recall bias. However, the
duration of reassessment of only approximately 10 days
likely limited recall bias, and is less than the recom-
mended duration of 2 weeks for the assessment of test-
retest stability [21].
Fourth, we used cross-sectional data to assess the val-
idity of the resilience measures; such data do not allow
us to draw causal inferences regarding the associations
among the domains assessed by the study measures. Fu-
ture research is needed to evaluate the causal relation-
ship between resilience and psychological functions in
individuals with chronic pain from Nepal.
Fifth, we assessed the measurement properties of CD-
RISC-NP in adult Nepalese with chronic pain only. The
findings therefore do not necessarily generalize to other
populations or who have other clinical conditions, for ex-
ample paediatric populations and those with mental
health conditions. Future research is required to evaluate
the validity of CD-RISC-NP measures in these populations.
Finally, we did not evaluate the responsiveness of the
CD-RISC-NP measures to treatment. It would have been
ideal to evaluate the minimum important change (MIC)
score of the CD-RISC-NP, which could be used as refer-
ence to evaluate clinical meaningful improvement. Fu-
ture studies may evaluate responsiveness and MIC to
determine the utility of the CD-RISC-NP scales as out-
come measures would be useful.
Conclusions
In summary, the 10-item CD-RISC-NP scales evidenced
good measurement properties; the findings support the
use of this measure in research studying resilience in
chronic pain populations. The results provide less sup-
port for the reliability and validity of the 2-item CD-
RISC-NP, but indicate that it could be used in studies
using larger samples (e.g., survey studies). Research is
needed to better understand the causal influence of re-
silience on psychological function, and how this might
differ as a function of language and culture.
Appendix 1
Key cross-cultural adaptation of the Nepali CD-RISC-10
items
 Item 1: Item 1 was originally translated as “कुनै
परिवर्तन हँुदा म परिस्थिति अनुसार ढल्न सक्छु”. The
original Nepali word used in this item for “adapt”
was “ढल्न”. However, during the pre-testing for first
few participants, patients misunderstood this word
Table 4 Construct validity (r) of the Nepali versions of the 10- and
2-item Connor Davidson Resilience Scales
Sample N PCS BDI BAI PROMIS
CD-RISC-10
Total sample 265 −.35** −.27**
EFA sample 131 −.45** −.37**
CFA sample 134 −.30** −.23**
Stable group 113 −.36** −.19**
CD-RISC-2
Total sample 265 −.30** −.27**
EFA sample 131 −.35** −.38**
CFA sample 134 −.23** −.17*
Stable group 119 −.24** −.23**
Sample 3 140 −.43** −.31** −.27**
*P < .05; **P < .01
CD-RISC-10 10-item Connor Davidson Resilience Scale, CD-RISC-2 2-item Con-
nor, Davidson Resilience Scale, BDI Beck Depression Inventory, BAI Beck Anx-
iety Inventory, NRS Numerical Pain Rating Scale, PROMIS PROMIS pain intensity
scale short form 3a
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as “fall” or “faint” which are other meanings of this
word. Thus, during the pre-testing phase, we added
“परिवर्तन हुन” within parenthesis which translated to
“change” to clarify meaning of “ढल्न” as “adapt” or
“change.” After making this change, remaining major-
ity of participants witnessed further issues with this
item during pre-testing after this change was made.
 Item 3: Item 3 was originally translated as “जब म
कुनै समस्याजनक परिस्थितिमा हुन्छु, म त्यसका हास्यास्पद
पक्षहरू हेर्ने प्रयास गर्छु”. However, participants
struggled to understand meaning of Nepali word for
“humor”. We therefore added “रमाइला” to the item,
which means “fun” within parenthesis of “हास्यास्पद”
which clarified the meaning of the item. There were
no further issues with this item during pre-testing
after this change was made.
 Item 4: The forward translations of this item was
translated as “तनावको सामना गर्नाले मेरो बल झन् दरो
हुन्छ”. The use of the word “बल” which means
strength in Nepali is ambiguous. Thus, in the expert
committee meeting, we decided to replace the word
by “मनोबल” which means “mental strength” to clarify
its meaning in Nepali.
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AbstrACt
Introduction Low back pain (LBP) is the leading cause 
of years lived with disability in Nepal and elsewhere. 
Management of LBP that is evidence-based, easily 
accessible, cost-effective and culturally appropriate is 
desirable. The primary aim of this feasibility study is to 
determine if it is feasible to conduct a full randomised 
clinical trial evaluating the effectiveness of pain education 
as an intervention for individuals with LBP in Nepal, 
relative to guideline-based physiotherapy treatment. The 
findings of the study will inform the planning of a full 
clinical trial and if any modifications are required to the 
protocol before undertaking a full trial.
Methods/analysis This protocol describes an assessor-
blinded feasibility clinical trial investigating feasibility 
of the pain education intervention in patients with non-
specific LBP in a physiotherapy hospital in Kathmandu, 
Nepal. Forty patients with LBP will be randomly allocated 
to either pain education or guideline-based physiotherapy 
treatment (control). Outcomes will be assessed at baseline 
and at a 1 week post-treatment. The primary outcomes are 
related to feasibility, including: (1) participant willingness 
to participate in a randomised clinical trial, (2) feasibility 
of assessor blinding, (3) eligibility and recruitment rates, 
(4) acceptability of screening procedures and random 
allocation, (5) possible contamination between the groups, 
(6) intervention credibility, (7) intervention adherence, (8) 
treatment satisfaction and (9) difficulty in understanding 
the interventions being provided.
Ethics/dissemination The protocol was approved 
by Nepal Health Research Council (NHRC; registration 
number: 422/2017) and University of Otago Human Ethics 
Committee for Health (registration number: H17/157). 
The results of the study will be presented at national 
and international conferences and published in a peer-
reviewed journal.
trial registration number NCT03387228; Pre-results.
IntroduCtIon 
Low back pain (LBP) is a highly preva-
lent health condition worldwide.1 2 It is the 
leading cause of disability2 and imposes huge 
economic burden to the society in both devel-
oped and developing countries.3–6 LBP is 
among the most common health conditions 
contributing to years lived with disability in 
Nepal.2 Although the prevalence of LBP is 
high in Nepal, ethnographic research has 
noted that LBP-related disability may be low 
in rural areas,7 perhaps due to the very low 
socioeconomic status of individuals living 
in rural Nepal, which forces them to keep 
working despite the presence of pain. Consis-
tent with this idea, another study highlighted 
that 80% of people with chronic pain in Nepal 
continue to work.6 However, it is alarming 
that number of spine surgeries for spinal pain 
has been increasing in Nepal over the years,8 
despite lack of evidence supporting efficacy 
for this treatment.1 9 
Interventions for management of LbP
Many interventions have been investi-
gated for the management of LBP. These 
include surgery,10 11 pharmacotherapy,12–17 
exercises,18–20 advice for self-management 
including advice to remain physically active11 
and psychological therapies.21 22 As alluded 
to earlier, biomedically focused interventions 
such as surgery and pharmacotherapy are 
not recommended for a non-specific LBP as 
the evidence does not support their effective-
ness.1 14 Moreover, they are associated with 
significant risks for adverse events and are 
costly.5
Clinical practice guidelines for LBP 
recommend self-management including 
strengths and limitations of this study
 ► Assessor and statistician will be blinded to group 
allocation of the participants.
 ► Therapist and patient blinding is not possible in 
this study because of the nature of the treatments 
provided.
 ► Conclusions regarding the effectiveness of the in-
tervention cannot be made because of the feasibility 
design of the current study.
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reassurance, education and advice to remain active as the 
first line of care that should be provided to all the patients 
with LBP. Superficial heat and manual therapy (massage/
manipulative therapy) are recommended for acute LBP, 
whereas exercise and psychological therapies are recom-
mended for chronic LBP.23–25
Pain education for LbP
Patient education for LBP that has been investigated in 
randomised   controlled trials is basically of two types: 
biomedical education and pain biology education.26 The 
first refers to educating patients about vertebral anatomy 
and pathoanatomy of the spine, which has been shown 
to be ineffective and may even have negative effects on 
LBP outcomes.26 However, the second type of educa-
tion—pain biology education (hereafter called as ‘pain 
education’)—has been shown to have positive effects on 
both pain and disability.27 28 Pain education is structured 
education programme with specific aims and objectives.29 
This intervention has a list of target key concepts to be 
delivered and includes the curriculum contents to deliver 
the key concepts using up-to-date pain science knowl-
edge, stories and metaphors.
It has been previously hypothesised that this type of 
education programme using metaphors and stories may 
be an effective intervention in Nepalese with chronic 
pain.30 However, the pain education materials that have 
been developed in western cultures are not necessarily 
valid and equally effective in reducing pain and disability 
in non-western cultures. Therefore, when developing 
pain education materials in a newer language or culture, 
(significant) cultural adaptations of the education mate-
rials may be required to make it suitable for the target 
population, as culturally inappropriate education may 
not produce desirable results.
Therefore, in order to evaluate the effectiveness of 
pain education in individuals with non-specific LBP from 
Nepal, culturally appropriate pain education materials 
should first be developed for Nepal, specifically. However, 
it is possible that the adaptations made could potentially 
reduce its effectiveness. Thus, before testing the adapted 
pain education in a full clinical trial, a feasibility study is 
needed in order to determine if a full clinical trial based 
on the adapted intervention is warranted, or if additional 
modifications may be needed prior to performing the full 
trial.
Why the feasibility trial?
We propose a feasibility trial because: (1) the interven-
tion (ie, pain education) will need significant cultural 
adaptation, although it has been evaluated for efficacy 
previously in other languages and western cultures; (2) 
the adapted intervention has never been investigated for 
its efficacy or effectiveness before; (3) the population in 
question (individuals with extremely low socioeconomic 
status and educational attainment in Nepal) is unique; 
and (4) a high-quality clinical trial in individuals with LBP 
has not been conducted in Nepal to our knowledge, and 
we therefore do not know if a full trial is feasible. The 
findings from the proposed feasibility study will inform 
the planning and design of a full trial, if the results indi-
cate that a full trial is warranted.
The results of the full trial will have significant clinical 
implications for the management of LBP in Nepal and 
similar cultures, providing empirical evidence if pain 
education is a viable treatment for the management of 
LBP, and if it is effective in reducing pain, disability and 
emotional distress.
Aims and objectives
The primary aim of the study is to evaluate the feasibility 
of a full randomised clinical trial (RCT) for assessing the 
effects of pain education as an intervention for patients 
with LBP of any duration in a physiotherapy facility in 
Nepal after developing culturally appropriate, evidence-
based pain education materials. The primary objectives 
of the study are related to feasibility of an RCT, specifi-
cally: (1) willingness to participate in an RCT, (2) feasi-
bility of assessor blinding, (3) eligibility and recruitment 
rates, (4) acceptability of screening procedures and 
random allocation, (5) possible contamination between 
the groups, (6) intervention credibility for patients with 
LBP, (7) intervention adherence, (8) treatment satisfac-
tion and (9) difficulty in understanding the intervention 
being provided.
MEthods And AnALysIs
study design and setting
This is a feasibility study that is being performed to deter-
mine if a full RCT can be successfully conducted using the 
procedures and protocol of the feasibility study, or if modi-
fications of the protocol are needed prior to conducting 
the full trial. The study findings will inform the design of 
the full trial, if the trial is found to be feasible.31
The definition of a feasibility study highlights the ques-
tion, ‘Can this study be done?’. The Standard Protocol 
Items: Recommendations for Interventional Trials 
(SPIRIT) statement,32 the Consolidated Standards of 
Reporting Trials statement extension to pilot and feasi-
bility randomised trial31 were followed in the planning of 
the study and reporting of the protocol.
The study will be an assessor-blinded, two-arm, feasi-
bility RCT. The study is registered in  Clinicaltrials. gov 
(trial registration number: NCT03387228). The study will 
be conducted in the Sahara Physiotherapy Hospital, Kath-
mandu, Nepal.
overview of the study
Advertisement of the trial will be made in social media, 
and all the patients with LBP presenting at the study 
site will be invited to participate. Interested candidates 
will be screened for eligibility. Eligible patients with 
non-specific LBP will then be enrolled in the trial and be 
randomly assigned to one of the two study groups. All the 
participants in the experimental group will receive pain 
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education and those in the control group (CG) will receive 
guideline-based physiotherapy treatment. All the partic-
ipants will be assessed at baseline and 1 week following 
treatment. Details describing the schedule of enrolment, 
interventions and assessment are presented in table 1, in 
the manner recommended by SPIRIT checklist.32








−T1 T0 T1 T2 T3
Enrolment 
  Eligibility screening X
  Explain study procedure/provide participant information sheets X
  Informed consent X
  Random treatment allocation X
Intervention 
  Experimental intervention (PEG) X
  Control group (CG) X
Assessment 
  Baseline descriptive variables




   Pain history (site of pain, duration of pain, continuous or intermittent pain, 
aggravating and relieving factors)
X
   Comorbidities X
  Feasibility
  Willingness to participate in a randomised controlled trial X
   Acceptability of random allocation to one of the two groups X
   Acceptability of intervention session (one session in a week with home 
treatment programme throughout the week)
X
   Feasibility of blinding the assessor* X
   Eligibility and recruitment rates X
   Acceptability of screening procedures* W
   Understanding possible contamination between the groups X
   Evaluating the credibility of the intervention X X
   Adherence to intervention X
   Treatment satisfaction X
   Difficulty in understanding the treatments X
  Secondary outcomes
   PROMIS Pain interference X X
   PROMIS Pain intensity X X
   Quality of life X X
   PROMIS Sleep disturbance X X
   PROMIS Depression X X
   GROC – X
   PCS X X
   CD-RISC-10 X X
*Assessed by the therapist providing intervention; all other outcomes are assessed by the blinded outcome assessor. 
CD-RISC-10, 10-item Connor-Davidson Resilience Scale; GROC, Global Rating of Change; PCS, Pain Catastrophizing Scale; 
PROMIS , Patient-Reported Outcome Measurement Information System; T1, enrolment time; T0, allocation time; T1 , baseline 
assessment (before treatment); T2, during treatment; T3, 1 week post-treatment; W, assessment at the end of every week on Fridays.
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Participants
Patients with non-specific LBP seeking rehabilitative 
services at Sahara Physiotherapy Hospital will be invited 
to participate. Interested patients will be screened by a 
research assistant (physiotherapist by training) involved 
in the research.
Inclusion criteria
Non-specific LBP (LBP other than those excluded, 
see exclusion criteria below) of any duration with pain 
primarily localised between T12 and gluteal folds, in 
patients aged 18 years or older, with average pain inten-
sity reported as moderate, severe, or very severe on 
a Patient-Reported Outcome Measurement Informa-
tion System (PROMIS) five-point PROMIS Pain Inten-
sity Short-form Scale33 over the past week, and who is a 
Nepalese and is able to understand and speak Nepali 
fluently will be included in the study.
Exclusion criteria
Participants with likely specific causes of LBP will be 
excluded using a triage procedure as suggested by Bardin 
and colleagues.34 This includes exclusion of participants 
having history of prolonged use of corticosteroid, history 
of malignancy, recent history of fever or chills, history of 
other diseases associated with compromise in immune 
system, history of recent spinal surgery or dental proce-
dures, recent history of trauma to spine or a fracture of a 
spine, history of bladder and bowel dysfunction, history 
of perineal or saddle anaesthesia and history of weakness 
of lower extremity or loss of sensation in lower extremity. 
Additionally, current pregnancy and history of diagnosed 
mental health conditions that would limit adherence to 
the trial procedures will be excluded.
sample size
For a feasibility study, it is inappropriate to calculate 
sample size based on desired statistical power to detect a 
treatment effect,35 because the primary aim of the study is 
to assess if a full trial can or should be conducted. Feasi-
bility outcomes are descriptive in nature; therefore, infer-
ential statistics regarding treatment effects will not be 
computed. To achieve the primary objectives related to 
feasibility outcomes, the research team estimated that 40 
participants would be adequate.36 Twenty patients will be 
randomly allocated to each treatment condition.
Participant screening and recruitment
Consecutive participants with non-specific LBP will be 
invited to participate in this study. The study purpose and 
procedures will be described to potential participants. 
This will include information about the benefits and 
potential harms of the intervention, the time required for 
the completion of the study, follow-up duration, voluntari-
ness of participation, cost of participation and the rights 
to withdraw from the study at any point. A study informa-
tion sheet will be provided to all potential participants.
If the potential participants are interested in partici-
pating, they will be screened for eligibility by a research 
assistant who is a physiotherapist. If the participants are 
found eligible, informed consent will be obtained. For 
those who cannot sign the consent, a witness will sign on 
their behalf, or the study participant will provide a thumb 
print on the form for those who cannot write or sign the 
form as per the ethical guidelines provided by Nepal 
Health Research Council (NHRC). We will include uned-
ucated patients who cannot sign an informed consent 
in order to increase the inclusion of uneducated or low 
education group, given that 31% people in Nepal who are 
5 years old or more cannot read and write.37 Additionally, 
exploration of feasibility of pain education in those with 
no schooling or low educational attainment is important 
in order to inform clinical practice.
Participants will be informed that they will receive one 
of the two treatments randomly. It will be highlighted that 
both of the treatment options are thought to be effective 
for LBP and that the goal of the main study is to compare 
the interventions; however, the current study will more 
specifically evaluate the feasibility of such a study.
Group allocation, randomisation and blinding
Random number sequence, in random blocks of 4 and 
6, will be generated using www. randomization. com, by 
a researcher (JHA) who is not involved in recruitment 
process. Allocation concealment will be performed using 
opaque, sealed envelopes. The participants will be allo-
cated to one of the two groups by a hospital staff member 
who is not the assessor. The two groups will be: pain 
education group (PEG) and CG.
Intervention
The Template for Intervention Description and Repli-
cation Checklist was followed when planning the study 
intervention.38 39 Manuals of standard operating proce-
dures will be followed during the delivery of the inter-
ventions in both the groups. This will ensure treatment 
uniformity and fidelity. It is not possible to blind the inter-
vention providers based on the design of the study.
Participants in intervention group (PEG) will receive 
detailed pain education as described in the next para-
graph, and those in the CG will receive guideline-based 
physiotherapy treatment. After the completion of the 
post-treatment assessment at 1 week, study participants in 
both the groups will receive the treatment being provided 
by physiotherapists at Sahara Physiotherapy Hospital. 
Participants in both the groups will be encouraged not 
to seek for other medical care for LBP during the 1-week 
study period, unless they have to. If they do undertake 
other forms of treatment, they will be requested to report 
this during the follow-up assessment, and this will be 
recorded.
Pain education group
The pain education will be delivered to the PEG only. 
We will use the pain education handouts in Nepali for 
Nepalese with LBP based on the resources developed 
by Moseley and Butler, called Explain Pain.29 40 41 It 
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has evolved in over 15 years42 and undergone changes 
and advances.29 40 41 43 44 Pain education is delivered to 
provide reassurance, which means removal of fear and 
concerns about illness.45 Reassurance is among the core 
aspects of management of patients with non-specific 
problems such as LBP.46 Although there are no gold stan-
dard ways to provide reassurance and alleviate fear and 
concerns about a disease or its consequences, empathy 
and collaboration are thought to play important role.47 
The Pain education intervention will be provided by the 
lead investigator (SS) who is trained in the delivery of 
this treatment and has about 10 years of experience in 
the management of musculoskeletal disorders, including 
LBP.
In order to develop the pain education resources in 
Nepali, the first step is the development of curriculum 
for pain education for patients with LBP29 in Nepal. 
The curriculum was first outlined in English (by SS) in 
the similar manner recommended by the developers29 
and was reviewed and approved by both the developers 
(see online supplementary appendix 1). Based on the 
curriculum, the pain education materials and patient 
handouts were created (by SS) in Nepali. The clinical 
cases and pain stories that were compiled are actual 
stories collected from patients and clinicians in Nepal but 
will be anonymously shared to provide reasoning based 
on contemporary pain biology knowledge.29 Pictures that 
are found in Explain Pain resource materials29 40 41 were 
adapted in the Nepali version.
The pain education handout and materials that are 
produced in Nepali is proofread and will first be pretested 
in 5–10 Nepalese with LBP as needed, and corrected, 
if necessary, before using in the feasibility study partici-
pants. The final handouts will then be printed for the use 
in the current study. This adapted process will ensure that 
the Nepali pain education materials produced are valid 
and culturally appropriate. However, for the purpose of 
the full trial, the difficulty in understanding the treat-
ment will be assessed in the current feasibility study, and 
any modifications required will be made.
Dosage of the PEG intervention
A single approximately 1 hour pain education will be 
delivered to the PEG, because evidence indicates that: 
(1) interventions as brief as 5 min have been shown to 
have reassuring effects lasting for up to a year,44 and a 
single consultation has been found to be as reassuring 
as the multiple session interventions.47 We prefer a 
single session treatment over multiple session treatment, 
because for many patients in rural Nepal, it is difficult to 
deliver a multiple session treatment in reality. Thus, we 
plan to provide a single session delivering key concepts 
of Explain Pain, which will be reinforced by providing 
patient handouts to look at and read at home. In fact, 
a 1-hour session should be adequate to cover the key 
Explain Pain concepts by keeping the content simple and 
jargon free. Use of a plain language in the health-related 
education is important to adapt in low health literacy.48
Home advice for PEG group
A printed handout of the pain education material will be 
provided only to the study participants in the PEG. Partic-
ipants will be advised to read them, and perform phys-
ical activity including walking for approximately 30 min. 
Education accompanied by written information has been 
reported to yield the largest effects on fear component 
of emotional distress.47 However, education level of 
Nepalese is low (65%); 37 we will adapt the written mate-
rials to incorporate many more images than text.
For those who cannot read, the family member(s) will 
be encouraged to read out the materials to them. To 
complement the written materials, we will also provide 
an audio-recording of the pain education session to the 
patients as an online URL link to Nepali patient educa-
tion material stored in the cloud or will be copied to their 
smart phones or both for those who have the facilities 
to use them. The pain education advice will be directed 
towards reducing brain’s perception of movement and 
exercise as a threat encouraging participants to slowly 
pace the movement, physical activity and exercise. This 
is thought to desensitise the sensitive nervous system 
and improve function. A written instruction to perform 
general exercises and physical activity will be sent to the 
participants. Participants will be discouraged to use a 
lumbar corset and rest as coping strategy, whereas phys-
ical activity and return to work will be encouraged. A 
reminder to perform home exercises will be sent to all 
participants for a total of 5 days in the week.
Control group
The intervention will be provided by the physiothera-
pists working at the study site. Treatment integrity in the 
CG will be improved by providing an interactive seminar 
to all the physiotherapists delivering CG intervention 
by the lead researcher. The seminar will incorporate 
evidence-based information, including assessment and 
management of LBP based on the current recommen-
dations from clinical practice guidelines.23 49–51 Research 
articles and simplified evidence-based summary will be 
provided to the physiotherapists before the interactive 
seminar for self-study. At the end of the seminar, a brief 
multiple-choice quiz will be conducted for the study phys-
iotherapists that will assess evidence-based management 
of LBP. The therapists will need to score a minimum of 
80% before they deliver treatment to the CG.
Intervention in the CG
The control participants will receive physiotherapy care 
based on the recent clinical practice guidelines from three 
different western countries: (1) American College of 
Physicians, USA (2017),23 (2) National Institute for Health 
and Care Excellence, UK (2016)49 51 and (3) Toward Opti-
mized Practice, Canada (2015).50 These guidelines are 
used because they are recent and highly regarded. We 
did not find any evidence-based clinical practice guide-
lines for the management of LBP in Nepal or other devel-
oping countries. The CG interventions were derived by 
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comparing the recommendations made by each of the 
three guidelines on specific management strategies. The 
CG treatment components were selected if: (1) two or 
more guidelines recommended the treatment compo-
nent, (2) all the authors of the current study agreed that 
the component should be included, (3) the component 
was culturally acceptable and feasible to deliver in Nepal, 
(4) the component was determined to be appropriate to 
deliver at first contact and (5) the total duration of all of 
the components would sum up to 1 hour (approximately) 
to make the contact hour comparable with the approxi-
mately 1 hour of pain education that would be provided 
to the experimental group. Similarities and differences 
in the clinical practice guidelines across the countries are 
common and are influenced highly from the experience 
of the expert committee responsible for developing a clin-
ical practice guideline and local practice trends.52 For this 
reason, we chose to adapt the recommendations made in 
the available guidelines to fit with the expertise of the local 
physiotherapist, practice trends that are widely accepted 
in Nepal and the feasibility of delivering the treatment 
within the context of the study.
Thus, the CG intervention will contain of: (1) educa-
tion (advice to remain active, education about prog-
nosis of LBP for acute LBP and avoid bed rest and 
braces)23 50 51 for 10–15 min, including time spent to listen 
to each participant’s pain story; (2) back massage23 51 for 
about 10 min; (3) superficial heat23 50 for 10–15 min; and 
(4) static cycling or (treadmill) walking with the aim to 
promote physical activity23 50 51 including any rest period 
for a total of approximately 20 min. Although superficial 
heat is recommended in the acute/subacute LBP,23 50 we 
included this as a common treatment for all types of LBP 
including chronic LBP, which could be a part of self-man-
agement. Any forms of electrotherapy and acupuncture 
will not be offered to the study participants.49 The control 
intervention will strictly exclude the use of pain biology 
education.
Dosage of intervention for the CG
The control intervention will last for 1 hour to match the 
experimental group.
Home advice for the CG
Participants will be advised to self-manage their back 
pain based on the information provided. Home exercise 
leaflet with emphasis on the value of exercise to increase 
strength and endurance, followed by a 30 min walking. 
Advice preceding the exercises will state that exercises 
are needed to keep you strong, healthy and pain free. 
A written instruction to perform general exercises and 
physical activity will be sent to the participants. Partici-
pants will be discouraged to use a lumbar corset and rest 
as coping strategy, and return to work and physical activity 
will be encouraged in the control participants, as they are 
in the experimental group. A reminder to perform home 
exercises will be sent to all the participants for 5 days 
during the week.
outcome measures
The details of primary feasibility outcomes are presented 
in table 2.
All but one secondary outcome measures have been 
shown to be reliable and valid in Nepali populations. The 
measure of quality of life (QOL) is not yet validated at the 
time of writing the protocol; however, we have included it 
as a secondary outcome measure, because assessment of 
QOL is a recommended measure by core outcome sets in 
clinical trials for LBP.53 We hypothesise that this measure 
is comprehensible and will show adequate validity in 
the Nepalese sample. We will evaluate the validity of the 
measure before using it in the full clinical trial.
A research assistant will interview all the study partic-
ipants to make the study procedures consistent and 
to allow for the inclusion of participants with little or 
no education. The interviews will be administered by a 
physiotherapist who will be blind to group assignment. 
Secondary measures include the four PROMIS short-
form measures assessing pain interference,54 pain inten-
sity,54 sleep disturbance,54 and depression,54 as well as the 
13-item Pain Catastrophizing Scale,55 Connor-Davidson 
Resilience Scale,56 Global Rating of Change57 58 and a 
QOL scale. All the items in each PROMIS measure will 
be summed to obtain raw scores for each scale. The raw 
scores of each measure will then be converted to T-scores, 
with a mean of 50 and SD of 10 and recorded (www. 
assessmentcenter. net). Details of the measures with their 
measurement properties are presented in table 3.
The risk of adverse events in both the groups are very 
low. Participants will be asked to choose the amount of 
home exercises (such as walking) they will perform based 
on a level that is comfortable. Participants will be asked to 
change the duration and/or pace of exercises if they feel 
the initial level is too high.59 Participants will be asked to 
record any adverse events that occur and report these to 
the researcher. Adverse events in both the groups will be 
reported and compared between the groups.
Additional measures
Additional questionnaires will be administered to obtain 
data related to: (1) sociodemographic information (age, 
sex, education level, employment status, income, religion 
and ethnicity); (2) pain history, including duration of 
pain, aggravating and relieving factors, other associated 
comorbidities; and (3) pain location using pain drawings. 
Other information such as resources required to conduct 
the trial (eg, cost) and time required to complete the 
recruitment of desired number of participants will also 
be recorded.60 Total duration of home exercises in each 
group will also be recorded.
Criteria for feasibility
The results of this feasibility trial will indicate if the study 
as designed is feasible, which will inform the decision of 
progressing to a full trial with the recommendations. The 
decision will be one of the following: (1) do not proceed 
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to a full trial if any preplanned changes may not help 
improve the feasibility; (2) modify the protocol further 
prior to conducting a full trial; (3) continue with the full 
trial using the same procedures used in the feasibility 
trial without modifications; however, monitor the study 
procedures closely; and (4) continue without modifica-
tions, as it is in the feasibility trial, close monitoring is not 
required.61 The criteria for the feasibility are presented 
in table 4.
Limitation of the study
As this is a feasibility study, the results of the current study 
will not provide findings regarding the efficacy of the 
interventions being tested. The study will only evaluate if 
this research study is viable as a full trial and inform any 
recommendations for modification of the protocols for 
the full trial resulting from the findings of this feasibility 
trial.
Plan for supervision and monitoring
The study will be conducted and monitored by the lead 
investigator under the supervision of the coauthors 
(JHA and MPJ), with assistance from research assis-
tant(s). All the ethical principles as provided by Declara-
tion of Helsinki will be followed by all the members of this 
research throughout the study. The investigators will not 
violate any of the rules and ethical principles of NHRC. 
Monitoring for the NHRC ethical principles will be regu-
lated by the primary investigator and followed by all 
researchers and research assistants involved in the study.
Plan for data integrity and management
The research data will be collected by a research assis-
tant who will be trained to collect the research data and 
manage the data by compiling in a file for individual 
patient. Participant identifiers (including name, address 
and contact information) will be removed from the 
research data and will be stored separately. Data will be 
entered in Microsoft Excel. Identification of the groups 
as intervention and CG will be removed from the excel 
sheet. Research data will be monitored weekly by scruti-
nising entered data. Any errors in entry will be identified 
(if any) and amended. Consent forms will be scanned 
and stored in password-protected computers of the lead 
researcher and at the University of Otago along with 
other research data files.
data analysis plan
Descriptive statistics will be computed to describe the 
baseline and demographic characteristics of the study 
participants. As it is a feasibility study, level of significance 
and hypothesis testing regarding treatment efficacy will 
not be performed. Effect sizes representing between-
group differences in change in the primary and secondary 
outcomes will be computed, but these effect sizes will not 
be considered as a criteria for sample size estimation for 
the full trial, nor as a criteria to proceed to the full trial, 
because of the inadequate power of the current feasi-
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measures will be presented as means, SD and CIs of the 
means. Difference between the mean scores of each 
secondary outcome will be compared with the minimum 
important change (MIC) values of the outcome measures, 
if the MIC scores are available. The analysis plans of the 
primary feasibility objectives are described in table 2.
Patient and public involvement
The research question was informed by the clinical 
observation that many patients from rural Nepal showed 
significant improvement in their LBP outcomes after 
reassurance and advice to remain physically active. We 
therefore designed this trial to assess the feasibility of 
conducting a study to compare the effectiveness of pain 
education and structured guideline-based physiotherapy 
treatment in Nepalese people with non-specific LBP.
Patients were not involved in the design of the study 
protocol but were directly involved in the development 
of Nepali versions of outcome measures. Patients will 
also provide feedback and comments in the Nepali pain 
education materials during pretesting before using it in 
the feasibility study. Similarly, the development of Nepali 
Pain Education materials have incorporated real pain-re-
lated stories of Nepalese living with pain. The name 
and identity of all patients were kept confidential. Any 
information that discloses identity of the patients were 
excluded in the written pain education booklet.
During the initial assessment, all participants will be 
asked if they would like to know about the results of the 
study. A plain language summary of the study results 
will be written both in English and Nepali, which will be 
published online. The principal investigator of the study 
(SS) will also post an audio summary of the research 
results online for those who cannot read. The link of 
these will be sent to the participants as text messages.
EthICs And dIssEMInAtIon
The results of the study will be presented at national and 
international conferences and published in a peer-re-
viewed journal.
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AbstrACt
Objectives The aims of this study were to: (1) develop 
pain education materials in Nepali and (2) determine the 
feasibility of conducting a randomised clinical trial (RCT) 
of a pain education intervention using these materials in 
Nepal.
Design A two-arm, parallel, assessor-blinded, feasibility 
RCT.
setting A rehabilitation hospital in Kathmandu, Nepal.
Participants Forty Nepalese with non-specific low back 
pain (mean [SD] age 41 [14] years; 12 [30%] women).
Interventions Eligible participants were randomised, 
by concealed, 1:1 allocation, to one of two groups: (1) 
a pain education intervention and (2) a guideline-based 
physiotherapy active control group intervention. Each 
intervention was delivered by a physiotherapist in a single, 
1-hour, individualised treatment session.
Primary outcome measures The primary outcomes 
were related to feasibility: recruitment, retention and 
treatment adherence of participants, feasibility and 
blinding of outcome assessments, fidelity of treatment 
delivery, credibility of, and satisfaction with, treatment. 
Assessments were performed at baseline and at 1 week 
post-treatment.
secondary outcome measures Pain intensity, pain 
interference, pain catastrophising, sleep disturbance, 
resilience, global rating of change, depression and quality 
of life. Statistical analyses were conducted blind to group 
allocation.
results Forty participants were recruited. Thirty-
eight participants (95%) completed the 1-week 
post-treatment assessment. Most primary outcomes 
surpassed the a priori thresholds for feasibility. Several 
findings have important implications for designing a 
full trial. Secondary analyses suggest clinical benefit 
of pain education over the control intervention, with 
larger decrease in pain intensity (mean difference=3.56 
[95% CI 0.21 to 6.91]) and pain catastrophising 
(mean difference=6.16 [95% CI 0.59 to 11.72]) in the 
pain education group. Pain intensity would seem an 
appropriate outcome for a full clinical trial. One minor 
adverse event was reported.
Conclusion We conclude that a full RCT of pain education 
for back pain in Nepal is feasible and warranted.
trial registration number NCT03387228; Results.
IntrODuCtIOn  
Low back pain (LBP) is the leading cause of 
disability in both low-income and high-in-
come countries and is associated with large 
direct (healthcare) and indirect costs.1–3 The 
limited available literature on LBP in Nepal 
indicates LBP prevalence of between 35% 
and 65%4 5 and that prevalence will prob-
ably increase in the next decade.3 There-
fore, timely use of interventions that are 
evidence informed, effective and inexpensive 
is urgently required.
Internationally, clinical practice guidelines 
on LBP consistently recommend non-pharma-
cological and non-surgical approaches as the 
first line of treatment.6–8 For acute back pain, 
core common recommendations are educa-
tion or advice for reassurance, remaining 
active, returning to work and avoiding bed 
rest and lumbar supports. For chronic back 
pain, recommendations are education, 
strengths and limitations of this study
 ► This is the first study to examine the feasibility of a 
clinical trial on low back pain in Nepal.
 ► We developed a culturally suitable pain education 
programme using local patient stories before using 
it in the feasibility trial.
 ► We blinded the assessor and data analyst to group 
allocation; however, due to the nature of the inter-
vention, we could not blind the therapists and study 
participants.
 ► We used guideline-based care as an active control 
group.
 ► Conclusions regarding the effectiveness of the inter-
vention should not be made because this was a fea-
sibility study, not a clinical trial; however, significant 
between-group differences on proposed outcome 
measures justify proceeding with a full definitive 
trial.
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exercise and psychological therapies.6–9 Remarkably, 
although many high-income countries are moving away 
from primarily drug and surgical management of LBP 
because of their associated risks and costs, and general 
lack of efficacy,10 such interventions are now increasingly 
provided in Nepal.11 12 Unfortunately, there is little or no 
research, nor clinical evidence, that evaluates the efficacy 
of any treatments for LBP in Nepal, including the first-
line treatments that are now recommended in clinical 
guidelines elsewhere.
Although education is almost universally recommended 
for LBP, there are no clear curricula for delivering it, and 
little attention is given to training, methods, settings or 
context.13 One type of education that is an exception to 
this rule and has been widely studied focuses on improving 
patient understanding of the biological mechanisms that 
underpin pain and how best to promote recovery.14 15 
This form of pain education (widely known as ‘Explain 
Pain’ or ‘Pain Neuroscience Education’)15–24 was devel-
oped in Australia and has been adapted in numerous 
Western countries, demonstrating mixed results for 
effectiveness for managing LBP.15 17 21 23–25 Education can 
be brief, around 10 min to deliver the key messages, or 
extended (1 hour to several hours). Although no strong 
evidence exists in support of effectiveness of longer versus 
shorter education duration, a short education session is 
time efficient. However, longer forms of pain education 
have several advantages over shorter forms; specifically, 
they allow for the integration of contemporary principles 
of conceptual change and education (eg, including stories 
and metaphors26) and can provide adequate time for 
guidance on self-management strategies such as graded 
exposure to difficult or painful activities.15 27 28 Longer 
duration pain education also allows for greater tailoring 
of individual curriculum and target concepts, provides 
patients with time and opportunity to voice doubts and 
ask questions and allows the clinician to assess learning 
in real time.28
Treatment that is effective in one culture may not 
necessarily be effective in another. We know of no reports 
of pain education being adapted or evaluated within an 
Eastern cultural context. The critical first step then is to 
determine whether indeed it is feasible to do so.29 We 
therefore: (1) developed evidence-based pain education 
materials in Nepali for application in tertiary and primary 
care settings in Nepal and (2) investigated the feasibility of 
conducting a randomised clinical trial (RCT) comparing 
effectiveness of pain education to an appropriate control 
condition. We aimed to determine whether it would be 
feasible to undertake a full RCT within the Nepalese 
healthcare system and to identify any modifications that 
may be needed before doing so.
MethODs
The research was conducted in two stages. First, we devel-
oped pain education materials in Nepali, followed by a 
feasibility trial evaluating the feasibility of conducting an 
RCT to evaluate the effectiveness of pain education.
Development of pain education in nepali
The primary investigator (SS) developed the pain educa-
tion resources in Nepali, based on the ‘Explain Pain’ pain 
education materials (NOIgroup Publishing, Adelaide, 
Australia).28 30 Figure 1 lists the development process, 
which included five steps.
In the first step, SS developed a context and culture-spe-
cific pain education curriculum according to the process 
set out in Moseley and Butler.28 The curriculum was 
reviewed by the authors of that guide (including coauthor 
of this paper: GLM). Four key concepts (described below) 
were identified, with one additional optional concept if 
time permitted. The final curriculum, including the key 
concepts to deliver, details of contents and methods of 
delivery were published in our protocol paper31 and are 
also presented in online supplementary file 1 .
In the second step, a pain education handbook was 
created using contents from Explain Pain28 30 and clin-
ical practice guidelines on LBP.6–8 We used pain stories 
from Nepal to help explain the target concepts.31 We kept 
the Nepalese adaptations as simple as possible, so that 
patients with little to no formal education would under-
stand them.
In the third step, the material was reviewed by four 
Nepalese with a medical (n=2) or non-medical (n=2) 
background and revised as a result. In the fourth step, we 
Figure 1 Steps in the development of pain education 
handbook. LBP, low back pain.
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undertook initial pilot testing of the pain education hand-
book with six patients with chronic LBP. We focused here 
on its readability, the relevance of the stories and whether 
the new pictures created for the handbook delivered 
their intended meaning. The handbook text was revised, 
but no changes were made to the pictures. Finally, three 
native Nepali-speaking persons proof-read the handbook, 
and a final version was completed.
research design
We conducted a two-arm, assessor-blinded, feasibility RCT. 
We registered the trial protocol at  ClinicalTrials. gov. We 
used the Standard Protocol Items: Recommendations for 
Interventional Trials statement32 during the development 
of the protocol and followed the Consolidated Standards 
of Reporting Trials statement extension for a pilot and 
feasibility randomised trials33 for reporting. Feasibility 
was to be determined based on a priori criteria.31 For the 
detailed review of the research methods, we refer readers 
to the published protocol.31
Participants
We included adults (age 18 years or more) with non-spe-
cific LBP of any duration. We excluded patients with 
specific causes of LBP such as malignancy, fracture, infec-
tion or inflammatory arthritis identified from history or 
investigations. We also excluded pregnant women and 
patients presenting with the history of bladder and bowel 
incontinence or perineal anaesthesia.
We recruited participants from a rehabilitation hospital 
in Kathmandu, Nepal. We invited consecutive patients 
presenting at the centre to participate in the study. Addi-
tionally, we made advertisements on social media about 
the research to improve the recruitment, as almost 28% 
of Nepalese use Facebook ( www. internetworldstats. com). 
We provided an appointment to interested candidates for 
screening at the centre. A research assistant (a trained 
physiotherapist) screened all potential participants for 
eligibility who expressed a willingness to participate in 
the current study. All participants signed the consent 
form prior to baseline assessment.
Interventions
We used the Template for Intervention Description and 
Replication (TIDieR) Checklist to plan and report the 
study interventions.34 35 There were two interventions in a 
two-arm RCT design. We provided pain education to the 
participants who were randomly allocated to the experi-
mental group (pain education group [PEG]) and guide-
line-based physiotherapy treatment to the participants 
who were randomly allocated to the control group (CG). 
Treatment time for both groups was 1 hour.
the PeG group: delivery of pain education
The principal investigator (SS), who has received extensive 
training in Explain Pain via NOIgroup Professional Devel-
opment and one-on-one mentoring with pain education 
experts, delivered the treatment. The pain education deliv-
erer first asked two questions to the patients in the PEG: (1) 
‘Is there anything in particular that you would like to learn about 
your low back pain, or pain in general?’ and (2) ‘Do you know 
what caused your low back pain? Can you please explain the cause 
of your low back pain from what you have understood, or what you 
have been told?’. Up to 15 min was allotted to addressing, with 
evidence-informed answers, any questions participants had 
and to clarify any misconceptions the patients had regarding 
their LBP. The rest of the session was used to deliver informa-
tion regarding the target concepts.
Target concepts delivered
The key target concepts were: (1) pain is normal and almost 
everyone experiences it at different times during their life; 
(2) the body sends danger signals (ie, not necessarily infor-
mation about physical damage, but the danger of poten-
tial physical damage), and the brain decides whether to 
produce pain; (3) learning about pain physiology changes 
pain, and anything previously associated with pain (eg, 
past learning, social factors and environmental cues) can 
influence current pain; and (4) the body can learn to expe-
rience pain and become more overprotective over time. 
One additional target concept ‘pain and tissue damage 
are poorly related’ was delivered if there was time available 
after the four key concepts were addressed. During the pain 
education session, strategies for graded exposure to painful 
or difficult activities were also provided to the patients to 
increase their physical activity.
Guideline-based physiotherapy treatment
CG treatment consisted of guideline-based physiotherapy 
interventions extracted from recent clinical practice guide-
lines on LBP.6 36 37 Criteria for the CG treatment compo-
nent required that it be: (1) a first-line recommended 
treatment, or (2) a second-line recommended treatment to 
make the total duration of the session be 1 hour (to match 
PEG treatment time); (3) feasible to be delivered during 
the first clinical contact; and (4) one that is routinely deliv-
ered in, and can be competently delivered by, physiother-
apists at the recruitment centre. Given these criteria, the 
CG treatment condition included: (1) brief education to 
reassure the patient, advice to remain active and remain 
at or return to work (if the participant had been working 
prior to pain onset), general education about the favour-
able prognosis of LBP that it will generally get better in two 
to 6 weeks and advice to avoid bed rest and lumbar corsets 
(10–15 min),6 36 37 (2) superficial heat (10–15 min),6 37 (3) 
back massage (10 min)6 36 and (4) static cycling to promote 
physical activity (remaining time; between 20 min and 
30 min).6 36 37 Although treatment in CG involved commu-
nication between the treating therapist and patients, this 
communication was strictly limited to providing either: (1) 
brief education as described above or (2) active listening. 
Key concepts delivered in the PEG were not provided to the 
patients in this group.
Home treatment
We also prescribed a home programme for both groups. 
This included a leaflet providing brief education on 
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self-management of LBP, with pictures to remind the 
participants to remain physically active, education 
regarding positive prognosis, advice to walk for 30 min 
daily (with rest if required) and to avoid bed rest or 
lumbar corsets.
In addition to the leaflet that was also provided to the 
CG, participants in the PEG received the pain education 
handbook. We suggested to participants that they read 
the booklet at least once during the following week. If 
the patients could not read, they were advised to request 
a family member to read the pain education handbook 
to them. Adherence to both exercise (eg, walking) and 
reading the pain education handbook at home was 
recorded, by self-report, 1 week post-treatment.
Participants in both treatment groups were required to 
pay the same fee for physiotherapy services as usual for 
non-trial patients. This payment was identical for both 
interventions.
Outcome measures
Demographic data were collected as per the recommen-
dations of the National Institutes of Health (NIH) task 
force on research standards for chronic LBP.38
Primary outcome measures
The primary outcomes were related to feasibility: recruit-
ment, retention and treatment adherence of participants, 
feasibility and blinding of outcome assessments, fidelity 
of treatment delivery and credibility of, and satisfaction 
with, treatment. To assess recruitment-related feasibility 
outcomes, we recorded the numbers of potential partic-
ipants who were eligible and recruitment rates. Partic-
ipation-related feasibility outcomes were: (1) rates of 
willingness to participate in an RCT and (2) acceptability 
of random allocation to a treatment group. Feasibility 
outcomes related to outcome assessment were: (1) feasi-
bility of assessor blinding procedures and (2) acceptability 
of screening procedures. Finally, the treatment-related 
feasibility outcomes were: (1) possible contamination 
between the groups, (2) the credibility and acceptability 
of the interventions, (3) adherence to the interventions, 
(4) treatment satisfaction, (5) difficulty in understanding 
the treatment and (6) adverse events related to the inter-
ventions. Details of these feasibility outcome measures are 
presented in  online supplementary file 2.
Secondary outcome measures
The secondary outcome measures selected were those 
that had the potential to be primary or secondary 
outcomes of a potential full clinical trial, based on the 
core outcome sets recommended for LBP.39 40 We used 
eight outcome measures previously translated and 
cross-culturally adapted to the Nepali language: four 
Patient-Reported Outcome Measurement Informa-
tion System (PROMIS) short form measures assessing 
pain intensity, pain interference, sleep disturbance and 
depression41; a two-item quality of life scale, seven-point 
Global Rating of Change42 43; the Pain Catastrophizing 
Scale (PCS)44; and the 10-item Connor Davidson Resil-
ience Scale (CDRISC).45
sample size
Sample size estimation was performed to achieve the 
primary feasibility outcomes goals, as described in the 
protocol31 and registration documents, and not to 
detect differences in the secondary treatment effects 
outcomes.46 Based on guidance in the literature,47 the 
research team estimated that a sample size of 40 (20 in 
each treatment arm) would be sufficient to adequately 
evaluate the feasibility of undertaking a full clinical 
trial.31
randomisation
The published research protocol31 was strictly followed. 
Allocation sequence was generated in random blocks of 4 
and 6 using www. random. org by a researcher (JHA) who 
was not involved in recruitment. Allocation concealment 
was performed using sequentially numbered opaque, 
sealed envelopes, prepared by JHA, and maintained until 
the interventions were assigned to the study participants. 
The group allocation was revealed to the study partici-
pants and intervention providers only after completion 
of the baseline assessment.
blinding
The assessor performing all the assessments was blinded 
to group allocation of the participants throughout the 
study. The data analyst (SS) was also blinded to group 
allocation. That is, after the assessor entered data in 
the Excel spreadsheet without knowledge of group allo-
cation, the entered data were sent to JHA, who added 
codes for group allocation (red and blue) before the 
data analyses were performed. Unblinding of group 
allocation occurred after all planned analyses were 
complete.
statistical methods
Baseline characteristics for demographic and clinical data 
of the participants were reported using descriptive statis-
tics. The plans for analysis of primary outcome measures 
are presented in online supplementary file 2.
We planned the exploratory analysis of between-
group differences in the secondary outcome measures 
using two-group t-tests, with the understanding that 
the current study was not powered to detect statistically 
significant between-group differences in the secondary 
outcomes. Rather, analyses of between group differ-
ences were computed primarily for descriptive purposes 
in order to inform decisions regarding the selection 
of measures for a possible future full clinical trial. 
The scores of the PROMIS measures were transferred 
into the template provided by www. assessmentcenter. 
net, which computed the total raw scores, T-scores 
and SEs. The assessment centre automatically handles 
missing items when performing the analysis. For other 
measures, missing items were imputed using the mean 
of the present items for that patient. The details of the 
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measures with the psychometric properties are outlined 
in online supplementary file 3.
Patient and public involvement
Patients with LBP and non-clinician volunteers provided 
significant feedback in the development of the Nepalese 
pain education materials. We incorporated real but 
anonymous pain-related stories of Nepalese so that the 
intervention is relatable. Neither patients nor members 
of the public were involved in the design of the study.
results
Data were collected between February and April 2018, 
with mean (SD; range) duration to follow-up of 7.63 (1.08; 
7–11) days. Recruitment was stopped after achieving 
the desired sample size of 40. Twenty participants were 
randomised to each treatment arm.
sample characteristics
The majority of participants in each group were men, 
married and Hindu. Baseline demographic characteris-
tics were comparable between the groups. However, base-
line scores on the secondary outcomes were somewhat 
higher in the PEG than the CG. Details of the baseline 
sample characteristics are presented in table 1.
Missing data
One item (item #10) in the baseline assessment of the 
PCS and one item in the follow-up assessment of CDRISC 
(item #8) were missing for one participant. Missing values 
were replaced by the mean score of the items responded 
to of each measure for that participant. One item in the 
baseline depression scale was missing for one participant, 
which was imputed by the PROMIS assessment centre 
during the analysis.
Primary (feasibility) outcomes
Results related to feasibility outcomes are presented in 
table 2, and summary results on feasibility criteria are 
presented in table 3.
Recruitment-related feasibility outcomes
Seventy candidates were invited to participate in the 
study. Twenty-eight participants (70%) were recruited 
from the data collection centre; 12 (30%) from commu-
nity advertisements. Fifty-seven per cent of invited 
candidates participated. Of those who did not, 27 
(90%) declined participation and 3 (10%) did not meet 
inclusion criteria. Forty out of 43 candidates (93%) 
screened were eligible to participate. All 40 participants 
(100%) who met the inclusion criteria provided written 
informed consent and were randomised to one of the 
study arms. One participant in each group was lost to 
follow-up. The reasons for all exclusions and losses to 
follow-up are outlined in the participant flow diagram 
(figure 2).




N (%) or 
mean (SD)
N (%) or 
mean (SD)
Recruitment, N (%)
  Advertisement 6 (30) 6 (30)
  Hospital 14 (70) 14 (70)
Sex, N (%)
  Men 15 (75) 13 (65)
  Women 5 (25) 7 (35)
Marital status
  Married 16 (80) 15 (75)
  Single 4 (20) 3 (15)
  Separated or widowed 0 (0) 2 (10)
Religion, N (%)
  Hindu 19 (95) 16 (80)
  Buddhist 1 (5) 3 (15)
  Others 0 (0) 1 (5)
Race/ethnicity, N (%)
  Chettri 6 (30) 5 (25)
  Brahmin 4 (20) 9 (45)
  Newar 4 (20) 2 (10)
  Others 6 (30) 4 (20)
Education, N (%)
  No school 3 (15) 2 (10)
  Primary school (<5 years) 3 (15) 1 (5)
  Upto high school (6–
12 years)
5 (25) 8 (40)
  Bachelor degree and over 9 (45) 9 (45)
Primary occupation, N (%)
  Business or office work 13 (65) 7 (35)
  Unemployed 0 (0) 5 (25)
  Homemaker 2 (10) 3 (15)
  Currently sick leave for 
LBP
1 (5) 1 (5)
  Other 4 (20) 2 (10)
Smoking history, N (%)
  Never smoked 10 (50) 12 (60)
  Currently smoker 8 (40) 5 (25)
  Have quit smoking 2 (10) 3 (15)
Have left work for more 
than 1  month   due to LBP, 
N (%) 
  Yes 4 (20) 4 (20)
  No 16 (80) 16 (80)
Medications used for LBP, 
N (%)
Continued
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Participant-related feasibility outcomes
Willingness to participate in a randomised trial
The main reasons for unwillingness to participate were: (1) 
wanting to receive comprehensive physiotherapy treatment 
as an in-patient (n=8), (2) not wanting to pay for treatment 
(n=6), (3) not having time to participate in the study and 
complete the post-treatment assessment at 1 week (n=6) and 
(4) wanting to receive electrotherapy treatment for 1 week 
because it was recommended by their physician (n=5).
Acceptability of random allocation to a treatment group
Random allocation of the treatment was acceptable to 
57 out of 70 individuals (81%). Of the 13 participants 
who did not accept random allocation, 5 (7%) wanted to 
receive electrotherapy treatment specifically and 8 (11%) 
wanted to be admitted at the centre to receive compre-
hensive physiotherapy treatment (including electro-
therapy) twice a day for a week as advised by their treating 
physician or physiotherapists.
Outcomes assessment-related feasibility outcomes
Feasibility of blinding the assessor
The assessor did not receive any definitive information 
about participants’ group allocation for any of the partic-
ipants during the study. The assessor’s guess was correct 
for 12 participants (60%) in the PEG condition and for 11 
participants (55%) in the CG condition. On questioning, 
the assessor identified some clues that may have influenced 
a correct guess: (1) ‘duration of treatment time’ (see below) 
(n=5; three correct and two incorrect guesses), (2) patients 
reporting the treatment as ‘interesting’ (n=2; both incor-
rect guesses) and (3) the treating therapist’s description of 
the treatment as interactive (n=1; correct guess).
Acceptability of screening procedures by the assessor
Mean (SD; range) time taken to complete the screening 
process (including time to sign the consent) was 7 (6; 
6–45) minutes. Mean (SD; range) time taken to complete 
all the forms during the baseline assessment was 20 (5; 
12–35) minutes.
The screener reported that the screening procedures 
were acceptable, but there were two problems. First, 
the duration of screening was occasionally too long, for 
example, when patients told stories about their pain 
rather than keeping answers focused on the questions that 
were asked, or an accompanying friend kept responding 
on the patient’s behalf. Second, interspersing assessments 
unrelated to pain (eg, CDRISC, sleep disturbance, depres-
sion and quality of life) between assessments related to 
pain (eg, pain intensity and pain interference) made it 
difficult for some participants to switch focus between the 
pain and general domains. As a result, some participants 
kept answering about pain when the questions asked 
about other domains such as sleep or depression.
Treatment-related feasibility outcomes
Contamination
There were no detected instances of contamination 
between the two groups. Table 2 presents the results of 
the five separate contamination questions.
Credibility and acceptability of the interventions
The credibility scores of the two conditions at 1-week 
assessment and average treatment time were similar 
(table 2). Both interventions were acceptable to all the 
participants. However, patients in the PEG often expected 
some form of physiotherapy interventions in addition to 
education. For example, one patient, assigned to the PEG 
condition, had severe pain and stated that he wanted a 
physical treatment for his back pain. Similarly, most of 
the patients in the CG mostly expected back-specific exer-
cises and/or electrotherapy treatment over the painful 
sites. One comment from a participant after completing 
cycling was ‘Okay, this was exercise for my general health. What 
exercise should I perform for my back pain?’. Similarly, many 
participants in the CG were keen to receive pain educa-
tion intervention, which they did (n=15) after post-treat-
ment assessment at 1 week.
Adherence to intervention and treatment satisfaction
Adherence to intervention and treatment satisfaction 
were similar in both groups (table 2). Twelve out of 38 
patients who completed the post-treatment assessment at 
1 week (32%; five in the PEG and seven in the CG) wished 
to receive their regular physiotherapy treatment (mostly 
electrotherapy) at the centre between the two assessment 





N (%) or 
mean (SD)
N (%) or 
mean (SD)
  NSAIDs 3 (15) 6 (30)
  Pregabalin 2 (10) 3 (15)
  Vitamin B12 3 (15) 1 (5)
  Gabapentin 1 (5) 0 (0)
  Opioids 1 (5) 0 (0)
  Antidepressant 1 (5) 0 (0)
Secondary outcomes
  Pain intensity* 54.38 (3.48) 52.72 (2.45)
  Pain interference* 62.28 (6.62) 58.92 (7.69)
  Sleep disturbance* 51.84 (7.68) 45.63 (8.71)
  Depression* 56.99 (8.08) 53.60 (11.25)
  Quality of life 5.70 (1.22) 6.10 (1.21)
  Pain catastrophising 22.70 (10.99) 20.50 (12.56)
  Resilience 26.95 (9.14) 28.60 (8.08)
*T scores.
CG, control group; LBP, low back pain; NSAIDs, non-steroidal anti-
inflammatory drugs; PEG, pain education group.
Table 1 Continued 
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Table 2 Feasibility results for the two study groups
Feasibility outcomes
PEG
N (%) or 
Mean (SD)
CG
N (%) or 
Mean (SD)
Mean difference 
(95% CI) or p values Summary
Attrition rate 1 (5%) 1 (5%) 1.000 No difference in attrition rates between 
groups.
Assessor’s correct guess for group 
allocation
12 (60%) 11 (55%) 0.756 Assessor correctly guessed the group 
allocation slightly more often for the 
PEG than the CG.
Understanding possible contamination 
between groups (n=19)
No contamination between groups.
  1. Have you talked to other 
participants about the intervention?
0 (0%) 0 (0%) –
  2. If yes, was your attitude/
intervention changed?
0 (0%) 0 (0%) – 
  3. Are you aware of the intervention 
that participants in the other group 
are receiving?
0 (0%) 0 (0%) – 
  4. Are participants in the other group 
aware of the type of intervention you 
are receiving?
0 (0%) 0 (0%) – 
  5. For the control group: did you 
read the pain education booklet 
provided to the experimental group?
– 0 (%) – 
  Credibility and acceptability of 
interventions (scale 0–20)
Similar credibility scores between 
groups.
  Baseline assessment (n=20) 12.55 (2.89) 12.95 (3.80) 0.40 (−2.56 to  1.76)
  Final assessment (n=19) 12.37 (2.63) 12.26 (4.17) 0.11 (−2.19 to  2.40)
Adherence to treatment
(number of days)
Participants were adherent to the 
treatment in both groups, with 
significantly more adherence reported 
by the CG participants.
  Followed advice (n=19) 17 (89%) 18 (95%) 0.501
  Performed home exercises (mean 
days [SD])
3.84 (2.43) 5.53 (1.58) −1.68 (−3.03 to –0.33)
Number of patients who received other 
treatments (total)
5 (26%) 7 (37%) 0.471 Slightly more CG participants received 
regular physiotherapy at the centre, 
massage or acupuncture, and NSAIDs.  Regular physiotherapy at the centre* 4 (21%) 5 (26%) 0.719
  Massage or acupuncture 1 (5%) 2 (10%) 0.563





61.00 (7.88) 60.60 (8.85) Treatment time is very similar between 
the two treatment conditions and 
consistent with the planned treatment 
duration of treatment.
Satisfaction (scale 0–4) 3.89 (0.46) 3.68 (0.75) 0.21 (−0.20 to  0.62) Satisfaction of treatment scores were 
similar between groups with non-
significant between group difference.
Difficulty (scale 0–5); mean (SD) 2.26 (0.56) 2.16 (0.60) 0.10 (−0.28 to  0.49) Majority of the participants (75%) 
reported both treatments as easy. There 
were no significant between-group 
difference in difficulty score.
  Very easy 0 (0%) 1 (5%)
  Easy 15 (75%) 15 (75%)
  Neither easy nor difficult 3 (15%) 2 (10%)
  Difficult 1 (5%) 1 (5%)
  Very difficult 0 (0%) 0 (0%)
*Mostly included electrotherapy treatment.
CG, control group; NSAIDS, non-steroidal anti-inflammatory drugs; PEG, pain education group.
 on 27 M









pen: first published as 10.1136/bm





8 Sharma S, et al. BMJ Open 2019;9:e026874. doi:10.1136/bmjopen-2018-026874
Open access 
Difficulty in understanding the treatment
In both groups, 15 participants (75%) reported that the 
treatment was ‘easy’ to understand (table 2). This result 
contravened our a priori cut-off point for this criterion 
of 50%.
Adverse events
One participant in the CG reported lower extremity 
pain after cycling for 20 min. The increase in her 
lower extremity pain lasted for 2 days and then subsided. 
None of the other participants reported any other adverse 
events associated with the treatments.
Results of secondary outcomes
We found significant within-group improvements from 
pre-treatment to post-treatment in all the secondary 
outcomes, except resilience for the PEG participants. In 
the CG group, we found pre-treatment to post-treatment 
improvements in pain interference, depression and cata-
strophising. We found statistically significant between-
group differences in favour of PEG for pain intensity and 
pain catastrophising (table 4).
Other findings
The standard LBP treatment protocol at the data collec-
tion centre typically included non-guideline-based care 
such as advice to rest, advice against physical activity, 
admission for bed rest and intensive passive therapies 
(mostly electrotherapy). Such a care pathway contrasts 
with the recommendations and treatments presented in 
both groups. We found it challenging to alter the physio-
therapists’ usual practice.
Related to this, all of the physiotherapists who provided 
the CG treatment reported being dissatisfied with not 
being able to provide interventions they would normally 
provide, many of which were treatments that patients 
also wanted to receive, such as spine-specific exercises 
and manual therapies. Moreover, five of the physiother-
apists who were initially trained in the guideline-based 
care prior to the initiation of the study left the treatment 
centre during the trial recruitment period. They were 
replaced by four physiotherapists who therefore had not 
been trained in guideline-based care as part of this study.
DIsCussIOn
We aimed to determine whether it would be feasible 
to undertake a full RCT within the Nepalese health-
care system and to identify any modifications that may 
be needed before doing so. Seven of the eight a priori 
feasibility criteria were met, which suggests that a clin-
ical trial to evaluate the effectiveness of pain education 
and evidence-based physiotherapy treatment in Nepal 
is feasible. This feasibility trial also provided important 
additional information that inform the design of the full 
trial.
Table 3 Were the feasibility criteria met?
Criteria
Feasibility 
criteria met? Recommendations for full trial
Blinding of assessor Yes Treatment providers should try to keep the treatment duration close to or equal to 
1 hour to avoid any guesses of group allocation between the treatment groups.
Recruitment rate Yes Incorporating advertisement to recruit the patients was a good idea, which should 
be considered in the full trial.
Attrition rate (in both arms) Yes Phone call reminders for the follow-up assessment helped reduce the drop-outs and 
which should be considered in the future trial.
Feasibility of outcome assessment Yes 1. Practice administration of the outcome measures on real patients who are older 
and have lesser education before the actual recruitment by learning ways to keep 
patients focused on the questions being asked.
2. Keep the relatives and friends of the patients separate from the participant during 
screening and assessment.
3. Self-administration of the questionnaires for participants who can read and write 
could improve the efficiency of completing the screening and data collection 
forms.
4. Separate the pain-related questionnaires and general questionnaires during 
administration.
Contamination of intervention Yes Having an appointment time for follow-up helps avoid contamination.
Credibility of treatment Yes The credibility scores of the two treatment conditions were within 0.50 SD of each 
other; therefore, no changes in the treatment conditions are required.
Adherence to treatment Yes Not many patients read the handbook provided to them. Creating interesting short 
audios or videos with the key messages may be helpful for improving the adherence 
to home advice.
Difficulty level of the intervention No A large proportion of patients reported the interventions to be ‘easy’. The complexity 
of the pain education content may be increased by providing more complex 
neurophysiological knowledge to the patients. However, this may demand longer 
duration of treatment time, and/or compromise the effectiveness of the intervention, 
and may require pretesting of the changed intervention before using it in the full trial.
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Primary feasibility outcomes
The recruitment rate exceeded our target of four partic-
ipants enrolled every week. We used advertisements 
in social media, and we suspect that recruitment was 
aided by patient-to-patient word of mouth as the trial 
progressed. This, and the finding that our attrition rate 
(5%) was well below our a priori maximum rate of 20% 
(which is thought to lead to serious threats to validity48) 
was surprising, considering that most patients in both 
groups did not receive the care they expected to receive. 
This is encouraging because it suggests that a broader 
education strategy, to prepare potential patients for an 
alternative approach to their problem before including 
them in a trial, is probably not required.
Although screening and data collection procedures 
were generally acceptable to the assessor, the assessor 
provided important recommendations to improve overall 
screening and data collection. For example, extended 
assessment sessions might be avoided by upskilling the 
assessors in dealing with patients, who are often elderly 
and uneducated and who tend to tell stories about their 
pain rather than provide direct answers to the questions 
being asked. An important caveat here, however, is the 
potentially critical role that this extra time and attention—
particularly insofar as it is dedicated to listening to patient 
stories—may have had in subsequent engagement and 
participation, particularly against the backdrop of unex-
pected care. The patients’ stories in fact provide a context 
and meaning of their health problems,49 which may be a 
therapeutic intervention in itself, and are important to 
establish a good doctor–patient relationship.50 Clearly, 
the cost–benefit relationship of time-limited assessment is 
likely to be individually specific and nuanced.
The advantages and disadvantages of interviewing 
patients without their friends or family members present 
are also worthy of consideration. There were instances 
when excluding an accompanying family member would 
have reduced the data collection time and possibly 
improved the accuracy of the answers. However, the rela-
tionships patients have with those around them play an 
important role in the experience of pain51 52 and what 
people do about it51; exclusion of important others at a 
Figure 2 Participant flow diagram.
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critical time may also disengage the patient or instil other 
barriers to their participation in the project. A final prag-
matic modification to improve assessment would be to 
organise pain-related and pain-unrelated questions into 
different sections of the data collection protocol, so as 
to avoid patients being confused regarding the domains 
being assessed.
Blinding appeared to be successful, and contamination 
appeared to be avoided. Most controlled trials do not 
adequately examine assessor blinding,53 even though it is 
widely considered a very important component of good 
study design.54 We were able to blind the assessor here 
because we could provide a separate office space that was 
isolated from the treatment area. We were also able to 
schedule appointments to avoid contact with assessors 
that would unblind them to group assignment. Our inclu-
sion of participant-reported items to evaluate contamina-
tion is not routinely included in feasibility or full clinical 
trials; the common approach is to implement strategies to 
minimise the risk a priori but not investigate it post hoc. 
However, in settings such as that involved here, where the 
community is well connected and word of mouth appears 
to be a significant recruitment pathway, we considered 
it important to also examine potential contamination 
post hoc. Limiting the number of patient recruitments 
performed in a single day to two may also have helped 
avoid contamination, but to see no evidence of contami-
nation was surprising.
Treatment credibility and satisfaction were high for 
both groups (even though the participants did not receive 
the treatment they expected). That most participants 
in the PEG found the material ‘easy’ or ‘very easy’ was 
surprising and contrary to an a priori feasibility criterion. 
Our protocol31 stipulated a response to this outcome 
requiring that the material presented be viewed as diffi-
cult before proceeding to full trial. Whether we should 
increase difficulty by increasing the number of concepts 
covered, or going more fully into the four concepts we 
chose, or both, will require some pilot testing. That 
secondary outcome data findings suggesting a beneficial 
effect in the PEG condition appears to support making 
such a change.
secondary outcomes
Statistically significant improvements over time were 
observed for 7/8 outcomes in the PEG condition and 4/8 
outcomes in the CG condition. Although assessment of 
the effectiveness of the interventions on the secondary 
outcomes was not a primary aim of this study, the signifi-
cant between-group differences that were found were in 
favour of PEG, and the apparent effect was substantial 
on two key target outcomes: pain intensity and pain cata-
strophising (table 4). However, the consistently larger 
improvements in all of the other outcomes for the PEG 
condition, relative to the CG condition, suggests the possi-
bility of wide benefits of pain education as compared with 
guideline care in Nepal. It should be remembered that 
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analyses and therefore at risk of false positive results. 
However, these results add pertinence to the feasibility 
results; a full-scale clinical trial appears warranted.
recommendations
Although the findings suggest that a clinical trial evalu-
ating effectiveness of an adapted pain education interven-
tion within Nepali primary and tertiary care is feasible, 
some improvements could be made. First, to improve 
the compliance of the physiotherapists with the CG treat-
ment—guideline-based care—and adherence of patients 
to that care, the CG treatment condition may need to be 
modified. Ideally, this modification would be made so that 
the control treatment was consistent with the evidence-
based practice paradigm as much as possible, for example, 
by giving participating patients and their therapists the 
ability to choose treatments that are mostly consistent 
with guideline recommendations for LBP treatment. For 
example, the guideline-based treatment could have two 
components: (1) mandatory first-line care recommended 
by the guidelines (education and reassurance, promotion 
of physical activity, early return to work and advice about 
positive prognosis for back pain), in addition to (2) a 
more pragmatic approach to LBP treatment. This second 
component may include any form of exercise (treadmill, 
static cycling or back-specific motor control or movement 
exercises), manual therapy (massage, mobilisation or 
manipulation, based on therapist’s preference) or elec-
trotherapy treatment, according to therapist and patient 
preference (as per recommendations of evidence-based 
care55), as long as it is safe and does not extend treatment 
time to beyond 1 hour. We should also consider fidelity 
assessment of the interventions provided by the ther-
apist to be certain that per-protocol treatment is being 
provided in each treatment arm.
A final modification would be the addition of economic 
analysis. Nepalese individuals are often poor, and the 
Nepalese public health system is resource poor. Not 
surprisingly, cost was a barrier to participation for 9% 
of potential participants. Pain education intervention 
appears to be a less resource-intensive alternative to 
current practice and could be delivered outside of the 
public health system, in community settings, although the 
costs and time of physiotherapist would be no different 
from guideline-based care as delivered in a physiotherapy 
department. Pain education might require more training 
of therapists, although training in guideline-based care 
may be necessary too. As such, a full trial would benefit 
from the addition of a full economic evaluation.
strengths and limitations
The current study has a number of strengths: we used an 
active guideline-based care as the comparator group; we 
successfully blinded the assessor and analyst and assessed 
both blinding and contamination; outcomes were consis-
tent with NIH recommendations on research stan-
dards for chronic LBP38 and core outcome sets for LBP 
research39; and we submitted our protocol prior to data 
collection and remained transparent in all reporting.56
To our knowledge, this is the first study to examine the 
feasibility of a clinical trial on LBP in Nepal. Conducting 
a feasibility study is an important step before conducting 
a full clinical trial,47 especially in a setting where a high-
quality clinical trial has never been conducted, which 
lacks recommendations from previous experiences for 
such a study. For example, we had planned a full clin-
ical trial in 201557 but were unable to recruit participants 
because the clinicians were too busy to collect data and 
provide interventions as per protocol, and we encoun-
tered difficulty ensuring access to an assessor blinded to 
group allocation because of multiple responsibilities of 
the clinicians. These are feasibility problems that would 
have been revealed in a preliminary feasibility study.47
The current study also has a number of important 
limitations. Our follow-up was shorter than we would 
use in a full clinical trial. The short follow-up duration 
was chosen because 1-week assessment was sufficient to 
answer the feasibility-related questions, but whether long-
term follow-ups are feasible in this setting and population 
remains to be demonstrated. We did not assess treat-
ment fidelity in the current study, because we did not 
have the resources to do so. That the current practice in 
the LBP management at the study site was very different 
from clinical practice guidelines made it harder for the 
physiotherapists to comply with the guideline-based 
care. Another limitation was that we did not include 
any measure of physical activity as a secondary outcome, 
despite improved physical activity being one aim of pain 
education. In a definitive trial, we may consider using 
a measure to assess physical activity such as Interna-
tional Physical Activity Questionnaire,58 or an objective 
measure of physical activity, such as Actigraphy.59 Finally, 
the experimental group treatment was provided by the 
primary author of the study who may have inadvertently 
communicated more enthusiasm for the experimental 
group treatment than the therapists providing the CG 
treatment; this may have influenced the study findings. A 
full clinical trial would ideally include a number of ther-
apists who would be trained to deliver both treatments, 
as one way to control for the therapist effects. This could 
also improve the generalisability of the study findings.
suMMAry AnD COnClusIOns
We conclude that a clinical trial to evaluate the effective-
ness of pain education and evidence-based physiotherapy 
treatment in Nepal is feasible and warranted, although 
some minor modifications are required.
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Chronic  pain  is  one  of  the  most  common  and  costly  health
conditions  worldwide.1 A  single  solution  to  this  problem  has
not  yet  been  identified,  perhaps  due  to  the  complex  ways
that  biological,  psychological,  and  social  factors  interact  to
contribute  to  and  maintain  this  problem.  Culture  is  one  such
factor.
Culture  refers  to  the  goals,  beliefs,  and  traditions  relat-
ing  to  an  individual’s  racial,  religious,  and  social  group,
which  are  socially  transmitted  and  acquired.  The  most  com-
mon  proxy  measures  of  culture  used  in  pain  research  are
ethnicity/race  and  country  of  origin.  However,  it  is  challeng-
ing  to  assess  culture  as  distinct  from  other  social  factors.  For
example,  socioeconomic  status,  a  non-culture  social  vari-
able,  is  often  associated  with  both  country  of  origin  and
race/ethnicity.
The role of culture in chronic pain
Evidence  supports  the  idea  that  culture  can  influence  many
pain-related  factors,  including  but  not  limited  to,  how  an
individual  communicates  pain,  an  individual’s  emotional
responses  to  someone  else’s  pain  (empathy),  pain  inten-
sity  and  tolerance,  beliefs  about  and  coping  with  pain,
and  pain  catastrophizing.  All  of  these  can  play  key  roles
in  the  onset  and  maintenance  of  chronic  pain  states.  How-
ever,  in  this  editorial,  we  will  focus  on  three  primary
pain-related  domains:  pain  communication,  beliefs,  and
coping.
The role of culture in pain communication
How  different  people  communicate  about  pain  is  influ-
enced  by  their  culture.  For  example,  in  some  Asian  cultures,
there  is  a  tendency  to  avoid  talking  about  one’s  own
pain.  Moreover,  when  Asian’s  do  communicate  about  pain,






1413-3555/© 2018 Associação Brasileira de Pesquisa e Pós-Graduação em han  when  communicating  with  someone  from  the  same
thnicity.2,3 This  has  important  implication  in  the  mana-
ement  of  chronic  pain  in  the  Asian  individuals,  especially
hen  treated  by  a  non-Asian  clinician  speaking  a  different
anguage.
he role of culture in pain beliefs
ulture  can  also  influence  pain  beliefs.  For  example,  edu-
ated  individuals  who  have  access  to  (often  inaccurate)
ealthcare  information  on  the  internet  may  believe  that
he  cause  of  their  low  back  pain  is  a  ‘‘disc  bulge’’,  even
hough  research  indicates  that  disc  budges  tend  to  resolve
n  their  own4 and  50%  of  asymptomatic  individuals  aged  40
ears  without  low  back  pain  has  a  disc  buldge.5 Individuals
ho  have  such  a belief  may  restrict  their  activities  when
hey  experience  pain,  so  as  not  to  make  the  so-called  disc
ulge  worse.  On  the  other  hand,  many  individuals  in  rural
epal  did  not  report  having  low  back  pain  when  we  surveyed
or  musculoskeletal  pain  prevalence,  because  they  believed
hat  their  low  back  pain  is  related  to  ‘‘normal’’  aging  pro-
esses.  As  the  result,  Nepalese  in  rural  communities  tend  to
ontinue  to  carry  on  with  their  normal  activity  of  daily  living
ithout  complaints  or  requests  for  medical  examinations  or
maging.
ole of culture in pain coping
ow  people  cope  with  their  pain  can  also  have  a  significant
mpact  on  chronic  pain.  Passive  coping  responses  such  as  rest
nd  use  of  appliances  are  not  usually  recommended  and  may
urther  cause  harm,  while  active  coping  such  as  appropriate
hysical  activity  tend  to  be  effective.6 Similarly,  a  general
ense  of  external  locus  of  control  (i.e.,  believing  that  physi-
ians  or  traditional  healers  are  responsible  for  the  treatment
r  even  ‘‘cure’’  of  pain)  can  be  detrimental  to  pain  manage-
ent,  whereas,  a  general  sense  of  internal  locus  of  control
i.e.,  believing  that  it  is  up  to  the  individual  to  manage  pain)











































ends  to  be  associated  with  better  long-term  adjustment.7
hether  or  not  an  individual  chooses  to  use  active  ver-
us  passive  coping  or  has  a  general  internal  versus  external
ocus  of  control  can  be  influenced  by  that  individual’s
ulture.
linical implications
nowledge  of  a  patient’s  culture  may  provide  valuable  infor-
ation  regarding  likely  beliefs  about  the  cause(s)  of  and
oping  mechanisms  for  pain,  both  of  which  will  inform  the
anagement  and  or  prognosis.  Clinicians  should  therefore
e  aware  of  how  culture  affects  these  variables.  Use  of  a
atient-centered  approach  when  performing  the  evaluation
ay  be  particularly  useful  for  assessing  the  patient’s  beliefs
bout  pain  and  how  they  cope  with  it  in  the  context  of
hat  patient’s  culture.  Similarly,  culture  may  influence  the
cceptability  and  appropriateness  of  treatments  designed  to
mpact  cognitive  and  behavioral  changes;  as  a  result,  treat-
ents  that  have  been  developed  by  clinicians  in  one  culture
ay  not  necessarily  be  relevant  or  effective  in  another
ulture;  such  treatments  may  need  to  be  adapted  in  order
o  maximize  their  efficacy  when  used  to  treat  patients  in  a
ew  culture.8
ummary and future directions
ulture  is  an  important  social  domain  that  clinicians
hould  consider  in  the  treatment  of  chronic  pain.  Given
hese  cultural  effects,  it  is  important  to  adapt  biopsy-
hosocial  assessments  and  treatments  to  a  culture  before
sing  it  in  clinical  practice.  Future  research  on  cultu-
al  comparison  between  pain-related  factors  including
ain  communication,  beliefs,  and  coping  can  provide  sig-
ificant  insight  in  management  of  pain  across  different
ultures.
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THE IMPACT OF PAIN IN LOW- AND MIDDLE-INCOME COUNTRIES
Although pain is experienced across the life course, the prevalence, particularly of musculoskeletal pain, 
increases with age [1]. Musculoskeletal pain disproportionately affects people in low- and middle-income 
countries (LMICs) and the associated disease burden continues to rise [2]. About 25% of the general pop-
ulation in LMICs experience chronic musculoskeletal pain, and this 
estimate increases by two to four times among working populations 
[1]. Musculoskeletal conditions represented the leading cause of 
disability in people aged 50-69 years among low-middle sociode-
mographic index (SDI) countries in the 2017 Global Burden of Dis-
ease (GBD) study and the second leading cause in people aged 70 
years and over (Figure 1) [2]. Pain management, particularly for 
musculoskeletal conditions, is necessary for improving quality of 
life and enabling functional ability, work and participation to avoid 
poverty. In the context of rapid global ageing, particularly in LMICs 
[3], system strengthening approaches for pain management are ur-
gently needed to respond to this global health burden.
DRIVERS OF AN INCREASING PAIN BURDEN 
IN LMICS
A myriad of factors contribute to the increasing burden of pain in 
LMICs. First, most LMICs are now facing sociodemographic and 
health challenges previously considered problems of high-income 
countries (HICs). Disproportionately rapid ageing populations in 
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Figure 1. Burden of disease for musculoskeletal in people 
aged 50-69 years [2]. YDL – years lived with disability, 
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LMICs are more prone to frailty, sarcopenia and falls-related injuries such as low-trauma fractures due to 
bone fragility [3]. LMICs are also experiencing an increasing burden of NCDs and their risk factors (phys-
ical inactivity, poor nutrition, pollution and substance abuse) and injury-related pain particularly due to 
road traffic accidents and violence, all on a background of an existing substantial burden of communicable 
diseases [2]. More complex health presentations associated with ageing, characterised by multimorbidity 
of NCDs, are increasingly common in LMICs [4] and musculoskeletal pain conditions are a very common 
component of multimorbid health profiles. Similarly, neuropathic pain is common in neurological condi-
tions such as stroke, spinal cord injuries, and multiple sclerosis; communicable diseases such as AIDS/HIV, 
leprosy, and herpes zoster; and genetic disorders such as sickle cell anaemia [5]. LMICs experience addi-
tional burden from higher rates of injuries related to trauma, violence and natural disasters compared to 
HICs [2], which further predispose people to long-term pain-related problems across the life course.
Second, work in LMICs is disproportionately physically demanding, especially in rural areas and lower 
socioeconomic groups. Work-related pain is accentuated in LMICs by longer hours of work in fields or 
factories, manually ploughing fields, and carrying heavy loads for extended periods in difficult terrains.
Third, access to pain management services in LMICs is limited and available health services are ill-
equipped to manage case complexity. Limited access to health care and health information, limited skills 
among health workers for treating pain, limited long-term care systems for older adults, and inadequate 
support for optimising self-care are notable challenges in LMICs [3], which point to the need for a system 
strengthening approach to pain care in these settings.
PAIN MANAGEMENT
Untreated pain not only threatens healthy ageing and contravenes the 2010 Declaration of Montréal, 
which advocated that access to pain relief is a fundamental human right; but also represents a broader 
threat to achieving targets of the Sustainable Development Goals (SDGs) including poverty and econom-
ic growth. Human suffering from unrelieved pain is a major global health problem, particularly in LMICs, 
where many terminally ill patients and patients with acute pain do not receive essential analgesic medi-
cations [6]. For example, 71% of the world’s population has an extremely low consumption of opioids 
for acute pain relief [6]. In contrast, HICs consume 79% of global morphine stock, including when often 
not indicated, for example, in chronic non-cancer pain (CNCP) [6]. Management for CNCP, typically of 
musculoskeletal origin, varies to the management approach for acute pain. First-line treatment consists 
of education including reassurance, staying employed in productive work, supporting graded activity, 
psychological therapies, among others [7]. For many people with 
chronic and disabling pain, multidisciplinary care is needed, but rare-
ly accessible in LMICs.
RESPONDING TO THE BURDEN OF PAIN IN 
LMICS
Considering the magnitude and burden of pain in LMICs, strong and 
comprehensive system-level responses are required to positively re-
form health and social care services and systems, integrating with oth-
er global system-strengthening initiatives that target population health 
needs in ageing, long-term care, rehabilitation, palliative care, and 
prevention and control of NCDs. The 2020-2030 Decade of Healthy 
Ageing and 2030 targets for the SDGs provide an opportune time to 
prioritise pain care in LMICs.
Public health and service delivery
Population-level public health interventions such as mass media cam-
paigns can be effective and resource-efficient interventions for a large-
scale public health problem such as low back pain [8]. An evidence-in-
formed pain education programme was recently developed in Nepal 
using local contexts for preventive, curative, and rehabilitative ap-
proaches for pain conditions, which can be used in population health 
campaigns using various delivery methods [9].
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Access to community-based and effective health services for pain management is needed, particularly for 
older people. The World Health Organization (WHO) Integrated Care for Older People (ICOPE) approach 
provides a service-level framework to guide the implementation of community-based health services, 
where musculoskeletal health is considered a key determinant of healthy ageing [10].
Access to essential analgesic medicines and rehabilitation services
While access to essential analgesic medicines for palliative care, post-surgical pain, acute injury and child-
birth is often limited or sometimes unavailable in LMICs [6], paradoxically some individuals with chronic 
pain conditions in the same LMICs receive opioid analgesics when they are not appropriate or safe – hav-
ing been associated with poor outcomes including no functional improvement, hyperalgesia and death. 
Although calls for access to pain relief in LMICs have largely focused on availing opioids for essential pain 
relief for acute pain, cancer and palliative care, extrapolating this call of making opioids available in LMICs 
for CNCP is common and unhelpful, highlighting the need for appropriate regulation. Based on the expe-
riences in HICs, particularly in the United States, this may worsen the disability burden associated with 
CNCP in LMICs.
One viable alternative to avoid overuse and adverse effects of opioids/analgesics in CNCP is improving 
multidisciplinary rehabilitation services. Rehabilitation services are increasingly important in LMICs be-
cause of increasing life expectancies with an increasing number of functional impairments related to mus-
culoskeletal pain conditions. Additionally, the current rehabilitation services in the LMICs, if at all avail-
able, are not adequate to meet the rehabilitation needs of the ageing population [3]. To meet this 
disparity, the WHO Rehabilitation 2030 initiative has called for improvement to global rehabilitation ser-
vices by 2030 (https://www.who.int/rehabilitation/rehabilitation_health_systems/en/). Provision of appro-
priate rehabilitation services as a component of universal health coverage (UHC) for older people is es-
sential not only to improve individuals’ functional levels and community participation, but will 
contribute to the achievement of the SDG targets for health and poverty.
Health workforce
A workforce (ideally community-based) of adequate volume and competencies is needed to address the 
burden of pain in LMICs. Here, workforce training and broadening of work cadres, such as communi-
ty-based health workers, will be important to address population needs [10]. For LMICs, upskilling 
community-based health workers and carers in appropriate pain care will be essential, as well as the im-
plementation of human resource systems to support the paid and unpaid workforce and plan for future 
workforce needs. It is important to co-design these services with health professionals delivering the in-
terventions and patients receiving them so that the services are accepted by both of these end-users.
Health information systems
Many LMICs countries currently lack population surveillance and workforce distribution data, or systems 
to generate data regarding the population burden of pain conditions. Optimisation of health information 
systems that include surveillance of pain, as demonstrated recently in the Solomon Islands [11], will as-
sist with current and future population health planning. Use of existing technologies to support health 
information sharing, such as mHealth, has great potential for application in health surveillance, system 
navigation and self-management for consumers.
Financing
In order to maintain the financial sustainability of health systems, financing models must support val-
ue-based pain care within UHC essential packages. This may be achieved through a range of regulatory 
and legislative levers, such as incentivising integrated, multidisciplinary care for people with chronic pain 
and minimising out-of-pocket expenses through financial protection for socioeconomically deprived peo-
ple (eg, India’s ‘Modicare’ scheme); harmonising funding between health and social care services to sup-
port holistic, person-centred care; and defunding low-value care options. Without radical reform to health 
financing, LMICs are unlikely to meet SDG 3 targets.
Leadership and governance
Development, championship and implementation of health policy that includes pain care are needed in 
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or sustainable in fragile health systems, highlighting the need for integration of pain care within existing 
or emerging policies for healthy ageing, prevention/management of NCDs, rehabilitation and palliative 
care. Consumers, civil society, clinicians and health service managers should be supported to help shape 
the pain care agenda in LMICs to ensure local needs are considered. Existing models of care and strate-
gies for pain care can then be appropriately adapted and shared with LMICs, as required.
CONCLUSION
Health system strengthening to improve pain care and surveillance should be priorities in LMICs. If giv-
en priority commensurate with the burden of disease, it may have positive impacts on healthy ageing, 
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